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ABSTRACT
Cutaneous squamous cell carcinoma (SCC) is a common cancer yet its
treatment is under-researched. The objective of this thesis was to develop a
proposal for a randomised controlled trial (RCT) to address uncertainties
relating to the management of the condition, and to ultimately improve the
management of affected patients.
Two systematic reviews were initially conducted to appraise the current
evidence base for SCC treatments. Only one RCT was eligible for inclusion in
the Cochrane systematic review; a small study which found no significant
difference in time to recurrence between patients treated with post-
operative 13-cis retinoic acid and interferon, and those not receiving adjuvant
treatment. Systematic review and meta-analysis of observational studies
included 118 studies. Pooled estimates of recurrence were lowest after
cryotherapy and curettage and electrodesiccation, although lesions treated by
these modalities were mostly small and low-risk. Although pooled recurrence
after Mohs surgery appeared lower than after conventional excision or
radiotherapy, the differences were not significant with overlapping 95%
confidence intervals. For photodynamic therapy, pooled recurrence after
apparently successful initial treatment was particularly high (26%). Evidence
relating to the effectiveness of topical and systemic treatments was very
limited. Estimates of recurrence were used to inform the sample size
calculation for the proposed RCT.
A survey of healthcare professionals was conducted to establish research
priorities and identify clinically important management uncertainties from
which initial trial scenarios were formulated. High-risk SCCs were identified as
a research priority, with optimal surgical management and the role of
adjuvant radiotherapy being key areas of uncertainty. Through multi-
disciplinary collaboration, a proposal for a two-stage RCT has been developed;
in the first stage, locoregional recurrence after conventional surgery with a
controlled excision margin will be compared with Mohs surgery, and in the
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second stage locoregional recurrence will be compared between patients
treated with adjuvant radiotherapy versus those receiving no adjuvant
treatment.
Feasibility work conducted during the development of the trial has involved:
a) A retrospective analysis of SCCs treated over twelve-months to
determine the number of patients and types of SCCs potentially
eligible for recruitment into the proposed trial and to further inform
the sample size calculation. Within five years of treatment 6% of 357
patients experienced local recurrence, 3% had regional recurrence and
1.5% died of their SCC. Comparison of the most recent American Joint
Cancer Council (AJCC7) and an alternative Brigham and Women’s
Hospital (BWH) classification showed that approximately 50% of SCCs
were T2 in both schemes and eligible for entry into the first stage of
the proposed trial. However, an additional BHW T2b substage better
stratified outcomes dependent on the number of risk features, and
indicated that 19% of all SCCs would potentially be also eligible for the
second stage of the trial.
b) A questionnaire and focus group study to assess the acceptability of
the RCT and to identify possible barriers to recruitment. Participants
had a desire to be better informed about SCC, wanting information
relating to the trial to be provided in a variety of formats. 71% of
participants were hypothetically willing to be randomised into the
surgical stage of the proposed trial but had more concerns about the
second stage involving adjuvant radiotherapy. Lack of equipoise and
confusion about the concept of randomisation will need to be
carefully addressed when presenting the trial to participants.
The proposed trial will be the first to directly compare treatments for the
types of SCC seen commonly in clinical practice. For the trial to be
adequately powered, an estimated 5400 participants will need to be
recruited, so a multi-centre, multi-disciplinary approach will be necessary.
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1CHAPTER 1:
CUTANEOUS
SQUAMOUS CELL
CARCINOMA
BACKGROUND
21 BACKGROUND
Definition1.1
Squamous cell carcinoma of the skin (SCC) is a type of non-melanoma skin
cancer (NMSC) which arises from keratinocytes in the epidermis of the skin
(Figure 1). The presence of malignant cells in the dermis that have breached
the epidermal basement membrane is characteristic of SCC, thus making the
distinction between invasive SCC and the precursors of SCC an architectural
one rather than histological.
Figure 1: Diagrammatic representation of the architecture of the epidermis of normal skin
Invasive SCC has the potential to cause significant local tissue destruction,
may metastasise to regional lymph nodes and distant organs, and occasionally
may cause death.
3Epidemiology1.2
1.2.1. Incomplete registration
Cutaneous SCC is the second most common cancer in the world, with only
basal cell carcinoma (BCC), the most prevalent kind of nonmelanoma skin
cancer, being more common. Lack of standardisation of data collection and
incomplete registration of non-melanoma skin cancer confound accurate
comparisons of incidence in different regions. Recommendations from the
European Network of Cancer Registries (ENCR)(European Network of Cancer
Registries, 2000), The United Kingdom Association of Cancer Registries
(UKACR)(United Kingdom Association of Cancer Registries, 2013), and the
International Agency for Research on Cancer (IARC)(International Agency for
Research on Cancer, 2004) are that only the first NMSC of each histological
type is registered per individual. However, cancer registries vary in their
completeness of SCC registration. In Scotland, the aim is to register all SCCs,
not just the first diagnosed, and similarly in Ireland although in practice only
the first ones are recorded there (National Cancer Intelligence Network,
2013). However, in Wales lack of resources precludes registration of even first
SCCs so the UKACR standard is not met (National Cancer Intelligence Network,
2013).
By registering all malignant skin cancers over a one year period in the South
West of England onto a pilot standalone skin cancer dataset and comparing
the number of cancers with those registered on the South West Public Health
Observatory Cancer Registry (the lead cancer registry for skin in England and
Wales), it has been estimated that almost 30% of SCCs go unrecorded (Poirier
et al.). This is likely to be a reflection of second and subsequent SCCs for
which there is currently no requirement to be registered, and concurs with
other studies that have attempted to compare number of SCCs treated with
those actually recorded on cancer registries (van der Geer et al., 2013).
Apart from subsequent SCCs, a number of new SCCs are slipping through the
registration net. Significant variation between registries in recording NMSCs
4has been shown, ranging from 12% to up to 44% of SCCs failing to be
recorded (Lucke et al., 1997, Brewster et al., 1996), although these studies are
now quite old. More recently, the South West Public Health Observatory
Network estimated a range of expected number of NMSCs for Cancer
Networks across England by multiplying the incidence of malignant melanoma
in each area by seven and 10, demonstrating that under-completeness of new
NMSC recording is particularly marked in London and the south-east of
England compared with other English cancer registries (South West Public
Health Observatory, 2010). A survey conducted on behalf of the National
Cancer Intelligence Networks found that a costly and labour-intensive
registration process, lack of efficient electronic systems and low use of the
Royal College of Pathologists’ histology reporting proforma were barriers to
registering SCC and other types of NMSC (National Cancer Intelligence
Network, 2010). Furthermore, some SCCs may escape registration if they are
treated privately, or if they are not recognised as SCCs and are treated
without pathological confirmation, although the vast majority of SCCs are
believed to confirmed histologically (Lucke et al., 1997).
1.2.2. International variation
Worldwide the highest incidence of SCC is found in Australia where
population based epidemiological surveys suggest age standardised incidence
rates of more than 1000 cases per 100 000 per population per year (Green et
al., 1996, Buettner and Raasch, 1998, Staples et al., 2006). In the United
States incidence rates range from 32 and 155 per 100 000 population for
males, and 8 to 29 per 100 000 population for females (Miller and Weinstock,
1994, Diepgen and Mahler, 2002), which although far less than those seen in
Australia is generally higher than age-standardised rates seen across northern
Europe where recorded incidence rates range from 11 to 46 per 100 000 per
population for males and from 5 to 23 per 100 000 for females (Hoey et al.,
2007, Brewster et al., 2007b, Holme et al., 2000, Katalinic et al., 2003, Hussain
et al., 2010). Variations in incidence are also seen within countries and almost
certainly reflect differences in ultraviolet radiation exposure at different
5altitudes or the distribution of susceptible ethnic groups within the country
(Lomas et al., 2012).
Several studies have reported rising incidence rates in various parts of the
world of between 2 and 11% per year in the latter part of the twentieth
century (Glass and Hoover, 1989, Gloster and Brodland, 1996, Demers et al.,
2005, Karagas et al., 1999, Holterhues et al., 2010, Staples et al., 2006).
Between 1985 and 1992, the incidence of SCC more than doubled across
Australia as a whole (Staples et al., 2006), and in the United States the
incidence increased threefold (Miller and Weinstock, 1994). Similarly a
systematic review of the worldwide incidence of NMSC has shown a trend
towards increasing incidence rates of SCC across Europe, albeit not such rapid
increases as the rates seen for BCC (Lomas et al., 2012). The National Cancer
Intelligence Network has shown that across the UK as a whole, there was an
increase in the incidence of SCCs from 2000-2002 to 2008 to 2010 of 34% in
males and 39% in females (National Cancer Intelligence Network, 2013), some
of which may be attributable to more complete registration although this is
unlikely to account for all the increase.
Some studies suggest that incidence rates of SCC may be stabilising in
subgroups of the population. A Canadian study found that there was a trend
towards stabilisation of invasive SCC rates in 1995 (annual percentage change
0.36%)(Jung et al., 2010), a finding which is consistent with a study of
incidence in south-eastern Arizona where SCC incidence plateaued or even
declined slightly between 1985 and 1996 (Harris et al., 2001). There was also
no significant difference between world age-standardised incidence rates for
SCCs between 1988 and 1998 in West Glamorgan in South Wales, although
BCC incidence had increased significantly over the same period (Holme et al.,
2000). In Northern Ireland age-adjusted incidence in females remained steady
at 22 per 100 000 population between 1993 and 2002, although rates in men
increased from 41 to 48 per 100000 population over this time (Hoey et al.,
2007), and in New Zealand where the overall annual incidence of SCC had
increased by 1.1% between 1997 and 2007, the only subgroup in which there
6was a significantly increased annual percentage was men over 80 years
(Brougham et al., 2011). Of particular interest is the finding that in Australia,
although there has been an overall increase in the incidence of NMSC since
1985, there appears to have been no significant increase in the incidence of
SCC in people under 50 years of age or BCC in those under 60 (Staples et al.,
2006). Furthermore, although the number of NMSCs treated in Australia
between 1997 and 2010 increased by 86%, and is estimated to increase by a
further 22% between 2010 and 2015, there was a relative decrease in the
number of treatments in people aged 45 years when taking into account the
15% increase in population growth in this age group. It is in the older age
groups where the impact of increased incidence will be greatest, with the
ŶƵŵďĞƌŽĨƐŬŝŶĐĂŶĐĞƌƚƌĞĂƚŵĞŶƚƐĨŽƌƚŚŽƐĞĂŐĞĚ ? ?ƚŽ ? ?ǇĞĂƌƐĂŶĚA? ? ?ǇĞĂƌƐ
predicted to have increased by 171% and 215% respectively by 2015, far
outstripping the predicted population growth of 57% and 68% respectively in
these groups (Fransen et al., 2012). As those under 50 years of age were
among the first generation to receive cancer education programmes such as
the ‘Sunsmart’ campaign, the results of these studies are providing early
evidence of the value of such public health campaigns and their potential
impact on future generations. In an economic evaluation of the SunSmart
programme in the Australian state of Victoria, where the scheme was
originally instigated in the 1980s, it has been calculated that between 1988
and 2003 more than 94000 NMSCs and 9000 melanomas were averted as a
result of the campaign, with prevention of more than 1000 deaths from all
types of skin cancer (Shih et al., 2009). However, the effectiveness of the
programme on NMSC was only based on the change in the age-specific BCC
rate, and not SCC, as an earlier study had failed to show any impact on SCC
whereas a decrease in BCC had been demonstrated in people under 50 years
old (Staples et al., 1998). Nonetheless, the authors of the economic
evaluation argue that sustained modest investment in the skin cancer
programme is excellent value for money and that with an upgraded national
Australian programme for the forthcoming 20 years 120 disability-life-years
will be averted with associated reductions on the use of health care resources
7(Shih et al., 2009). The ‘Sunsmart’ campaign has a high profile in Australia;
elsewhere in the world skin cancer programmes are varied and dependent on
funding and input from government sources and non-government sectors.
Since the mid-1990s there have been several public health awareness
campaigns in the UK, the first of which was the ‘Sun Know How’ campaign
delivered by the Health Education Authority until 2000. In 2003, Cancer
Research UK was commissioned to run the SunSmart UK campaign, with
different audiences, such as outdoor workers, teens and holidaymakers
targeted each year. Other UK charities and professional organisations have
run their own sun-awareness programmes, such as the BAD Sun Awareness
Campaign (www.bad.org.uk/for-the-public/sun-awareness-campaign),
Teenage Cancer Trust ‘Shunburn’ campaign
(www.teenagecancertrust.org/what-we-do/education/shunburn/), and the
Karen Clifford Skin Cancer Charity (SKCIN) ‘Sun Safe Schools’ and ‘Sun Safe
Workplaces’ campaigns (www.skcin.org/Sun-Safety/How-to-Prevent-Skin-
Cancer), whilst other skin charities such as the British Skin Foundation
promote sun awareness messages on their website
(www.britishskinfoundation.org.uk/SkinInformation/SkinCancer.aspx). It will
be interesting to evaluate the impact of skin cancer awareness campaigns in
other countries in the future. A survey on the overall impact of the ‘SunSmart
UK’ campaign between 2003 to 2008 reported that there had been a
significant increase in awareness of the importance of protecting children
(5.2% to 12.4%), checking moles (8.3% to 11.0%), avoiding sunburn (5.4% to
11.7%), seeking shade (34.8% to 41.0%), covering up (26.8% to 39.9%) and
avoiding sunbeds (1.2% to 7.5%), although no significant change in peoples’
attitudes to their perceptions of the benefits or risks of the sun was seen
(Cancer Research UK, 2008). However, generally the evidence for what type
of skin cancer prevention activity works in the UK population is limited,
although evidence from Australia suggests that long-term commitment and
investment with regular reinforcement of key messages will be important if
sustained changes are to made and the risk of developing skin cancer is to be
reduced in the population (Dobbinson et al., 2008).
81.2.3. Incidence in the United Kingdom
The most recent figures available from Cancer Research UK indicate that in
2010, when the population of the UK was 62.3 million, there were almost
100,000 new cases of NMSC registered in the United Kingdom with just under
13,000 new cases of malignant melanoma (Cancer Research UK, 2013) (Figure
2). This would equate to approximately 25000 new cases of SCC, based on a
ratio of SCC: BCC of 1:4. However, as discussed above the number of
registered NMSCs is likely to be a significant underestimate.
Figure 2: New cases of skin cancer during 2010
Based upon Australian figures indicating the occurrence of one melanoma for
approximately every 64 NMSCs, it has been suggested that true numbers of
NMSC in the UK may actually be closer to the 800,000 seen annually in
Australia (Sinclair, 2013). However, this is based on the assumption that the
ratio of melanoma: nonmelanoma is of a similar magnitude in Australia and
the UK, which cannot be assumed as UV exposures are different and there
may be inherent differences between the populations in each country, and is
significantly greater than the rate-ratio of seven to 10 indicated by the
majority of Local Authorities in the South-West and West Midlands and which
was used by the South West Public Health Authority to estimate the number
12,818
99,549
Malignant melanoma
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9of NMSCs across Cancer Networks in the UK (South West Public Health
Observatory, 2010).
In 2010 there were 590 deaths attributed to NMSC in England and Wales
(Cancer Research UK, 2013), most of which would be due to SCC, with smaller
numbers resulting from BCC and other NMSCs such as Merkel Cell Carcinoma,
although the data available does not categorise deaths according to type.
Furthermore, a recent retrospective study of cases of fatal cases of SCC
recorded over an 11-year period, has highlighted the potential inaccuracy of
death certification data that is recorded as being due to SCC, with 13 of 58
(22%) reported cases being due to other causes, particularly malignant
adnexal tumours, and only 21 of 58 (36%) cases being definitely attributed to
SCC (Rose et al., 2013).
Clinical Features1.3
1.3.1. Presentation
SCC frequently arises in areas of the skin where there is evidence of pre-
existing photodamage such as actinic keratosis (AK), irregular pigmentation,
hyperkeratosis and telangiectasia. Induration of the skin, usually not sharply
defined and extending beyond visible tumour, is an early sign of SCC
development. The tumour itself may appear as an enlarging firm papule,
plaque, nodule or ulcer although clinical appearance and behaviour varies
with site of origin (Figure 3, Figure 4, Figure 5). SCCs which arise on mobile
parts of the body such as the lip may initially appear as a fissure or small ulcer
which fails to heal and bleeds intermittently. Subungual SCCs, although rare,
may be mistaken for other conditions, resulting in delayed diagnosis and
often only correctly diagnosed once the tumour has invaded the distal
phalanx sufficient to cause radiological changes.
Well-differentiated tumours may appear papillomatous with a keratotic crust,
which when shed reveals an ulcerated or eroded tumour underneath that
bleeds easily when traumatised.
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Invasive SCCs can be asymptomatic, although the patient may experience
pruritus, tenderness, pain and bleeding. Perineural involvement may be
indicated by pain, paraesthesia, anaesthesia or weakness, and on rare
occasions such symptoms may precede visible signs of tumour (Schroeder et
al., 1998).
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Figure 3: A well-defined SCC with central hyperkeratosis
Figure 4: Raised erythematous invasive SCC on a light-exposed site in an elderly patient
Figure 5: An elevated hyperkeratotic SCC of the temple with surrounding erythema (images
reproduced with kind permission of Dr William Perkins, consultant dermatologist, Circle HHS
Treatment Centre, Nottingham)
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1.3.2. Variants of SCC
The term ‘squamous cell carcinoma’ encompasses a number of variants as
part of a heterogeneous group of tumours which display much variation in
terms of clinical behaviour and aggressive potential (Cassarino et al., 2006b,
Cassarino et al., 2006a). Some of these rare variants warrant separate
mention in view of their tendency to cause extensive local tissue destruction
or by having a particular propensity to metastasise.
Epithelioma cuniculatum
Verrucous SCC is a rare variant of SCC that may be found at any cutaneous
site but the plantar surface of the foot is the most usual site of presentation
(epithelioma cuniculatum) (Aird et al., 1954), where it may be initially
misdiagnosed as a plantar wart. Growth is slow, but it eventually develops
into a large exophytic mass with multiple sinuses opening on the surface, with
release of greasy foul-smelling material if squeezed. Although it causes
extensive local tissue destruction, metastases from epithelioma cuniculatum
are uncommon.
Squamous cell carcinoma arising in chronic conditions
SCC may arise in areas of chronically damaged skin such as long-standing
ulcers or burn scars (Marjolin’s ulcer) (Da Costa, 1903, Treves and Pack,
1930)( Figure 6, Figure 7), sinus tracts (Pilipshen et al., 1981) or osteomyelitis
(Kirsner et al., 1996), or in chronic inflammatory conditions such as discoid
lupus erythematosus (Sulica and Kao, 1988), lupus vulgaris (Motswaledi and
Doman, 2007) and dystrophic epidermolysis bullosa (Weber et al., 2001,
Mallipeddi, 2002).
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Figure 6: SCC arising in a long-standing ulcer (image courtesy of Dr W Perkins)
Figure 7: SCC arising in an old burn scar (image courtesy of Dr W. Perkins)
Although rare, they are typically aggressive with between 36% and 54% of
SCCs arising in chronically damaged areas metastasising to regional lymph
nodes despite most of them having well- or moderately-differentiated
histology, with survival at 5 years being only 52% to 75% (Cassarino et al.,
2006a).
Spindle cell squamous cell carcinoma and radiation-associated SCC
First described in 1935 (Martin and Stewart, 1935), it was initially thought
that the rare spindle cell variant of SCC primarily arose in previously irradiated
areas of skin. However, it is now recognised that most cases arise on areas of
sun-exposed skin, and that indeed most SCCs arising in areas of previous
irradiation are conventional SCCs.
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Spindle cell SCCs arising in areas of previous radiation have been reported to
be more aggressive than those that are not associated with prior radiation
(Cassarino et al., 2006b), although this is somewhat contentious as reports of
their course have generally not described parameters such as depth of
invasion, location and tumour differentiation which affect metastatic
potential. Nevertheless, all types of SCC that are radiation-associated appear
to have a more aggressive course, with disease-specific death rates of
between 9.5% (Martin et al., 1970) and 12% (Pack and Davis, 1965) having
been reported for these cancers, along with earlier and frequent recurrences,
metastasis to lymph nodes and distant organs, and eventual death (Cassarino
et al., 2006a). Data is, however, lacking for subtypes of radiation-associated
SCCs. Given the lack of reliable data regarding the prognosis of spindle cell
SCC, British Association of Dermatologists (BAD) guidelines (Motley et al.,
2002)and the World Health Organisation (WHO) (Le Boit et al., 2006) regard
all spindle cell variants as high-risk, in addition to other types of SCCs in areas
of prior irradiation, whereas the American AFIP considers spindle cell SCCs to
be high-risk only if associated with radiation exposure (Patterson and Wick,
2006). Taking these uncertainties into account, the Royal College of
Pathologists’ (RCPath) most recent dataset for reporting primary cutaneous
SCC includes all spindle cell SCC variants as being potentially high-risk
(Chaudhuri et al., 2006).
Desmoplastic squamous cell carcinoma
By definition, desmoplastic SCC variants have a dense stromal response with
growth of fibrous tissue around the tumour occupying at least 30% of the
tumour volume. They are rare and again data is sparse regarding their
prognosis, but of the studies that have investigated this, the conclusion
appears to be that they tend to be more aggressive than conventional SCCs. A
prospective study of 594 SCCs of which 44 were desmoplastic reported
recurrence and metastasis of 27% and 23% respectively for desmoplastic SCCs
compared with 4% and 3% for other types of SCC (Breuninger et al., 1997).
Other studies have reported metastases in up to 77% of desmoplastic SCCs.
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Desmoplasia has also been shown to be an independent predictor of local
recurrence (Brantsch et al., 2008). These SCC variants are thus considered to
be high-risk in the BAD guidelines (Motley et al., 2002) and by the RCPath
(Chaudhuri et al., 2006).
Acantholytic squamous cell carcinoma
Also known as adenoid or pseudoglandular SCC, between 2% and 4% of all
cutaneous SCCs are acantholytic variants characterised histologically by the
loss of intercellular bridges. The metastatic potential of acantholytic SCC may
be higher than SCCs of no special type, but data is sparse. However, there
have been reports of mortality from this SCC variant in between 3 % to 19% of
patients (Johnson and Helwig, 1966, Nappi et al., 1989), so for the purposes of
assigning degree of risk the BAD Guidelines, WHO and RCPath consider SCCs
classified as acantholytic to be high-risk (Motley et al., 2002, Le Boit et al.,
2006, Chaudhuri et al., 2006)
1.3.3. Differential diagnosis
Diagnosis of a well-differentiated SCC arising in area of photodamaged skin is
usually straightforward, but needs to be distinguished from a
keratoacanthoma which is generally considered to be a distinct entity from
invasive SCC, which tends to grow very rapidly with a domed appearance and
regresses spontaneously within 6 months. Other lesions included in the
differential diagnosis include BCC, amelanotic malignant melanoma, actinic
keratosis, inflammatory ulcers, granulomas and viral warts and verrucae.
Natural history and progression1.4
In white-skinned individuals, SCCs most commonly present on sun-exposed
areas, with 50 % to 70% occurring on the head and neck (Marks, 1996, Sober,
1983). There is a strong association between the presence of precursors of
SCC, actinic keratosis and SCC in situ (Bowen’s disease), which are indicators
of sun-damaged skin, and the development of SCCs. Histological analyses of
invasive SCCs suggest that between 26% and 72% arise from AK (Mittelbronn
et al., 1998, Marks et al., 1988, Czarnecki et al., 2002). It is debateable how
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frequently AKs transform into SCC and appears to depend upon the extent of
sun-damage and to be time dependent. Although 10% to 15% of individual AK
lesions regress spontaneously (Marks et al., 1986, Harvey et al., 1996), a
review of studies published between 1988 and 1998 found that the overall
risk of AKs transforming ranged from 0.025% up to 16% per year (Glogau,
2000). In a more patient-centred approach, one study has suggested that for
a patient with approximately 8 AKs, the probability of at least one of them
transforming during a 10 year period is 10% (Dodson et al., 1991). A
retrospective analysis of pathologically confirmed AKs which progressed to
invasive SCC at the same site indicated that, for those AKs which do progress,
it takes approximately 2 years for progression to occur (95% confidence
interval 21.04 to 28.16 months) (Fuchs and Marmur, 2007). This study was
limited however by the small number of SCCs which were judged to have
arisen from an AK (n=91), and was not able to account for time lags in the
diagnosis of AKs and SCCs, and may have excluded patients in whom AKs were
present at the site of an SCC but which had not been biopsied and
pathologically proven. Clinically, it is not yet possible to determine which AK
lesions are likely to develop into SCCs, so some professional bodies such as
the American Academy of Dermatology advocate treating all AKs (1999).
However, the most recent AK management guidelines from the British
Association of Dermatologists (BAD) recommend that the decision whether to
treat or not should be made on an individual basis according to signs,
symptoms and history as there is currently insufficient evidence to justify
treating all AKs, and that thin AKs may warrant no treatment (de Berker et al.,
2007). SCC in situ (Bowen’s disease), in which dysplastic cells fill the entire
thickness of the epidermis, also has the potential to progress to SCC, with an
estimated 3% to 5% of lesions progressing to invasive SCC (Peterka et al.,
1961, Kao, 1986). These data are again drawn from retrospective studies, and
may not be an accurate reflection of true progression rates as many patients
with Bowen’s disease may not seek medical advice or may be treated in
primary care without pathological confirmation. There are several treatment
options for SCC in situ from topical creams to surgery and PDT, although some
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thin, slowly progressing lesions, particularly those on the lower leg, may
warrant observation rather than aggressive intervention (Morton et al.,
2014).
Squamous cell carcinomas generally grow at a faster rate than BCCs, although
not as rapidly as keratoacanthomas which resolve spontaneously if left
untreated.
Invasive SCC (Rowe et al., 1992) has the potential to recur and to metastasise,
with an overall 5-year recurrence rate of 8% for primary cutaneous lesions,
and a 5-year rate of metastasis of approximately 5%. Metastases from
cutaneous SCC are most frequently seen in the regional lymph nodes initially,
followed by the lungs, liver, and other organs. Factors favouring metastasis
include tumour site, depth, diameter, rate of growth, histological
differentiation, perineural, lymphatic and vascular invasion, and host
immunosuppression (Motley et al., 2002). Later chapters in this thesis include
a detailed discussion of outcomes and prognostic features of cutaneous SCC
so will not be described further in this section.
Risk factors1.5
The risk of developing SCC depends on the inter-relationship between
extrinsic factors and the individual’s response to these. Intrinsic and extrinsic
risk factors are summarised in Table 1.
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Table 1: Risk factors for development of SCC
Host-related Factors Extrinsic Factors
x Older age x Ultraviolet radiation:
o Cumulative sunlight exposure
o Sunbed use
o Medical UV treatment
x Male gender
x Fair complexion:
o Red/blond hair
o Hazel/blue eyes
o Fitzpatrick skin types I and II
x Genetic conditions:
o Albinism
o Xeroderma pigmentosum
o Recessive epidermolysis bullosa
o Epidermodysplasia verruciformis
x Chemical carcinogen exposure:
o Smoking
o Arsenic
o Petroleum by-products
o Insecticides/herbicides/fungicides
x Pre-malignant skin conditions
x History of skin cancer x Radiation exposure:
o Ionising radiation
o Thermal radiation
x Chronic conditions:
o Chronic ulcers
o Burn scars
o Osteomyelitis sinuses
o Hidradenitis suppuritiva
x Weakened immune system:
o Organ transplant recipient
o HIV/AIDS
o Chronic lymphocytic leukaemia
x Human Papillomavirus infection
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1.5.1. Intrinsic (host-related) factors
Cutaneous SCC is more prevalent in older people, males and those with pre-
malignant skin conditions or a prior history of skin cancer, all of which may be
surrogate markers for cumulative ultraviolet radiation exposure. Phenotypic
features such as red hair, lack of ability to tan and propensity to freckling are
well recognised features which correlate with an individual’s risk of
developing SCC (Gallagher et al., 1995).
Conditions in the host that increase susceptibility
Host responses that influence the development of SCC include chronic
inflammation, such as chronic ulcers and burn scars. Some individuals also
have increased genetic susceptibility to SCC in certain syndromes such as
xeroderma pigmentosum (Robbins, 1988) (in which the DNA repair
mechanism is defective causing severe sensitivity to UV radiation and the
early development of multiple SCC), albinism, and epidermodysplasia
verruciformis (a rare, autosomal recessive inherited skin disorder
characterised by eruptions of wart-like lesions caused by infection with the
human papillomavirus) (Diepgen and Mahler, 2002). People with the inherited
condition recessive dystrophic epidermolysis bullosa (RDEB), in which there is
a defect in the type VII collagen gene whereby either no collagen VII or very
low levels are produced resulting in a mechanically fragile skin, have a 50
times greater than normal risk of developing SCC. Approximately 90% of
those with RDEB-Hallopeau-Siemens, the most generalised subtype of RDEB,
will have developed cutaneous SCC by the age of 55 years (Fine et al., 2009).
It is not yet known why these individuals are at increased risk, apart from
them having chronic non-healing scars.
Organ Transplant Recipients and immune system compromise
Impaired host immunity is an important risk factor in the development of SCC,
and as the number of successfully transplanted and longer-living organ
recipients rises, SCC is a particular concern in this group. In transplant
recipients, skin cancers account for 90% of all diagnosed malignancies, with
SCCs being the most common type. Reversal of the SCC: BCC ratio seen in the
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general population is also a feature of the skin cancers seen in this group
(Hardie et al., 1980, Ramsay et al., 2002, Moloney et al., 2006).
The risk of developing SCC of the skin post-transplantation is 65 to 253 times
greater than in the non-transplanted population and related to the degree of
immune suppression (Hartevelt et al., 1990, Jensen et al., 1999). A more
recent large cohort study from the UK in which more than one thousand
ethnically diverse organ transplant recipients were prospectively followed
over a 2 year period (Harwood et al., 2013), has shown a 153-fold excess risk
for developing SCC and dying from it compared with the general population.
The incidence rates of SCC development increase according to the time post-
transplant, with incidence rates in an Australian study rising from 23% at 5
years to 44% after 9 years (Hardie et al., 1980), and up to 70% after 20 years
(Bouwes Bavinck et al., 1996); higher than the incidence rates of 10% to 15%
seen at 10 years and 40% at 20 years after transplantation in European
countries (Hartevelt et al., 1990, London et al., 1995, Naldi et al., 2000).
Furthermore, SCCs that develop in organ transplant recipients may be more
aggressive than in the general population. In a study of heart and heart plus
lung recipients, 4% developed an aggressive SCC within 10 years of their
transplant, with two-thirds of these developing distant metastases or dying as
a result of the SCC (Veness et al., 1999).
Non-iatrogenic induced immune suppressed individuals are also at greater
risk of developing SCC. This may be the result of congenital disorders, viral
infection, chronic lymphocytic leukaemia, or human immunodeficiency virus
(HIV). People infected with HIV have been found to be at three to five times
greater risk of developing SCC than non-infected people and to develop it at a
significantly younger age, but unlike organ transplant recipients there is no
reversal of the BCC: SCC ratio in this group (Wilkins et al., 2006, Demopoulos
et al., 2003). However, SCCs that develop in the HIV infected people do seem
to have a more aggressive course, with higher risk of local recurrence,
metastasis and 50% mortality (Nguyen et al., 2002).
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1.5.2. Extrinsic factors
Ultraviolet radiation
Ultraviolet (UV) radiation forms part of the solar electromagnetic spectrum,
and can be broadly divided into three wavelength bands: UVA (315-400nm)
which is not absorbed by the earth’s ozone layer; UVB (280-315nm) which is
mostly absorbed by the ozone layer; UVC (100-280nm) which is completely
absorbed by the ozone layer and the earth’s atmosphere.
For the general population, exposure to ultraviolet (UV) radiation, usually as a
result of a lifetime’s sun exposure but also arising from sunbed use or as a
part of medical treatment, is the most important risk factor for SCC
development, with approximately 50% to 60% of SCCs resulting from UV
radiation exposure (Lucas et al., 2008). Cumulative lifetime sun-exposure is
strongly associated with the risk of developing SCC, in contrast to BCC where
it is believed intermittent and childhood exposure are more important
(Madan et al., 2010).
There is now a body of evidence suggesting a causal link between the use of
sunbeds (which predominantly emit UVA) and the development of SCC. The
International Agency for Research on Cancer (IARC) stated in 2011 that there
was limited evidence that sunbed use was linked to the development of SCC
(Cogliano et al., 2011). However, a recent meta-analysis including 12 studies
with 9328 patients with NMSC in which people who had ever used an
artificial indoor tanning device were compared with those who had never
used one, found a positive association with SCC risk (Relative Risk (RR) 1.67
[95% CI 1.29 to 2.17])(Wehner et al., 2012).
The protective effect of skin pigmentation is reflected in the low incidence of
non-melanoma skin cancer (NMSC) seen in black populations. Asian and
Hispanic groups, in which skin pigmentation is intermediate, share
epidemiologic and clinical features of dark-skinned and white groups, so
although the incidence is higher than in black people, it does not approach
that seen in white populations (Gloster and Neal, 2006, Leong et al., 1987,
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Pennello et al., 2000). A national survey conducted in the United States
showed an annual age-adjusted incidence for all NMSCs of 3.4 per 100,000
population for African Americans compared to 232.6 per 100,000 among
whites, indicating that whites are around 70 times more likely to develop skin
cancer (Scotto et al., 1981). However, the mortality among black people has
been shown to be disproportionately high in comparison with incidence
(Weinstock, 1993). Whereas the sun-exposed skin of the head and neck is the
most common site for the occurrence of SCC in white populations, non-sun-
exposed sites are more frequently involved in black people, suggesting that
sunlight exposure is a less important aetiological factor in this group. The
presence of chronic scarring processes and areas of chronic inflammation are
the most important risk factors in blacks (Halder and Bridgeman-Shah, 1994,
Mora and Perniciaro, 1981) and SCCs associated with these predisposing
factors tend to be more aggressive, with a 20% to 40% risk of metastasis
compared with a rate of 1% to 2% in sun-induced SCC (Mora and Perniciaro,
1981, Rowe et al., 1992).
Chemical carcinogens
Exposure to chemical carcinogens has also been shown to increase the risk of
developing SCC. A recent systematic review including pooled data from 6
studies showed a significant association with smoking, with a 52% increase in
odds of developing cutaneous SCC (OR 1.52, 95% CI 1.15-2.01), most
pronounced in current smokers and those who had ever smoked (Leonardi-
Bee et al., 2012). Prolonged exposure to arsenic is also positively associated
with the development of squamous cell carcinomas, particularly of the skin
and lung and is believed to result from genetic and epigenetic changes
resulting in a dramatic increase in the expression of keratins (Martinez et al.,
2011). Nowadays most significant exposure is via drinking water sources in
various parts of the world with high natural arsenic levels rather than
medicinal exposure, although this can still occur in parts of the world where
arsenic may still be used in preparations such as Asiatic pills and in some
Chinese herbal medicines and traditional Indian medicines (Prasad et al.,
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2006). Other carcinogens which have been implicated in the development of
SCC of the skin include ionising radiation, psoralen-UVA therapy, and
petroleum by-products, with weaker potential associations also being made
with exposure to insecticides, herbicides, fungicides and seed treatments
(Lichter et al., 2000, Lindelof et al., 1999, Karagas et al., 2007, Gallagher et al.,
1996).
Human Papillomavirus
Human papillomaviruses (HPV) have long been recognised as important
aetiological agents in the development of cervical cancer and some types of
ano-genital cancer and head and neck SCCs, but their role in the development
of cutaneous SCCs has been rather more contentious. The potential role of
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of SCCs in the rare genetic disorder epidermodysplasia verruciformis
(Majewski and Jablonska, 1995). However, whilst many studies have shown
that 16% to 54% of SCCs from immunocompetent individuals are infected
with HPV, the presence of HPV DNA in SCCs is not universal (Arron et al.,
2011). This may in part be due to variation in the sensitivity of detection
methods between studies. Other possible explanations for the lack of HPV in
SCCs include the possibility that HPVs may be implicated in the initiation of
tumour development but that their continued presence is not necessary for
tumour promotion or maintenance, or that the SCC develops via a separate
molecular pathway in which HPVs are not implicated, or simply that they are
innocent bystanders during oncogenesis. A recent meta-analysis of 17 articles
concluded that SCCs were more likely to carry HPV than normal looking skin
(pooled effect estimate 3.43, 95% confidence intervals 1.97 to 5.98,
P<0.0001), although it was somewhat limited by the degree of heterogeneity
between the included studies in terms of types of SCC, assays used (broad-
spectrum versus limited spectrum polymerase chain reaction, and
immunocompetent versus immunosuppressed patients (I2=76%) (Wang et al.,
2014). The mechanisms of the aetiological role of HPVs remain unclear
(Harwood and Proby, 2002, Karagas et al., 2006, Bouwes Bavinck et al., 2010)
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although further elucidation of these mechanisms could provide exciting
prospects for targeted therapies in the future.
Histopathology1.6
Invasive SCC is characterised by the presence of nests or chords of malignant
cells within the dermis and an associated inflammatory infiltrate.
In the 1930’s, Broders devised a grading system for SCCs based upon the
percentage of differentiated cells present (Broders, 1932), and much of the
SCC literature uses this classification:-
x Grade I >75% cells differentiated
x Grade II 50-75% cells differentiated
x Grade III 25-50% cells differentiated
x Grade IV <25% cells differentiated
However, the most recent staging guidelines from the American Joint
Committee on Cancer (AJCC7) grade SCCs as ‘low-grade’ or ‘high-grade’
without guidance on the percentage of differentiated cells which need to be
present to make this distinction (Edge and Compton, 2010). When developing
the most recent dataset for the histological reporting of SCC, the Royal
College of Pathologists has thus adopted the approach that tumours should
be classified as well, moderately or poorly/undifferentiated, based upon
appearance of the most poorly differentiated part of the SCC regardless of the
percentage of differentiated cells present (Chaudhuri et al., 2006). When
assessing differentiation, the degree of keratinisation, the presence or
absence of intercellular bridges, the degree of pleomorphism, and the
number and type of mitoses are taken into account.
The cells seen in well-differentiated SCCs are typically nucleated with
prominent nucleoli and abundant cytoplasm containing tonofibrils and well-
developed intercellular bridges (prickles). Pleomorphism is minimal and
mitotic figures are uncommon. Keratinisation is often abundant (Figure 8).
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Figure 8: A well-differentiated SCC (image courtesy of Dr I Leach, consultant histopathologist, NUH
NHS Trust)
Moderately differentiated SCCs are structurally more disorganised, with cells
showing more pronounced nuclear and cytoplasmic polymorphism and more
frequent mitotic figures. SCCs that are poorly differentiated have cells with
nuclear atypia and frequent mitotic figures and less keratinisation, and may
be difficult to definitively diagnose histologically as SCC unless intercellular
bridges or small areas of keratinisation are observed (Figure 9).
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Figure 9: Poorly differentiated SCC with little keratinisation and much nuclear atypia (image courtesy
of Dr I Leach)
Rarely cells may be completely anaplastic and give few clues as to the origin
of the tumour on microscopy.
Perineural invasion (PNI), defined as ‘the observation of cytologically
malignant cells in the perineural space of nerves’ (Dunn et al., 2009) (Figure
10), occurs in approximately 6% of cases of SCC (Leibovitch et al., 2005b).
Such PNI may be ‘microscopic’ and an incidental finding on routine
microscopy in a clinically asymptomatic patient, or ‘extensive’ in which case
the disease is widespread and found either clinically, on radiology, or is
apparent at surgery (Han and Ratner, 2007).
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Figure 10: Perineural invasion of 0.25mm calibre nerve (image courtesy of Dr I Leach)
Spread through the perineural sheath offers a low-resistance pathway for
extension of tumour that is also relatively protected from the host’s defences.
Perineural invasion usually extends up to 1cm, although may be much more
extensive along cranial nerves with retrograde spread to nerve foramina or
the base of the skull and leptomeningeal involvement (Dunn et al., 2009).
Studies of SCCs with PNI suggest that they carry a poorer prognosis,
particularly for local recurrence (Jambusaria-Pahlajani et al., 2013, Veness et
al., 2006, Schmults et al., 2013). A retrospective cohort study of 114 SCCs with
PNI suggested that there was greater risk of nodal metastasis (HR 5.6 [95% CI
1.1 to 27.9]) and death from disease (HR 4.5 [95% CI 1.2 to 17] when nerves
of calibre greater than 0.1mm were involved compared to involvement of
smaller calibre nerves, but this was partly attributed to the association
between PNI and other risk factors such as tumour diameter and depth of
invasion, so the prognostic significance of nerve diameter currently remains
unclear (Carter et al., 2013).
Pathogenesis1.7
Chronic exposure to ultraviolet radiation, particularly UVB (280-315nm) from
sunlight is the major factor in the development of SCC, believed to result from
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a chain of events ultimately resulting in DNA damage and mutation formation
(Runger, 2007).
Mutations in the TP53 tumour suppressor gene are the most well-recognised
and intensely studied aberrations in the pathogenesis of SCC, being present in
more than 90% of SCCs in the United States and in the majority of
precancerous lesions, suggesting that alteration of the p53 protein function is
an early event towards the development of invasive SCC (Brash, 2006). p53
has a pivotal and complex role in many cellular control mechanisms. In
response to its activation by numerous cellular stresses such as DNA damage
or hypoxia, p53 is activated, forming tetramers that bind to DNA and
activating many genes which results in DNA repair, arrest of the cell cycle and
apoptosis (programmed cell death) (Latonen and Laiho, 2005). The gene
encoding the p53 protein is located on the short arm of chromosome 17 and
is highly conserved (Lamb and Crawford, 1986). A characteristic UVB
‘signature’ is seen for most of the gene’s mutations, with transition of
ƉǇƌŝŵŝĚŝŶĞďĂƐĞƐ ?ƵƐƵĂůůǇĐǇƚŽƐŝŶĞ ? ?APƚŚǇŵŝŶĞ ?d ? ?ŽƌAPdd ?ƌĂƐŚĞƚĂů ? ?
1991). TP53mutations are also found in keratinocytes from normal-looking
skin in addition to skin showing frank sun-damage, but normal skin turnover
may lead to their elimination. However, it has been shown that UV exposure
not only produces mutations but can also be a driver of clonal expansion of
mutant keratinocytes by the induction of apoptosis of surrounding normal
cells, allowing repopulation of the microenvironment by the relatively
apoptotic-resistant mutant cells and thus providing an expanded population
of abnormal cells for the acquisition of mutations in other driver oncogenes
which may then cause progression to invasive SCC (Brash et al., 2005).
The role of UVA (315-400nm) in carcinogenesis is less well understood than
that of UVB, and appears to be less mutagenic than UVB and less efficient at
producing cyclobutane pyrimidine dimers and pyrimidine-pyrimidine
photoproducts. Most UVA damage appears to be indirect through formation
of reactive oxygen species and the transfer of energy to DNA via mutagenic
oxidative intermediates (Ridley et al., 2009).
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Activation or downregulation of other cellular pathways such as those
involving epithelial growth factor (EGFR) (Toll et al., 2010, Shimizu et al.,
2001) and matrix metallopeptidases (MMPs) (Mitsui et al., 2013) are
recognised as having a role in the pathogenesis, maintenance and spread of
SCC. Nevertheless, the identification of somatic mutations that drive tumour
genesis has remained elusive. Activating mutations of the Ras oncogene are
present in low frequency in SCC, and alone may not be sufficient to cause
malignant transformation. However, there is concern that Ras-mutation
primed cells may render patients treated with RAF inhibitors for BRAF v600E
mutation-positive melanoma more susceptible to SCC, although the
mechanism of this remains unclear (Oberholzer et al., 2012). Mutations in the
genes encoding Notch 1 and Notch 2 receptors, which regulate many aspects
of cell development and survival and play a central role in
microenvironmental communication, are found in approximately 75% of SCCs
and are also a recent source of interest in the search for tumour drivers
(Dotto, 2008, Wang et al., 2011). Further elucidation of genetic mutations and
their effect on cellular control will continue to be of importance as the search
for more targeted therapies for SCC advances.
Management overview1.8
The aims of treatment of SCC of the skin are to completely remove or destroy
the tumour with minimal functional or cosmetic impairment.
A number of treatments are used for SCC and will be outlined briefly below.
However, as appraisal of the evidence of the effectiveness of these
treatments constitutes a major part of this thesis, outcomes after treatments
will be discussed further in chapters 3 and 4.
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1.8.1. Surgical Excision
The current treatment of choice for most SCCs of the skin is surgical excision
as this allows histological confirmation of complete excision. It is usually
carried out as an out-patient procedure under local anaesthetic. The
technique involves delineation of clinically obvious tumour either by eye or by
curettage, although there is no good evidence that curetting before excision
confers any benefit (Chiller et al., 2000). An additional clinically normal
appearing margin of skin is excised with clinically apparent tumour, the size of
which is based upon the presence of prognostic features and in accordance
with current guidelines. Current UK guidelines advise a margin of normal
looking skin of 4mm for low-risk tumours, and 6mm for those with high-risk
features. These recommendations are based on a single study (Brodland and
Zitelli, 1992), in which 95% of SCCs which were excised by Mohs micrographic
surgery would have been excised completely with these margins. However,
microscopic extension beyond the clinically visible tumour may be more
extensive for tumours with poorly delineated clinical borders, tumours larger
than 2cm in diameter, and recurrent tumours, so wider margins are more
appropriate for tumours such as these (Choo et al., 2005). Indeed, the
excision margins recommended in the Australian and US SCC management
guidelines are more conservative than those in the UK (Cancer Council
Australia and Australian Cancer Network, 2008; National Comprehensive
Cancer Network, 2010) with margins up to 10mm recommended. There is
therefore no international consensus regarding acceptable margins and no
RCTs have been done to address this.
After excision, tissue is either fixed in formalin for histological assessment of
completeness of excision, or examined by frozen section. The resulting wound
is sutured or allowed to heal by secondary intent, and skin grafting may be
necessary if a large tumour is removed or in cosmetically complex areas.
1.8.2. Mohs Micrographic Surgery
Frederick Mohs first developed and described the technique of excision with a
micrographically controlled margin when he was a medical student in the
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1940s (Mohs, 1947). There have since been refinements and adaptations of
the original in vivo zinc paste tissue fixation technique (chemosurgery),
although the general principle has remained the same. Essentially the tumour
is excised with a narrow margin of clinically normal looking skin and frozen
sections are prepared such that the entire margin from the epidermis to the
deepest margin can be examined microscopically (usually by the Mohs
surgeon who is specially trained in this technique). Margins are marked and
mapped, and where residual tumour exists, further tissue is excised. The
whole process is repeated until all the margins are clear of tumour so the
patient may be in the theatre suite for an entire day and may not be
appropriate for those who may not be able to tolerate such a long procedure.
As only areas where further tumour is identified are re-excised, the technique
tends to be more tissue-sparing than standard surgical excision and is
considered to be the gold-standard treatment where tumours are located in
areas where cosmetic and functional considerations are important, and also
for recurrent tumours and those exhibiting perineural invasion as the
technique allows the tumour to be traced along the nerve (Leibovitch et al.,
2005b, Lawrence and Cottel, 1994).
1.8.3. Radiotherapy
SCCs of the skin are generally radiosensitive and treatment by this method
may be cosmetically and functionally beneficial in certain anatomic locations
such as the lip, canthi of the eye, and tip of the nose (Stranc et al 1987). Some
sites such as the dorsum of the hand and lower limb are less amenable to
radiotherapy, and the use of radiotherapy is best avoided for tumours
overlying bones and cartilage where there is the risk of radionecrosis. Its use
should also be avoided in younger patients where the late effects from
irradiation such as atrophy, hypopigmentation and telangiectases may be
cosmetically less acceptable than a surgical scar; furthermore ionising
radiation carries with it the small but present risk of development of
carcinoma within the treatment field (Karagas et al., 1996). UK management
guidelines recommend radiotherapy for tumours which are not resectable or
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poorly-defined, with liaison in a multi-disciplinary clinic when there is debate
about the best treatment option (Motley et al., 2002).
There is a diverse range of radiotherapy techniques used which are tailored
according to tumour characteristics and site, with radiation doses generally
being fractionated over a period of weeks to minimise radionecrosis.
Generally this involves superficial external irradiation of the tumour and a
margin of normal-looking skin, with protection of uninvolved tissue by
specially fitted lead masks or shields. Sometimes brachytherapy is used for
treatment, with direct application of the radioactive source via interstitial
wires or surface moulds, and usually requiring shorter treatment times than
conventional radiotherapy.
In addition to the use of radiotherapy as the sole treatment modality for SCC,
adjuvant radiotherapy is sometimes used post-operatively, administered
either to the tumour-bed alone or to first-echelon lymph nodes, with the aim
of eradicating residual tumour cells. It is generally used for tumours
considered at high risk of recurrence, and particularly for those that
demonstrate PNI or that have been incompletely excised. However, the use of
adjuvant radiotherapy varies among clinicians and with the facilities available
(personal communication).
1.8.4. Cryotherapy
Cryotherapy employs the use of liquid nitrogen to freeze and destroy cells,
usually as two or three cycles with one to five minutes for each cycle, but
there is much variation in practice. The diagnosis should be confirmed by
biopsy before the procedure, but as with curettage-electrodesiccation,
histological confirmation of clearance is not possible. Currently cryosurgery is
only recommended for use by experienced practitioners to treat small, well-
defined, low-risk tumours (Motley et al., 2002).
1.8.5. Electrodesiccation/cauterisation and curettage
As tumour tissue is usually more friable than surrounding normal tissue, initial
curettage of the lesion debulks and helps to delineate extensions of the
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tumour, the base of which is then electrodesiccated or cauterised several
times to destroy residual tumour, along with a margin of normal looking
tissue. The current UK guidelines recommend the use of curettage and
electrodesiccation for the treatment of small, well-defined low-risk lesions
only, and only then by experienced clinicians. (Motley et al 2002).
Furthermore, as with cryotherapy, histological confirmation of complete
destruction of the tumour is not possible with this technique.
1.8.6. Photodynamic Therapy (PDT)
In photodynamic therapy a topically applied prodrug, 5-aminolaevulinic acid
(ALA) or its methyl ester methylaminolaevulinate (MAL), is converted to the
photosensitiser protoporphyrin IX (Pp IX) in the biosynthetic pathway for
haem. As haem-containing enzymes are required for energy metabolism,
every nucleated cell has the capacity to synthesize PpIX, which is the
immediate precursor of haem, although under normal circumstances the
pathway is closely regulated so that PpIX does not accumulate to
photosensitising concentrations. ALA and MAL selectively accumulate in
tumour tissues, possibly as a result of increased permeability of abnormal
keratin (Kennedy et al., 1990). Exposure to visible light causes the production
of reactive oxygen species which are believed to mediate cell damage, and
the inflammatory response and damage to vascular endothelium may also
contribute to destruction of tumour cells (Dougherty, 1987).
There have now been RCTs assessing the use of topical PDT for treating
NMSCs, in which it has been shown to be effective for the treatment of thin
actinic keratoses, Bowens disease and superficial BCCs (Braathen et al., 2007),
and it may be considered for treating nodular BCC in situations where surgery
may be suboptimal (Morton et al 2008). However, the evidence supporting
the use of PDT for treating invasive SCC is very limited.
1.8.7. Other Treatments
Not all SCC patients can be treated surgically or with radiotherapy, and such
treatments may also not be appropriate for patients with genodermatoses or
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those who are immunosuppressed in whom multiple tumours may be a
particular problem. There is currently an unmet need for effective topical and
systemic therapies, but as new insights into the molecular pathogenesis of
these tumours advances, so does the prospect of new targeted treatments.
The use of treatments such as imiquimod, 5-flurouracil and interferon has
largely been restricted to very small case series or case reports of patients
with unresectable SCCs and their routine use is not currently recommended
(Motley et al 2002). The evidence of the effectiveness of these treatments will
be considered in greater depth in chapter 4.
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CHAPTER 2:
RATIONALE
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2 RATIONALE
Introduction2.1
There are few people in the United Kingdom who can say that they have not
in some way and at some time been affected by a skin condition, either in
themselves or in those they care for. Between 23% and 33% of the population
are estimated to have a problem with their skin at any one time, and
dermatological conditions of all types are the most frequent reason for
people to visit their general practitioner. Almost 13 million people in England
and Wales consulted their GP with a skin related problem during 2006, and of
these 0.8 million (6%) were referred to a specialist (Schofield et al., 2009). The
burden of dermatological diseases in today’s society cannot be
underestimated. Skin cancers form an increasing part of this dermatological
burden, and indeed the two most common types of non-melanoma skin
cancers, basal cell and squamous cell carcinoma, are the most common
cancers in the world. The research presented in this thesis has had, and will
have, an impact on the people who are affected by just one of the cancers
that can causes such a huge amount of distress and is encountered not only in
dermatology but across many specialties: squamous cell carcinoma (SCC).
The SCC research described was just one stream of a wider programme of
work, ‘Setting Priorities and Reducing Uncertainties for People with Skin
Disease’ (www.nottingham.ac.uk/research/groups/cebd/projects/nihr-
programme-grant.aspx), funded by the National Institute for Health Research
(NIHR) under its Programme Grant for Applied Research scheme, and which
also included research on eczema prevention and treatment, vitiligo and
pyoderma gangrenosum. The overall aim of the programme of work was to
set priorities and reduce uncertainties in the prevention and treatment of skin
disease using a range of methods, starting with reviews of work already done,
identifying research gaps and prioritising these for clinical trials in order to
provide answers about uncertainties in the management of these common
skin disorders.
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This chapter outlines the rationale underpinning this SCC research, the aims
and objectives of the PhD, and the role that I have played throughout, with a
brief overview of each chapter in order to give insight into the bigger picture.
Rationale2.2
2.2.1. The burden of squamous cell carcinoma
As discussed in chapter 1, squamous cell carcinoma is a very common cancer
in white populations which is particularly prevalent in older people. As
average life expectancy increases and the number of older people in society
grows, so the number of nonmelanoma skin cancers, including SCC, is set to
rise even further. Although the prognosis after treatment is generally good
and mortality low, the sheer numbers of SCC means that the burden of
morbidity associated with the disease is actually very high. The impact of this
morbidity is felt not only by patients and their carers, but by society in general
and the healthcare economy particularly (Table 2).
Table 2: Overview of the burden of squamous cell carcinoma
Patients x Physical cost of cancer itself and its
treatment
x Associated mortality
x Psychological impact
x Impact on Quality of Life
x Lost days of productivity
x Financial costs incurred for care
Carers x Psychological impact
x Financial costs incurred
x Lost days of productivity
Society x Inability to work due to illness or
treatment
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Economy x Direct costs of diagnosis and treatment
x Indirect cost of lost days
x Lost working life years because of
premature death
Direct costs to the healthcare system include GP consultations, inpatient
admissions, day case treatment and outpatient follow-up. The number of
bed-days per year for all types of nonmelanoma skin cancer is double that for
melanoma, although this is just the tip of the iceberg as the vast majority of
nonmelanoma cancers are treated on an out-patient basis (National Cancer
Intelligence Network, 2010). In England in 2002, the estimated total cost of
treating skin cancers other than malignant melanoma was more than £71
million, of which nearly £58 million were direct NHS costs and the remainder
were indirect costs associated with morbidity and mortality and patient
incurred costs (Morris et al., 2005), with the cost of treating each NMSC
estimated to be between £889 and £1226 (Vallejo-Torres et al., 2014). These
figures are, however, likely to be a significant underestimate in view of
problems with capturing activity data for NMSCs. (Morris et al., 2005). With
cases of NMSC predicted to continue to rise, the increased burden will have
policy implications for medical resources and infrastructure (Fransen et al.,
2012); this is a cancer which will continue to have huge cost and resource
implications for health services in the United Kingdom and around the world
well into the foreseeable future.
2.2.2. Squamous cell carcinoma as a research priority
In 2006, the National Institute for Health and Clinical Excellence (NICE) in its
guidance ‘Improving outcomes for people with skin cancer including
melanoma’, highlighted the lack of good-quality research on the effectiveness
of treatments for skin cancer and called for studies with long-term follow-up
to compare different treatments (Brewster et al., 2007b). An All Party
Parliamentary Group on Skin which reported in 2008, also raised concern that
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skin cancer had in previous years been afforded a lower priority than it
deserved in terms of efforts to prevent it and in planning the services
required to manage it, pointing out inadequacies of data collection for skin
cancer and calling for more resources to research the cause, prevention and
treatment of skin cancer (All Party Parliamentary Group on Skin, 2008).
2.2.3. Why research SCC treatments?
The UK Government has acknowledged the need for more research into all
types of skin cancer. As advances are made at bench level to identify
molecular aberrations that can result in the development of skin cancer, so
the number of potential treatments targeting those aberrations is set to
increase. This is an exciting prospect for the future. However, as the already
heavy skin cancer workload of busy dermatologists and other clinicians looks
set to rise even further, it is important that hitherto unanswered questions
about the effectiveness of the current commonly used treatments are first
addressed. Patients should have the right to expect a practical and consistent
approach to their management based upon the very best evidence available.
Yet despite the fact that SCC presents a considerable burden globally, it has
been largely overlooked as a distinct type of nonmelanoma cancer which
merits being researched in its own right.
For SCC, evidence of the comparative effectiveness of the mainstay
treatments recommended in management guidelines has been lacking. It is
possible to speculate about why this has been the case. Historically, it may
be that all NMSCs were regarded as a single entity to be treated in a similar
fashion, and that studies looking at treatments did not separate SCCs from
BCCs and other less common types of NMSC. Additionally, there may in the
past have been a misconception among both clinicians and the public that
these tumours are merely a temporary inconvenience, readily treated and
without future implications, and thus that further investigation of well-
established treatments was not warranted. SCCs however do not behave in
the same way as BCCs; they have different patterns of behaviour and a
greater propensity to recur, metastasise and cause death.
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There are undoubtedly challenges to conducting high-quality research studies
comparing treatment effectiveness for SCCs, not least because they are a very
heterogeneous group in terms of both prognostic indicators in the tumours
themselves and in the characteristics of the patients affected. Such
heterogeneity will need to be taken into account when designing research
studies, and should be regarded as an incentive rather than a barrier to
conducting such research in that important answers can be addressed about
prognostic models and the appropriate targeting of treatment resources.
Conducting prospective studies with long-term follow-up of a condition which
is most common in an elderly population, many of whom have other co-
morbidities, may also be viewed as a disincentive to this type of research.
However, as the clinical impact of SCC is not set to wane in the near future,
and as the elderly population and other susceptible groups such as chronically
immunosuppressed continues to grow, this should really be a driving force to
spur the development of pragmatic trials whose results are relevant to the
people most affected.
Aim and objectives of this research2.3
All patients who are diagnosed with SCC have the right to receive the optimal
treatment for them as an individual which is based upon the best evidence
available. This optimal treatment will be satisfactory to them as an individual,
giving the best chance of having their tumour completely removed or
destroyed whilst minimising the risk of recurrence, metastasis and tumour-
related death, and at the same time causing them as little discomfort as
possible in terms of quality of life, pain, disfigurement, functional impairment
and adverse effects of treatment. With this in mind, the aim and objectives of
the research I have been conducting are summarised below.
2.3.1. Aim
To develop a proposal for a well-designed clinical trial that will address areas
of management uncertainty for cutaneous SCC and which will help to inform
the evidence based management of future SCC patients.
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2.3.2. Objectives
¾ To appraise, summarise and identify gaps in the current evidence-base
of the effectiveness of SCC treatments.
¾ To identify areas of management uncertainty and potential areas for a
future trial.
¾ To assess the feasibility of potential randomised controlled trials
(RCTs) through:
o Evaluation of the number and types of SCCs treated over a
one-year period
o Baseline feasibility work with SCC patients themselves
o Multi-disciplinary collaboration with clinicians
¾ To help inform current development of national guidelines of SCC
management.
¾ To develop the proposal and funding application for the randomised
clinical trial identified.
The Research Cycle2.4
I sincerely hope that the first revolution of the research cycle with which I
have been involved (Figure 11) will be the first of many more revolutions of
the cycle and the start of a much longer journey. I envisage that the findings
from the trial which results from this work will help to develop the existing
evidence base, generate more questions, and ultimately stimulate further
research. Thus the cycle continues.
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Figure 11: The Research Cycle
The role that I have played in the research2.5
The research cycle illustrated gives a broad overview of how this work has
flowed in order to meet the overall aim of the project and the development
of a trial proposal. The work has been made up of a series of individual
projects which have linked together and which have each formed a significant
piece of research in their own right.
Each piece of work has been done in collaboration with my supervisors and
colleagues from various disciplines, and has been overseen as a whole by the
NIHR Programme Grant Executive Committee. I have been involved with this
research from its beginning, playing a key role in planning and designing each
of the specific projects. I have co-ordinated the research, carried out the vast
majority of the work, generated ideas, collaborated with colleagues who will
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be influential in conducting the definitive trial itself and are involved in the
development of management guidelines, and disseminated the results of the
work through peer-reviewed articles and presentations at national and
international conferences.
A brief summary of subsequent chapters follows, with an outline of my
contribution where applicable:
Chapter 3: Appraisal of the Evidence  a Cochrane Systematic Review
The first step on the road to the project’s aim was to conduct a Cochrane
systematic review which would evaluate the evidence from randomised
controlled trials that have compared the effectiveness of different treatments
for non-metastatic SCC. The title for this review had previously been
registered with the Cochrane Skin Group in 2006 but had not been pursued. It
was decided by the Executive Committee that this was a good starting point
for the research and needed to be carried forward, so I became lead author
on the review, working with the Cochrane Skin Group to develop the search
strategies, and working in concert with my supervisors to identify potential
titles, source papers for potentially relevant RCTs, and to undertake the
double extraction of data. Only one eligible RCT was identified in the review
so data analysis was negligible, but I was responsible for drafting the review
and responding to referee’s comments.
Despite the lack of RCTs, this review has proved an extremely valuable point
from which to launch the research; it has highlighted the shocking state of
affairs that the second most common cancer has attracted so little in the way
of ‘gold-standard’ research in the past, and emphasises the importance that
this situation really need to be redressed, as has been alluded to in the
rationale discussed earlier in this introduction.
Chapter 4: Appraisal of the Evidence  a Systematic review of Observational
Studies
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Following on from the Cochrane systematic review, I decided that it really was
necessary to evaluate the current evidence-base more comprehensively by
looking at the evidence from non-RCT studies. Only by doing this would
information on, for example, event rates and variations in techniques be
obtained which would be helpful in planning the trial proposal. The search
strategy for this review was designed with assistance of a specialist librarian; I
developed the data extraction form myself, and identified potentially relevant
studies working in parallel with my supervisors. I extracted all the data from
the identified studies, which was also done independently by two other data
extractors. As this type of systematic review is quite novel, advice and help
with statistical analysis was given by my supervisor, a statistician. I was
responsible for interpreting the results and drafting the paper for publication.
Although there are many challenges in conducting this type of systematic
review, it would not have been possible to progress the work overall without
the information that it has yielded.
Chapter 5: Identification of potential topics for a randomised controlled trial
The poor state of the evidence base for SCC treatments has been shown in
chapters 3 and 4. There are many uncertainties that surround the
management of this common cancer. Yet what are the questions that
clinicians feel are the most pressing and which should be addressed in a trial?
In order to answer this, I devised a survey which was sent to clinicians
responsible for treating patients with SCC. Colleagues from dermatology,
plastic surgery and clinical oncology helped to pilot this and facilitate the
survey to be sent to members of their professional organisations. I was
responsible for analysing and interpreting the results from the survey.
Chapter 6: Evolution of a trial
Following analysis of the results of the clinician survey, I formulated four
scenarios for possible RCTs based upon clinically important management
uncertainties identified in the survey. As the success of any SCC RCT trial will
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depend upon multidisciplinary collaboration, I presented the scenarios to the
National Cancer Research Institute (NCRI) non-melanoma subgroup of the
melanoma Clinical Studies group in order to engage with them at an early
stage and to facilitate the development of trial proposal. This chapter
describes the evolution of the trial from the rationale behind the initial trial
scenarios and through their further development.
Chapter 7: Case series of SCCs treated in Nottingham
The Executive Committee overseeing the Programme Grant work specified at
the outset that feasibility work needed to be undertaken to inform any
proposed trial. This chapter describes the evaluation of SCCs that I considered
to be a necessary part of this feasibility work, as it would give information
about the numbers of SCCs that are treated in a typical regional centre and
the types of SCCs presenting in terms of their prognostic features. After
looking initially at these issues for SCCs treated fairly recently, I decided that
by extending the evaluation to include SCCs that had been treated 5 years ago
it would also be possible to gain information about the number of baseline
recurrences, metastases and deaths that occur within 5 years of treatment;
information that would be crucial for any future trials. This involved designing
a database which could both capture pathological information on SCCs
submitted to the histopathology department and clinical outcome data. I
designed the key elements of this database, which was constructed and
maintained by a colleague with specialist skills in this area. Colleagues in
histopathology and dermatology populated the database with information
which I then analysed and interpreted.
Chapter 8: Feasibility study with patients
This chapter describes the feasibility study that I decided to conduct in order
to evaluate potential participants’’ hypothetical willingness to be randomised
into the proposed trial, and to examine possible barriers to recruitment which
would need to be taken into consideration in the trial design. This work
involved a postal questionnaire with open and closed questions, which I
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designed myself and piloted with the CEBD patient panel, and a focus group
which I organised but which was moderated with my assistance by a
qualitative research colleague who has plenty of experience in this role. Data
were transcribed, analysed and interpreted by myself using a thematic
framework approach.
Chapter 9: The development of the trial proposal
The aim of this PhD has been to develop a proposal for a clinical trial to be
taken forward for a funding application. The background work behind this has
been described in previous chapters. This chapter outlines how the proposal
has evolved to the current trial proposal. The development has been an
iterative process, with amendments occurring en route and leading to the
proposal as it currently stands and which is to be submitted for a funding
application for a full trial. A multidisciplinary approach is crucial in a trial of
this nature and as such the involvement of NCRI non-melanoma subgroup of
the melanoma CSG is a necessity if the trial is to be successfully funded. I
have been involved at every stage as the proposal has developed, having
initially presented the trial ideas to the subgroup and taking an active part in
all the group’s meetings and discussions as the proposal has evolved.
Chapter 10: Impact and conclusions
In the final chapter, I shall summarise the research as a whole, with a
discussion of the impact that it is having, how patients have been involved
with the research, and its implications for clinical practice and future
research. The research cycle that was described in this chapter will be
revisited to evaluate how all the research has fitted into the cycle.
This PhD has been a significant part of my life over the past five years. This
thesis would therefore not be complete with a personal reflection on the
journey that I have trodden and the future one upon which I am yet to
embark.
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CHAPTER 3:
APPRAISAL OF THE
EVIDENCE.
A COCHRANE
SYSTEMATIC REVIEW
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3 APPRAISAL OF THE EVIDENCE: A COCHRANE
SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED
TRIALS
Abstract3.1
Background
Squamous cell carcinoma (SCC) is the second most common skin cancer, and
is becoming increasingly common around the world. Left untreated, it may
spread to other parts of the body, and, although the risk is low, it may
ultimately lead to death. Surgical excision is the first line of treatment for
most skin SCCs, although other forms of treatment are also used depending
upon the nature and site of the tumour and individual participant factors. A
multi-professional approach is therefore required for the management of
people with this condition.
Objectives
To assess the effects of treatments for primary non-metastatic squamous cell
carcinoma of the skin.
Methods
In February 2010 we searched for relevant trials in The Cochrane Skin Group
Specialised Register, The Cochrane Library (Issue 1, 2010), MEDLINE, EMBASE,
PsycINFO, AMED, LILACS, and the ongoing trials registries.
Only randomised controlled trials (RCTs) of interventions for primary SCC of
the skin were included. Participants with one or more histologically proven
invasive SCC were eligible for inclusion. The primary outcome measures were
time to recurrence one to five years after treatment, and quality of life.
Secondary outcomes included early treatment failure within six months,
number and type of adverse events by the end of treatment, aesthetic
appearance as assessed by the participant and clinician, discomfort to the
participant during and after treatment, and death.
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Two authors independently carried out study selection and assessment of
methodological quality and data extraction.
Main results
Only one trial involving 65 participants met the inclusion criteria, which
compared the time to recurrence in participants with aggressive skin SCC who
were randomised to receive either adjuvant 13-cis-retinoic acid and
interferon alpha after surgery with or without radiation treatment, or no
adjuvant therapy after their initial treatment. There was no significant
difference in time to recurrence of tumour between the two groups (hazard
ratio 1.08, 95% confidence intervals 0.43 to 2.72).
Most studies identified from the searches were excluded as they were either
uncontrolled case series, did not include participants with invasive primary
SCC, or included only participants with recurrent or metastatic disease.
Conclusions
Very limited evidence exists from RCTs comparing the efficacy of different
interventions for primary cutaneous SCCs exists. There is a clear need for
well-designed randomised studies in order to improve the evidence base for
the management of this condition.
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Introduction3.2
3.2.1. What is evidence-based medicine?
The concept of ‘evidence-based medicine’ (EBM) is not new and its
philosophical origins can be traced back to at least the seventeenth century.
However, interest in modern EBM really took off in the 1970s and 1980s and
has continued to develop since then (Sackett et al., 1996). One of the
founders of modern EBM, David Sackett, defined its practice as “the
conscientious, explicit and judicious use of current best evidence in making
decisions about the care of individual patients” (Sackett et al., 1996). Thus
good evidence-based practice is a combination of the healthcare
practitioner’s clinical expertise with the best available external evidence, with
the aim of providing the optimal treatment for each patient based on their
individual circumstances.
3.2.2. The hierarchy of evidence
Randomised controlled trials and systematic reviews of several RCTs have
become the ‘gold standard’ studies for assessing treatment efficacy, as they
are regarded as being most likely to inform and at lowest risk of bias. An
example of an evidence hierarchy for studies of treatment effect is shown in
Figure 12. There is however, no single universally accepted hierarchy and
there has over the years been much debate about the order of study types
within hierarchies. For example, Guyatt placed the N-of-1 RCT ( a multiple
crossover trial in which patients undertake pairs of treatment periods with
administration of the target treatments during one period and placebo or
alternative treatment during the other) at the top of the hierarchy of
strengths of evidence for treatment decisions (Guyatt and Rennie, 2002).
Others argue that a single, large well-conducted RCT is preferable to a
systematic review and meta-analysis of several smaller studies (Cappelleri et
al., 1996).
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Figure 12: Hierarchy of evidence for treatment effects. Reproduced with permission from State
University of New York Downstate Medical Centre, Medical Research Library of Brooklyn Guide to
Research Methods. The Evidence Pyramid. Evidence Based Medicine Course.
(http://library.downstate.edu/EBM2/2100.htm (SUNY Downstate Medical Center).
However, hierarchies of evidence have been criticised for their lack of
flexibility and simplistic approach to EBM (Smith and Pell, 2003). Indeed,
some have called for the abandonment of hierarchies of evidence altogether
on the basis that proponents of EBM have deliberately overlooked the
methodological limitations of RCTs and meta-analyses:
In reality, the hierarchy of evidence has done nothing more than glorify the
results of imperfect experimental designs on unrepresentative populations in
controlled research environments above all other sources of evidence which
may be equally valid or far more applicable in given clinical circumstances. The
hierarchy of evidence has had no basis whatsoever as a principle of scientific
method but has received an almost universal acceptance among
biostatistically minded colleagues. (Miles et al., 2000)
When seeking out the best evidence relating to a specific clinical question, it
is important to bear in mind that different categories of question are best
served by different study designs and that for questions relating to prognosis,
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aetiology or diagnostic accuracy, the RCT may not be the most appropriate
study design (Petticrew and Roberts, 2003, Guyatt et al., 2000, Glasziou et al.,
2004). Case control or cohort studies, for example, are likely to be more
useful than RCTs to answer questions about prognosis, aetiology of diseases
and harm from treatment, whereas for diagnostic accuracy evaluation cross-
sectional studies will be more appropriate than RCTs.
Furthermore, some flexibility is required when considering hierarchies of
evidence and it is important to take into consideration the quality of studies
when seeking the best evidence; a large well-designed observational study
may be more meaningful than a small poorly-designed RCT. Although levels of
evidence such as those proposed by the Centre of Evidence-Based Medicine
in Oxford (OCEBM Levels of Evidence Working Group, 2011) provide a useful
hierarchy of the likely best evidence for a range of clinical questions, they do
not provide a definitive judgement on the quality of the evidence so it is
important that clinicians have essential critical appraisal skills which allow
them to interpret the evidence available in a manner which is most
meaningful for their own patients.
3.2.3. The role of systematic reviews in evidence based
medicine
Systematic reviews and meta-analyses are important steps in the objective
application of evidence to patient-centred management, allowing potentially
large amounts of information to be assimilated by health care providers,
researchers and policymakers. The process of systematic reviewing is
formalised and rigorous, following a step-wise process:
x Framing of a clearly focussed research question
x Systematically searching for and retrieving all relevant literature which
meets the pre-specified eligibility criteria
x Assessment of the quality of the retrieved literature
x Summarising the evidence, with meta-analysis if appropriate
x Interpretation of the evidence
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By using a systematic and explicit methodology, studies with weak design and
increased risk of bias can be identified and consistency of results across
studies compared, allowing for the systematic interpretation of the data and
an assessment of the validity of the findings and the implications for clinical
practice and future research. Thus recommendations emanating from
systematic reviews are, by virtue of their scientific methodology, more
reliable and accurate than the potentially biased personal views of ‘experts’
conducting traditional reviews but which are not conducted in systematic
way.
Meta-analysis, in which statistical methods are used to summarise the results
of included studies, may increase the precision of the overall result of a
systematic review, with increased power and narrower confidence intervals
(Biondi-Zoccai et al., 2011). However, it is certainly not appropriate to carry
out a meta-analysis for every systematic review, and there may be too much
heterogeneity across included studies in terms of population, intervention,
and outcome or study design for meta-analysis to be feasible.
As the systematic review described in this chapter is a Cochrane systematic
review which was co-ordinated by the Cochrane Skin Group, the Cochrane
Collaboration will be discussed in further detail in subsequent sections.
However, it is important to appreciate that not all systematic reviews are
quantitative and also that other organisations play an important role in the
production of systematic reviews in healthcare. Cochrane reviews are
predominantly concerned with systematic reviews of the effectiveness of
interventions and diagnostic test accuracy systematic reviews. Systematic
reviews of primary research may also be carried out for qualitative studies,
with meta-synthesis of evidence as appropriate, and for health economic
evaluations. Furthermore systematic reviews may be comprehensive (in
which evidence from two or more different types of evidence is considered),
overarching umbrella reviews of systematic reviews, or scoping reviews in
which the research question is generally very broad and the purpose of the
review is to map the existing literature and identify gaps without focussing
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greatly on the quality of the individual studies. The Joanna Briggs Institute
(JBI)(http://joannabriggs.org/) is an example of a body that works closely with
the Cochrane Collaboration to produce systematic reviews that would
generally not be in the remit of the Cochrane group. Established in 1996 by
the Royal Adelaide Hospital and University of Adelaide and with more than 70
collaborating centres worldwide, the strength of the JBI lies particularly in the
development and conduct of systematic reviews of qualitative, economic and
policy research to support and promote the translation of research evidence
into practice globally. In the field of education, criminal justice, social policy
and social care, the Campbell Collaboration
(http://www.campbellcollaboration.org/) is Cochrane’s sibling organisation
with close affiliation between the two in recognition that social interventions
are also relevant in the wider field of healthcare. Additionally, systematic
reviews are also conducted under the auspices of other organisations such as
the National Institute for Health and Care Excellence (NICE) in the UK, and the
Agency for Healthcare Research and Quality (AHRC) in the United States.
3.2.4. Cochrane systematic reviews
In 1972 Archie Cochrane (Figure 13), a physician and significant contributor to
the development of epidemiology as a scientific discipline, published his book
“Effectiveness and Efficiency: Random Reflections of Health Services”, in which
he strongly advocated using evidence from RCTs to make medicine more
efficient and effective (Cochrane, 1972). His subsequent challenge to the
medical profession to critically evaluate the evidence from RCTs, was a spur
for the development of the systematic review:
It is surely a great criticism of our profession that we have not organised a
critical summary, by specialty or subspecialty, adapted periodically, of all
relevant randomised controlled trials. (Cochrane, 1979)
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Figure 13: Archie Cochrane, after whom the Cochrane Collaboration is named (image courtesy of
Cardiff University Library, Cochrane Archive, University Hospital Llangough)
The first Cochrane Centre opened in Oxford in 1992, followed by the
foundation of the Cochrane Collaboration in 1993 under the leadership of Sir
Iain Chalmers who was strongly influenced by the writings of Archie
Cochrane.
Figure 14: Logo of the Cochrane Collaboration
The Cochrane Collaboration (Figure 14) is a not-for-profit independent
worldwide network of health practitioners, researchers and patient advocates
which has the aim of promoting evidence-based health decision making
through the production and publication of readily accessible high-quality and
up-to-date systematic reviews and meta-analyses.
Cochrane reviews are systematic reviews that are carried out according to the
methodology of the Cochrane Collaboration as set out in the Cochrane
Handbook (Higgins and Green, 2011), and which are included in the Cochrane
Library (available at www.thecochranelibrary.com/ ). Cochrane reviews have
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been regarded as the benchmark for systematic reviews as they are generally
considered to be methodologically rigorous, less prone to bias, better
reported and more frequently updated than non-Cochrane systematic
reviews published in peer-reviewed journals (Egger et al., 1997, Jadad et al.,
1998, Jadad et al., 2000).
3.2.5. Risk of Bias assessment
Interpretation of the data in a systematic review depends upon whether the
results of included studies are internally valid; in other words, that the results
are a fair reflection of the truth and that the study is free from systematic
errors, or biases, that could lead to either an under- or over-estimation of
effect size. Many tools and scales have been used to assess the quality of
RCTs included in systematic reviews (Moher et al., 1995, Moher et al., 1996),
although many of these also included assessment of the reporting and
methodological quality of studies rather than focussing on methodological
flaws which could introduce bias, which may be considered to be separate
issues. The Cochrane Collaboration places emphasis on assessing the degree
to which potential sources of bias have been avoided in individual studies by
evaluation of the risk of bias using a domain-based risk of bias tool (Table 3),
as even studies which are conducted to the highest possible standard may still
have significant biases if they are methodologically flawed (Higgins and
Green, 2011)
Table 3: Potential sources of bias in RCTs and domains in the Cochrane Collaboration's Risk of Bias
tool which address these (Higgins and Green, 2011)
Source of Bias Domain in risk of bias tool
Selection (systematic differences
between baseline characteristics in
the comparator groups)
Sequence generation (was the
sequence allocation adequately
generated? e.g. random number
generator, coin tossing)
Allocation concealment (could the
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assignment have been foreseen?)
Performance (systematic difference
between the groups in the care
provided)
Blinding of participants, trial
personnel and outcome assessors
(were measures taken to prevent
participants, trial personnel and
outcome assessors having knowledge
of which intervention was allocated?)
Attrition (systematic differences in
study withdrawals between the
groups)
Incomplete outcome data (were
incomplete outcome data addressed
adequately?)
Blinding of participants, trial
personnel and outcome assessors
Detection (systematic differences in
outcome determination between the
groups)
Blinding of participants, trial
personnel and outcome assessors
Reporting (systematic differences
between reported and unreported
findings)
Selective outcome reporting (were
expected and pre-specified primary
and secondary outcomes addressed?)
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3.2.6. The Cochrane Skin Group
First registered in 1997, the Cochrane Skin Group (www.skin.cochrane.org) is
one of 53 Cochrane collaborative review groups whose aim is to produce the
best possible evidence on the effectiveness of healthcare interventions for
people with skin problems by the production and updating of reviews of trials
relating to skin conditions.
The title for this Cochrane systematic review was registered with the
Cochrane Skin Group, who assisted with design of the search strategies and
the editorial process. The protocol for the review was published in the
Cochrane Library prior to publication of the final review (Lansbury et al.,
2009).
3.2.7. Why it was important to do this review
The burden of SCC to both individuals and to the healthcare system is only
likely to grow due to the increased proportion of elderly people in the
population. More than 80% of NMSCs occur in people aged 60 years and
older, and with an increasingly ageing population, a 50% increase in NMSC
workload for UK dermatologists by 2030 has been predicted (Watson and
Torgerson, 2006). Consequently, a consistent and practical approach to the
management of SCC will become imperative in future years.
A variety of treatment methods have been used in the management of SCC,
although there has previously appeared to be a paucity of large randomised
trials that have compared their effectiveness. Several case series have
reported the common treatment modalities (Rowe et al., 1992) and current
SCC management guidelines are largely based on evidence from these
(Motley et al., 2002). There have, however, been no systematic reviews
previously conducted in this area and management guidelines have been
largely based on evidence from treatment of other types of NMSC and case
series. The Cochrane systematic review described in this chapter was a
starting point from which to identify any RCTS that had been done in the field,
to appraise the current evidence base of the effectiveness of different
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treatments from any identified RCTs, to identify where more evidence
appraisal is required, and to help direct researchers towards future research
requirements.
3.2.8. Objective of the review
The objective of this review was to assess the evidence available from RCTs
for the effectiveness of treatments used in the management of cutaneous
SCC.
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Methods3.3
Details of the search strategies for this review may be found in Appendix 1.
MeSH and text words were developed and searched based on the condition
and interventions, and filters developed by the Cochrane Collaboration were
used to identify RCTs.
3.3.1. Types of studies
Published and unpublished RCTs comparing treatments for primary non-
metastatic, invasive SCC were eligible for inclusion in the review.
Observational studies were not included, and these will be discussed
separately in chapter 4 of this thesis.
3.3.2. Types of Participants
Randomised controlled trials were eligible for inclusion in the review if they
included participants of either sex who had one or more histologically proven
primary non-metastatic SCC and who were eligible to be randomised to either
active treatment, placebo or other treatment. Studies which had only
participants with Bowen’s disease and/or actinic keratosis or only
immunosuppressed participants were excluded. Participants were not
included if they had persistent (i.e. a number of treatments had been tried
without success), recurrent or metastatic SCCs. Non-cutaneous SCCs (head
and neck, lung, gastro-intestinal, urinary tract and genital) were also excluded
as these sites require special interventions and a different approach.
3.3.3. Types of interventions
Interventions included:
¾ Surgery
o Excisional surgery
o Mohs micrographic surgery
¾ Destructive treatments
o Curettage and cautery or electrodesiccation
o Cryosurgery
o Photodynamic therapy
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o Laser therapy
o Radiotherapy
¾ Other interventions
o Topical therapy e.g. imiquimod, 5-fluorouracil
o Intralesional treatments e.g. interferon
o Chemotherapy.
Adjuvant treatments in combination with any of the above treatments were
also included. Complementary therapies were not addressed in this review.
3.3.4. Outcomes
Primary outcomes of interest were:
a) Recurrence (time-to-event), one to five years after treatment,
measured clinically at the site of the original tumour, or at the local
lymph nodes, or distant metastasis, after apparently successful initial
treatment
b) quality-of-life.
Secondary outcomes of interest were:
a) early treatment failure within 6 months confirmed histologically;
b) number of adverse events by the end of treatment;
c) cosmetic appearance as assessed by i) the participant, or ii) the
clinician;
d) discomfort to the participant during and after treatment; and
e) death.
3.3.5. Search methods for identification of studies
An electronic search was performed for relevant published trials in the
following databases:
o The Cochrane Skin Group Specialised Register;
o Cochrane Central Register of Controlled Trials (Clinical Trials) in The
Cochrane Library;
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o MEDLINE (from 2005 to 11 February 2010);
o EMBASE (from 2007 to February 2010);
o PsycINFO from inception;
o AMED (Allied and Complementary Medicine) from inception;
o LILACS (Latin American and Caribbean Health Science Information
database) from inception.
In addition I searched the following trials registers for ongoing trials:
o the metaRegister of Controlled Trials (www.controlledtrials.com);
o the US National Institutes of Health ongoing trials registry
(www.clinicaltrials.gov);
o the Australian and New Zealand Clinical Trials Registry
(www.anzctr.org.au);
o the World Health Organisation International Clinical Trials Registry
platform (www.who.int/trialsearch);
o the Ongoing Skin Trials Register
(www.nottingham.ac.uk/ongoingskintrials).
Bibliographies of published studies and key review articles were scanned for
possible references to randomised controlled trials.
Attempts were made to find unpublished studies through correspondence
with key authors publishing in the area.
There were no language restrictions imposed and studies were translated into
English if necessary.
3.3.6. Data collection
Two reviewers checked the titles and abstracts identified from the searches,
and independently assessed the full text of potentially relevant studies to
decide if they met the inclusion criteria. Studies were excluded if it was clear
that they were not RCTs comparing treatments for cutaneous SCC. If it was
unclear whether this was the case then the full paper was obtained for
independent assessment. Any disagreements were resolved by discussion and
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a consensus decision was made. If data was missing from potentially relevant
reports, the trial author was contacted to try to obtain the data.
Data for each study were independently extracted by two reviewers, with
resolution of discrepancies by a third reviewer. Data were checked and
entered into RevMan.
3.3.7. Risk of Bias assessment
A risk of bias assessment was done according to the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins and
Green, 2011) based on the following components:
o the method of generation of the randomisation sequence;
o method of allocation concealment;
o blinding of participants, clinicians and outcome assessors;
o loss of participants to follow-up in each arm and if analysis was on an
intention-to-treat basis
The following were also assessed:
o the degree of certainty that participants had SCC; and
o baseline comparison of the study arms in terms of disease severity.
The results were summarised in a Risk of Bias table.
3.3.8. Data analysis
Time-to-event outcomes were expressed as hazard ratios (HR) with 95%
confidence intervals.
The log hazard ratio and its variance was estimated using a Microsoft Excel
spreadsheet authored by Matthew Sydes (Cancer Division) in collaboration
with the Meta-Analysis Group of the MRC Clinical Trials Unit, London, which is
based on Parmar’s methods (Parmar et al., 1998).
The unit of analysis was randomised participants rather than lesions.
In the protocol for the full review, an intention-to-treat analysis would have
been conducted if participant drop-out lead to missing data, with the last
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recorded value carried forward for participants with missing continuous
outcome data, and for dichotomous outcomes, participants with no recorded
data would be regarded as treatment failures and included in the analysis.
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Results3.4
3.4.1. Search results
Figure 15: Flowchart of studies in the review
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The results of the literature search are summarised in Figure 15. From a total
of 14 studies assessed at full text and 2 ongoing trials, only one study was
eligible for inclusion in the review (Brewster et al., 2007a).
3.4.2. Included study
Characteristics of Included Study
The included RCT (Brewster et al., 2007a) was a single-centre, parallel-group
study from the USA which included 65 evaluable male and female patients
with pathologically-confirmed aggressive skin SCC. The primary outcome was
time to tumour recurrence or development of a second primary tumour. A
total of 31 participants received adjuvant 13-cis-retinoic acid and interferon
alpha after surgical treatment, whereas the 34 participants in the control arm
received no adjuvant chemotherapy after primary surgical treatment.
Characteristics of the included study are shown in Table 4.
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Table 4: Characteristics of included study (Brewster et al., 2007a)
Methods Single Centre
Design: Parallel
Participants Tertiary care, USA
Randomised: 66 (1 withdrew consent immediately after
randomisation)
Evaluable: 65
61 males, 4 females
Age range 34-81 years
Pathologically confirmed aggressive skin SCC exhibiting one of
ĨŽůůŽǁŝŶŐ PƐŝǌĞA? ?ĐŵĚŝĂŵĞƚĞƌ ?ƉĞƌŝŶĞƵƌĂůŝŶǀĂƐŝŽŶ ?ĚĞĞƉ
invasion of muscle, cartilage or bone or fixation to these; proven
regional metastases.
Interventions T1: Adjuvant therapy with 13-cis -retinoic acid (1mg/kg/d orally)
and Interferon alpha (3 x 106U subcutaneously 3 times weekly)
for 6 consecutive months after surgery or radiation therapy.
T2: No adjuvant therapy after surgery or radiation therapy
Outcomes Follow up: complete physical and skin examinations at 3,6,18
and 24 months post-randomisation
Primary end point: Time to tumour recurrence or development
of a second primary tumour.
Secondary end point: quantitative and qualitative toxicity during
 ?ŵŽŶƚŚƐŽĨ ? ?ĐZĂŶĚ/&E ?ɲƚŚĞƌĂƉǇ
Notes 7 patients discontinued prematurely: 1 withdrew consent
immediately after randomisation; 3 lost to follow-up at 7,12 and
18 months; 2 patients died after cardiac arrest (1 in treatment
group 5 months after completing treatment, and 1 in
observation group); 1 patient in intervention group dropped out
because of adverse events after 1 week of adjuvant therapy.
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Risk of Bias in the Included study
Assessment of the risk of bias is summarised in Figure 16.
Figure 16: Diagrammatic representation of risk of bias assessment for included study (Brewster et al.,
2007a)
The randomisation method was described as ‘permuted block randomisation
within strata’ but details about the adequacy of concealment of allocation
were not available. Neither clinicians nor participants were blinded to
allocation due to the nature of the intervention. Analysis of the primary
outcome was carried out on all evaluable participants apart from one who
withdrew consent immediately after randomisation. Histological confirmation
of SCC was obtained for all participants, and there were no clinically relevant
or demographic baseline differences between participants in each trial arm.
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Effects of interventions
Primary outcomes
Time to recurrence
In the one included study, no statistically significant difference in the time to
recurrence was seen between participants who received adjuvant
chemotherapy and those who did not, HR 1.08, 95% CI 0.43 to 2.72 (Figure
17).
Figure 17: Forest plot comparing time to recurrence between 13-cis-retinoic acid plus interferon alpha
treatment arm and control arm
Quality of life
The included trial did not compare QoL between the treatment and control
arm participants.
Secondary outcomes
Adverse events
The most frequently reported adverse events among participants in the
treatment arm of the included trial were dry skin, fatigue and generalised lip
and eye reactions. However, a total number of adverse events could not be
determined, as it was possible that participants may have experienced more
than one adverse event each.
Death
No treatment-related deaths were reported in the included trial. There were
two non-treatment-related deaths during follow-up, one in the treatment
arm and one in the control arm.
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No data were available for the other secondary outcomes of early treatment
failure, aesthetic appearance, and discomfort to participants.
3.4.3. Excluded and Ongoing Studies
Thirteen articles, of which 11 were fully published and 2 were abstracts, were
excluded from the review (Brandt et al, 2007, Cham et al, 1991, Coates et al,
1984, Haas et al., 1976, Healy, 1969, Landthaler and Braun-Falco, 1989, Lui et
al., 2004, Moseley et al, 1976, Medical Research Council, 1976, Perez et al.,
1991, Seyss, 1968, Eedy, 2003, Radny et al, 2006).
Two other trials were also identified, one had just been completed but was
excluded as there were no participants with cutaneous SCC (CHARTWEL trial)
(http://clinicaltrials.gov/show/NCT00021125). No published results were
available at the time from the other ongoing trial (TROG 05.01) which is
comparing post-operative chemo-radiotherapy (carboplatin) with post-
operative radiotherapy alone for high-risk advanced primary or nodal
cutaneous SCC of the head and neck to improve loco-regional relapse.
(www.who.int/trialsearch/trial.aspx?trialid=ACTRN12607000146493). At the
time of writing this study is still recruiting with estimated study completion in
late 2018.
Characteristics of Excluded Studies
Fourteen potentially eligible RCTs were excluded from the review. Three
studies were excluded as there were no participants with invasive SCC (Lui et
al., 2004, Eedy, 2003, Seyss, 1968), and a further three as there was no
specific cutaneous SCC data (Brandt et al, 2007, Coates et al, 1984, Haas et al.,
1976). The remaining studies were excluded for the following reasons: SCC
diagnosis was not confirmed histologically and there was no data on the
distribution of SCCs in the intervention and control groups (Healy, 1969); SCCs
were located only on ineligible subsites (Medical Research Council, 1976); all
SCCs were recurrent or metastatic (Perez et al., 1991); only one eligible
participant had cutaneous SCC (Moseley et al 1976); there were no
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participants with cutaneous SCC in the control group (Cham et al, 1991); it
was not possible to determine from the full-text if the study was randomised
(Landthaler and Braun-Falco, 1989); no information was provided about
included participants and tumours (Radny et al, 2006).
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Discussion3.5
3.5.1. Summary of the evidence
Only one RCT met the inclusion criteria for this systematic review (Brewster et
al., 2007a). However, the risk of bias in the included study was unclear across
several of the domains assessed (Figure 16). The included study compared a
group of patients who received adjuvant treatment with 13-cis-retinoic acid
plus interferon alfa with a group who did not have adjuvant treatment after
initial surgery and/or radiotherapy. There were 65 participants, with no
statistically significant difference between the two groups in terms of time to
recurrence or time to development of second primary tumour. The tumours
included in the study were, by definition, high-risk, aggressive tumours with a
very high risk of an event during the first two years after initial treatment. The
study may have been underpowered to detect a significant difference
between the two groups given the wide confidence intervals around the
hazard ratio, and the trial authors acknowledged that this may limit
interpretation of their results, highlighting the difficulty of accruing a
sufficient number of patients with the aggressive types of SCCs which were
being evaluated in the trial, even from a tertiary centre.
A large number of potential studies were retrieved in the database search.
However, the majority could not be considered for inclusion in the review, as
they were either uncontrolled case series (Chapter 4), or they were RCTs
which only included BCCs or non-invasive SCCs such as actinic keratosis or
Bowen’s disease.
3.5.2. Completeness and applicability of the evidence
This review highlights the paucity of RCT data relating to the management of
non-metastatic cutaneous SCC. Furthermore, the only prospective trials that
have been or are being conducted to date, have addressed the most
aggressive and high-risk types of SCC, rather than those which are considered
to be lower risk. It may be that the perception of cutaneous SCC as a relatively
innocuous tumour which can be easily treated by surgical excision has led to
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the smallest and lowest-risk tumours being largely ignored in prospective
trials and given a low research priority. Nonetheless, if the same argument
were applied to the most common form of NMSC, BCC, one would similarly
expect to see few RCTs for this tumour; this is not the case and there is no
shortage of RCTs comparing treatment modalities for BCC (Bath-Hextall et al.,
2007).
On the other hand, it may be that the more aggressive nature of SCCs and
their propensity to recur and metastasise may result in a reluctance among
researchers to randomise participants to novel treatment arms on ethical
grounds. Also, even though SCC is a common tumour, it displays much
heterogeneity in terms of prognostic features and for the results of a trial to
be externally valid and relevant to people with similar types of SCCs, tumour
characteristics should be taken into account when designing trials. Therefore
the number of eligible SCCs may be limited, and accruing sufficient numbers
of participants to ensure that the study is adequately powered to detect a
significant difference between treatments could be challenging and require a
multi-centre approach.
The review has therefore highlighted the lack of evidence from RCTs
regarding the effectiveness of treatments for non-metastatic SCCs and those
that are less aggressive than the cases assessed in the included trial. It is,
however, the less aggressive SCCs that are most commonly seen in clinical
practice, and for which the evidence base for treatments is currently lacking.
3.5.3. Potential biases in the review process
The systematic literature search and contact with leading experts on the field
of SCC managements makes it unlikely that eligible RCTs have been missed.
Meta-analysis was not possible in this review as there was only one eligible
RCT included.
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3.5.4. Agreement and disagreements with other studies or
reviews
This is the first systematic review that has attempted to assess the evidence
from RCTs for interventions for non-metastatic SCC. Current guidelines on SCC
management are based largely on the evidence from case series (Motley et
al., 2002), and appraisal of this evidence will be discussed in chapter 4 of this
thesis.
3.5.5. Implications for clinical practice
Due to the lack of RCTs, coupled with the limitations (including small sample
size) in the one included trial, it was not possible to make specific
recommendations for clinical practice from this review.
3.5.6. Implications for research
Invasive SCC is a common NMSC, yet its management has not been
investigated in the form of rigorous RCTs to the same extent as BCC or intra-
epithelial neoplasia. Gaps in the evidence base which may be usefully
investigated by future RCTs are discussed later in this thesis (chapters 4 and
5). However, the shocking lack of RCTs revealed in this review has highlighted
an overwhelming need for well-designed randomised studies to compare
treatment modalities for primary SCC in order to provide high-quality
evidence upon which to base clinical decision- making. Below are some
suggestions for items which should be considered when designing future
trials:
x Primary invasive SCCs should be studied separately from other types
of nonmelanoma skin cancers and non-invasive tumours.
x Standardised outcome measures would improve consistency across
studies and make their findings easier to compare.
x Outcomes which should be assessed include 5-year recurrence, quality
of life, safety and tolerability profiles, cosmetic appearance, and cost
implications.
75
x Tumour prognostic features such as diameter, depth, histology and
site should be taken into consideration when designing trials and
analysing the results.
x Studies should be adequately powered and multicentre trials
undertaken if accrual rates are likely to be low.
x The management of the patient with SCC may be multidisciplinary, so
collaboration between specialities should be encouraged.
The management of people at particularly high risk of developing SCC, such as
those who are immunosuppressed or with a predisposing genetic condition,
has not been addressed in this review. It is, however, an important issue, and
an area worthy of separate review.
This Cochrane systematic review only included RCTs. However, it is important
to consider the evidence from study types that are lower in the evidence
hierarchy than RCTs if the current evidence-base of the effectiveness of
treatments is to be fully appraised and to be of use in guiding future clinical
practice and research and in the development of a trial proposal. Therefore,
the next chapter will describe a second systematic review that has been
conducted as part of this research addressing the evidence from
observational studies, which contribute to the overwhelming majority of the
evidence for primary cutaneous SCC.
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CHAPTER 4:
APPRAISAL OF THE
EVIDENCE. A
SYSTEMATIC REVIEW
AND META-ANALYSIS
OF OBSERVATIONAL
STUDIES
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4 APPRAISAL OF THE EVIDENCE: A SYSTEMATIC REVIEW
ANDMETA-ANALYSIS OF OBSERVATIONAL STUDIES
Abstract4.1
Objectives: To assess the effects of treatments for non-metastatic invasive
cutaneous squamous cell carcinoma using evidence from observational
studies, given the paucity of evidence from randomised controlled trials
(RCTs), in order to help focus the research question for a future RCT of SCC
treatments.
Design Systematic review of observational studies.
Data sourcesMedline, Embase, to December 2012 and bibliographies of
published studies.
Eligibility criteria Observational studies of interventions for primary non-
metastatic invasive cutaneous SCC in which recurrence during follow-up,
quality of life, initial response to treatment, adverse events, cosmetic
appearance, or death from disease were reported. Studies were excluded if
data for primary cutaneous SCC was not separable from other data.
Data extraction and analysis Data were extracted independently by two
reviewers. Meta-analysis was performed where appropriate using a random
effects model to estimate the pooled proportion of an event with 95%
confidence intervals.
Results 118 publications were included covering seven treatment modalities.
Pooled estimates of recurrence were lowest after cryotherapy, and curettage
and electrodesiccation (0.8% [95% CI 0.1-2.2; 8 studies], and 1.7% [95% CI 0.5-
3.4; 7 studies]) respectively, but the majority of treated SCCs treated were
small, low-risk lesions. Following Mohs micrographic surgery, the pooled
estimate of local recurrence during variable follow-up periods from 10 studies
was 3.0% (95% CI 2.2-3.9), lower than the pooled average local recurrence of
5.2% (95%CI 2.5-9.1) for standard surgical excision (12 studies), and 6.4%
(95% CI 3.0-11.0) following external radiotherapy (7 studies), although as the
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confidence intervals overlap these differences were not statistically
significant. After an apparently successful initial response to photodynamic
therapy, the pooled average recurrence of 26.4% (95% CI 12.3-43.7) (8
studies) was relatively high. Evidence was limited for laser treatment (1
study), and topical and systemic treatments (mostly single case reports or
small non-comparative series with limited follow-up).
Conclusions A large number of observational studies have been published
that look at many different treatment modalities, but the evidence base for
the effectiveness of interventions is poor. Comparison of outcomes after
different treatment modalities has to be interpreted cautiously due to biases
inherent in the types of study included and lack of head-to-head comparisons
to enable the estimation of relative treatment effect.
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Introduction4.2
4.2.1. Why it was important to do this review
The Cochrane systematic review described in chapter 3 has highlighted that
RCTs that compare the effectiveness of different treatments for cutaneous
squamous cell carcinoma (SCC) simply do not exist. Nonetheless, whilst
searching for RCTs it was apparent that there have been many observational
studies published which describe outcomes after treatment of SCC, and that
these are overwhelmingly case series. Indeed, current management
guidelines for SCC are based predominantly on the evidence from such
studies (Motley et al., 2002). However, observational studies reporting SCC
treatment outcomes have not previously been reviewed systematically
following the principles of systematic reviewing outlined in the previous
chapter of this thesis.
Whilst recognising that observational studies are subject to inherent biases
which will be discussed shortly, there is also much useful information that can
be obtained from them, particularly in an area like this where there are so
many uncertainties. It was therefore vital to systematically assess these
studies, not only to have a wider overview of the SCC treatment evidence
base as it currently stands, but more importantly to provide background
quantitative and qualitative data that will allow for better planning of a
randomised controlled trial, such as information about outcome event rates
and standardisation of interventional techniques .
As the vast majority of studies included in this systematic review were case
series, with a small number of case reports for more anecdotal treatments,
the discussion in this section will focus mainly on case series.
4.2.2. Definition of a case series
A case series is a descriptive study in which a group of patients who have
received a similar intervention are followed over a period of time. There is no
appropriate comparison group.
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4.2.3. Limitations of case series
A key problem with case series is that they lack a comparator group and so
are inherently prone to bias Table 5. Consequently the lack of a comparison
group may make it seem as though there is an association between an
intervention and outcome, when this may not necessarily be the case, and
causal inferences should not be drawn from case series regarding the
relationship between a treatment and an outcome (Kooistra et al., 2009).
Table 5: Potential sources of bias in case series
Potential bias Possible reasons for bias
Selection bias o Patients in series not representative
of the general population e.g.
selected on the basis of the likelihood
of response to intervention
o Non-consecutive patients.
o Retrospective design may decrease
completeness of inclusion, data
collection and follow-up.
Performance bias o Patients in series treated differently
in some way from others e.g. extra
visits.
o Lack of blinding.
Detection bias o Outcomes assessed to favour
intervention
o Lack of blinding.
Reporting bias o Only patients with favourable
outcomes reported
o Lack of blinding
Survival bias o Some patients may not be reported
as having died or did not return for
follow-up due to treatment failure or
success.
o Incomplete follow-up data.
Publication bias o Favourable outcomes more likely to
be reported and published than those
that are negative.
Confounding o A systematic influence beyond the
treatment may influence the
outcome but cannot be adjusted for
in the absence of a control group.
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Unlike RCTs, most case series have no published protocol and are not subject
to the same quality control measures as RCTs, which may make them more
susceptible to data manipulation and fraud (Albrecht and Bigby, 2008).
4.2.4. Strengths of case series
Case series and reports are often regarded as the least methodologically
robust study designs for reasons mentioned above, although well-designed
and reported case series do have a place in furthering medical knowledge
(Kempen, 2011, Kooistra et al., 2009, Black, 1996).
In the absence of RCTs, it may be that the only evidence available is from case
series. There are some circumstances in which it would be considered
inappropriate to conduct an RCT to establish the effectiveness of a treatment,
for example for ‘all-or-nothing’ interventions such as insulin for type 1
diabetes in which all patients would die without administration of the drug, or
the use of penicillin for group A streptococcal infections. Additionally, for a
treatment that is already considered to be clearly effective and accepted into
practice, it may be very difficult to get funding to conduct an RCT to compare
it with an alternative treatment, although if the evidence upon which such
treatments are based is weak then their effectiveness really should be
questioned. The effectiveness and safety of many ‘accepted’ interventions
has been refuted after an RCT was finally conducted, an example being the
use of dexamethasone in patients with cerebral malaria which was introduced
into practice in the 1960s but which was subsequently shown to be
deleterious in these patients (Warrell et al., 1982). Furthermore, ethical
considerations may preclude randomisation of patients with particular
diseases to non-treatment arms, and sometimes it is practically unfeasible to
recruit a sufficient number of participants to adequately power RCTs
evaluating treatment of rare diseases or those in which outcomes are
infrequent, very long-term and for interventions with rare adverse events.
The first indication of rare adverse events or rare outcomes may therefore
come from case series.
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Although causal inferences should not be deduced from case series, they may
provide the initial information that is required in order to generate a
hypothesis that can be tested further through more formalised experimental
designs.
A major perceived advantage of case series over RCTs is their higher external
validity, particularly if they include a diverse range of patients who are not
subject to the often rigorous inclusion and exclusion criteria laid out in
explanatory RCTs, which aim to measure the efficacy of a treatment under
ideal conditions and often use carefully defined subjects. Explanatory RCTs
are in contrast to pragmatic RCTs which assess the effectiveness of
treatments in routine clinical practice and reflect the variations between
patients that occur in real clinical practice with the aim of informing choices
between treatments. However, case series may be favoured by some
clinicians as they are less costly and quicker than RCTs, with clinicians and
patients retaining control over decisions made about treatment (Kooistra et
al., 2009, Audige et al., 2006, Hartz and Marsh, 2003).
Ultimately, the value of a case series, as with all study designs, will depend
upon the quality of its design and the steps that have been taken to minimise
bias when possible, in addition to the quality of the report itself which will
enable healthcare practitioners to judge whether the patients in the series
are comparable with their own patients.
4.2.5. Assessing the quality and risk of bias in case series
Lack of planning, incomplete or inconsistent data collection (for example,
information about prognostic factors) and poor reporting of key diagnostic
and therapeutic details can severely compromise the validity of non-
randomised studies (Ergina et al., 2009).
A key component of any systematic review and meta-analysis is an
assessment of the limitations of the primary studies contained within it,
regardless of the studies’ design, in order that a fair interpretation of the
results may be made. There is a distinction between methodological quality,
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risk of bias and the quality of reporting of the study, and strength or
weakness in one of these components is not necessarily reflected in the
others. For example, a well-executed study may nonetheless have design
flaws which put it at high risk of bias. Similarly a study may theoretically be at
low risk-of bias by virtue of its design, but if it is poorly reported the reader
may not have adequate information to make an informed decision about this
(Huwiler-Muntener et al., 2002).
There are many tools that have been proposed for assessing the quality and
risk of bias in studies that are included in systematic reviews, including scales,
checklists and domain-based evaluations. Many, such as the Jadad score
(Jadad et al., 1996), Delphi list (Verhagen et al., 1998) and Megens-Harris list
(Megens and Harris, 1998) have been designed specifically to appraise
controlled trials. Between 2005 and 2007, collaboration between
methodologists, editors and systematic review authors under the auspices of
the Cochrane Collaboration led to the development of the Cochrane Risk of
Bias tool (Higgins and Green, 2011) which is now well-validated. However,
less attention has been paid to the quality and risk of bias assessment for
observational studies that are included in systematic reviews, and this is an
area where further development is still required. A Health Technology
Assessment found little evidence to support the use of many of the criteria
included in the quality assessment tools they assessed, although none of the
tools they examined were designed specifically for case series or appeared to
be evidence based. It called for further investigation of the relationship
between methodological features of case series and outcomes in view of the
frequency with which case series were being used in Health Technology
Assessments (Dalziel et al., 2005). In an evaluation of non-randomised
intervention studies, Deeks et al (Deeks et al., 2003) identified 194 tools to
assess non-randomised studies, although most were poorly developed and
omitted key quality domains. Six tools were identified as potentially useful for
assessing quality of non-randomised studies in systematic reviews but all
required revision. In a more recent systematic review, Sanderson et al
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reviewed 86 tools for assessing quality in observational studies, of which 41
were checklists, 12 were checklists with additional summary judgement, and
33 were scales (Sanderson et al., 2007). There was a lot of variation between
the number and nature of items, but the review highlighted that there is no
one obvious single tool for assessing the quality of observational studies and
that such tools should be rigorously developed, valid, easy to use and focus
on the assessment of sources of bias.
Tools are currently being developed for assessing non-randomised studies
which are based on the Cochrane Collaboration’s domain-based Risk of Bias
assessment, which are showing moderate reliability, and acceptable feasibility
and validity, although they require further validation and refinement (Kim et
al., 2013, Palmer et al., 2011). Some of the authors developing these tools
would, however, argue that in areas where the quality of studies is regarded
as being low, the added time and complexity of assessing the risk of bias may
not be worthwhile (MacLennan et al., 2011).
The tools that are already in existence or under development are generally applicable to non-
applicable to non-randomised study designs that do have a control group and they have not been
they have not been designed to evaluate case series, for which there are currently no validated
currently no validated quality and risk of bias assessment tools. Therefore, in the absence of a
the absence of a suitable tool, the assessment of study quality and risk of bias in this systematic
in this systematic review is based upon the Cochrane risk of bias assessment tool (Higgins and Green,
tool (Higgins and Green, 2011) which has been modified for the purpose of this review, together with
this review, together with a tool based upon suggestions drawn up by Joerg Albrecht for improving
Albrecht for improving the quality of case series (Williams et al., 2008)(
Table 6 and Table 7). As some of Albrecht’s criteria relate more to the quality
with which the study was reported rather than specifically the risk of bias, for
example they do not address survival bias and information bias relating to
unblinded outcome assessment, the two tools are used together in this
review. Albrecht’s criteria are based on a few published articles (Moses, 1984,
Abel, 1999, Jenicek, 2001) and on Albrecht’s own experience of systematic
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reviews and ethical considerations of case series and reports (Albrecht et al.,
2009a).
These are not validated assessment tools for the purpose of systematically
reviewing of case series, and were used in the absence of any more suitable
tool.
Of importance to note is that assessment of quality of case series can be
severely hampered by poor reporting (Dalziel et al., 2005). In 2007 a group of
researchers, methodologists and editors developed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) statement
which aimed to establish a checklist of items that should be included in
reports of observational studies (Vandenbroucke et al., 2007). This is not
intended as a tool by which the quality of the research should be evaluated,
but as adherence to its principles is now required by the editors of many
leading medical journals, it should make the assessment of quality of
observational research a somewhat easier task in the future.
4.2.6. Objective of this systematic review
The objective of this review was to assess the evidence for SCC treatments
available from studies other than RCTs, in order to help plan for a future trial
addressing the management of cutaneous SCC, to feed into management
guidelines, and to stimulate further research in the field.
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Table 6: Checklist for quality assessment for case series and case reports, based on Albrecht's criteria
(Albrecht et al., 2009b)
Diagnosis Are diagnostic criteria clearly identified
and met by patients in the case series?
Inclusion and exclusion criteria Are inclusion and exclusion criteria clearly
stated?
Selection bias
Informed consent Has patient consent been documented?
For prospective studies, has ethical
approval been documented?
Consecutive cases Are all consecutive cases treated by one
clinician or at one institution included?
Selection bias by reporting selected cases.
Natural course of the disease Is there any reference to the natural course
of the disease, or, if applicable the course
on standard treatment?
Dosages Are the dosage, duration and titration of
the treatment adequately described so that
they are reproducible?
Outcome measures Are the outcomes of the treatment well
defined and clinically relevant?
Patient perception Is there any documentation of the patient’s
perception of the outcome of treatment?
Safety Do the authors describe known risks
associated with the intervention?
Authors conclusions Do the authors abstain from making
unfounded claims about safety and
efficacy?
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Table 7: Modified risk of bias tool for this systematic review (based on (Higgins and Green, 2011)
Domain Description
Blinding (Yes/No/Unclear) Were outcome assessors blinded?
Incomplete outcome data
(Yes/No/Unclear)
Were attrition and exclusions
adequately describes and addressed
?Survival bias
Other potential sources of bias 
retrospective versus prospective
design (Yes/No/Unclear)
Was the study retrospective?
?Selection bias if not all eligible
patients included
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Methods4.3
The systematic review was conducted according to the MOOSE guidance for
meta-analysis of observational studies (Stroup et al., 2000). Details of the
protocol for this systematic review were registered on the PROSPERO
database (International Register of Systematic Reviews) and can be accessed
at www.crd.york.ac.uk/Prospero/display_record.asp?ID=CRD42011001450.
4.3.1. Types of studies
All studies other than RCTS were eligible for inclusion if they reported surgical
excision, Mohs micrographic surgery, radiotherapy (external radiotherapy,
brachytherapy and adjuvant radiotherapy), laser irradiation, photodynamic
therapy, cryotherapy, curettage and electrodesiccation, topical treatments (5-
fluorouracil and imiquimod), or other chemotherapy as treatment of
previously untreated invasive cutaneous SCC, which was non-metastatic at
presentation.
4.3.2. Types of participants
Studies were eligible for inclusion if they included participants of either sex
who had one or more histologically proven primary non-metastatic invasive
SCC. Participants with Bowen’s disease and/or actinic keratosis only were not
eligible for inclusion in the data analysis. Participants were not included if
they had persistent SCC (i.e. a number of treatments had been tried without
success, or their SCC was recurrent and/or metastatic). Non-cutaneous SCCs,
including head and neck, mucosal, lung, gastrointestinal urinary tract and
genital SCCs, were also excluded from this review.
4.3.3. Types of interventions
¾ Surgery
o Excisional surgery
o Mohs micrographic surgery
¾ Destructive treatments
o Curettage and cautery or electrodesiccation
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o Cryosurgery
o Photodynamic therapy
o Laser therapy
o Radiotherapy
 External radiotherapy
 Brachytherapy
 Adjuvant radiotherapy after initial treatment
¾ Other interventions
o Topical therapy e.g. imiquimod, 5-fluorouracil
o Intralesional treatments e.g. interferon
o Chemotherapy
o Other adjuvant therapies
4.3.4. Outcomes
Primary outcomes of interest, based upon those in the Cochrane systematic
review, were :
a) Recurrence during follow-up from 1 month to 10 years after
apparently successful treatment, recorded as being at the site of the
original tumour (local recurrence), or to the regional lymph nodes
(regional recurrence), to distant organs (distant metastases), or
unspecified recurrence.
b) Quality-of-life
Secondary outcomes of interest were:
c) Initial response to treatment
d) Cosmetic appearance of treated area
e) Adverse events related to treatment
f) Death due to disease
4.3.5. Search strategies
The MEDLINE (1948 onwards) and EMBASE (1980 onwards) databases were
searched to December 2012 for relevant studies using search criteria for
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observational studies based on Scottish Intercollegiate Guideline Network
(SIGN) filters (http://www.sign.ac.uk/methodology/filters.html#obs). The
bibliographies of included studies and recent review articles were also
checked for additional articles which were relevant. Due to the large number
of studies and limited accuracy of translation, only studies published in
English were retrieved.
4.3.6. Study Selection and data extraction
Three review authors independently checked the titles and/or abstracts of
studies that potentially met the inclusion criteria. Studies which clearly did
not refer to treatment of SCC of the skin were excluded. The full-text was
obtained for those studies that potentially fulfilled the inclusion criteria or for
which the scope was unclear. Any disagreements were resolved through
discussion between the authors.
Studies were excluded if it was not possible to extract data for primary non
metastatic SCC, for example, those containing data for mixed populations of
SCC and BCCs, previously treated and untreated SCCs, or primary and
metastatic SCCs. Studies in which separate data were not reported for
different treatment modalities were also excluded. Due to the large number
of studies, studies reporting outcomes after surgical excision and Mohs
micrographic surgery were only included if there were 20 or more eligible
participants, unless they were restricted to a specific anatomical location,
such as periorbital or auricular.
Data were extracted independently by two reviewers and entered onto a
standardised, pre-piloted data extraction form for assessment of study quality
and evidence synthesis. A third author resolved any discrepancies.
4.3.7. Quality of reporting and Risk of Bias
As discussed in the introduction, the quality of the reporting of each study
was evaluated , using a self-developed tool based on criteria suggested by
Albrecht for reporting case series and case reports (Williams et al., 2008) and
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on a modified Cochrane Risk of Bias table (Higgins and Green, 2011). Case
series and open-label studies were scored for the number of reporting quality
items present and arbitrarily rated as being of poor (score 0-3), intermediate
(4-7) or good quality (8-10).
For those studies in which pharmaceutical preparations were an integral part
of the treatment modality, we also recorded the declaration of sponsorship
by a pharmaceutical manufacturer.
4.3.8. Data analysis
For each study, raw proportions were calculated using the number of events
divided by the total number of people in the study. The variances of the raw
proportions were stabilised using the Freeman-Tukey variant of the arcsine
square root transformation (Stuart and Ord, 1994). Pooled analyses were
conducted on the transformed quantity using a random effect model, to allow
for heterogeneity resulting from inherent biases within the studies. Analyses
were conducted using StatsDirect Version 2. There was no accepted cut-off
for the I statistic, as it has been argued by Julian Higgins that any level of
heterogeneity is acceptable, provided that the predefined eligibility criteria
for the meta-analysis are sound and that the data are correct (Higgins, 2008).
As there were tight predefined eligibility criteria and recommended methods
were used to ensure the data were correct, it was therefore felt appropriate
to present the results from the meta-analysis as this gives crucial information
regarding likely recurrence across treatments.
It was not possible to directly allow for differences in length of follow-up
using time-to-event as an outcome measure due to lack of such data in the
papers. However, when possible, subgroup analysis was performed with
comparison of the outcomes in those studies in which the mean follow-up
was given as less than 2 years, between 2 and 5 years, and greater than 5
years.
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To examine the effect of removing studies with greatest potential for risk of
bias, a sensitivity analysis was conducted where possible by repeating the
analysis with data from selected papers meeting at least three of the
following criteria: 50 or more SCCs reported; mean follow-up greater than 3
years; recurrence type specified; scoring 8–10 on the reporting quality
assessment.
Adverse events and cosmetic appearance outcomes were described
qualitatively.
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Results4.4
4.4.1. Studies included in this review
The searches identified 3826 publications after removal of duplicates, of
which 451 were potentially eligible based on their titles; on review of the
abstracts 161 records were not relevant to the review. Two hundred and
ninety full-text articles were assessed for eligibility, of which 172 were
excluded, mainly due to lack of separable primary SCC data, leaving 118 which
were included in the review (Figure 18). There were 106 non-comparative
studies, and 12 single case reports, which were included due to a lack of more
robust study designs for particular interventions. Four studies reported
outcomes for more than one treatment modality. (Full details of the studies,
including details of the methodology, types of SCC included, and quality of
reporting are included in the supplemental appendix of the published paper
(Lansbury et al., 2013).
Figure 18: Flow chart of studies
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4.4.2. Risk of Bias in the included studies
A summary of the risk of bias for the studies is presented in Figure 19.
Figure 19: Risk of Bias assessment in the included studies
Forty-eight per cent of studies were evaluated as having a retrospective
design, and 36% as prospective; the remaining studies could not be evaluated
with regard to the design due to the lack of sufficient information reported in
the publications. Overall, 41% of studies were assessed as being at high or
unclear risk of attrition bias due to analyses not accounting for losses to
follow-up. Selection of a specific treatment modality on the basis of tumour
or patient characteristics was assessed as presenting a high risk of bias in 54%
of the studies, with low risk in 15%. Risk of bias relating to selection could not
be assessed in the remaining 31% of included studies due to insufficient
reporting in the publications.
There was no blinding of outcome assessors in any of the included studies.
Overall 13% of the case series were classified as being of poor reporting
quality, 56% as intermediate quality, and 30% as high quality. Of 24 studies in
which topical or systemic treatments were reported, 7 (29%) received some
form of sponsorship from a pharmaceutical company but did not declare that
the sponsor had had no involvement in the design, results and analysis of the
study.
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4.4.3. Surgical excision
There were 12 included studies (1144 patients). Local recurrence during
follow-up after surgical excision ranged from 0% to 15% (Baker et al., 2001,
Rank, 1973, Donaldson et al., 2002, van der Eerden et al., 2010, Nemet et al.,
2006, Reifler and Hornblass, 1986, Shiu et al., 1980, Thomas and Matthews,
1994, Fitzpatrick and Harwood, 1985, Shiffman, 1975, Griffiths et al., 2002,
Pless, 1976), with an estimated overall pooled recurrence of 5.4% (95% CI 2.5
to 9.1, I2=81%) (Figure 20).
Figure 20: Surgical excision - local recurrence proportion meta-analysis plot [random effects]
Duration of follow-up varied between the studies. One study had a mean
follow-up period of less than 2 years (16 months) with local recurrence of
1.8% of surgically excised SCCs of the head and neck region (van der Eerden et
al., 2010). In those studies with mean follow-up of between 2 and 5 years
(736 patients), recurrence ranged from 0% to 13.0%, with a pooled estimate
of recurrence of 5.0% (95% CI 2.3 to 8.3, I2=62%)(Donaldson et al., 2002,
Rank, 1973, Baker et al., 2001, Nemet et al., 2006, Reifler and Hornblass,
1986, Thomas and Matthews, 1994, Fitzpatrick and Harwood, 1985, Shiffman,
0.0 0.1 0.2 0.3 0.4
combined 0.054 (0.025, 0.091)
van der Eerden 2010 0.019 (0.002, 0.065)
Nemet 2006 0.059 (0.016, 0.144)
Donaldson 2002 0.000 (0.000, 0.100)
Griffiths 2002 0.000 (0.000, 0.042)
Baker 2001 0.040 (0.018, 0.074)
Thomas 1994 0.130 (0.054, 0.249)
Reifler 1986 0.083 (0.002, 0.385)
Fitzpatrick 1985 0.048 (0.001, 0.238)
Shiu 1980 0.105 (0.029, 0.248)
Pless 1976 0.153 (0.104, 0.215)
Shiffman 1975 0.065 (0.008, 0.214)
Rank 1973 0.014 (0.004, 0.035)
proportion (95% confidence interval)
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1975). One of the 12 studies had a minimum follow-up period of 5 years and
reported no local recurrences of 86 surgically excised SCCs at various sites
(Griffiths et al., 2002). Three studies reported recurrence of 4.8% for eyelid
SCCs (Fitzpatrick and Harwood, 1985), 10.5% for trunk and extremity SCCs
(Shiu et al., 1980), and 15.3% for SCCs of the pinna (Pless, 1976) but did not
specify for how long patients were followed.
SCCs located in the ear region were associated with highest recurrence rates.
Three studies (N=261) in which SCCs of the pinna were surgically excised gave
a pooled average local recurrence of 14.1% (95% CI 10.2 to 18.5, I2=0%)
(Thomas and Matthews, 1994, Shiffman, 1975, Pless, 1976) , compared with a
significantly lower pooled average of 3.2% (95% CI 1.5 to 5.5, I2=57%) for the
nine studies (N=916) in which SCCs at other sites were included (Figure 21 and
Figure 22) (Baker et al., 2001, Rank, 1973, Donaldson et al., 2002, van der
Eerden et al., 2010, Nemet et al., 2006, Reifler and Hornblass, 1986, Shiu et
al., 1980, Fitzpatrick and Harwood, 1985, Griffiths et al., 2002).
Figure 21: Surgical excision local recurrence ear location proportion meta-analysis plot [random
effects]
0.0 0.1 0.2 0.3
combined 0.141 (0.102, 0.185)
Thomas 1994 0.130 (0.054, 0.249)
Pless 1976 0.153 (0.104, 0.215)
Shiffman 1975 0.065 (0.008, 0.214)
proportion (95% confidence interval)
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Figure 22: Surgical excision local recurrence non-ear location proportion meta-analysis plot [random
effects]
A non-significant tendency for increased local recurrence with increasing SCC
diameter was noted in one series, with local recurrences in 12.2% (95% CI 4.6
to 24.7) of the 49 lesions smaller than 10mm in diameter, 14.3% (95% CI 7.8
to 23.2) of the 91 lesions 10–30mm in diameter, 21.7% (95% CI 7.4 to 43.7) of
23 lesions 30–40mm in diameter, and 42.8% (95%CI 9.9 to 81.6) of the 7
tumours greater than 40mm in diameter (Pless, 1976).
Sensitivity analysis of the four papers meeting the criteria for studies at
lowest risk of bias had no significant effect on local recurrence (4.2% [95% CI
0.6 to 10.8, I281.4%]) (Thomas and Matthews, 1994, Nemet et al., 2006, van
der Eerden et al., 2010, Griffiths et al., 2002).
Recurrence in regional lymph nodes after surgical excision of SCC was
reported in eight series (comprising of 786 patients), ranging from 0% to 9.7%
(Reifler and Hornblass, 1986, Donaldson et al., 2002, van der Eerden et al.,
2010, Baker et al., 2001, Thomas and Matthews, 1994, Pless, 1976, Mourouzis
et al., 2009), with pooled average recurrence of 4.4% (95% CI 2.4 to 6.9,
I2=50%)(Figure 23).
0.0 0.1 0.2 0.3 0.4
combined 0.032 (0.015, 0.055)
van der Eerden 2010 0.019 (0.002, 0.065)
Nemet 2006 0.059 (0.016, 0.144)
Griffiths 2002 0.000 (0.000, 0.042)
Donaldson 2002 0.000 (0.000, 0.100)
Baker 2001 0.040 (0.018, 0.074)
Reifler 1986 0.083 (0.002, 0.385)
Fitzpatrick 1985 0.048 (0.001, 0.238)
Shiu 1980 0.105 (0.029, 0.248)
Rank 1973 0.014 (0.004, 0.035)
proportion (95% confidence interval)
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Figure 23: Surgical excision regional recurrence proportion meta-analysis [random effects]
Sensitivity analysis in which only the three papers considered at lowest risk of
bias were included had no significant effect on regional recurrence (4.6%
[95%CI 1.3 to 10.0, I2=72%] (van der Eerden et al., 2010, Thomas and
Matthews, 1994, Mourouzis et al., 2009).
One study (108 patients) (van der Eerden et al., 2010) had a mean duration of
follow-up of less than 2 years, with 0.1% recurrence (95% CI 0 to 5.1). In four
studies, (Baker et al., 2001, Donaldson et al., 2002, Reifler and Hornblass,
1986, Mourouzis et al., 2009) specified mean duration of follow-up was
between 2 and 5 years with pooled average recurrence of 3.6% (95% CI 1.9 to
5.9, I2=11%). None of the studies had mean follow-up of greater than 5 years,
and in three papers, follow-up duration was either not specified or given as a
broad range (Thomas and Matthews, 1994, Shiffman, 1975, Pless, 1976).
The pooled average regional recurrence in those series in which only SCCs
located around the ear were treated was 7.7% (95% CI 4.8 to 11.2, I2=0%)
(Thomas and Matthews, 1994, Shiffman, 1975, Pless, 1976), which was
substantially greater than the pooled average regional recurrence of 2.9%
(95% CI 1.4 to 5.0, I2=27%) for the five remaining studies which included other
0.0 0.1 0.2 0.3
combined 0.0441 (0.0246, 0.0688)
van der Eerden 2010 0.0093 (0.0002, 0.0505)
Mourouzis 2009 0.0515 (0.0250, 0.0928)
Donaldson 2002 0.0000 (0.0000, 0.1000)
Baker 2001 0.0284 (0.0093, 0.0650)
Thomas 1994 0.0926 (0.0308, 0.2030)
Reifler 1986 0.0000 (0.0000, 0.2646)
Pless 1976 0.0625 (0.0316, 0.1091)
Shiffman 1975 0.0968 (0.0204, 0.2575)
proportion (95% confidence interval)
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head and neck locations (Reifler and Hornblass, 1986, Donaldson et al., 2002,
van der Eerden et al., 2010, Baker et al., 2001, Mourouzis et al., 2009)(Figure
24 and Figure 25).
Figure 24: Surgical excision regional recurrence ear location proportion meta-analysis plot [random
effects]
Figure 25: Surgical excision regional recurrence non-ear location proportion meta-analysis plot
[random effects]
0.0 0.1 0.2 0.3
combined 0.08 (0.05, 0.11)
Thomas 1994 0.09 (0.03, 0.20)
Pless 1976 0.06 (0.03, 0.11)
Shiffman 1975 0.10 (0.02, 0.26)
proportion (95% confidence interval)
0.0 0.1 0.2 0.3
combined 0.0292 (0.0139, 0.0499)
van der Eerden 2010 0.0093 (0.0002, 0.0505)
Mourouzis 2009 0.0515 (0.0250, 0.0928)
Donaldson 2002 0.0000 (0.0000, 0.1000)
Baker 2001 0.0284 (0.0093, 0.0650)
Reifler 1986 0.0000 (0.0000, 0.2646)
proportion (95% confidence interval)
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There were two studies which reported distant metastases after surgical
excision. Of 211 patients with SCCs at various sites who were followed up for
at least a year, only one developed distant metastasis (Knox et al., 1967).
There were no distant metastases in any of 35 patients with periocular SCC
during a mean follow-up period of 31.1 months (Donaldson et al., 2002).
In four articles (comprising 146 patients), recurrence was reported but not
defined as being local, regional or distant. Two of these studies had mean
follow-up periods greater than 5 years, with pooled average recurrence of
5.8% (95% CI 0.7 to 27.6) (Ang et al., 2004, Friedman et al., 1984). There were
no reported recurrences in the study in which mean follow-up was less than 5
years (Werlinger et al., 2002). The fourth study included 13 patients with
stage I or II SCC of the external ear, with a relatively high recurrence of 61.5%
(95% CI 31.6 to 86.1) during follow-up which ranged from 6 months to 20
years (Yoon et al., 1992).
From analysis of eight studies (485 patients) with primary SCC, deaths
attributable to disease ranged from 0% to 8.1% during follow-up, with a
pooled average of 4.1% (95% CI 1.7 to 7.6, I2=58%)(Reifler and Hornblass,
1986, Donaldson et al., 2002, Baker et al., 2001, Thomas and Matthews, 1994,
Shiu et al., 1980, Friedman et al., 1984, Shiffman, 1975, Griffiths et al.,
2002)(Figure 26). Three studies in which the follow-up period was specified as
between 2 and 5 years (Reifler and Hornblass, 1986, Baker et al., 2001,
Donaldson et al., 2002) had a significantly lower pooled average of 0.8% (95%
CI 0 to 2.5, I2=0%), than the two studies with follow-up of more than 5 years
from which the pooled average percentage of patients dying from their
disease was 8.6% (95% CI 4.7 to 13.6)(Friedman et al., 1984, Griffiths et al.,
2002). In three papers, duration of follow-up was not specified or was given
as a range only (Shiu et al., 1980, Thomas and Matthews, 1994, Shiffman,
1975) No deaths were reported in either of the two included studies in which
SCCs of the eyelid were surgically excised (Reifler and Hornblass, 1986,
Donaldson et al., 2002).
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Figure 26: Surgical excision deaths attributable to disease proportion meta-analysis plot [random
effects]
Incompleteness of surgical excision was reported in 11 studies (comprising
2343 excisions). Overall, the pooled average estimate of incomplete excisions
was 8.8% (95% CI 5.3 to 13.0, I2=89%) (Pua et al., 2009, Tan et al., 2007, Baker
et al., 2001, Thomas and Matthews, 1994, Ang et al., 2004, Bovill et al., 2009,
Nemet et al., 2006, Griffiths et al., 2002, Thomas et al., 2003, Bogdanov-
Berezovsky et al., 2005)(Figure 27). Definitions of incomplete excision within
the studies were not consistent, with four studies basing their definition as
the presence of tumour cells at the surgical margin (Bogdanov-Berezovsky et
al., 2005, Pua et al., 2009, Tan et al., 2007, Mourouzis et al., 2009), one study
as the presence of residual tumour at or within 1mm of the lateral or deep
margins of the excised specimen (Ang et al., 2004), one study as tumour
within one microscopic high-power field (0.5mm) (Thomas et al., 2003), and a
further study as the presence of tumour at or ‘close to’ the margin of the
resected specimen (Bovill et al., 2009).
0.0 0.1 0.2 0.3
combined 0.0414 (0.0169, 0.0762)
Griffiths 2002 0.0814 (0.0334, 0.1605)
Donaldson 2002 0.0000 (0.0000, 0.1000)
Baker 2001 0.0057 (0.0001, 0.0312)
Thomas 1994 0.0455 (0.0056, 0.1547)
Reifler 1986 0.0000 (0.0000, 0.2646)
Friedman 1984 0.0794 (0.0263, 0.1756)
Shiu 1980 0.0526 (0.0064, 0.1775)
Shiffman 1975 0.0323 (0.0008, 0.1670)
proportion (95% confidence interval)
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Figure 27: Surgical excision incomplete excision proportion meta-analysis [random effects]
There was variation in the excision margins employed. In one prospective
study, margins of 2mm to more than 10mm were used (Tan et al., 2007), with
6.2% of tumours being incompletely excised (95% CI 4.2 to 8.8). In a further
prospective series in which none of the SCCs were incompletely excised,
excision margins were based on the clinical diagnosis and surgeon’s
preference (Thomas et al., 2003). The other studies assessing incomplete
excision were retrospective reviews and in those in which the excision margin
was specified, margins between 3mm to 6mm were used (Pua et al., 2009,
Ang et al., 2004, Nemet et al., 2006, Mourouzis et al., 2009, Bogdanov-
Berezovsky et al., 2005). The highest percentage of incompletely excised
tumours were observed after excision of periorbital lesions with a 5mm
margin, with 25% being incompletely excised (95% CI 15.3 to 37.0) (Nemet et
al., 2006).
None of the included studies reported SCC specific quality of life, cosmetic
appearance, or adverse event data.
0.0 0.1 0.2 0.3 0.4
combined 0.09 (0.05, 0.13)
Pua 2009 0.00 (0.00, 0.05)
Mourouzis 2009 0.12 (0.08, 0.17)
Bovill 2009 0.18 (0.15, 0.21)
Tan 2007 0.06 (0.04, 0.09)
Nemet 2006 0.25 (0.15, 0.37)
Bogdanov-Berezovsky 2005 0.07 (0.04, 0.10)
Ang 2004 0.16 (0.08, 0.27)
Thomas 2003 0.00 (0.00, 0.13)
Griffiths 2002 0.04 (0.01, 0.11)
Baker 2001 0.07 (0.04, 0.11)
Thomas 1994 0.11 (0.04, 0.23)
proportion (95% confidence interval)
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Summary: Surgical excision
 Twelve studies, mostly retrospective case series of limited quality and
with follow-up periods which varied between studies
 Local recurrence varied due to different time points when assessed, with
average recurrence of 5.4% (95% CI 2.5 to 9.1,12 studies, N=1144)
 Regional recurrence average estimate 4.4% (95% CI 2.4 to 6.9, 8 studies,
N=786)
 Higher rates of local and regional recurrence seen in those treated with
SCC of the ear
 Unspecified recurrence average 5.8% (95% CI 0.7 to 27.6, 2 studies, N=
113)
 Death from disease average 4.1% (95% CI 1.7 to 7.6, 8 studies, N=485)
 Increased proportion of deaths attributable to disease in studies with
follow-up longer than 5 years compared with follow-up between 2 and 5
years 8.6%(95% CI 4.7 to 13.6, 2 studies, N=149) v 0.8% (95% CI 0.1 to 2.5,
3 studies, N=223)
 Incomplete excision average 8.8% (95%CI 5.4 to 13.0, 11 studies, N=2343)
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4.4.4. Mohs Micrographic Surgery
Sixteen studies reported outcomes after MMS. In a seminal series of papers,
Mohs reported 5-year cure rates for previously untreated SCCs of 95.7% for
SCC of the trunk and extremities (Mohs, 1978); 96.6% for the ear (Mohs et al.,
1988); 97.8% for facial, scalp and neck SCCs (Mohs, 1978); 98.5% for eyelid
SCCs (Mohs, 1986); and 98.8% for SCCs of the nose (Mohs, 1978);a pooled 5-
year cure rate 97.4% for the 2133 SCCs at all sites (95% CI 96.2 to 98.3,
I2=48%).
Ten studies reported local recurrence (Anderson, 1982, Pugliano-Mauro and
Goldman, 2010, van der Eerden et al., 2010, Vuyk and Lohuis, 2001, Turner et
al., 2000, Silapunt et al., 2005, Malhotra et al., 2004, Brantsch et al., 2008,
Leibovitch et al., 2005a, Dzubow et al., 1982) , ranging from 0% (95% CI 0 to
36.9) in one small study including eight periorbital SCCs (Anderson, 1982), up
to 5.7% (95% CI1.9 to 12.9) in a study of auricular SCCs (Silapunt et al., 2005).
For the ten studies (comprising 1572 participants), the pooled average local
recurrence was 3.0% (95% CI 2.2 to 3.9, I2=0%) (Figure 28).
Figure 28: MMS local recurrence proportion meta-analysis plot [random effects]
0.0 0.1 0.2 0.3 0.4
combined 0.0299 (0.0221, 0.0389)
van der Eerden 2010 0.0270 (0.0033, 0.0942)
Pugliano-Mauro 2010 0.0130 (0.0027, 0.0375)
Brantsch 2008 0.0293 (0.0174, 0.0459)
Silapunt 2005 0.0575 (0.0189, 0.1290)
Leibovitch 2005 0.0262 (0.0097, 0.0562)
Malhotra 2004 0.0357 (0.0044, 0.1231)
Vuyk 2001 0.0189 (0.0005, 0.1007)
Turner 2000 0.0208 (0.0005, 0.1107)
Dzubow 1982 0.0351 (0.0130, 0.0748)
Anderson 1982 0.0000 (0.0000, 0.3694)
proportion (95% confidence interval)
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Sensitivity analysis, including only the six studies meeting the pre-specified
criteria, had no significant impact on local recurrence (2.7%; 95% CI 1.9 to 3.7,
I2=0%)(Turner et al., 2000, Malhotra et al., 2004, Pugliano-Mauro and
Goldman, 2010, van der Eerden et al., 2010, Brantsch et al., 2008, Leibovitch
et al., 2005a).
Recurrence in the one study with specified mean follow-up of less than 2
years (Dzubow et al., 1982) was 3.5% (95% CI 1.3 to 7.5), which did not differ
significantly from the average recurrence of 2.8% (95% CI 2.0 to 3.9, I2=0%) in
seven studies with mean follow-up of between 2 and 5 years (Anderson,
1982, Pugliano-Mauro and Goldman, 2010, Silapunt et al., 2005, Turner et al.,
2000, van der Eerden et al., 2010, Vuyk and Lohuis, 2001, Brantsch et al.,
2008, Dzubow et al., 1982), and 3.1% (95% CI 1.4 to 5.4) in the two studies
with mean follow-up greater than 5 years (Malhotra et al., 2004, Leibovitch et
al., 2005a).
Six studies reported recurrence in the regional lymph nodes after treatment
with MMS (van der Eerden et al., 2010, Pugliano-Mauro and Goldman, 2010,
Turner et al., 2000, Anderson, 1982, Brantsch et al., 2008, Cherpelis et al.,
2002). On pooled analysis (comprising 1162 patients) the average regional
recurrence was 4.2% (95% CI 2.3 to 6.6, I2=56%; Figure 29). There was no
significant impact on regional recurrence in the sensitivity analysis, which
included only four studies meeting the criteria (Turner et al., 2000, Pugliano-
Mauro and Goldman, 2010, van der Eerden et al., 2010, Brantsch et al., 2008),
with average recurrence of 3.2% (95% CI 1.9 to 5.0, I2=29%).
Specified mean follow-up was between 2 and 5 years in five studies
(Anderson, 1982, Pugliano-Mauro and Goldman, 2010, Turner et al., 2000,
van der Eerden et al., 2010, Brantsch et al., 2008), with pooled regional
recurrence of 3.4% (95% CI 1.8 to 5.3, I2=34%). None of the studies had mean
follow-up greater than 5 years.
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Figure 29: MMS regional recurrence proportion meta-analysis plot [random effects]
One study reported no distant metastases during at least 5 years of follow-up
in 229 patients treated with MMS (Leibovitch et al., 2005a). In a case series of
87 auricular SCCs, no distant metastases were reported during a mean follow-
up period of 34.6 months (Silapunt et al., 2005). One smaller series of 48 SCCs
treated by MMS observed one patient with distant metastasis during a mean
follow–up of 3.4 years (Turner et al., 2000), and a further series including
eight patients with periocular SCC also noted one patient with metastases to
the lung (Anderson, 1982), although the authors presumed that this patient
had subclinical spread of tumour prior to treatment with MMS as there was
no evidence of local recurrence.
Five studies (766 patients) did not define recurrence as being local, regional
or distant (Tomsick and Menn, 1984, Mohs, 1976, Skaria, 2010, Thomas et al.,
2007, Yoon et al., 1992) with a pooled average unspecified recurrence of 4.7%
(95% CI 0.7 to 11.7, I2=81%) (Figure 30). The highest proportion of unspecified
recurrences was seen in a small series of 16 external ear SCCs during follow-
up of between 6 months to 20 years, in which 31% of tumours recurred (95%
CI 11.7 to 58.7)(Yoon et al., 1992).
0.0 0.2 0.4 0.6 0.8
combined 0.0419 (0.0232, 0.0658)
van der Eerden 2010 0.0135 (0.0003, 0.0730)
Pugliano-Mauro 2010 0.0173 (0.0047, 0.0437)
Brantsch 2008 0.0423 (0.0278, 0.0613)
Cherpelis 2002 0.0753 (0.0418, 0.1231)
Turner 2000 0.0417 (0.0051, 0.1425)
Anderson 1982 0.1250 (0.0032, 0.5265)
proportion (95% confidence interval)
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Figure 30 MMS: unspecified recurrence proportion meta-analysis plot [random effects]
Three studies (735 patients) specified mean duration of follow-up as being
between 2 and 5 years (Mohs, 1976, Thomas et al., 2007, Skaria, 2010). For
these studies, the average unspecified recurrence was 2.2% (95% CI 0.3 to
5.4, I2=61%). The remaining studies (Tomsick and Menn, 1984, Yoon et al.,
1992) did not specify the mean duration of follow-up.
Four studies with mean follow-up of between 2 and 5 years reported death
attributable to SCC (Silapunt et al., 2005, Pugliano-Mauro and Goldman, 2010,
Anderson, 1982, Brantsch et al., 2008), with an average of 1.1% (95% CI 0.2 to
2.6, I2=49%) of the 941 eligible patients dying from disease on pooled analysis
(Figure 31). One of the included studies reported a relatively high proportion
of deaths compared to the other studies, which related to a small series of
eight patients with periocular SCCs, one of whom developed regional
metastases and lung metastases without evidence of local recurrence,
indicating that the tumour had spread subclinically prior to treatment
(Anderson, 1982).
None of the included studies reported separate SCC data for quality of life,
cosmetic outcomes or adverse events.
0.0 0.2 0.4 0.6 0.8
combined 0.0470 (0.0077, 0.1173)
Skaria 2010 0.0185 (0.0005, 0.0989)
Thomas 2007 0.0455 (0.0095, 0.1271)
Yoon 1992 0.3125 (0.1102, 0.5866)
Tomsick 1984 0.0000 (0.0000, 0.2180)
Mohs 1976 0.0081 (0.0026, 0.0189)
proportion (95% confidence interval)
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Figure 31: MMS deaths attributable to disease proportion meta-analysis plot [random effects]
Summary: Mohs Micrographic surgery
0.0 0.2 0.4 0.6 0.8
combined 0.0108 (0.0022, 0.0258)
Pugliano-Mauro 2010 0.0043 (0.0001, 0.0239)
Brantsch 2008 0.0146 (0.0067, 0.0276)
Silapunt 2005 0.0000 (0.0000, 0.0415)
Anderson 1982 0.1250 (0.0032, 0.5265)
proportion (95% confidence interval)
 Sixteen case series, 4 prospective and 12 retrospective.
 Local recurrence average 3.0% (95% CI 2.2 to 3.9, 10 studies,
N=1572)
 Regional recurrence average 4.2% (95% CI 2.3 to 6.6, 6 studies,
N=1162)
 Unspecified recurrence average 4.7% (95% CI 0.7 to 11.7, 5 studies,
N=766)
 Death from disease average 1.1% (95% CI 0.2 to 2.6,4 studies,
N=941)
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4.4.5. External radiotherapy
There were 14, mostly retrospective, studies in which a total of 1018 primary
SCCs were treated with external radiotherapy (Stoll et al., 1964, Abbatucci et
al., 1989, Knox et al., 1967, Rank, 1973, Grosch and Lambert, 1979, Podd,
1992, Kwan et al., 2004, Honeycutt and Jansen, 1973, Holmes and Bomford,
1982, Barysch et al., 2012, Shiffman, 1975, Tsao et al., 2002, Matthiesen et al.,
2011, Hunter et al., 1982). Seven studies (comprising 761 patients) reported
local recurrence after external radiotherapy, with pooled average local
recurrence of 6.4% (95% CI 3.0 to 11.0, I2=76%)(Abbatucci et al., 1989, Rank,
1973, Stoll et al., 1964, Podd, 1992, Barysch et al., 2012, Shiffman, 1975, Tsao
et al., 2002) (Figure 32). Three studies were included in the sensitivity analysis
(Abbatucci et al., 1989, Barysch et al., 2012, Tsao et al., 2002), with no
significant effect on local recurrence (7.3%; 95% CI 2.1 to 15.4, I2=87%).
Figure 32: External radiotherapy local recurrence proportion meta-analysis plot [random effects]
From the four studies in which the mean follow-up period was between 2 and
5 years (Abbatucci et al., 1989, Barysch et al., 2012, Rank, 1973, Tsao et al.,
2002) the pooled average recurrence was 6.1% (95% CI 2.2 to 11.7, I2=85%).
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.064 (0.030, 0.110)
Barysch 2012 0.136 (0.089, 0.195)
Tsao 2002 0.065 (0.024, 0.135)
Podd 1992 0.059 (0.001, 0.287)
Abbatucci 1989 0.028 (0.009, 0.064)
Shiffman 1975 0.500 (0.013, 0.987)
Rank 1973 0.030 (0.012, 0.061)
Stoll 1964 0.032 (0.004, 0.112)
proportion (95% confidence interval)
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None of the studies had mean follow-up greater than 5 years, and in three
studies, duration of follow-up was not specified or given as a broad range
(Podd, 1992, Stoll et al., 1964, Shiffman, 1975).
Location in the ear and scalp region was found to be significantly associated
with relapse of tumour compared to other sites (p=0.025) in one study
(Barysch et al., 2012). Age and tumour size were also significantly correlated
with risk of relapse in this study (p=0.012 and p<0.0001 respectively), with a
trend towards better outcome with well-differentiated tumours, although
statistical significance was not reached (p=0.1). Two studies (with 155
patients in total) only assessed nasal SCCs, with a pooled average local
recurrence of 5.6% (95% CI 2.6 to 9.7) (Stoll et al., 1964, Tsao et al., 2002). In a
further two small studies (19 patients) which only included SCCs of the pinna,
the pooled average local recurrence was 20.3% (95% CI 0.0 to 64.6)(Podd,
1992, Shiffman, 1975), although the wide confidence intervals suggest this is
not significantly different from recurrence of nasal SCCs.
Regional lymph node failure was also reported in three studies (comprising
272 patients in total) (Barysch et al., 2012, Shiffman, 1975, Tsao et al., 2002),
giving an average regional recurrence of 2.6% on pooled analysis (95% CI 0.04
to 8.9, I2=70%) (Figure 33). In both larger studies (Barysch et al., 2012, Tsao et
al., 2002), which included patients with SCCs of the nose and at various sites
respectively, the mean duration of follow-up was between 2 and 5 years. In
the third study, there were only two eligible patients with SCC of the pinna,
one of whom developed metastasis (Shiffman, 1975). Excluding this study
from the analysis had little impact on the outcome.
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Figure 33: External radiotherapy regional recurrence proportion meta-analysis plot [random effects]
One study reported loco-regional recurrence after either local radiotherapy
alone, or after local radiotherapy plus radiotherapy to first echelon lymph
nodes (Kwan et al., 2004). Overall recurrence in the 37 SCCs treated with local
radiotherapy alone was 30.0% (95% CI 15.9 to 47.0), ranging from 14.3% (0.3
to 57.9) for the seven tumours classified as T2, to 29.2% (95% CI 12.6 to 51.1)
of the 24 T3 tumours, up to 50% (95% CI 11.8 to 88.2) for the six T4 tumours.
However, with wide overlapping confidence intervals, statistical significance
cannot be inferred from these differences. For the five T4 tumours which
were treated with local radiotherapy plus nodal radiotherapy there was one
(20%) recurrence (95% CI 0.5 to 71.6).
Recurrence was not defined as local, regional or distant in a further six studies
(Holmes and Bomford, 1982, Grosch and Lambert, 1979, Honeycutt and
Jansen, 1973, Knox et al., 1967, Matthiesen et al., 2011, Hunter et al., 1982).
Pooled data from the 220 treated SCCs from the studies gave an average
recurrence of 4.8% (95% CI 0.6 to 12.8, I2=70%; Figure 34).
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.0260 (0.0004, 0.0893)
Barysch 2012 0.0056 (0.0001, 0.0311)
Tsao 2002 0.0215 (0.0026, 0.0755)
Shiffman 1975 0.5000 (0.0126, 0.9874)
proportion (95% confidence interval)
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Figure 34: External radiotherapy unspecified recurrence proportion meta-analysis plot [random
effects]
Two of the studies (Grosch and Lambert, 1979, Matthiesen et al., 2011) had a
mean duration of follow-up of less than 2 years with pooled recurrence of
27.2% (95% CI 2.0 to 89). However, the total number of patients in the two
studies was very small (5), and in one of the studies (Matthiesen et al., 2011),
only T4 tumours were treated with recurrence in two out of three patients.
Average recurrence in the two studies with specified mean duration of follow-
up of between 2 and 5 years was 6.1% (44 patients, 95% CI 0 to
22.6)(Honeycutt and Jansen, 1973, Hunter et al., 1982). There were no studies
in which the mean follow-up period was greater than 5 years, with
unspecified mean follow-up duration on the remaining two studies (Knox et
al., 1967, Holmes and Bomford, 1982).
There were five studies including 191 patients that reported deaths as a result
of SCC (Holmes and Bomford, 1982, Shiffman, 1975, Tsao et al., 2002,
Matthiesen et al., 2011, Hunter et al., 1982), with an average of 9.1% of
patients dying from their disease on pooled analysis (95% CI 1.4 to 22.8,
I2=79%)(Holmes and Bomford, 1982, Hunter et al., 1982, Matthiesen et al.,
2011, Shiffman, 1975, Tsao et al., 2002) (Figure 35). The greatest proportion
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.048 (0.006, 0.128)
Matthiesen 2011 0.667 (0.094, 0.992)
Hunter 1982 0.115 (0.024, 0.302)
Holmes 1982 0.000 (0.000, 0.054)
Grosch 1979 0.000 (0.000, 0.522)
Honeycutt 1973 0.000 (0.000, 0.185)
Knox 1967 0.020 (0.002, 0.070)
proportion (95% confidence interval)
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of deaths was observed in a study of advanced T4 tumours in which two of
three patients with eligible SCCs died (66%, 95% CI 9.4 to 99.1) (Matthiesen et
al., 2011), during a mean follow-up period of 14 months. For studies with
mean duration of follow-up between 2 and 5 years, the average recurrence
was 4.8% (119 patients, 95% CI 1.6 to 9.8) (Tsao et al., 2002, Hunter et al.,
1982). None of the studies had mean duration of follow-up greater than 5
years.
Figure 35: External radiotherapy deaths from disease proportion meta-analysis plot [random effects]
SCC specific data for cosmetic appearance and adverse events was not
available from any of the included studies.
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.091 (0.014, 0.228)
Matthiesen 2011 0.667 (0.094, 0.992)
Tsao 2002 0.032 (0.007, 0.091)
Hunter 1982 0.077 (0.009, 0.251)
Holmes 1982 0.000 (0.000, 0.054)
Shiffman 1975 0.500 (0.013, 0.987)
proportion (95% confidence interval)
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Summary: External radiotherapy
4.4.6. Brachytherapy
Six studies (comprising 88 SCCs) reported recurrence after
brachytherapy(Allan et al., 1998, Rio et al., 2005, Lee et al., 1997, Svoboda et
al., 1995, Ashby et al., 1989a, Guix et al., 2000) (Figure 36), giving a pooled
average local recurrence of 5.2% (95% CI 1.6 to 10.5, I2=0%). Of these, four
were prospective reports (35 SCCs) (Allan et al., 1998, Lee et al., 1997,
Svoboda et al., 1995, Guix et al., 2000) and two (53 SCCs) were retrospective
(Rio et al., 2005, Ashby et al., 1989a), with varying follow-up periods from an
average of 9.6 months (Svoboda et al., 1995) up to a median of 55 months
(Rio et al., 2005).
 One prospective and 13 retrospective series
 Variation between studies for radiation source and length of
follow-up
 Local recurrence average 6.4% (95% CI 3.0 to 11.0, 7 studies,
N=761)
 Regional recurrence average 2.6% (95% CI 0.04 to 8.9, 3 studies,
N=272)
 Unspecified recurrence average 4.8% (95% CI 0.6 to 12.8, 6
studies, N=220)
 Death from disease average 9.1% (95% CI 1.4 to 22.8, 5 studies,
N=191)
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Figure 36: Brachytherapy local recurrence proportion meta-analysis plot [random effects]
Four studies had no recurrences during follow-up (Rio et al., 2005, Lee et al.,
1997, Svoboda et al., 1995, Allan et al., 1998). In the largest study, a
retrospective review in which 48 SCCs at various sites were treated with a
superficial radon mould, there were two local recurrences of hand and scalp
SCCs at 10 and 6 months respectively (Ashby et al., 1989a). The other
reported SCC recurrence occurred 23 months after high dose rate
brachytherapy with a 192Ir surface mould and was a 4cm tumour located on
the frontal area (Guix et al., 2000). No patients in this study developed
regional or distant metastases after treatment.
One study reported that four of 48 (8.3%) SCCs treated with a radon mould
persisted after initial treatment and required treatment by other methods to
ablate the lesions (Ashby et al., 1989a). The study authors attributed their
high failure rate to the inclusion of tumours with a high volume, or in which
the thickness was greater than 4mm, which had been inappropriately treated
by brachytherapy.
0.0 0.2 0.4 0.6 0.8
combined 0.052 (0.016, 0.105)
Rio 2005 0.000 (0.000, 0.522)
Guix 2000 0.056 (0.001, 0.273)
Allan 1998 0.000 (0.000, 0.708)
Lee 1997 0.000 (0.000, 0.708)
Svodoba 1995 0.000 (0.000, 0.285)
Ashby 1989 0.042 (0.005, 0.143)
proportion (95% confidence interval)
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None of the included studies reported on deaths attributable to disease.
Furthermore, SCC-specific data for cosmetic appearance and adverse events
were not available from any of the included studies.
Summary: Brachytherapy
4.4.7. Adjuvant radiotherapy
Nine studies were included in which adjuvant radiotherapy (ART) was used
with surgery to treat previously untreated SCCs which were non-metastatic at
presentation.
ART was administered for PNI in five retrospective studies (comprising 22
patients)(Osguthorpe et al., 1997, Geist et al., 2008, Cottel, 1982,
DeAmbrosis and De'Ambrosis, 2010, Barrett et al., 1993). In one of these
studies (DeAmbrosis and De'Ambrosis, 2010), local recurrence occurred in
two of six patients with asymptomatic PNI in nerve branches of 0.4mm
diameter. All excised SCCs had clear surgical margins of at least 3mm. One of
these patients also had regional metastasis and the other distant metastasis
after treatment. Metastasis to the skull 1 year after treatment was reported
in one patient with symptomatic PNI affecting the supraorbital nerve in a
further series (Cottel, 1982). In the other three studies, two of which included
patients with asymptomatic PNI in unnamed nerves (Barrett et al., 1993, Geist
 Four prospective, two retrospective studies
 Variable methods of application and radiation and generally short
follow-up periods
 Generally small numbers of patients
 Local recurrence average 5.2% (95% CI 1.6 to 10.5, 6 studies,
N=88)
 No regional or distant metastases or deaths attributable to
disease reported
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et al., 2008) and one in which there was involvement of named cranial nerves
(Osguthorpe et al., 1997), there were no reports of recurrence following
treatment during follow-up ranging from 10.4 months to 104.8 months.
Four studies (47 patients) reported outcomes after ART for SCCs other than
those with PNI. These included patients with pinna SCCs , trunk and extremity
SCCs (Lifeso et al., 1990, Shiffman, 1975, Khan et al., 1999, Veness et al.,
1999), and those with aggressive SCCs post cardiothoracic transplant (Veness
et al., 1999). The basis upon which patients were selected to receive ART as
opposed to surgical monotherapy was not clearly identified in any of the
studies. Three of the included studies were retrospective (Veness et al., 1999,
Lifeso et al., 1990, Shiffman, 1975). The fourth was a prospective assessment
of ART to draining lymph nodes in a group of patients with trunk and
extremity SCCs (50% of which developed in an area of erythema-ab-
igne)(Khan et al., 1999). ART was administered to the draining regional lymph
nodes in both included studies of trunk and extremity SCC (Lifeso et al., 1990,
Khan et al., 1999). The irradiation field was not specified in the other studies
(Veness et al., 1999, Shiffman, 1975). Three of the four studies reported
recurrence after treatment during follow-up ranging from less than 1 year to
more than 3 years. Three patients of 26 (12%) developed local recurrence 6–
12 months after treatment in the included prospective study, with regional
recurrence in one patient. No distant metastases were reported during
follow-up of up to 12 months (Khan et al., 1999). Local recurrence was also
reported in two of six patients who developed SCC after cardiothoracic
transplantation, one of whom also developed regional recurrence. A further
patient in this series also had a ‘systemic’ relapse despite local control of their
SCC (Veness et al., 1999).
One study reported two deaths (of four eligible patients) attributable to SCC
at 6 and 11 months post treatment for PNI involving named cranial nerves.
Both patients had intracranial disease extending through a peripheral
foramen but had refused an intracranial operation (Osguthorpe et al., 1997).
No deaths attributable to SCC after ART treatment for PNI were reported in
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any of the remaining three studies (16 patients) (DeAmbrosis and
De'Ambrosis, 2010, Barrett et al., 1993, Geist et al., 2008).
Three studies (comprising 21 patients) addressing ART of other SCCs had data
on patient deaths, with one reporting the death of three patients out of six
who had post cardiothoracic transplant SCCs between 8 months and 54
months after diagnosis (Veness et al., 1999). No deaths were reported in the
other studies (Lifeso et al., 1990, Shiffman, 1975), which included patients
with trunk and extremity SCCs, and those with SCC of the pinna (Pooled data
are presented in Table 8).
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Table 8: Outcomes after adjuvant radiotherapy
Proportion of patients (95% CI), I
2
, Number of patients
Local recurrence Regional recurrence Distant metastases Patient died from disease
Adjuvant radiotherapy for perineural invasion
(Cottel, 1982, Geist et al., 2008, Barrett et al.,
1993, DeAmbrosis and De'Ambrosis, 2010,
Osguthorpe et al., 1997)
18.2% (3.8% to
39.8%), I2= 37%,
n=22
8.3% (1.1% to 21.4%),
I2= 0%, n=22
11.5 (2.4% to 26.1%),
I2= 1%, n=22
11.1% (0.4% to 33.1%),
I2=45%, n=20
Adjuvant radiotherapy for other types of SCC
(Khan et al., 1999, Lifeso and Bull, 1985, Shiffman,
1975, Veness et al., 1999)
11.1% (2.4% to
25.0%), I2= 35%,
n=47
8.5% (2.5% to 17.6%),
I2= 0%, n=47
3.2% (0.1% to 10.4%),
I2= 9%, n=47
13.9% (0.05% to 50.2%), I2=
74%, n=21
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In one study, initial failure of wide local excision and ART to control disease
locally was reported in one patient (of 6) (Veness et al., 1999), who died 15
months after treatment.
Mild erythema, dry and moist desquamation and alopecia of hair-bearing
areas in the irradiated field after ART were the most commonly reported
adverse events in included studies (Barrett et al., 1993, Khan et al., 1999,
Cottel, 1982). Single adverse events recorded were wound infection and
serous otitis media (Barrett et al., 1993), self-limiting mucositis, radiation
dermatitis and residual mild xerostomia (Geist et al., 2008) , and reactive
lymphoedema of the leg (Khan et al., 1999).
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Summary: ART
ART for PNI:
Five small retrospective studies
 Local recurrence average 18.2% (95% CI 3.8 to 39.8, 5 studies, N= 22)
 Regional recurrence average 8.3% (95% CI 1.1 to 21.4, 5 studies, N=22)
 Distant metastasis average 11.5% (95% CI 2.4 to 26.1, 5 studies, N=22)
 Death from disease average 11.1% (95% CI 0.4 to 33.1, 4 studies,
N=20)
ART for other SCCs:
One prospective, three retrospective small studies
 Local recurrence average 11.1% (95% CI 2.4 to 25.0, 4 studies, N=47)
 Regional recurrence average 8.5% (95% CI 2.5 to 17.6, 4 studies, N=47)
 Distant metastasis average 3.2% (95% CI 0.1 to 10.4, 4 studies, N=47)
 Death from disease average 13.9% (95% CI 0.04 to 50.2, 3 studies,
N=21)
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4.4.8. Curettage and electrodesiccation
Only one small retrospective study of 15 patients with SCC of the pinna
described local and regional recurrence separately after treatment by
curettage and electrodesiccation (Shiffman, 1975). Of the 15 patients
included, three had local recurrence (20%), of whom one (7%) developed
regional disease and two died as a result of their disease.
Seven studies (comprising 1131 patients) which included SCCs from various
sites reported on recurrence after curettage and electrodesiccation, but did
not specify the nature of the recurrence (Knox et al., 1967, Honeycutt and
Jansen, 1973, Reschly and Shenefelt, 2010, Tromovitch, 1965, Whiting, 1978,
Williamson and Jackson, 1964, Werlinger et al., 2002). On pooled analysis,
average recurrence was 1.7% (95% CI 0.6 to 3.4, I2=59%) (Figure 37). A
sensitivity analysis was not performed as none of the studies met the criteria
for this (outlined in section 4.3.8).
Figure 37: Curettage and electrodesiccation unspecified recurrence proportion meta-analysis plot
[random effects] (1) triple cycles of CED (2) double cycles of CED
0.0 0.1 0.2 0.3
combined 0.0169 (0.0055, 0.0343)
Reschly 2010 (2) 0.0000 (0.0000, 0.2316)
Reschly 2010 (1) 0.0000 (0.0000, 0.0342)
Werlinger 2002 0.0357 (0.0044, 0.1231)
Whiting 1978 0.0426 (0.0052, 0.1454)
Honeycutt 1973 0.0107 (0.0022, 0.0309)
Knox 1967 0.0018 (4.65E-05, 0.0102)
Tromovitch 1965 0.0345 (0.0009, 0.1776)
Williamson 1964 0.0377 (0.0046, 0.1298)
proportion (95% confidence interval)
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For the two studies (Werlinger et al., 2002, Williamson and Jackson, 1964)
with specified mean follow-up periods between 2 and 5 years, the pooled
recurrence was 4.5% (109 patients, 95% CI 1.4 to 9.0). Just one study
(Tromovitch, 1965) had a mean follow-up of more than 5 years, with
recurrence in 1 of 29 patients (3.4%; 95% CI 0 to 17.8). The remaining studies
did not specify mean duration of follow-up.
Most of the treated SCCs in these series were small, with a total of 91%
having a diameter less than 2cm in the studies in which data about diameter
were provided (Knox et al., 1967, Honeycutt and Jansen, 1973, Reschly and
Shenefelt, 2010, Williamson and Jackson, 1964). Increased lesion size as a
significant prognostic feature was observed in one study; recurrence in the
17 SCCs larger than 2cm was 11.8% (95% CI 1.4 to 36.4) compared with 0.4%
(95% CI 0.0 to 2.1) in the 264 SCCs smaller than 2cm (Honeycutt and Jansen,
1973). One study separated results according to the number of treatment
cycles used with no recurrences after either two or three cycles (Reschly and
Shenefelt, 2010). Two studies specified the number of cycles of
electrodesiccation as either double (Tromovitch, 1965), or triple (Whiting,
1978) but this information was not reported for the remaining studies.
Cosmetic outcome was reported in just one of the included studies (41
patients) (Whiting, 1978), and rated as 'good' in 29% of SCCs, 'satisfactory' in
54% or 'poor' in 17%, although no definition of each of these terms was
provided and it was unclear how soon after treatment the assessment of
cosmesis was made.
None of the included studies reported adverse event data.
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Summary: curettage and electrodesiccation
4.4.9. Cryotherapy
There were eight studies (comprising 273 patients) that described recurrence
after cryotherapy (Kuflik, 2004, Fraunfelder et al., 1980, Kuflik, 1986, Fontana
and Muti, 1975, Nordin and Stenquist, 2002, Peikert, 2011, Lindemalm-
Lundstam and Dalenback, 2009, Holt, 1988). Only one of these reported a
case of recurrence after cryotherapy (Holt, 1988), from a study population of
34 patients with SCCs at any site who were treated with a double freeze-thaw
cycle using liquid nitrogen. Data from the 273 patients in the eight studies
gave a pooled average recurrence of 0.8% (95% CI 0.1 to 2.2, I2=0% (See
Figure 38). Sensitivity analysis was not conducted as only one study met the
pre-specified criteria outlined in section 4.3.8 (Lindemalm-Lundstam and
Dalenback, 2009), with no reported recurrences (53 patients; 95% CI 0 to 6.7).
 Eight retrospective series of variable follow-up periods
 Treated SCCs mostly <2cm diameter
 Unspecified recurrence average 1.7% (95% CI 0.5 to 3.4, 7
studies, N=1131)
 20% recurrence after curettage and electrodesiccation of pinna
SCC (1 study, N=20)
 Lesion size >2cm significantly greater average recurrence than
those <2cm: 11.8% (95% CI 1.4 to 36.4, 17 SCCs) versus 0.4%
(95% CI 0.0.0 to 2.1, 264 SCCs, 1 study)
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Figure 38: Cryotherapy unspecified recurrence proportion meta-analysis plot [random effects]
In five studies (Fontana and Muti, 1975, Fraunfelder et al., 1980, Kuflik, 2004,
Lindemalm-Lundstam and Dalenback, 2009, Peikert, 2011) the mean duration
of follow-up was between 2 and 5 years, with pooled average recurrence of
0.4% (221 patients; 95% CI 0 to 1.7, I2=0%). None had mean follow-up of
greater than 5 years, and for three studies (Holt, 1988, Kuflik, 1986, Nordin
and Stenquist, 2002) follow-up was given as a range only.
An overall cure rate of 97% was reported after either a single or double
freeze-thaw cycle with liquid nitrogen in a retrospective series of 563 SCCs at
any site which were treated over a 23-year period (Graham and Clark, 1990).
The authors did not define ‘cure’, so this rate may include lesions which failed
to respond to the initial treatment in addition to those which recurred. The
duration of follow-up was not specified.
Failure to respond to initial treatment was reported in one patient of 34 (3%)
in one prospective series (Holt, 1988). A double freeze-thaw cycle was used to
treat the original SCC, a 5mm lesion on the scalp, which showed little clinical
response despite a second course of cryotherapy 2 months after the initial
treatment.
0.0 0.2 0.4 0.6 0.8
combined 0.0079 (0.0009, 0.0216)
Peikert 2011 0.0000 (0.0000, 0.4593)
Lindemalm-Lundstam 2009 0.0000 (0.0000, 0.0672)
Kuflik 2004 0.0000 (0.0000, 0.0272)
Nordin 2002 0.0000 (0.0000, 0.2471)
Holt 1988 0.0294 (0.0007, 0.1533)
Kuflik 1986 0.0000 (0.0000, 0.5218)
Fraunfelder 1980 0.0000 (0.0000, 0.1611)
Fontana 1975 0.0000 (0.0000, 0.4096)
proportion (95% confidence interval)
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None of the studies in which cosmetic appearance and adverse events were
reported separated results obtained for SCCs and BCCs treated by
cryotherapy, but presented results for NMSCs as a whole.
Summary: cryotherapy
4.4.10.Photodynamic therapy
There were 14 small prospective studies (comprising 297 patients) which
evaluated the response of SCCs to PDT (Lui et al., 1995, Baptista et al., 2006,
Calzavara-Pinton, 1995, Fink-Puches et al., 1998, Ziolkowski et al., 2004,
Calzavara-Pinton et al., 2008, Haddad et al., 2004, Fritsch et al., 1998, Harth et
al., 1998, Pennington et al., 1988, Wolf et al., 1993, Feyh et al., 1990, Kubler
et al., 1999, Kennedy et al., 1990). Three studies separated SCCs according to
level or depth of invasion (Calzavara-Pinton, 1995, Calzavara-Pinton et al.,
2008, Kennedy et al., 1990), and one was a non-randomised two- arm
comparison of topical PDT either with or without a 5% glycolic acid
penetration enhancer (Ziolkowski et al., 2004). On pooled analysis, an average
of 72.0% of treated lesions appeared to respond completely to treatment
(95% CI 61.5 to 81.4, I2=71%) (Figure 39). Five studies specified that
histological assessment of at least some of the treated areas was done to
confirm apparent clinical response (Calzavara-Pinton, 1995, Kubler et al.,
1999, Lui et al., 1995, Pennington et al., 1988, Feyh et al., 1990).
In eight of the included studies, SCCs that had apparently completely
responded to PDT initially were observed for recurrence (Baptista et al., 2006,
 Six prospective, three retrospective series with variable follow-up
periods
 Mostly <2cm diameter, low-risk lesions
 Recurrence average 0.8% (95% CI 0.1 to 2.2, 8 studies, N=273)
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Calzavara-Pinton, 1995, Calzavara-Pinton et al., 2008, Fink-Puches et al., 1998,
Pennington et al., 1988, Wolf et al., 1993, Feyh et al., 1990, Kubler et al.,
1999). Pooled recurrence data from these studies (119 SCCs) gave an odds of
recurrence of 26.4% (95% CI 12.3 to 43.7, I2=72%) (Figure 40). Mean duration
of follow-up ranged from 6 months (at which time the trial was abandoned
due to recurrence in more than 50% of lesions) (Pennington et al., 1988), to
38 months (Baptista et al., 2006).
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Figure 39: PDT apparent complete response proportion meta-analysis plot [random effects]
(1) elevated (2) early invasive (3) nodular (4) superficial (5) no glycolic acid (6) plus glycolic acid
(7) invasive (8) microinvasive
0.00 0.25 0.50 0.75 1.00
combined 0.720 (0.669, 0.768)
Calzavara-Pinton 2008(8) 0.800 (0.644, 0.909)
Calzavara-Pinton 2008(7) 0.452 (0.273, 0.640)
Baptista 2006 0.250 (0.006, 0.806)
Ziolkowski 2004 (6) 1.000 (0.735, 1.000)
Ziolkowski 2004 (5) 0.636 (0.308, 0.891)
Haddad 2004 0.744 (0.588, 0.865)
Kubler 1999 1.000 (0.664, 1.000)
Harth 1998 0.800 (0.284, 0.995)
Fritsch 1998 0.750 (0.578, 0.879)
Fink-Puches 1998 0.543 (0.366, 0.712)
Lui 1995 0.000 (0.000, 0.842)
Calzavara-Pinton 1995 (4) 0.833 (0.516, 0.979)
Calzavara-Pinton 1995 (3) 0.500 (0.118, 0.882)
Wolf 1993 0.833 (0.359, 0.996)
Kennedy 1990 (2) 1.000 (0.541, 1.000)
Kennedy 1990 (1) 0.000 (0.000, 0.842)
Feyh 1990 1.000 (0.478, 1.000)
Pennington 1988 0.813 (0.636, 0.928)
proportion (95% confidence interval)
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Figure 40: PDT recurrence after apparent complete response proportion meta-analysis plot [random
effects] (1) superficial (2) nodular (3) microinvasive (4) invasive
One study evaluated cosmetic appearance on a scale of 1 to 4 (excellent to
poor) at two time points (3 months and 24 months) after treatment
(Calzavara-Pinton et al., 2008), with high agreement between patient and
investigator scores for both. At 3 months, 4% of 46 treated microinvasive
(Clark level II) and invasive (Clark level III/IV) SCCs were assessed as having
‘excellent’ cosmetic appearance, with 48% ‘good’, 44% ‘fair’ and 4% ‘poor’. By
24 months, of 31 assessable treated lesions, 6% were rated as being of
‘excellent’ cosmetic appearance, 36% ‘good’, 48% ‘fair’ and 10% ‘poor’.
Tumour thickness, depth of dermal penetration and the degree of cell atypia
were found by the authors to be univariate predictors of outcome (Kruskal-
Wallis test p<0.01). One smaller study also evaluated cosmetic appearance on
a scale of 1 (very good) to 4 (poor), with five (55.6%, 9 patients) treated
lesions being assessed as having very good appearance, 3 (33%) as good, and
1 (11%) as fair (Kubler et al., 1999). None were deemed have poor
appearance in this study. Two further studies described ‘very satisfactory
cosmetic results’ (Ziolkowski et al., 2004), or ‘very good’ with no scar
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.26 (0.12, 0.44)
Calzavara-Pinton 2008 (4) 0.43 (0.18, 0.71)
Calzavara-Pinton 2008 (3) 0.28 (0.14, 0.47)
Baptista 2006 0.00 (0.00, 0.98)
Kubler 1999 0.00 (0.00, 0.34)
Fink-Puches 1998 0.69 (0.41, 0.89)
Calzavara-Pinton 1995 (2) 0.50 (0.01, 0.99)
Calzavara-Pinton 1995 (1) 0.00 (0.00, 0.71)
Wolf 1993 0.00 (0.00, 0.52)
Feyh 1990 0.00 (0.00, 0.52)
Pennington 1988 0.50 (0.32, 0.68)
proportion (95% confidence interval)
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formation and only transient residual hypo- or hyperpigmentation (Baptista et
al., 2006).
None of the studies in which adverse events were reported separated results
obtained for SCCs and BCCs treated by PDT, but presented results for NMSCs
as a whole.
Summary: PDT
4.4.11.Treatments with less robust data
Laser therapy
One retrospective study examined the treatment of 86 facial SCCs (excluding
eyelid carcinomas) with neodymium laser irradiation at a total dose ranging
from 118 to 3520J (Moskalik et al., 2010). Patients were followed for a mean
follow-up period of 8.2 years (range 5-11 years). Of a total of 3275 patients
(all NMSCs) treated by neodymium laser during the study inclusion period,
438 (14%) were not followed up during the first 5 years. Overall, there were
four recurrences in the remaining 86 SCC patients (4.6%). Of the 48 tumours
smaller than 1cm in diameter, one recurred (2.1%, 95% CI 0.05 to 11.1),
compared with 6.4% of the 31 tumours between 1 and 2 centimetres (95% CI
0.8 to 21.4), and 14.2% (95% CI 0.4 to 57.9) for the seven SCCs greater than
2cm in diameter, but with wide and overlapping confidence intervals these
differences were not statistically significant.
x Fourteen small prospective case series
x Histological confirmation of apparent initial clinical response
sought in 5 of 14 studies
x Follow-up for recurrence in eight of 14 studies
x Apparent initial complete response average 72.0% (95% CI 61.5
to 81.4, 14 studies, N=297)
x Recurrence after apparent initial complete response average
26.4% (95% CI 12.3 to 43.7, 8 studies, N=119)
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Death from disease was not reported in this study.
One year post treatment, 65% of treated areas was assessed as having 'good'
cosmetic appearance (lesion not visible) and 35% as 'acceptable' (slightly
visible scarring, redness or depigmentation) by a clinician. By the third year of
follow-up, 74% of areas were graded as having good appearance, and the
remainder were acceptable.
Most of the observed effects in this study occurred in the first few days post-
irradiation, most commonly reactive hyperaemia, oedema and slight soreness
which were mild in severity and transient. No systemic adverse events were
noted.
Topical Imiquimod
There were nine papers reporting the use of topical Imiquimod to treat SCCs
eligible for this review. There was one prospective case series which included
three patients with four SCCs (Peris et al., 2006), one retrospective case series
in which there was one eligible patient with SCC (Ross et al., 2010), and the
remainder were case reports of one or two patients (Eklind et al., 2003, Florez
et al., 2004, Konstantopoulou et al., 2006, Martin-Garcia, 2005, Nouri et al.,
2003, Oster-Schmidt and Dirschka, 2005, Oster-Schmidt, 2004).
Outcomes after treatment for these studies are summarised in Table 9.
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Table 9: Outcomes after imiquimod
Study Type of study
(N=eligible
patients)
Dose Initial response Follow-up Recurrence Adverse events Cosmesis
Peris 2006 Open-label trial (3
patients/4 SCCs
(temple, inner
canthus,
leg,forehead), all
unsuitable surgical
candidates)
Od/5x per wk/ 8-
12 wks
4/4 complete
clinical regression.
No histologically
evidence tumour on
post-treatment
biopsies.
Mean 25
months
(24-27)
None Erythema (3/3); erosion
(2/3); pruritus (3/3);
burning (1/3);
hypopigmentation (1/3);
ulceration (1/3). No
systemic AEs.
-
Ross 2010 Retrospective case
series (1 SCC of
upper eyelid)
5x/week initially,
decreased to
2x/wk due to
irritation and
chemical
conjunctivitis
Complete clinical
regression at 3
months (not
confirmed
histologically)
6 months None in 6 months Skin irritation and
chemical conjunctivitis
resolved when frequency
of application decreased
-
Eklind 2003 Case reports (2
renal transplant
patients  temple
and sternum)
Self-applied 3x
per wk/12 weeks
Pt 1. No evidence of
SCC on 6 month
biopsy
Pt 2. Free of
cancer at 8 months
6 and 8
months
None at 6/8
months
Pt 1. Some scaling and
scar at initial site at 16
weeks.
Pt 2. Encrusted and
inflammatory erythema
5 wks post treatment.
Erythema at week 12
gradually subsiding
-
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Florez 2004 Case report (SCC of
leg, surgery
refused)
Under occlusion
every other day
for 8 hours/8
weeks
No histological
evidence of SCC in
excised residual
papule at 2 months
12 months None Local erythema,
superficial erosive
changes, discomfort. No
systemic AEs.
-
Konstantopoulou 2006 Case report (1
patient/3 SCCs foot
and lower leg,
surgery refused,
radiotherapy
considered poor
option)
3x per week for 8-
12 hours initially
then increased to
5x per week/19
weeks or no
clinical evidence
of residual tumour
at sites showing
response
Complete clinical
response in 2/3
SCCs at 2 weeks
with no histological
evidence of invasive
SCC on biopsy.
One SCC failed to
respond (excised)
16 months No recurrence in
2 SCC showing
complete
response initially
- -
Martin-Garcia 2005 Case report (nasal
SCC, surgery
refused)
Daily/2 weeks
then 5x/week.
Total duration 12
weeks
Complete clinical
disappearance
confirmed
histologically 2
weeks post
treatment
1 year No local or
regional
recurrence
- -
Nouri 2003 Case report
(invasive superficial
SCC of nasal tip,
other treatments
refused)
Self-applied od/6
weeks total (2
week break due to
irritation)
No visible or
histological SCC 1
month post
treatment
4 weeks - Irritation and crusting
midway through
treatment necessitating
treatment break. No
visible erythema post
treatment.
Cosmetically
pleasing - no
fibrosis, scarring,
discolouration,
residual erythema
Oster-Schmidt 2004 Case reports (2
patients with ear
Od/5x per week
for 2 weeks
Histological
clearance on 3
21 months
and 8
No clinical
evidence of
No AEs reported Remarkable
improved cosmetic
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lobe and upper leg
SCCs unsuitable for
surgery)
months post
treatment biopsy
for both SCCs
months recurrence at 21
months or 8
months (patient
died of unrelated
cause)
result
Oster-Schmidt 2005 Case report (1
patient, SCC of
back of hand, other
treatments
refused)
o.d. for 4 weeks
initially, repeated
at 6 months
Histological
clearance 4 weeks
after initial course
4 years No recurrence Oedema and mild
burning. No systemic
AEs.
Excellent
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Post-treatment complete response was observed in all patients in eight of the
studies (comprising 12 patients)(Peris et al., 2006, Ross et al., 2010, Eklind et
al., 2003, Florez et al., 2004, Martin-Garcia, 2005, Nouri et al., 2003, Oster-
Schmidt, 2004, Oster-Schmidt and Dirschka, 2005) with histological
confirmation of clearance in all but one study (Ross et al., 2010). One case
report of topical Imiquimod use observed no response in one of three foot
and lower leg SCCs in the same patient(Konstantopoulou et al., 2006). All the
studies apart from one (Nouri et al., 2003) followed patients for recurrence
for varying periods ranging from 6 months to 4 years, with no reported
recurrences. None of the studies reported on deaths attributable to disease.
Skin irritation was commonly reported (Peris et al., 2006, Ross et al., 2010,
Eklind et al., 2003, Florez et al., 2004, Nouri et al., 2003, Oster-Schmidt and
Dirschka, 2005), with chemical conjunctivitis reported in one patient with
periocular SCC (Ross et al., 2010) No systemic adverse events were reported.
5-Fluorouracil (5-FU)
There were four studies in which single agent 5-fluorouracil was used to treat
eligible SCCs, two of which related to intralesional treatment (Kraus et al.,
1998b, Morse et al., 2003) and two to topical administration of 5-FU
(Hamouda et al., 2001, Litwin et al., 1972) (Table 10).
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Table 10: Studies and outcomes with 5-fluorouracil
Study Type of study
(N=eligible
patients)
Dose Initial response Follow-up Recurrence Adverse events Cosmesis
Intralesional 5-FU
Kraus 1998 Prospective
multi-centre open
label pilot (23
evaluable
patients with
SCCs confined to
upper half of
reticular dermis)
Intratumoral
FU/epinephrine at 1ml
(30mg)/lesion/week at
weekly intervals for up
to 6 treatments. Mean
cumulative dose 3.7ml
(0.6-6ml)
22/23 histologically
confirmed clearance
16 weeks
(treated
area )complet
ely excised
- 19/23 (82.6%)
superficial erosions,
9/23 (39.1%) necrosis,
clearing several weeks
after last treatment.
Localised temporary
alopecia around
treated scalp lesions
No clinically sig
systemic reactions or
AEs
Clinician assessed  91%
good to excellent.
Patient assessed  100%
good to excellent
Morse 2003 Case report, SCC
nasolabial fold
Intralesional 5-FU. 0.8-
2.4ml once per week
for 8 weeks. Total dose
12.8ml
No residual SCC after
8th injection
5 months None - -
Topical 5-FU
Hamouda
2001
Prospective
cohort of XP
patients with
multiple facial
SCCs (N=10)
BD topical application.
Mean treatment
duration 6 months (2-
36)
7/10 superficial
regression.
Of 5 patients biopsied
post-treatment, 1
had no residual
tumour, 4 had
persistent tumour in
deep dermal layer
Every 2
months. Mean
not specified
- Well tolerated, some
cases of pruritus with
erythema
8/10 crust disappearance
and tumour decrease.
4/10 improved QoL
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Litwin 1972 Prospective
cohort (33
patients with 53
SCCs)
Topical 5-FU (5%,10%
or 20%), od or bd. Av
treatment time 10.2
weeks (5-37). 79.2%
had 1 course, 17% 2
courses, 3.8% 3
courses
42/53 (79%)
complete post-
treatment regression
(64% confirmed
histologically). 8/53
(15%) partial
regression.
3/53 (6%)
progression of SCC
Average 23.2
months (3-48)
None in those
free of disease
at least 1 year
after completion
of treatment
Pain in lesions
overlying cartilage
-
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There was one prospective multi-centre pilot study (23 patients) which
evaluated intratumoral 5-FU, with histologically confirmed clearance in 22
patients (96%) 16 weeks post treatment (Kraus et al., 1998b). Recurrence was
not assessed. A case report of intralesional 5-FU reported no recurrence 5
months after treatment (Morse et al., 2003).
One series of 33 patients with 53 SCCs reported complete post-treatment
regression of tumour in 42 SCCs (79%) treated with up to three courses of 5%,
10% or 20% topical 5-FU, of which 27 (64%) were confirmed histologically.
The remaining SCCs regressed partially (15%) or progressed (6%). No
recurrences were observed in those who were disease-free at least 1 year
after treatment (Litwin et al., 1972). Another series which only included
patients with xeroderma pigmentosum reported superficial regression in 7 of
10 patients with multiple SCCs, although the number of lesions assessed was
not specified. Residual tumour remained in the deep dermal layer in 4 of 5
patients biopsied and recurrence was not assessed. Four of the ten patients
reported improved quality of life, although this was not formally assessed
(Hamouda et al., 2001).
None of the studies reported deaths attributable to SCC.
Cosmetic outcome was reported in one study of intralesional 5-FU, with
physicians rating cosmetic outcome as good to excellent in 91% of cases,
slightly lower than the 100% good to excellent rating of patients (Kraus et al.,
1998b). This study reported superficial erosions in 19 of the 23 (83%) patients,
and necrosis in 9 (39%), which cleared after several weeks, plus local
temporary alopecia around scalp lesions. No systemic adverse events were
noted in any of the studies.
Interferon
There were four case series that reported outcomes after intralesional
administration of interferon at varying total doses (Edwards et al., 1992,
Wickramasinghe et al., 1989, Ikic et al., 1995), (Kim et al., 2004), the details of
which are summarised in Table 11.
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Table 11: Studies and outcomes after interferon
Study Type of study
(N=eligible
patients)
Dose Initial response Follow-up Recurrence Adverse events Cosmesis
Edwards 1992 Prospective
multicentre open
label trial, 27 SCCs
in actinically
damaged skin
Intralesional IFN-alfa-2b, as
many injections of 1.5 million
units as required to blanch
tumour & small margin of
normal looking skin 3x per
week/9 treatments
24/27 (88.9%)
histological clearance
18 weeks (site
excised)
- 65% (of all 48 in trial)
had >1 AE  myalgias,
headache, fever.
Rigors, flu-like
symptoms.
10% severe AE
causing interruption of
daily activity but none
dangerous or long-
lasting.
14.6% mildly Ĺ LFTs.
6.2% Ļ granulocyte
count.
4.2% Ļ platelet count
Patient assessed:
76.9% excellent,
15.4% very good,
3.8% good, 3.8%
satisfactory, 0%
poor.
Clinician assessed:
76.9% excellent,
15.4% very good,
7.7% good, 0%
satisfactory, 0%
poor.
Wickramasing
he 1989
Prospective series,
3 patients with SCC,
lower leg
Intralesional recombinant
,)1Į2 0.9 million units 3x
per week/3 weeks
3/3 Complete clinical
response confirmed
histologically
3 months - Transient local
discomfort at site.
Depressive mood in 1
of total of 19 patients
in series
-
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Ikic 1995 Retrospective (?)
series, 28 patients
with eligible SCCs
a) Human natural leucocyte
IFN (HNLI) 400,000-1.2
million units/12-13
applications/3-6 weeks. Total
5.6-21.6 million units
or
E5HFRPELQDQW,)1Į2c (rIFN)
2-5 million units/20
applications/4 weeks. Total
40-100 million units.
a) Complete
response in 32 of 52
patients (all SCCs in
series). Unclear if
remainder were
partial/non
responders and what
became of them.
b) Initial response not
reported for rIFN
treated
Unclear a) 1/24 (ear
SCC at 4 years)
b) 0/4 over 3-7
years
- -
Kim 2004 Case series
including 1 patient
with ear SCC
,QWUDOHVLRQDO,)1Į2b 2 million
units/3x per week/3 weeks.
Total 18 million units
- 23 months No recurrence Influenza-like
symptoms, short-term
neurologic effects
(dizziness,
parasthaesia,
weakness, confusion,
dysarthria, short-term
memory loss.
Depression at higher
doses, transiently
elevated LFTs,
reversible dose-
related bone marrow
suppression.
-
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The largest prospective multi-centre series reported histologically confirmed
clearance in 24 of 27 (89%) SCCs in actinically damaged skin, but did not
assess recurrence as the site was excised after 18 weeks (Edwards et al.,
1992). A small prospective series observed histologically confirmed clearance
at 3 months in all three included patients with lower leg SCCs, but again
recurrence was not assessed (Wickramasinghe et al., 1989). One case series
(Ikic et al., 1995) reported recurrence of an ear SCC 4 years after treatment
with human natural leucocyte IFN in one of 24 patients, although it was
unclear how many patients had appeared to respond initially to treatment
and what became of those who failed to show a complete response. No
recurrence was seen after 23 months in the one patient with an ear SCC who
was included in a series of NMSCs treated with intralesional IFN (Kim et al.,
2004).
None of the included studies reported on deaths attributable to SCC.
One study evaluated cosmetic outcome, with both patients and clinicians
rating the appearance as excellent or very good for 93% of lesions treated,
and the remainder being rated as either good or satisfactory (Edwards et al.,
1992).
Adverse events were described in three studies (Edwards et al., 1992,
Wickramasinghe et al., 1989, Kim et al., 2004) , with flu-like symptoms and
transient derangement of liver function being the most commonly reported
events. Depression of mood and reversible dose-related bone marrow
suppression were also reported. Severe adverse events causing disruption of
daily activity were reported in 10% of all 48 patients treated in 1 study,
although none were dangerous or lasting (Edwards et al., 1992).
Retinoids
Oral 13-cis-retinoic acid (0.3-0.5mg/kg/day) was administered with calcitriol
(1,25-dihydroxyvitamin D3) (0.5-1 microgram/day) for 3 to 14 months in a
prospective series which included six patients who between them had 27
previously untreated histologically proven SCCs at various sites and who were
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selected on the basis of them being unsuitable for standard local therapy due
to the multiplicity of their lesions and their location (Skopinska et al., 1997).
Treatment was stopped at 3 months in one of the six patients due to lack of
response. One patient had ‘complete regression’ (assessed by clinical
reduction in lesion size but not assessed histologically) of their three SCCs at
15 months, and the remaining four patients had partial reduction in tumour
size of between 30 and 85% although it was unclear at what time point this
response was assessed and some of patients had remained on treatment. All
patients treated had mild skin and mucosal reactions, with more pronounced
inflammation and crusting of the scalp in three male patients which improved
with antibiotic ointment. Two patients also had a transient slight increase in
serum triglycerides, and two others had a transient increase in urine calcium,
all of which resolved when the dose was decreased. No SCC-related deaths
were reported.
There was one case report of the use of single agent oral isotretinoin (13 cis-
retinoic acid) given at a dose of 2mg/kg/day for 6 months in a patient with
multiple cutaneous SCCs of the legs (Levine et al., 1984). Although the
number of treated lesions was not specified accurately, one lesion of
‘approximately’ 20 SCCs remained after 6 months and was reported as a
keratoacanthoma when examined microscopically after excision. None of the
regressed lesions recurred during the 36 months after treatment, although
three new SCCs arose in previously unaffected areas. There was no mention
of adverse events in this study.
Other treatments
Cetuximab
We found one case report of the use of cetuximab (a monoclonal antibody
which binds to the epidermal growth factor receptor [EGFR]) in combination
ǁŝƚŚɶ ?ŝƌƌĂĚŝĂƚŝŽŶƚŽƚƌĞĂƚĂůĂƌŐĞƵŶƌĞƐĞĐƚĂďůĞ ? ?Đŵ^ŽĨƚŚĞƚĞŵƉůĞ
(Goppner et al., 2010). Cetuximab was given 24 hours pre-irradiation at a
dose of 400mg/m2 and in 200mg/m2 infusions at weekly intervals throughout
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the irradiation (total radiation dose 45Gy). By 4 weeks post treatment the
tumour was regressing, and although histologically confirmed tumour was still
present at 8 months it had decreased in size to 0.2 x 1.0cm and was excised
surgically, with no evidence of further spread 14 months after treatment. The
treatment was well tolerated with a follicular-pustular exanthema which
healed quickly with corticosteroid therapy.
Combination systemic treatments
Treatment of eligible SCCs with various combinations of drugs was described
in five studies (Fujisawa et al., 2006, Olieman et al., 1999, Sadek et al., 1990,
Sheen et al., 2003, Tantranond et al., 1992). These were generally small case
series with only a small number of patients with eligible SCCs, or case reports,
and are summarised in Table 12. In all of the studies definitive initial
treatment with surgery or radiotherapy was not possible. Different
chemotherapy regimens and modes of administration were used in each
study, with follow-up ranging from 8 months to over 7 years. One study
reported limb salvage in two patients after hyperthermic limb perfusion with
chemotherapy, with amputation in a third patient with progressive disease
after treatment (Olieman et al., 1999). Of three patients with SCCs of
disfiguring size who were treated with neoadjuvant chemotherapy prior to
surgery, complete response was seen in two patients, although one of them
had a local recurrence of tumour after 8 months, and no response was seen in
one patient who died from their disease 10 months after treatment(Sadek et
al., 1990). No recurrences or metastasis were reported in the remaining
studies, although these were all single case reports (Fujisawa et al., 2006,
Sheen et al., 2003, Tantranond et al., 1992). All of the studies reported
adverse events related to chemotherapy. Two treatment related deaths were
reported: one of 15 patients had multiorgan failure after hyperthermic
isolated limb perfusion (Olieman et al., 1999), and one of 14 died from a
pulmonary infection superimposed on lung fibrosis following neoadjuvant
chemotherapy (Sadek et al., 1990).
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Table 12: Studies and outcomes combined chemotherapy regimens
Study Type of study
(N=eligible patients)
Treatment details Outcome Follow-up Adverse events
Fujisawa 2006 Case report (76 year old,
non-metastatic SCC of
cheek, complete resection
too difficult)
IV cisplatin 4mg/m2/day on days 1-5,
plus 5-FU 400mg/m2/day for 7 days,
with concurrent external beam RT
2Gy/day 5x per week, total dose 64Gy
No recurrence or metastasis
during follow-up
5 years Mild grade 1
myelosuppression. Ulcer
resolving within 3 months
Olieman 1999 Prospective series (3
patients with locally
advanced eligible SCCs of
limbs, curative resection
not possible without severe
mutilation or impaired
function)
Hyperthermic isolated limb perfusion 
subcut U,)1Ǆ 0.2mg od for 2 days prior
WRPLQLQIXVLRQRIPJ,)1ǄSOXV
3mg (arm) or 4mg (leg) of 71)Ǆ & 10-
13mg/l melphalan under 39-400C
hyperthermic conditions with excision
at 6-8 weeks if possible
1/3 complete response (no
viable tumour cells); 1/3
partial response; 1/3 local
progressive disease and
regional disease at 2 months
post treatment (then
unavailable for follow-up)
Limb salvage in 2 patients
with complete or partial
response. Amputation in
patient with progressive
disease.
Mean 43 months for 2
patients available for
follow-up
Multiorgan failure, deep
infection, septic shock and
death in 1 of all 15 patients.
1/15 superficial wound
infection
Sadek 1990 Prospective series (3
patients with eligible SCCs
of disfiguring size)
Neoadjuvant chemotherapy: cisplatin
100mg/m2 day 1, 5-FU 650mg/m2 by
continuous IVI during 5 days,
bleomycin 15mg IV day1 then
16mg/m2/day continuous IVI during 5
days. Repeated every 3-4 weeks for 2-
3 cycles. Followed by surgery or
2/3 complete response, 1/3
no change (DoD at 10
months). Local recurrence
after apparent CR in 1/2 at 8
months. disease in 1
8,10 and 22+ months Pulmonary infection
superimposed on fibrotic lung
and death in 1 of all 14
patients.
Nausea and vomiting in all
patients.
Grade 3/4 haematologic
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interferon (not specified when in
relation to chemo)
abnormalities in 4/14.
Transient trophic and
pigmented bleomycin related
skin changes.
Sheen 2003 Case report (SCC big toe,
amputation refused)
Intra-arterial MTX 50mg/d infusion for
8 days plus IM leucovorin 6mg
6hourly for 8 days, then intermittent
arterial infusion of 50mg of MTX weekly
until wound healed
Complete response 2 months
after start of treatment (mass
disappeared). No recurrence
during follow-up
7 years 3 months Generalised skin rash and
grade 1 itch
Tantranond 1992 Case report (SCC of pinna,
surgery not indicated as
bone involvement, RT
doses prohibitive
Topical 5-FU plus IV cisplatin
60mg/m2 on d1 plus IV 5-FU d1-4 plus
oral isotretinoin 50mg/bd. 6 cycles in
total every 28 days
No evidence of residual SCC
after 5th course. No
recurrence during follow-up
2.5 years Isotretinoin discontinued after
60 days due to severe cheilitis
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Discussion4.5
Despite the high burden associated with the treatment of SCC, the evidence
base for the different treatment modalities is limited. The Cochrane
systematic review of treatments for primary, non-metastatic cutaneous SCCs
has shown the lack of high-quality data from randomised controlled trials
(chapter 3). This systematic review of observational studies was therefore
conducted in order to review the evidence for different treatments, to help
inform management guidelines, and to provide information relating to the
outcome rates for different treatments to aid in the development of future
clinical trials to assess the effectiveness of selected treatment(s).
4.5.1. Overall summary of the results and clinical implications
Caution needs to be exercised when comparing outcomes after different
treatment modalities due to the limitations of the included studies discussed
in the introduction. Additionally overlapping confidence intervals for average
effect estimates for the different treatments suggest that apparent
differences between treatments may not be significant. Results for the main
treatment modalities are summarised in Table 13.
Surgery with a predefined excision margin is the treatment of choice for the
majority of cutaneous SCCs, with MMS being recommended for SCCs
considered to be higher risk or in cosmetically sensitive areas. The pooled
analysis suggests lower local recurrence rates and deaths attributable to
disease after MMS; despite the fact that tumours treated by this method are
likely to be higher risk although there have been no RCTs to directly compare
the two treatments. However, using pooled analysis, regional recurrence was
of a similar magnitude for both treatment modalities, which may be
suggestive of subclinical spread of some higher risk tumours treated with
MMS to regional lymph nodes at the time of treatment.
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Table 13: Summary of SCC treatments
Intervention Local recurrence
(%)
Regional recurrence (%) Unspecified recurrence
(%)
Death attributable to SCC
(%)
Surgical excision 5.4 (2.5 to 9.1); 12
studies, n=1144
4.4 (2.4 to 6.9); 8 studies,
n=786
5.8 (0.7 to 27.6); 2
studies, n=113
4.1 (1.7 to 7.6); 8 studies,
n=485
Mohs micrographic
surgery
3.0 (2.2 to 3.9); 10
studies, n=1572
4.2 (2.3 to 6.6); 6 studies,
n=1162
4.7 (0.7 to 11.7); 5
studies, n=766
1.1 (0.2 to 2.6); 4 studies,
n=941
External
radiotherapy
6.4 (3.0 to 11.0); 7
studies, n=76
2.6 (0.04 to 8.9); 3 studies,
n=272
4.8 (0.6 to 12.8); 6
studies, n=220
9.1 (1.4 to 22.8); 5 studies,
n=191
Brachytherapy 5.2 (1.6 to 10.5); 6
studies, n=88
— — —
ART: PNI 18.2 (3.8 to 39.8);
5 studies, n=22
8.3 (1.1 to 21.4); 5 studies,
n=22
— 11.1 (0.4 to 33.1); 4 studies,
n=20
ART: Non-PNI 11.1 (2.4 to 25.0);
4 studies, n=47
8.5 (2.5 to 17.6); 4 studies,
n=47
— 14 (0.04 to 50.2); 3 studies,
n=21
Cryotherapy — — 0.8 (0.1 to 2.2); 8 studies,
n=273
—
Curettage and
electrodesiccation
— — 1.7 (0.5 to 3.4); 7 studies,
n=1131
—
Photodynamic
therapy
— — 26.4 (12.3 to 43.7);
8 studies, n=119]
—
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In the pooled analysis of external radiotherapy, average local recurrence was
slightly higher than that seen after conventional surgical excision, although
the differences are probably not significant with overlapping confidence
intervals. Interestingly the odds of regional recurrence were lower, although
this data was generated from just two studies (Barysch et al., 2012, Tsao et
al., 2002) with other studies not specifying whether the recurrences they
reported were local or regional failures, so the true significance of this is
unclear. The lower local recurrence rates from the studies in which
brachytherapy was used may be a reflection of the more superficial, lower
risk nature of the included SCCs treated by this method, although patients
numbers were generally small and limited follow-up of only a few months in
some of the studies may be inadequate to detect later recurrences.
The greater rates of recurrence, metastasis and death from disease observed
with adjuvant radiotherapy after surgical excision is in accordance with other
studies (Jambusaria-Pahlajani et al., 2009), although numbers in included
studies were small and for non-PNI SCCs the reasons justifying the use of ART
were not always clear. The results may therefore be a reflection of selection
of those SCCs with a particular poor prognosis, and the identification of
prognostic factors which may benefit from ART remains an area of
uncertainty and one in which prospective studies are required.
Lowest recurrence rates were observed after cryotherapy and ED&C
respectively, but the majority of SCCs included in these analyses were small
and considered to be low-risk lesions but the evidence is poor to advocate its
use in lesions considered at higher-risk of recurrence and recurrent SCCs.
Based on the results in this systematic review, the use of PDT to treat invasive
SCCs cannot be advocated. Few studies confirmed histological clearance in
apparently completely responsive SCCs, and in those which attempted to do
so, residual tumour remained in a number of biopsies. Furthermore, more
149
than a quarter of those tumours which had appeared to completely respond
to PDT initially recurred during follow-up.
Not all patients with SCC are amenable to surgical treatment or radiotherapy
and some people are susceptible to multiple SCCs as a result of a genetic or
immune predisposition. Such groups pose particular therapeutic challenges,
and there is a growing need for effective topical or systemic agents which
could be used in such cases. The current evidence for these agents to treat
primary SCCs is largely anecdotal, based on single case reports or very small
numbers of eligible patients in open-label trials with limited follow-up and
generally lacking recurrence data, but is an interesting area for further
development as new insights into the pathogenesis and targeted therapies
emerge.
Although quality of life was one of the outcomes in this review, none of the
included studies measured this. Patient Reported Outcome Measures
(PROMs) have great potential to improve the quality of health services by
providing validated evidence of health from the patient’s perspective. Two
recent systematic reviews of PROMs in skin cancer showed that there have
been limited evaluations of PROMs specifically designed for patients with
nonmelanoma skin cancers, and furthermore that the questionnaires
developed so far are not perfect for assessment of quality of life in these
particular patients (Gibbons et al., 2013, Bates et al., 2013). Nevertheless, the
incorporation of patient reported outcomes will undoubtedly be important in
the development of future clinical trials comparing treatments for SCC, and
should be able to capture quality of life issues which are important to patients
with this condition, including detailed assessment of cosmetic and functional
outcomes at specific time points.
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4.5.2. Bias and quality of reporting
Poorly reported studies can lead to discrepancies between data extractors
and hinder assessment of the risk of bias. The majority of the studies in this
review were published before the STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) statement (Vandenbroucke et al.,
2007) of 2007 which was introduced with the aim of improving the quality of
reporting of these types of studies, using similar principles to the CONSORT
(Consolidated Standards of Reporting Trials) checklist (Schulz et al.) for RCTs.
Just one study (Brantsch et al., 2008), which we assessed to be of good
reporting quality, declared overtly that STROBE guidelines had been followed.
Most of the included studies were of limited methodological quality and
prone to bias (Figure 19), with variable patient mixes in terms of prognostic
factors, overall disease severity and duration of follow-up. Recruitment bias
with selection of particular treatment modalities based on tumour or patient
characteristics is a serious consideration for case series and was positively
identified or was an unclear risk in 85% of the studies in this review, making it
impossible to directly compare the effectiveness of different treatments.
In 41% of studies, losses to follow up were either incompletely reported or
were not mentioned at all in which case it was difficult to assess the risk of
attrition bias. None of the studies included in this systematic review had
blinded assessment of outcomes which is a potential source of reporting bias.
However, by considered planning in advance it should be feasible to introduce
an element of blinding to prospective case series, for example by having
personnel collect data on patient and tumour characteristics independently
from those assessing outcome so that the latter have no prior knowledge of
these characteristics (Kooistra et al., 2009).
At present, there is no requirement for registration of non-randomised
studies, the presence of publication bias is more difficult to assess than for
RCTs, but is assumed to be present and is drawback in this kind of systematic
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review. A survey of published case series and reports revealed that 79%
reported only treatment success, 10% reported treatment failures as well as
successes but only 10% reported treatment failures (Albrecht et al., 2005).
4.5.3. Stratification of risk
A limited number of studies stratified outcomes according to particular
prognostic indicators, although in the majority of studies it was not possible
to stratify results from data provided. Ear location as a poor prognostic
feature is supported by the pooled analysis of data from studies in which ear
and other locations were considered separately. A pooled analysis of other
features considered high-risk was not conducted due to different reporting
methods in the studies in which these factors were considered.
Increased risk of recurrence with tumours greater than 2cm was noted in
some of the included studies (Pless, 1976, Cherpelis et al., 2002, Griffiths et
al., 2002), although this finding was not supported by Mourouzis (Mourouzis
et al., 2009) with 60% of metastases originating in SCCs smaller than 2cm, nor
by Dzubow (Dzubow et al., 1982) who found a trend towards significance with
tumours larger than 5cm in diameter.
Several studies showed the importance of SCC depth as a risk factor for
recurrence. No metastases were observed in SCCs less than 2mm in depth by
Mourouzis (Mourouzis et al., 2009), in accordance with Brantsch (Brantsch et
al., 2008) who reported a significantly increased risk of metastases for SCCs
greater than 2mm thick. Griffiths (Griffiths et al., 2002) also reported a
significant difference in thickness between SCCs in patients who died of their
disease and those who did not.
Poor differentiation was noted to be an adverse prognostic feature in two of
the included studies (Cherpelis et al., 2002, Mourouzis et al., 2009), with the
presence of PNI being significantly associated with a worse outcome in one of
the series (Cherpelis et al., 2002).
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4.5.4. Strengths and limitations of this Systematic Review
The combined systematic reviews described in this chapter and in chapter 3
are the first systematic reviews to assess the effectiveness of all treatment
modalities for primary non-metastatic SCC. This systematic review is the first
to focus on non-randomised studies of SCC treatments.
Although much effort was made to ensure that the literature search was as
thorough as possible, it is inevitable that some relevant studies were missed.
The Medline and Embase databases were searched, but it is possible that
there were relevant studies in other databases that were not searched.
Observational studies, and especially case series, are less easy to identify from
searching literature databases than RCTs; usually they are not identifiable
from the title and are less consistently indexed according to study design in
bibliographic databases. Searches that are sensitive enough to detect case
series generally lack specificity making it likely that some studies are not
identified (Dalziel et al., 2005). Many of the studies identified in the review
were identified after scrutinising reference lists. The search was limited to
those published in English, in part due to the large number of studies, but also
as the translation of studies which are generally only of limited reporting
quality could introduce an additional source of bias.
The treatment of recurrent SCCs and tumours known to be metastatic at
presentation was not addressed in this systematic review. Many studies have
been excluded as they included previously treated relapsed tumours without
separation of data from non-recurrent tumours. Such recurrent tumours may
have different features to those which have not been treated previously
which makes them more likely to recur or resistant to treatment.
Similarly, studies relating solely to the management of SCC in solid organ
transplant recipients were not specifically searched for, although some of the
studies did include such patients. Cutaneous SCC is an important cause of
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morbidity in this group of patients, associated with the likelihood of multiple
tumours and with a potentially more aggressive clinical course (Zwald and
Brown, 2011). It is therefore perhaps a subject suitable for separate
consideration and beyond the scope of this more general review.
4.5.5. Implications for future research
There is plenty of scope for further research to improve the evidence base for
SCC treatments, ideally with the development of well-designed adequately
powered RCTs which are currently lacking. The relationship between different
prognostic features is difficult to assess from the evidence currently available
yet is important in order that stratification according to risk can be made and
treatment decisions based upon this. Outcomes for future trials should be
standardised, with consistent follow-up at one years and two years and with a
minimum follow-up of at least 5 years. An intention-to treat approach, in
which all participants are analysed according to the initial treatment group
allocation irrespective of actual treatment received and whether there was
cross-over, full-compliance or drop-out, is regarded as the least biased
method to estimate treatment effects in RCTs and to deal with attrition of
participants (Newell, 1992). However, the intention-to-treat approach is often
inadequately described and applied by trialists and recommendations have
been made for the design, conduct, analysis and reporting of trials to address
such issues and assist researchers to design trials and readers to interpret the
validity of their results (Hollis and Campbell, 1999). This should include
minimisation of incomplete outcome data, with description of how missing
data will be handled and investigation of the possible effects of missing data.
A multidisciplinary approach to running such future trials should be
encouraged, as these tumours present across a variety of specialties and their
management is frequently co-ordinated by a specialist multi-disciplinary
team.
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Conclusion4.6
Cutaneous SCC is one of the most common cancers in humans and presents a
significant public health impact, yet the evidence base for the treatment of
SCC is poor. It is not possible to compare treatment outcomes accurately from
the available evidence and there is a need for targeted research to identify
which patients will benefit from most from particular treatment strategies.
This systematic review has complemented the Cochrane systematic review
that has been described previously (Chapter 3) by providing a thorough
appraisal of the treatments of cutaneous SCC. Furthermore, it has provided
information on event rates for different treatments for a range of clinically
important outcomes, and highlighted deficiencies common to many of the
published studies, such as a lack of patient-reported outcomes and detail
about prognostic features, which will need to be taken into account when
designing any future clinical trials involving interventions for SCC.
155
CHAPTER 5: SURVEY TO
IDENTIFY TREATMENT
UNCERTAINTIES
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5 SURVEY TO IDENTIFY TREATMENT UNCERTAINTIES
Abstract5.1
Objectives: This survey was conducted in order to inform the development of
a proposal for an RCT of cutaneous squamous cell carcinoma (SCC)
treatments. The objectives were: to gain an overview of current treatment
practices among healthcare professionals (HCPs) treating patients with SCC;
to identify clinically important areas of management uncertainty among HCPs;
to give this group the opportunity indicate their interest in involvement in and
to suggest topics for a future RCT.
Methods: An online survey was sent to a multidisciplinary group of healthcare
professionals having an interest in skin cancer treatment and research.
Professional organisations of which such people were likely to be members
identified and distributed the surveys (British Society of Dermatological
Surgery; British Association of Plastic, Reconstructive and Aesthetic Surgeons;
Royal College of Radiologists Site Orientated e-Network; and UK Dermatology
Clinical Trials Network). The online surveys sought to gather data on current
treatment practices, including biopsy and follow-up. Participants also had the
opportunity to identify areas of treatment uncertainty, to suggest which
treatments should have their effectiveness assessed in the form of an RCT,
and to indicate which core outcome measures should be used to assess the
effectiveness of treatments. The potential willingness of those taking part in
the survey to be involved in a future RCT was also evaluated.
Results: 1820 HCPs were sent or had to access to the survey, of whom 306
responded (17%). The vast majority of respondents (97%) treated SCC by
surgical excision with a predetermined margin. 12.3% of respondents were
also able to perform Mohs micrographic surgery. All 6 of the clinical
oncologists who responded treated SCC with radiotherapy either alone or as
an adjunct after surgery. Apart from the clinical oncologists who always
perform pre-treatment biopsies, biopsies are rarely performed or are only
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done in 25-50% of cases. Almost three-quarters of respondents would follow-
up a patient with high risk SCC for a minimum of 2 years, whereas more than
half of them would follow-up patients with low-risk SCCs for less than 1 year.
Optimisation of surgery and the role of radiotherapy and newer agents were
identified as areas where there is a need for more research, with survival and
loco-regional recurrence being identified as the most important outcomes to
assess. Specific areas of uncertainty related to optimal excision margins, the
role of adjuvant radiotherapy, ideal follow-up regimens and the lack of a
prognostic model for survival and recurrence.
Conclusions: This online survey identified areas of SCC treatment uncertainty
among HCPs and generated suggestions for possible future research. It also
identified what HCPs consider to be the most important outcome measures s
in such a trial. Through the identification of which treatments should have
their clinical effectiveness assessed, the results from the survey have
informed and contributed to the wider body of feasibility work that has been
undertaken in this research towards the development of future research.
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Introduction5.2
Surveys are well-established in healthcare research as tools for obtaining data
on healthcare practices, the organisation of care, and knowledge and
attitudes among providers.
This chapter describes an online electronic survey of healthcare professionals
(HCPs) involved in cutaneous squamous cell carcinoma (SCC) management
which was conducted to gain insight into current treatment practices, and to
identify areas where HCPs feel more research is required in order to answer
clinically important treatment uncertainties which they feel are not
answerable from the current evidence base.
5.2.1. Why it was important to conduct this survey
The appraisal of the evidence base for the efficacy of treatments for SCC is
poor, as has been discussed in earlier chapters of this thesis (chapters 3 and
4), being largely based on case series. Currently, no published data from
randomised controlled trials are available comparing treatments for the types
of SCC that are seen in routine clinical practice. Given the enormous service
burden of treating non-melanomas, the need for large, prospective studies to
compare different treatments has been recognised as a research priority in
the UK (Motley et al., 2002, National Institute for Health and Clinical
Excellence, 2006).
The treatment of SCC is undertaken by a wide range of clinicians;
dermatologists, plastic surgeons, clinical oncologists, and surgeons of several
disciplines such as general, ENT, maxillofacial and ocular surgery. Although it
is not recommended that general practitioners should definitively treat SCCs
themselves (National Institute for Health and Clinical Excellence, 2006), they
have an important role to play in diagnosing and urgently referring cases of
suspected SCC to a specialist member of the local skin cancer multidisciplinary
team (LSMDT) or specialist skin cancer MDT (SSMDT). Therefore, as the
management of SCC is frequently multidisciplinary, this survey was designed
to canvas a wide range of practitioners who have an interest in SCC treatment
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and was conducted as part of the background feasibility work towards
furthering research in this area. Assessment of adherence to current clinical
guidelines was not one of the objectives of the survey.
5.2.2. Objectives of this survey
The objectives of this survey were to:
x gain an overview of current SCC treatment practices
x invite HCPs to suggest potential research topics on SCC treatment, as a
guide for future discussions regarding the development of an RCT trial
proposal
x offer clinicians the opportunity to express their interest in taking part
in a future clinical trial
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Methods5.3
The vast majority of SCCs are treated by dermatologists, plastic surgeons or
clinical oncologists. Prominent professional bodies for these specialties were
identified as points of distribution for the survey, namely:
x The British Society for Dermatologic Surgery (BSDS),
representing dermatologists who carry out skin surgery;
x The British Association of Plastic Reconstructive and Aesthetic
Surgeons (BAPRAS), the membership of which is mainly plastic
surgeons but with some members from other surgical
specialties;
x The skin Site Orientated e-Network (SOeN) of the Royal
College of Radiologists, a subgroup of clinical oncologists with
an interest in skin cancer;
x The UK Dermatology Clinical Trials Network (UKDCTN), a
mixed group of dermatologists, GPs, clinical nurse specialists
in dermatology, and patients, all of whom have an interest in
promoting research in dermatology.
The survey was cross-sectional (administered at one time point) and
developed in an electronic format using the Survey Monkey professional on-
line tool (www.surveymonkey.com). Four different versions were generated,
one for each of the targeted professional bodies. Although all four surveys
sought answers to similar questions, each one was developed with one or
more members from each of the groups to ensure that the questions were
relevant to that particular group. The main structural difference between the
surveys related to the question regarding primary management of SCC.
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Approval of each survey was obtained from the President of the BSDS, the
Executive Committee of BAPRAS, and the President of the Royal College of
Radiologists. Surveys were piloted by members of the Centre of Evidence
Based Dermatology to test the functionality of the on-line format. Each survey
was presented over seven pages, with one to four questionnaire items per
page. Respondents were able to review and change their answers before
submitting. A copy of the survey sent to UKDCTN members is attached in
Appendix 3.
Between January and March 2010, each professional organisation sent an e-
mailed invitation letter and web link to the corresponding electronic survey to
members on their distribution list (BSDS, BAPRAS, UKDCTN), or posted it on
the specialist group website (SOeN). The invitation letter explained the
purpose of the work, approximately how long the survey would take to
complete, and reassured participants of the anonymity of their responses. For
the UKDCTN survey, potential participants were asked not to complete the
survey if they had already taken part via one of the other organisations
surveyed. The survey could only be accessed once from a particular IP
address, in an attempt to prevent duplicate entries. Completion of the survey
was voluntary, with no incentives offered. Surveys remained open for
responses for three weeks, a reminder being sent to members via each
organisation one week prior to closure. Responses were analysed from both
completed surveys and those that were terminated early (i.e. the respondent
did not complete all the questionnaire pages). Raw data were exported into
an Excel spreadsheet to allow simple statistical analysis of percentages and
means and generation of graphical representations. Free-text responses were
analysed manually. Response rates were calculated by dividing the number of
people who were sent the link to the survey by the number who started it,
multiplied by 100. Completion rates were calculated by dividing the number
who started the survey by the number who completed it, multiplied by 100. A
‘Checklist for Reporting Results of Internet E-Surveys’ (CHERRIES) was used for
reporting the results of the survey (McAlister et al., 2003)(Table 14).
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Table 14: Checklist for reporting results of internet surveys (McAlister et al., 2003)
Category Checklist item
Design x Survey design
Institutional Review Board approval x IRB
x Informed consent
x Data protection
Development and pre-testing x Development and testing
Recruitment process x Open versus closed survey
x Contact mode
x Advertising survey
Survey administration x Web/e-mail
x Context (description of site)
x Mandatory/voluntary
x Incentives
x Time/date
x Randomisation of items
x Adaptive questioning
x Number of items
x Number of screens
x Completeness check
x Review step
Response rates x Unique visitor site (e.g. based on
IP address)
x View rate
x Participation rate
x Completion rate
Preventing multiple entries from one
individual
x Cookies used
x IP check
x Log file analysis
x Registration
Analysis x Handling incomplete
questionnaires
x Questionnaire submitted with
atypical timestamp (i.e. didn’t
take long enough to complete)
x Statistical correction
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Results5.4
From a total of 1820 people who received the survey, 306 (16.8%) attempted
the survey, with 255 answering all the questions (Table 15).
Table 15: Response rates of organisations surveyed
Organisation Number
receiving
survey
Number
attempting
survey (response
rate %)
Number attempting
survey who answer all
the questions
(completion rate %)
BSDS 250 70 (28.0) 63 (90.0)
BAPRAS 851 138 (16.2) 110 (79.7)
SOeN 249 6 (2.4) 5 (83.3)
UKDCTN 470 92 (19.6) 77 (83.7)
Overall 1820 306 (16.8) 255 (83.3)
BSDS = British Society of Dermatological Surgeons; BAPRAS= British Association of Plastic,
Reconstructive and Aesthetic Surgeons; SOeN = Site Oriented e-Network of the Royal College of
Radiologists; UKDCTN = UK Dermatology Clinical Trials Network
5.4.1. Professional capacity
More than three-quarters of those who responded to the survey were
consultants in either dermatology, plastic surgery or clinical oncology (Figure
41), and 82.4% of respondents had been in clinical practice for more than 5
years (Figure 42).
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Figure 41: Professional capacity of survey respondents (n=302)
Figure 42: Length of clinical practice of respondents (n=205)
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5.4.2. Treatment practices
Based on data from respondents who were able to give a numerical estimate,
the average number of SCCs treated annually by members of each
organisation is shown in Table 16. A further 41 respondents gave a range for
number of SCCs treated, four were not certain and unable to estimate, one
was retired, and one was no longer doing skin cancer clinics. Respondents
who were members of BAPRAS treated on average 76 SCC patients annually,
compared with an average of 65 patients by BSDS members annually, 47
patients for UKDCTN members and 26 patients for the four radiologists who
responded.
Table 16: Mean numbers of SCCs treated by respondents over one year
Organisation Mean number of SCC treated per
annum (range; median)
BSDS (n=49) 65 (12 to 400; 50)
BAPRAS (n=92) 76 (0 to 500; 50)
UKDCTN (n=66) 47 (2 to 200; 30)
SOeN (n=4) 26 (8 to 50; 22.5)
BSDS = British Society of Dermatological Surgeons; BAPRAS= British Association of Plastic,
Reconstructive and Aesthetic Surgeons; SOeN = Site Oriented e-Network of the Royal College of
Radiologists; UKDCTN = UK Dermatology Clinical Trials Network
Overall 260 of 269 (96.6%) of BSDS, BAPRAS and UKDCTN respondents treat
primary invasive non-metastatic SCC by attempted single excision with a
predetermined margin (98.6%, 98.3% and 92.8% of respondents from these
groups respectively). Fewer respondents (33 of 269 [12.3%]) reported being
able to offer Mohs micrographic surgery (17.4%, 11.1% and 9.6%,
respectively). All the clinical oncologists use either radiotherapy alone or as an
adjuvant post operatively, and one also uses chemoradiation (although the
numbers who responded to the SOeN survey were only very small so this
should not be regarded as representative of the practice of all clinical
oncologists). Other treatments sometimes used by members of the BSDS and
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UKDCTN include curettage and cautery (some specified for lesions that
appear to be low risk, or in the very old and frail), cryotherapy and topical
cytotoxic agents. Radiotherapy was also reported to be a treatment used by a
few members of these groups, although presumably after discussion with
colleagues in their skin cancer specialist MDT and referral to a clinical
oncologist.
5.4.3. Biopsy
Most respondents from the BSDS, BAPRAS and UKDCTN reported that
biopsies of suspected SCCs are either rarely done, or are performed in only
about 25–50% of cases (Figure 43). In contrast, all six of the clinical
oncologists who responded stated that they always biopsy pre-treatment.
Figure 43: Pre-treatment biopsy rates by professional group
BSDS = British Society of Dermatological Surgeons; BAPRAS= British Association of Plastic,
Reconstructive and Aesthetic Surgeons; UKDCTN = UK Dermatology Clinical Trials Network
5.4.4. Follow-up
Almost two-thirds of respondents reported that they would follow up a
patient with an SCC they considered to be ‘high-risk’ for between 2 and 5
years (Figure 44), with a further 9% following them for at least 5 years,
compared to only 26% who would follow up for less than 2 years. In contrast,
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patients with what respondents considered to be ‘low-risk’ SCCs would be
followed up for less than 1 year by 57% of respondents, with a further quarter
following them for 1–2 years (Figure 45).
Figure 44: Follow-up of 'high-risk' lesions (n=275)
Figure 45: Follow-up of 'low-risk' lesions (n=267)
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5.4.5. Research topics
One of the aims of this survey was to identify clinically important
management uncertainties, in order to guide the development of ideas for
clinical trials to determine the relative effectiveness of the treatments. Based
on the pre-specified research categories proposed in the survey, optimisation
of surgical treatment, the role of radiotherapy, and the role of newer agents,
were the areas in which there was greatest interest (Table 17).
Table 17: Respondents' views on areas of perceived need for clinical trials
Research Category Number of response to Need for
a clinical trial (%)
Total
Yes No
Optimising surgery 181 (75.7) 58 (24.3) 239
Role of radiotherapy 157 (71.0) 64 (29.0) 221
Role of
chemotherapy
108 (54.3) 91 (45.7) 199
Role of newer
agents
174 (79.4) 45 (20.5) 219
Other 28 (40.0) 42 (60.0) 70
There were some differences in research area priorities between the groups.
Optimisation of surgery and the role of radiotherapy were considered the
most important areas for research by BSDS members (78.7% and 75.8%
respectively). For BAPRAS and UKDCTN members, the role of newer agents
(86.7% and 83.9% respectively) and the optimisation of surgery (78.8% and
71.6% respectively) were the top two areas.
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In addition, respondents were invited to submit free-text suggestions for
specific research questions and other comments relating to a potential clinical
trial. Several broad categories could be derived from the responses, and the
numbers of responses in each category were counted. Some respondents
entered free text which could be split into more than one category, so each
free-text comment was subdivided as necessary. The categories identified and
distribution of respondents’ comments are listed in Table 18.
Free-text replies tended to be general identification of topics for possible
research rather than specific ideas for clinical trials. Nonetheless, the top
three areas of uncertainty expressed by clinicians, and where there was felt to
be a need for more research, were excision margins, the role of radiotherapy
for high-risk SCCs or incompletely excised SCCs, and optimal follow-up
regimens. There was also recognition of the current lack of a prognostic
model upon which to base treatment and follow-up. Although the need for
more research into the role of other treatments such as chemotherapy and
newer therapies was generally considered to be a research priority, there was
a lack of research questions relating to specific agents in the free-text replies.
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Table 18: Research topics identified by respondents according to professional body in order of frequency of occurrence
Research topic BSDS n=26 (%) BAPRAS n=31 (%) UKDCTN n=18 (%) RCR n=3 (%) TOTAL n=78 (%)
Excision margins 8 (30.8) 12 (38.7) 4 (22.2) - 24 (30.8)
Role of radiotherapy 8 (30.8) 6 (19.4) 3 (16.7) 3 (100.0) 20 (25.6)
Follow-up 7 (26.9) 7 (22.6) 4 (22.2) - 18 (23.1)
Prognostic model 1 (3.8) 7 (22.6) 2 (11.1) - 10 (12.8)
Mohs versus excision 3 (11.5) 2 (6.4) - - 5 (6.4)
New agents 1 (3.8) 2 (6.4) 2 (11.1) - 5 (6.4)
Topical agents 1 (3.8) 2 (6.4) 1 (5.6) - 4 (5.1)
Curettage versus surgery for low-risk SCC 3 (11.5) - 1 (5.6) - 4 (5.1)
Chemotherapy/electro-chemotherapy - 3 (9.8) - - 3 (3.8)
Treatment of immune suppressed/transplant 2 (8.0) 1 (3.2) - - 3 (3.8)
Early diagnosis techniques - 1 (3.2) 2 (11.1) - 3 (3.8)
Imaging techniques 1 (3.8) 2 (6.4) - - 3 (3.8)
PDT - 2 (6.4) - - 2 (2.6)
Sentinel lymph node biopsy - 2 (6.4) - - 2 (2.6)
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5.4.6. Core outcomes
The survey also sought to identify which core outcomes were considered to
be of greatest importance to clinicians after treatment of SCC (Table 19).
Table 19: Relative importance of post-treatment outcomes, ordered by those considered to be very
important
Outcome Very
important
(%)
Important
(%)
Fairly
important
(%)
Not
important
(%)
Total
Survival 223 (86.1) 27 (10.4) 7 (2.7) 2 (0.8) 259
(100.0)
Regional
recurrence
224 (85.8) 34 (13.0) 2 (0.8) 1 (0.4) 261
(100.0)
Local
recurrence
206 (78.9) 50 (19.2) 5 (1.9) 0 (0.0) 261
(100.0)
Quality of life 126 (48.6) 107 (41.3) 23 (8.9) 3 (1.2) 259
(100.0)
Persistent
ulceration
108 (42.4) 101 (39.6) 41 (16.1) 5 (1.9) 255
(100.0)
Persistent
pain
103 (40.4) 99 (38.8) 47 (18.4) 6 (2.4) 255
(100.0)
Acceptability
to patient
77 (29.6) 128 (49.2) 53 (20.4) 2 (0.8) 260
(100.0)
Disfigurement 72 (27.8) 157 (60.6) 29 (11.2) 1 (0.4) 259
(100.0)
Contracture 38 (15.2) 132 (52.8) 74 (29.6) 6 (2.4) 250
(100.0)
Pain of
procedure
20 (7.8) 95 (37.3) 100 (39.2) 40 (15.7) 255
(100.0)
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Almost all of the short- and long-term outcomes suggested (with the
exception of pain of procedure) were considered to be ‘very important’ or
‘important’ by the majority of those who responded to the question.
However, survival and local and regional recurrence were the three outcomes
considered to be of greatest importance.
5.4.7. Theoretical willingness to recruit into a future
randomised controlled trial for squamous cell carcinoma
Clinicians were asked if they would be prepared to recruit their patients into
either a future full-scale clinical trial addressing an aspect of the treatment of
SCC, into a feasibility study only, or into both. The results are summarised for
each professional group in Table 20. Overall, there was interest in taking part
in a full-scale trial amongst 44% of respondents, with a further third indicating
that they may be interested in taking part.
Table 20: Hypothetical willingness of clinicians to recruit into an RCT of SCC treatments
Potential
willingness
to recruit
patients
BSDS BAPRAS UKDCTN RCR TOTAL
Yes, full-
scale RCT
32 (52.4) 38 (38.8) 31 (41.9) 4 (100.0) 105 (44.3)
Yes, but
feasibility
study only
2 (3.3) 2 (2.0) 1 (1.4) - 5 (2.1)
No 5 (8.2) 28 (28.6) 16 (21.6) - 49 (20.7)
Maybe 22 (36.1) 30 (30.6) 26 (35.1) - 78 (32.9)
TOTAL 61 (100.0) 98 (100.0) 74 (100.0) 4 (100.0) 237
(100.0)
173
Discussion5.5
Surveys are a useful research tool to elicit practice patterns, behaviours and
concerns of physicians (Creel et al., 2005). The purpose of this survey was to
gain an overview of how cutaneous SCCs are currently being treated across
the UK, and to help identify potential topics for an RCT based on what
healthcare professionals consider to be important areas of uncertainty in the
management of SCC.
5.5.1. Current treatment practices
Treatment
Several treatment options are available for managing SCCs, and guidance for
clinicians is given in multiprofessional guidelines, based upon whether the
tumour is considered to be at low or high risk of recurrence and/or
metastasis (Motley et al., 2002). From these guidelines, surgical excision is
generally the treatment of choice for the majority of SCCs and was
undertaken by the vast majority of specialists in this survey, other than
clinical oncologists who use radiotherapy. Thirty-three of the 255 respondents
(12.9%) were able to offer Mohs surgery, a treatment which may be
considered for high-risk tumours and those in functionally sensitive areas.
Other treatments such as cryotherapy, and curettage and cautery, which the
guidelines state may be indicated for small, low-risk tumours, were also used
by respondents although less frequently than surgical options. Topical
cytotoxics were also used by 19 respondents (7.4%), although their use is not
recommended in the guidelines; evidence in support of their value is very
limited and based mostly on single case reports.
Biopsy
Over three-quarters of respondents from BSDS, BAPRAS and UKDCTN replied
that they either rarely biopsied before treatment, or only biopsied between
25% and 50% of suspected SCCs. This is perhaps not surprising as surgical
excision generates histology anyway. In contrast the clinical oncologists
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always biopsied suspected SCCs before radiotherapy. Between 32% and 47%
of SCCs may be incorrectly diagnosed prior to surgery (Brown and Lawrence,
2006, Ashby et al., 1989b), and it has been suggested that pre-treatment
biopsies may be required in a greater number of cases so that excision may be
expedited. Furthermore, lack of histology from destructive treatments such as
cryosurgery, or curettage and cautery, may contribute to the under-reporting
of SCCs that is recognised in the UK (Alecu et al., 1998). However, it has been
estimated that if pre-treatment biopsies were carried out for every skin
tumour, there would be a seven-fold increase in the number of tumours
assessed (Brown and Lawrence, 2006), which could be prohibitively costly and
unfeasible.
Follow-up
Uncertainty about optimal follow-up was raised by 23% of all respondents in
this survey. The purpose of follow-up is to identify recurrent and metastatic
disease and to identify new lesions. Specific guidance in the current UK
management guidelines is somewhat limited, with advice that it would ‘seem
reasonable’ for patients with high-risk SCCs to be closely for observed for
recurrent disease for at least two and up to five years, based on 75% of
recurrences being detected within two years, and 95% in five years (Rowe et
al., 1992, Motley et al., 2002). No recommendations are made regarding low
risk lesions. The results of the survey would suggest that most respondents
are following this guidance for high-risk lesions, but that there is more
division among respondents regarding low-risk lesions. In Australia, where the
incidence of skin cancer is so high, the Australian Cancer Network does not
make any specific follow-up recommendations for low-risk SCCs, although
advises that all patients who have had skin cancer should have an annual skin
examination as part of a routine health check. Patients with SCCs treated non-
surgically where there is no evidence of histological clearance, and any SCCs
considered to be high-risk, are recommended to be closely monitored for up
to three years (Australian Cancer Council Australia and Australian Cancer
Network, 2008). There have, however, been no studies that have directly
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compared regular follow-up by medical practitioners with follow-up by
patients themselves.
5.5.2. Identification of research topic and trial scenario
The appraisal of the evidence conducted as part of this thesis showed that the
evidence base for the effectiveness of SCC treatments is poor (Chapters 3 and
4). In the absence of evidence from RCTs, this survey has provided useful
cross-speciality information about the kind of trials that clinicians would find
valuable to guide practice in the treatment of SCC. The results of the survey
suggest that there is real enthusiasm among HCPs for research in this area,
with nearly half the respondents expressing their provisional expression of
willingness to take part in future trial work, either in the form of a full-scale
trial or feasibility study, and a further third responding that they may be
interested in taking part. However, this is likely to be an overestimate, and
willingness to actually recruit patients is will depend upon the actual research
question that is taken forward, which at this stage was not known, and the
facilities available at their centre. Furthermore, the population who returned
the survey are probably those who have an active interest in clinical research
which may have biased the results somewhat.
Particular areas of uncertainty identified by the respondents related to
optimal excision margins, the role of adjuvant radiotherapy in the
management of higher-risk SCCs, and follow-up regimens for SCC patients.
There was also interest in the role of newer therapies to treat SCCs,
comparison of Mohs surgery with standard excision, and also concern about
the lack of a prognostic model on which to base treatment decisions. These
topics reflect gaps in the evidence found in the systematic reviews described
in chapters 3 and 4, and indicate that there is potential need for well-
designed trials in this area.
Development of a scenario for a clinical trial
The results of the clinicians’ research priorities were presented to a
multidisciplinary group of clinicians, statisticians and a patient representative
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from the NCRI non-melanoma subgroup of the Melanoma Clinical Studies
Group. Further to the survey and systematic reviews of the effectiveness of
existing treatments for SCC (chapters 3 and 4), extensive multi-disciplinary
discussions have taken place, through which a trial proposal has evolved. The
development of this scenario is discussed in chapters 6 and 9 of this thesis.
5.5.3. Participation in the survey
Advantages of web surveys
Electronic surveys such as the one described in this chapter, have some
advantages over mailed surveys in that they are between one third and two
thirds less costly to administer (VanDenKerkhof et al., 2004, Raziano et al.,
2001), have the potential to be more flexibly designed (Couper, 2001), which
subsequently provides more complete responses (Medway and Fulton, 2012,
Schleyer and Forrest, 2000), can be administered over a shorter field period
(Nguyen and Ho, 2002, Beebe et al., 2007), and as data fields are populated
by the respondent there is less opportunity for manual data entry errors
(Raziano et al., 2001, VanDenKerkhof et al., 2004).
Potential disadvantages of surveys
Despite the advantages of web-based surveys, it is important to appreciate
that they also have some potential drawbacks compared with other types of
survey. For example, in the general population response rates may be around
10% lower for web surveys when compared with other modes of survey or
mixed modes (Manfreda et al., 2008, Shih and Fan, 2008). Administration of
web surveys also assumes access to the internet, a degree of computer
literacy in a sample frame that is representative of the population of interest,
and compatibility across web browsers to allow successful access, completion
and submission of the questionnaire (Nguyen and Ho, 2002, Schleyer and
Forrest, 2000).
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Improving the reporting of web-based surveys
There have long been calls to improve the quality of reporting of surveys in
order to allow the reader to make judgement about the validity of the
survey’s findings (Cummings et al., 2001, McLeod et al., 2013). Analogous
with the CONSORT and STROBE statements for reporting RCTs and
observational studies respectively (Schulz et al., Vandenbroucke et al., 2007),
a checklist for reporting results of internet e-surveys (CHERRIES) has been
compiled with the objective of improving the transparency and quality of
web-based surveys (McAlister et al., 2003). The checklist is comprised of 30
items in eight design categories (Table 14). The survey described in this
chapter is reported as much as possible according to the checklist, although
not all the checklist items are applicable (e.g. view rates of an open website
were not applicable as the survey was sent via an e-mail link, and no cut-off
was set for time to complete the questionnaire so none had an atypical
timestamp).
Healthcare professionals participation in surveys
Among healthcare professionals, response rates in surveys have shown great
variability (Braithwaite et al., 2003), but are typically poor (VanGeest et al.,
2007, Cummings et al., 2001), with clinician surveys consistently having lower
response rates than non-clinician surveys (Asch et al., 1997) (Cook et al.,
2009). As with surveys in the general population, clinician internet-based
surveys have lower response rates than those administered by other routes
(Raziano et al., 2001, Nguyen and Ho, 2002, VanDenKerkhof et al., 2004),
ranging from 11% to 58% (Kim et al., 2001, Cook et al., 2009, Raziano et al.,
2001). Furthermore, rates of response appear to have shown a small but
significant declining over time (Cummings et al., 2001).
Facilitators and barriers to participation
There are few studies that have examined the facilitators and barriers to
clinician participation in surveys and undoubtedly further research into these
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areas would provide an evidence base to help inform the most appropriate
design for optimal participation in future surveys (Klabunde et al., 2013).
Perhaps one of the most significant barriers to clinician participation is lack of
time and an increasing number of requests to complete surveys (Kaner et al.,
1998, Sudman, 1985). Additional barriers may include the perception that the
survey is of low value to the participant, concerns about confidentiality or
that the questionnaire items are biased or that a full range of possible
responses is not provided (Sudman, 1985). Clinicians may also fear that
responses indicating a lack of professional knowledge or practices not
meeting best practice standards may reflect negatively either on themselves
or on their profession (Klabunde et al., 2013). A Cochrane systematic review
of 32 RCTs that evaluated strategies to achieve higher response rates among
clinicians for web surveys found that the odds of response were greatest
when a ‘picture’ was included in an e-mail (OR 3.05, 95% confidence intervals
1.84 to 5.06) and when the questionnaire topic was interesting (i.e. questions
were particularly relevant to the study participant) (OR 1.85, 95% confidence
intervals 1.52 to 2.26)(Edwards et al., 2009). Other strategies that significantly
increased the odds of response included non-monetary incentives (e.g. gift
cards or lottery participation), having an e-mail that was personalised, and
including a submission deadline. However, the odds of response decreased
significantly when the word ‘survey’ was used in the e-mail subject header,
and if the e-mail was signed by a male (Edwards et al., 2009).
In this survey, the response rate varied across the professional organisations
from 2.4% from the SOeN of the Royal College of Radiologists up to 28% for
the BSDS membership, which is in line with the findings of other studies as
discussed above. The low rate seen with the SOeN may be a reflection of the
survey having been posted on a webpage with access restricted by the Royal
College of Radiologists, and would have required members to specifically log
on to the site before gaining access to the survey. As the survey was not
targeted specifically at clinicians with a particular interest in skin cancer, it is
likely that only those with such an interest will have responded, so there will
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be an element of self-selection bias. This is reflected in the average number of
SCCs treated by the respondents over a 1-year period (Table 16). Interest in
the survey subject has already been discussed above as being one of the
major incentives for participation in surveys (Edwards et al., 2009). This
survey incorporated many of the elements identified by Edwards et al. as
increasing the odds of participation, such as personalised e-mails, return
deadline, follow-up reminder after initial posting. No monetary or non-
monetary incentives were offered to participants in this survey. Monetary
incentives have not been shown to significantly increase response rates,
although there is evidence that non-monetary incentives do (Edwards et al.,
2009). The optimal value of non-monetary incentives is not known though,
and for this survey the administration of such an incentive scheme could have
proved costly due to the large number of potential participants and
impractical to administer.
The aim of this survey was to elicit information about practice and research
priorities from a relatively homogeneous group of clinicians who share an
interest in the treatment and research of nonmelanoma skin cancer.
Therefore the response overall response rates obtained in this survey, which
was not specifically targeted at those with an interest in skin cancer, may be
considered reasonable and the findings are felt to be valid for the purposes of
this research.
Non-response bias
With any survey the question of non-response bias is one which needs to be
addressed: is there a systematic difference between those who respond to
the survey and those who do not, and is this going to impact upon the
external validity of any conclusions drawn from the survey? An element of
non-response bias has been suggested by some studies of clinician postal
surveys, with reports that women, younger clinicians, non-specialists and
recently licensed clinicians are more likely to respond (Barclay et al., 2002,
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Cull et al., 2005, Creel et al., 2005). In contrast, a later study of postal survey
respondents across specialties found that men were more likely than females
to respond, although the level of bias was minimal (McFarlane et al., 2007).
Non-response bias has not yet been extensively studied in web surveys
(Dykema et al., 2013). However, there is evidence from several studies that
higher response rates are not necessarily associated with a lower level of
response bias, and even surveys with very high response rates may have
significant differences in demographic parameters between responders and
non-responders (Barclay et al., 1997, McFarlane et al., 2007). Most studies
however, have found no bias or minimal response bias, and it has been
suggested that this type of bias is less of a concern for clinician surveys than it
is for surveys of the general population as the sample frame is a more
homogeneous group and that less than optimal response rates may not
necessarily mean that there is excessive bias (Creel et al., 2005, Cull et al.,
2005).
5.5.4. Conclusions
This cross-sectional electronic survey has allowed identification of areas of
treatment uncertainty which are important to healthcare professionals. Taken
together with evidence gaps which were highlighted by the two systematic
reviews (Chapters 3 and 4), this has informed the development of four
scenarios for a potential RCT. These initial ideas for possible trials are
discussed in greater depth in chapter 6, in which the rationale behind them
will be described, along with discussion of how a trial proposal evolved
through multidisciplinary collaboration.
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6 EVOLUTION OF A TRIAL
Introduction6.1
This chapter describes the evolution of the initial ideas for possible clinical
trials that emerged from the management uncertainties identified in the
survey of healthcare professionals discussed in chapter 5. The survey,
together with the results of the systematic reviews (chapters 3 and 4), helped
to identify gaps in the evidence and have shaped the development of the trial
proposal which will be more fully discussed in chapter 9.
Initial trial scenarios6.2
Excision margins, the role of adjuvant radiotherapy, optimal follow-up
regimens, Mohs compared with standard excision, and the role of newer
agents, were the main areas where there were felt to be clinically important
uncertainties.
Four trial scenarios were initially formulated and proposed as a starting point
for further multidisciplinary discussion and the development of a trial
proposal:
1) 6mm versus 10mm excision margins for SCC classified as T2 by AJCC7
criteria on the basis of being larger than 2cm in diameter but with no
other high-risk features
2) 6mm versus 10mm excision margins for SCCs defined as T2 tumours
according to AJCC7 criteria on the basis of having two or more high-
risk features
3) Surgical excision alone with a 6mmmargin versus surgical excision
plus adjuvant radiotherapy for completely excised high-risk SCCs
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4) Surgical excision with 6mmmargin versus MMS for high-risk SCCs but
located at a low-risk site or at a site without cosmetic or functional
considerations where MMS may be preferable.
High-risk SCCs
All the trial scenarios focussed on high-risk SCCs since these were highlighted
in the survey of HCPs as being of a greater priority for research than low-risk
SCCs.
Definition of high-risk in these initial scenarios was based on the AJCC7
classification, in which T2 SCCs are defined either as 1) being greater than
2cm in diameter, or 2) of any diameter but which have two or more of the
following high-risk features: depth >2mm, poorly differentiated, perineural
ŝŶǀĂƐŝŽŶ ?ůĂƌŬůĞǀĞůA?/s ?ƌĞƚŝĐƵůĂƌĚĞƌŵŝƐŽƌďĞǇŽŶĚ ? ?ŽƌůŽĐĂƚŝŽŶŽŶƚŚĞĞĂƌŽƌ
hair-bearing lip.
Excision margins
6mm and 10mm excision margins were chosen based on current
management guidelines. UK guidelines of 6mm for high-risk SCCs are based
on the results of one study by Brodland and Zitelli in which histological
clearance of 95% of SCCs with high-risk features was achieved with a 6mm
margin (Brodland and Zitelli, 1992). A more recent study which also used
MMS found that margins closer to 5mm and 13mm would be required to
clear 95% of low and high risk SCCs respectively (Schell et al., 2013).
Recommendations regarding excision margins varies among international
guidelines; the US NCCN guidelines advise ‘ wider surgical margins’ than the
4-6mmmargin recommended for low-risk SCCs (National Comprehensive
Cancer Network, 2013), and the Australian guidelines advocating margins of
up to 10mm for SCC greater than 2cm in diameter with even wider margins
for very large tumours (Australian Cancer Council Australia and Australian
Cancer Network, 2008). There have however, been no prospective RCTs so
evidence for the adequacy of narrower versus larger surgical margins is
lacking.
184
Adjuvant radiotherapy
Current UK management guidelines recommend radiotherapy to treat non-
resectable tumours with well-defined margins, but do not give any specific
recommendation regarding which patients should be considered for adjuvant
radiotherapy (Motley et al., 2002), and this was clearly considered to be an
area of great clinical importance that was raised in the survey (chapter 5).
Australian guidelines advise that patients with any of the following high-risk
features should be considered for ART; T4, rapidly-growing, recurrent, close
histological margins (<5mm), PNI, lymphovascular invasion, in-transit
metastases or regional lymph node involvement (Australian Cancer Council
Australia and Australian Cancer Network, 2008). In the United Stated, ART is
recommended for any NMSC showing evidence of substantial PNI (involving
more than just a few small sensory branches, or a large nerve), of when
histological margins are positive after MMS or complete circumferential
excision with peripheral and deep margin assessment (National
Comprehensive Cancer Network, 2013). However, there have been no RCTs
comparing surgery alone to surgery plus ART, and a systematic review
conducted by Jambusaria-Pahlajani concluded that current data was
insufficient to identify the high-risk features for which ART may be beneficial
(Jambusaria-Pahlajani et al., 2009). This was confirmed by the systematic
review of observational studies undertaken as part of this thesis and
described in chapter 4.
Mohs micrographic surgery
The decision whether to excise cutaneous SCC by MMS or by surgical excision
with a pre-defined margin is largely based on the availability of an
appropriately trained Mohs surgeon and the facilities to perform the
procedure, in addition to the surgeon’s personal preference. Despite the
perception that there are fewer recurrences after MMS than after surgical
excision (Rowe et al., 1992), there have to date been no RCTs to directly
compare the techniques for cutaneous SCC, as discussed earlier in this thesis
(Chapter 3). In the case of BCCs, there has been an RCT that compared MMS
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with surgical excision for primary and recurrent facial BCCs which found no
statistically significant difference in recurrence of primary BCC at 5 years
(2.5% for MMS versus 4.1% for standard excision, p=0.397), although there
was a significant difference for recurrent BCCs (2.4% versus 12.1%,
p=0.015)(Mosterd et al., 2008). In the systematic review of observational
studies conducted as part of this thesis (chapter 4), there were overall fewer
local recurrences after MMS than after surgical excision, although as the
confidence intervals overlapped it could not be concluded that the difference
was statistically significant. Thus, for primary SCCs there is currently no strong
evidence that excision with MMS is superior to surgical excision in terms of
recurrences.
Mohs micrographic surgery has the advantage over standard excision in that
100% of the surgical margin is examined and it is more tissue sparing,
allowing the surgeon to follow clinically invisible extensions of the tumour to
clearance. Current UK management guidelines recommend consideration of
MMS for high-risk SCCs especially at difficult sites where wide surgical
margins would be difficult to achieve without functional impairment (Motley
et al., 2002). In Australia, MMS is recommended for poorly-defined SCCs,
those in anatomically sensitive areas, recurrent or residual tumours and for
extensive disease (Australian Cancer Council Australia and Australian Cancer
Network, 2008). In the United States, the rate of use of MMS in 2009 was
700% greater than it was in 1992 and it is estimated that 1 in 4 skin cancers
are excised by MMS (Donaldson and Coldiron, 2012). Recently published
appropriate use criteria for MMS from the United States are much more
inclusive than the guidelines elsewhere, rating MMS as appropriate for
treating SCCs at any body site if they have aggressive features (characterised
ĨŽƌƚŚĞƉƵƌƉŽƐĞƐŽĨƚŚĞƉĂƉĞƌĂƐA? ?ŵŵĚĞĞƉ ?ůĂƌŬůĞǀĞůA?/s ?ƉŽŽƌůǇŽƌ
undifferentiated, perineural/perivascular invasion, sclerosing, basosquamous,
small cell, spindle cell, pagetoid, single cell, clear cell, lymphoepithelial,
sarcomatoid, infiltrating, or central facial keratoacanthoma). However, the
uncertainty of the appropriateness of MMS to treat SCC without aggressive
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histological features that were between 1.1 and 2cm in diameter on the trunk
and extremities in healthy patients, and up to 1cm in diameter on the trunk
and extremities in immunosuppressed patients was highlighted. The only
inappropriate indications were for treating SCC with no aggressive features
and less than 1cm in diameter, located on the trunk and extremities of
healthy individuals (Connolly et al., 2012). The criteria were, however, based
largely upon expert opinions rather than high-quality evidence and the
indications for MMS remain debateable both in the United States and in
Europe (Kelleners-Smeets and Mosterd, 2013).
Further development of the trial scenarios6.3
The RCT being developed will be the first of its kind to directly address
treatment uncertainties for the kinds of primary cutaneous SCC that are
commonly seen in clinical practice. Early engagement with professionals who
will ultimately be instrumental in delivering the trial that emerges as a result
of the research in this thesis is therefore imperative if the trial is to be
accepted, funded and ultimately to provide data that will strengthen the
evidence-base for SCC treatments and be of benefit to patients in the long-
term. Consequently, after initial formulation of the above trial scenarios,
there was early liaison with the non-melanoma subgroup of the Skin Cancer
Clinical Studies Group of the National Cancer Research Institute (NCRI), which
has been central to the development of the trial proposal.
6.3.1. The NCRI Skin Cancer Clinical Studies Group
Established in 2006, the members of this national organisation include
dermatologists, plastic surgeons, clinical oncologists, medical oncologists,
medical statisticians and a patient representative. The aim of the group is to
promote and support high-quality, multicentre clinical trials, translational
research and other activities in the field of non-melanoma skin cancer, with
particular support for research into rarer NMSCs such as Merkel cell
carcinoma, dermatofibrosarcoma protuberans (DFSP) and Kaposi’s sarcoma,
and for initiatives to improve the evidence base for the treatment of the
common keratinocyte tumours such as SCC.
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As this research therefore falls into their remit to promote such work, the
support from the group has been, and will continue to be, of crucial
importance if the trial is to be delivered successfully. Discussions with them
have of necessity been detailed and have involved a considerable amount of
debate between the members. However, if the dearth of clinical trials in this
area is to be redressed, it is important that the trial that is submitted for a
funding application has been thought out as carefully as possible in advance.
Inevitably there are many issues that need to be addressed when designing a
trial like this and it is imperative that all interested stakeholders are on board
with the proposal if a funding application is to be successful and the trial is to
recruit optimally.
The above scenarios were presented to the NCRI non-melanoma subgroup in
January 2012, generating much interest and debate. It was felt that the
adequacy of excision was central to the development of future trials, in
addition to informing clinical guidelines. However, a trial of excision margins
alone would not adequately address important clinical issues around
management, such as acquiring a deeper knowledge of the biology of SCC
facilitating the development of a prognostic model for making treatment
decisions, and the question as to whether ART may be of benefit for particular
patients. In order to address such issues, a two-stage factorial design trial was
primarily regarded as the best way forward:
Surgical intervention
6mm 10mm
ART
Yes 9 ‘High-risk’ SCC 9 ‘High-risk’ SCC
No 9 ‘High-risk’ SCC 9 ‘High-risk’ SCC
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Participants: Patients with histologically proven high-risk SCCs (definition to
be discussed later in this chapter)
Interventions and Comparators:
First stage: Margin-controlled surgical excision, 6mm versus 10mm
margin of normal looking skin
Second stage: ART versus normal follow-up
Outcomes:
Primary - loco-regional recurrence, distant metastasis up to 3 years, 5
year survival
Secondary – completeness of excision, quality of life, cosmetic
appearance, adverse events.
6.3.2 Factorial randomised controlled trials
There are examples of factorially designed RCTs across many therapeutic
areas (Hull et al., 2013, Gridelli et al., 2007, Sever et al., 2001, Emmett et al.,
2005). A prime advantage of factorial RCTs is that they allow more than one
intervention to be evaluated in the same study, which consequently may be
less expensive than running two simultaneous trials, although they are only
suitable for interventions that can be used in conjunction with one another as
is the case with surgical excision and ART. In addition they can allow for the
effects of each intervention to be considered separately and in combination.
However, there are some design considerations that need to be taken into
account with factorial RCTs. A sample size calculation that is powered to
detect the main effects of each intervention makes the assumption that there
is no interaction between the interventions, in other words that the effect of
receiving the second intervention will remain the same regardless of the
treatment arm allocated for the first intervention. However, it is usually
difficult to make such a categorical assumption and this may be a particular
concern in studies in which the interventions are modifiers of behaviour or
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organisations (Montgomery et al., 2003). If investigation of the degree of
interaction between the interventions is of importance then a larger sample
size would be required in order for the trial to be adequately powered to
detect this.
In the case of the trial proposed, it was felt that such a factorial design would
be possible given that SCC is a common tumour (although complicated by
low-recurrence rates).
Extensive discussions have taken place throughout the development of the
trial proposal regarding the definition of ‘high-risk’ SCC for the purposes of
the trial, and also the size of histological margin that will be considered
acceptable for classifying an SCC as having been completely excised.
6.3.4 Defining high-risk SCCS
Initially, it was envisaged that AJCC7 criteria would be used to define SCCs at
higher risk of recurrence and metastasis and the initial trial scenarios
formulated were based on this classification. However, since the publication
of the UICC in 2009 and AJCC7 in 2010, there has been criticism of both
schemes for the classification of cutaneous SCCs. The AJCC classification and
the new BWH criteria that have been proposed as an alternative staging
system are discussed in depth in chapter 7 of this thesis. In summary, the
BWH classification is based on the number of risk factors present, with
subdivision of T2 tumours to allow for better discrimination of those deemed
to have a worse prognosis (Table 21).
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Table 21: BWH alternative staging system for SCC (Karia et al., 2013)
Primary tumour Criteria
T0 In situ SCC
T1 0 risk factors
T2a 1 risk factor
T2b 2-3 risk factors
T3 4 risk factors or bone invasion
ZŝƐŬĨĂĐƚŽƌƐA?A? ?ĐŵĚŝĂŵĞƚĞƌ ?ƉŽŽƌůǇĚŝĨĨĞƌĞŶƚŝĂƚĞĚ ?ƉĞƌŝŶĞƵƌĂůŝŶǀĂƐŝŽŶ ?
invasion beyond subcutaneous fat
Because of the deficiencies of the current AJCC system, the AJCC and BWH
criteria will therefore be compared in the analysis of SCCs described in
chapter 7. On the basis of these results and on the results in the original
publications describing the new BWH staging system (Jambusaria-Pahlajani et
al., 2013, Karia et al., 2013), it was decided that the BWH, or a modification
thereof, would be more suited for the purposes of the proposed trial,
particularly in the identification of the highest-risk tumours which would be
eligible for the second randomisation stage to receive ART or no ART.
However, there are some criticisms of the BWH classification. A major
drawback of this system is that it does not include depth as a risk factor, as
the authors found that this was not recorded in the pathology reports of the
tumours they included in their analysis and thus did not feature in their
multivariate analysis (Karia et al., 2013). Also, they did not define the
percentage of poorly differentiated cells required in order to define the
tumour as such. Although PNI was considered to be a risk factor if the nerve
involved had a calibre greater or equal to 0.1mm, there was no distinction
between intratumoral PNI (i.e. not extending beyond the edge of the SCC on
histology) or extratumoral (nerve invasion extending beyond the edge of
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surrounding tumour). However, it is believed that extratumoral spread carries
a worse prognosis (Miller et al., 2012).
As there is currently no one ideal classification system, the basic structure of
the BWH system will be used for the purposes of this trial, but the risk factors
upon which T2a and T2b are based will be modified to take into account the
core-data set items that are routinely collected in the UK on the RCPath
proforma. The differences are summarised in Table 22 .
Table 22: Comparison of BWH high-risk features and modified features for this trial
BWH high-risk features Modified criteria for
trial
Comment
2cm or greater diameter Greater than 2cm
diameter
RCPath dataset item
>2cm so modified
criteria would make
data easier to capture
Depth not a factor Greater than 4mm deep RCPath dataset item
>4mm
Poorly differentiated Poorly/undifferentiated Based on most poorly
differentiated region
irrespective of %
present
Perineural invasion in
ŶĞƌǀĞĐĂůŝďƌĞA? ? ? ?ŵŵ
Perineural invasion Nerve calibre not
recorded in dataset.
Invasion beyond
subcutaneous fat
Invasion beyond
subcutaneous fat
Recorded in RCPath
dataset
Site not a feature Ear or lip location Site not a feature of
BWH but ear or lip
location are a high-risk
feature in AJCC7
6.3.5 Histological margins
In the proposed trial only SCCs that have been adequately excised in the first
surgical stage will be eligible to be randomised in the second if they meet the
other eligibility criteria for the ART stage (i.e. T2b tumours). What constitutes
an adequate histological margin is very debateable and re-treatment based
on the size of histological margins is inconsistent among clinicians. In the
Brodland and Zitelli study upon which current clinical excision margins
recommendations are largely based (Brodland and Zitelli, 1992), histological
192
clearance was set at greater than one microscopic high power field (0.5mm),
and this has also been used in one other study as the cut-off for adequacy of
excision (Thomas et al., 2003). However, a recent study reported that of 79
SCCs that were re-excised due to involved or close histological margins
(<1mm), 11% recurred (9 of 79). Twenty-one of the re-excised SCCs had
residual tumour on re-excision, with recurrence in six (29%) of these,
compared with 5% recurrence in the 58 SCCs in which no residual tumour was
found (Bovill and Banwell, 2012). However, an unexpected finding in this
study was that 2 of 16 ‘closely’ excised SCCs (13%) had residual tumour on re-
excision, although numbers were small. On the basis of their findings the
authors recommended re-excision of any SCCs where narrow or close margins
were reported on histology. Nevertheless the evidence base regarding the
adequacy of histological margins is very limited.
The UK clinical guidelines (Motley et al., 2002) assume that an SCC has been
incompletely excised if tumour cells extend to the margin. The RCPath
requires a mandatory core minimum reporting of lateral and deep margins of:
a) margin involvement (0mm); b) margins clear but close (less than 1mm);
c) margins clear (1mm to 5mm); or d) margins clear (>5mm) (Chaudhuri et al.,
2006). It is the SCCs that fall into the ‘clear but close category’ (i.e. closer than
1mm) that are most controversial, and although one-third of regional
dermatologists considered SCCs reported as such to have involved margins,
there was no consistent approach to the re-excision of these SCCs (Chaudhuri
et al., 2006). This is undoubtedly an area where the evidence needs to be
strengthened in order to inform future guidance. Therefore, for the purposes
of this study and based on the data that is collected on the RCPath proforma,
only SCCs with peripheral and deep margins greater than 1mm will be eligible
for the second randomisation stage. However, one of the secondary
outcomes will be completeness of excision determined by histological margin
measurement following surgical excision, so this data which will add to the
evidence base regarding the adequacy of histological margins.
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Summary6.4
As a result of the clinically important treatment uncertainties that were
identified by healthcare professionals, four initial trial scenarios were drawn
up which were presented to the NCRI non-melanoma CSG with a view to
further development of a proposal for an RCT for submission for funding. The
next two chapters in this thesis describe feasibility work which was
undertaken in order to assess the likely numbers of patients and the types of
SCC that would be potentially be eligible for recruitment into the RCT being
developed, and to assess the acceptability of such a trial and possible barriers
to recruitment which would need to be considered when designing the trial.
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7 CASE SERIES OF SQUAMOUS CELL CARCINOMAS
TREATED IN NOTTINGHAM
Abstract7.1
Introduction
There is currently no consistent prognostic model for cutaneous SCCs and
further elucidation of the inter-relationship between the various prognostic
features and outcomes will require large prospective studies to be conducted.
The main objective of this part of the research was to determine the types
and numbers of SCC that are treated over the course of a year at a large
regional centre. This information will guide the design of a randomised
controlled trial (RCT) which will provide data that should help clinicians to
target particular SCCs treatments appropriately and more consistently than is
currently the case.
Methods
Using a specially designed database, data were collected on all cutaneous
SCCs submitted to the histopathology department for two 12-month periods,
2006-7 and 2010-11. Information was gathered on demographics, prognostic
features, and for the 2006-7 dataset information was also collected on the
occurrence of adverse outcomes within 5 years of treatment. The two
datasets were compared for demographic distribution and numbers treated.
An analysis of the specialties treating SCC was also done for the 2010-11
dataset. SCCs were classified according to AJCC criteria, and also according to
an alternative staging system, the Brigham and Women’s Hospital scheme,
which will be utilised to identify high-risk SCC eligible for entry into the
proposed RCT. The number of patients that would be eligible for each stage of
randomisation in the proposed trial was approximated based on the
percentages of SCCs classified in each T-stage.
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Results
The number of patients with SCC treated in Nottingham increased from 357 in
2006-7 to 423 in 2010-11, and there was also a significant increase in the age
of treated patients from 76 years to 78 years (independent sample t-test
p=0.04) . The majority of SCCs were treated by dermatologists and plastic
surgeons, with women and larger SCCs being more likely to be treated by
plastic surgeons.
Mean clinical excision margins were slightly above the 4mm for low-risk and
6-mm for high-risk margins, as recommended in current UK guidelines. There
was histological involvement of the surgical edge in 3% of excised SCCs, with
the deep edge being significantly more likely to be implicated than the
peripheral edge (p=<0.001).
Adverse outcomes within 5 years as a result of SCC were rare, with overall
local recurrence of 6.2%, regional recurrence of 3.3% and SCC-attributable
death of 1.5%. There were no distant metastases recorded in this dataset. On
multivariate analysis, local recurrence was associated with PNI and vascular
invasion, and regional recurrence with diameter of >2cm. Only increased age
was found to be significantly associated with SCC-related death.
Just over 50% of SCCs that were classifiable from the data available were T2
tumours by both the most recent AJCC7 classification scheme, and by the
alternative BWH scheme. However, BWH staging allows for an additional T2b
substage to better stratify outcomes dependent on the number of risk factors
present. Based on this scheme, 19% of all BWH classifiable tumours would be
classed as T2b, and potentially eligible for randomisation into the second
adjuvant radiotherapy (ART) stage of the proposed RCT. Inclusion of >4mm
depth as an additional risk factor would increase the number of T2b SCCs to
30.5% of all BWH classifiable tumours.
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Conclusion
SCC is a common tumour and large numbers are treated annually in this
regional centre. This study has allowed estimation of the types and numbers
of SCCs in order to give an approximation of the number of patients who
could potentially be eligible to be recruited into the proposed trial based on
the prognostic features associated with their SCC and its classification.
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Introduction7.2
This chapter describes work that has been done to gain an overview of the
numbers, types, and baseline 5 year outcomes of SCCs treated across
specialties at a regional centre each year, in order to assess likely numbers
and demographics of patients potentially eligible for recruitment into the
proposed RCT being developed and to guide sample size calculation for the
proposed trial. The evolution of the proposed trial has been discussed in
chapter 6 and the current trial proposal will be described in greater detail in
chapter 8; briefly it will involve two randomisation stages, the first to
compare outcomes between surgical excision with wide margins and Mohs
micrographic surgery, and the second stage to evaluate the effect of adjuvant
radiotherapy versus no adjuvant radiotherapy. SCCs have been assessed in
terms of the presence of various prognostic features and classified according
to both the most recent AJCC classification (Edge and Compton, 2010) and
also an alternative SCC staging scheme, the Brigham and Women’s Hospital
scheme (BWH)(Karia et al., 2013), which aims to better discriminate SCCs in
terms of their prognosis.
7.2.1. Tumour classification of SCC
The Tumour Node Metastasis (TNM) system was originally developed and is
maintained by the Union for International Cancer Control (UICC) in an
attempt to achieve consensus on one globally recognised standard for
classifying the extent of spread of cancer (Sobin et al., 2009). The TNM system
is also used by the American Joint Committee on Cancer (AJCC) (Edge and
Compton, 2010) for staging cancer, but unlike the UICC, the AJCC classifies
SCCs separately from other skin tumours and in the most recent edition
(AJCC7) has attempted to better discriminate tumours at higher risk of
recurrence based on the presence of particular features. Comparison of the
UICC, and the AJCC 6th and 7th editions is made in Table 23. Although a
considerable improvement on the AJCC6 criteria, neither the UICC nor AJCC
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classification has been deemed suitable for a realistic estimate of the risk of
metastasis of SCC (Breuninger et al., 2012). For the UICC classification in
which the cut-off between T1 and T2 tumours is solely maximum diameter of
greater than 2cm (Sobin et al., 2009), most poor outcomes occur in T1
tumours as this group contains many tumours with risk factors other than
diameter, whereas in the AJCC7 system, the bulk of poor outcomes occur in
T2 SCCs (Karia et al., 2013). The AJCC criteria have also been criticised for
their omission of particular features that are associated with increased risk,
such as occurrence of SCC in a chronic burn, scar or area of inflammation,
recurrent disease and immunosuppression in the host (Buethe et al., 2011a).
The authors of the AJCC7 criteria concede that their staging scheme is not
perfect and that further multivariate analyses are still required to determine
the relative contributions of the individual risk factors towards prognosis and
to inform the development of treatment algorithms (Farasat et al., 2011).
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Table 23: Comparison of the UICC, AJCC6 and AJCC7 staging schemes
UICC (Sobin et al., 2009) AJCC6 (Greene et al., 2002) AJCC7 (Edge and Compton, 2010)
T1 A? ?ĐŵŝŶŐƌĞĂƚĞƐƚĚŝŵĞŶƐŝŽŶ A? ?ĐŵŝŶŐƌĞĂƚĞƐƚĚŝŵĞŶƐŝŽŶ A? ?ĐŵŝŶŐƌĞĂƚĞƐƚĚŝŵĞŶƐŝŽŶďƵƚǁŝƚŚĨĞǁĞƌ
than 2 high-risk features*
T2 >2cm in greatest dimension >2cm up to <5cm in greatest
dimension
>2cm with fewer than 2 high-risk features*
OR
dƵŵŽƵƌĂŶǇƐŝǌĞǁŝƚŚA? ?ŚŝŐŚ ?ƌŝƐŬĨĞĂƚƵƌĞƐ ?
T3 Invasion of deep structures e.g.
muscle, bone, cartilage, jaws, orbit
>5cm in greatest dimension Invasion of mandible, maxilla, orbit,
temporal bone
T4 Direct or perineural invasion of skull
base or axial skeleton
Invasion of deep extradermal
structures
Invasion of the skeleton (axial or
appendicular) or PNI of the skull base
 ?AN ?ŵŵƚŚŝĐŬ ?ůĂƌŬůĞǀĞůA?/s ?ƉĞƌŝŶĞƵƌĂůŝŶǀĂƐŝŽŶ ?Ɖƌ ŵĂƌǇƐŝƚĞĞĂƌŽƌŶŽ ?ŚĂŝƌ ?ďĞĂƌŝŶŐůŝƉ ?ƉŽŽƌůǇŽƌƵŶĚŝĨĨĞƌĞŶƚŝĂƚĞĚ
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Alternative staging systems have been proposed since the publication of the
AJCC7 criteria and the rationale underpinning them will need consideration
when the AJCC criteria are updated for the eighth edition which is due in 2017
(https://cancerstaging.org/About/news/Pages/8th-Edition-Publication-Date-
Announced.aspx). A simplified T staging system has been proposed by
Breuninger (Breuninger et al., 2012) in an attempt to estimate risk of
ŵĞƚĂƐƚĂƐŝƐďĂƐĞĚŝŶŝƚŝĂůůǇŽŶĚŝĂŵĞƚĞƌ ?ĐůŝŶŝĐĂůd ?A? ?ĐŵA? RůŽǁ ?ƌŝƐŬ ?AN ?ĐŵA?
‘high’ risk), with further subdivision into ‘no risk’, ‘low risk’ and ‘high risk’
ƉŽƐƚ ?ŽƉĞƌĂƚŝǀĞůǇďĂƐĞĚŽŶƚŚĞĚĞƉƚŚŽĨŝŶǀĂƐŝŽŶ ?A? ?ŵŵ ?AN ? ? ?ŵŵ ?ĂŶĚAN ?ŵŵ
respectively). Desmoplastic and undifferentiated tumours, ear location and
immunosuppression are considered as co-risk factors for metastasis in this
proposed scheme. However, the presence of PNI is not included as a co-risk
factor as the authors considered this feature only to be exhibited by
desmoplastic SCCs (Breuninger et al., 1997), which were in their own
multivariate analysis significantly associated with local recurrences, with or
without PNI (Brantsch et al., 2008). However, as discussed above, other
studies have suggested that PNI is an important risk factor for poorer
prognosis, and none of the SCCs reported as having PNI in this study were
associated with desmoplastic pathology. As the presence of PNI is one of the
major factors upon which an MDT decision to administer ART is currently
made, albeit on a poor evidence base as discussed in chapter 4, it would be
difficult to reconcile using a staging system in the proposed trial which does
not take the presence of PNI into account.
A further alternative staging system has been recently proposed, which
although still based on the AJCC7 staging, appears to offer improved
prognostic discrimination (Jambusaria-Pahlajani et al., 2013, Karia et al.,
2013). The AJCC7 T2 stage is very heterogeneous and patients who do well
are clustered with those whose prognosis is poor, with 69% of all local
recurrences, 83% of regional metastases, and 92% of SCC attributable deaths
reported in the 91 SCCs (44% of a total of 207) that were categorised as T2
according to AJCC7 criteria (Jambusaria-Pahlajani et al., 2013). The alternative
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system attempts to improve the homogeneity (outcomes are similar within
staging groups), monotonicity (outcomes worsen with increasing stage) and
distinctiveness (outcomes differ between staging groups), based on four risk
factors that were identified by the authors’ own multivariate analysis (Table
24).
Table 24: Alternative SCC staging scheme (Karia et al 2013)
BWH Stage Criteria
T0 In situ SCC
T1 No risk factors
T2a 1 risk factor
T2b 2-3 risk factors
T3 4 risk factors OR bone invasion
 ?ƚƵŵŽƵƌĚŝĂŵĞƚĞƌA? ?Đŵ ?ƉŽŽƌůǇĚŝĨĨĞƌĞŶƚŝĂƚĞĚŚŝƐƚŽůŽŐǇ PWE/ŝŶ
ŶĞƌǀĞŽĨĐĂůŝďƌĞA? ? ? ?ŵŵ ?ŝŶǀĂƐŝŽŶďĞǇŽŶĚƐƵďĐƵƚĂŶĞŽƵƐĨĂƚ
The larger of the two studies (Karia et al., 2013) which included 1817 SCCs,
reported that although the higher T2b and T3 stages contained only 5% of
SCCs in the total cohort, they accounted for the 60% of poor outcomes,
including 70% of regional metastases. Although these findings require
refinement and validation, they suggested that the alternative scheme could
be used upon which to base further studies of sentinel lymph node biopsy
(SNLB) and adjuvant radiotherapy. A recent evaluation of the association
between positive sentinel lymph node biopsy and stage, concluded that there
appeared to be better stratification of outcomes in the alternative staging
system compared with the AJCC7 staging system, with positive SNLBs in none
of the 9 BWH T1 tumours, 6 of 85 (7%) T2a SCCs, 5 of 17 (29%) T2b SCCs, and
in 3 of 6 (50%) of T3 SCCs (p=0.02) (Schmitt et al., 2014).
In the proposed trial which will be discussed in greater depth in chapter 8, the
second stage will involve randomisation to receive ART or no ART. However,
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only SCCs that are considered to be particularly high-risk will be eligible for
this stage, as it is in this group where there is greatest uncertainty as to the
effectiveness of ART, which was borne out in the survey of healthcare
professionals described in chapter 5 of this thesis. Also, as there are potential
long-term adverse effects of administering radiotherapy, it would ethically be
unacceptable to subject patients to the procedure if their tumour is lower-risk
and the prognosis with surgery alone is relatively good. As the BWH scheme
does appear to give better stratification of prognosis for patients than that of
AJCC7, a modification of this scheme will be used in the proposed trial to
identify those patients with higher-risk SCC, and in whom it is important to
investigate whether ART has an important role or not. This chapter therefore
includes a comparison of the AJCC7 and BWH classification schemes, the
number of SCCs according to stage and an analysis of outcomes for each
scheme. However, the BWH scheme has been adapted slightly in accordance
with data that is collected routinely in the RCPath dataset (Chaudhuri et al.,
2006) in order to reflect more accurately what would happen in the actual
trial. Therefore, the BWH risk factor of ‘tumour diameter of 2cm or more’ is
modified to ‘greater than 2cm’, and instead of PNI in a ‘nerve calibre of equal
to or greater than 0.1mm’ any PNI will be considered to be a risk factor.
Invasion ‘beyond subcutaneous fat’ is modified to ‘subcutaneous or beyond’
as a compromise between the BWH and AJCC7 classification, in which
invasion at or beyond the reticular dermis is a risk factor. One of the major
criticisms of the BWH scheme is that it has not taken into account the Breslow
thickness of the tumour, as this was not routinely reported on their pathology
reports (Jambusaria-Pahlajani et al., 2013). However, depth above 4mm has
been shown to be an important independent risk factor for metastasis in
several studies (Kraus et al., 1998a, Dinehart and Pollack, 1989, Breuninger et
al., 1997, Brantsch et al., 2008), and is one of the RCPath’s high-risk features
(rather than >2mm which is incorporated into the AJCC7 classification as a
risk factor). Therefore, in order to better estimate likely numbers of SCC that
would be eligible in the proposed trial, those that are deeper than 4mm are
included in a separate analysis.
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Methods7.3
7.3.1. Data collection
An anonymised web-based Access database was created to collect
retrospective data on SCCs submitted to the Histopathology Department at
Queen’s Medical Centre, Nottingham. There were two data collection
periods: the first was conducted between 1 April 2011 and 31 March 2012
with the purpose of giving a rapid overview of the number of SCCs treated
annually in Nottingham, and by which specialty, and the second was between
1 April 2006 and 31 March 2007, data from which was analysed in greater
depth in terms of prognostic features and outcomes within five years after
treatment. Primary cutaneous SCCs were identified by the Systematized
Nomenclature of Medicine Clinical Terms (SNOMED CT codes) M80703,
80713, 80743, 80753 and 80513 and histopathology data from the dataset
recorded in the appropriate fields.
Features of the tumour including anatomic location, diameter, depth of
invasion, Clark level, differentiation, histological growth pattern, perineural
invasion and vascular invasion were recorded. In addition, for the 2006-7
database from which outcome data was to be assessed, excised tumours
were classified according to T classification based upon the sixth and seventh
editions of the American Joint Committee on Cancer (AJCC) staging criteria
(Edge and Compton, 2010) and the BWH criteria (Karia et al., 2013). T
classification in the sixth edition was based upon tumour diameter and did
not take into account additional high risk pathological features (T1 =<2cm,
T2=2-5cm, T3 >5cm), whereas in the seventh edition, T2 SCCs are those with
either a diameter of greater than 2cm, or those equal to or less than 2cm in
diameter, but which also have 2 or more additional high risk features (>2mm
deep, Clark level IV or beyond, the presence of perineural invasion, being
located on the ear or non-hair-bearing lip, or being poorly differentiated or
undifferentiated). BWH T classification was based upon the presence of the
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ŶƵŵďĞƌŽĨŚŝŐŚ ?ƌŝƐŬĨĞĂƚƵƌĞƐƉƌĞƐĞŶƚ ?A? ?ĐŵĚŝĂŵĞƚĞƌ ?ƉŽŽƌůǇĚŝĨĨĞƌĞŶƚŝĂƚĞĚ ?
PNI, invasion into subcutaneous fat or beyond). As data on depth and level of
invasion was only routinely available for excised SCCs, only these samples
were given a T classification. Treatment of tumour and clearance of lateral
and deep surgical margins was recorded when possible. Non-invasive SCCs,
actinic keratosis, Bowen’s disease and recurrent SCCs were not included in
the analysis. Tumours were excluded if they were in ano-genital locations or
mucosal.
SCCs identified from the earlier dataset were linked to the clinical record
database via hospital identification numbers and data on recurrences (local or
to regional lymph nodes), distant metastases, and death, either attributable
to SCC or from another cause, which occurred within five years of treatment
were recorded on the research database by the Dermatology Department.
Deaths that were recorded as attributable to SCC were checked by the
Dermatologist from the patient’s case records. For patients with more than
one SCC treated over the course of the year, the SCC with the greatest
number of adverse prognostic features was selected for analysis of potential
trial participant numbers.
7.3.2. Statistical analysis
Baseline demographic variables and clinical and histopathological data were
analysed using descriptive statistics and frequency tabulation in SPSS 21.
Statistical significance of differences between variables was assessed by chi-
squared test or, in the case of small frequencies, by Fisher’s test. Differences
between means of continuous variable were assessed with independent
samples T-test. Levene’s test was used to test for equality of variances. P
ǀĂůƵĞƐŽĨA? ? ? ? ?ǁĞƌĞĐŽŶƐŝĚĞƌĞĚƚŽďĞƐƚĂƚŝƐƚŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚ ?KƵƚĐŽŵĞ
frequencies were based upon excised tumours which had data recorded for
local recurrence, regional recurrence, distant metastases, and death.
The simultaneous impact of different risk factors was determined by
multivariable analysis using a logistic regression model on the full data set.
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Patients with missing exposure data were coded as ‘missing’ and included in
the analyses. Collinearity between variables was assessed using chi-squared,
Fisher’s Exact or t-tests, as appropriate. The regression models were built
using the variables identified as significantly related to the outcome in
univariable analyses. The models were then augmented through deleting
variables that became non-significant. Finally, variables which were not
significantly related to the outcome in the univariable analyses were added
individually to assess whether they became significant in the multivariable
model. The final multivariable models included variables which were
statistically associated with the outcome at the 5% level. Results from the
logistic regression analyses are reported as odds ratios with 95% confidence
intervals.
7.3.3. Approval
Written permission to conduct the study was obtained from the Cancer and
Associated Specialties Directorate Clinical Director of Nottingham University
Hospitals NHS Trust.
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Results7.4
7.4.1. Comparison of the 2006-7 and 2010-11 datasets
There were 518 primary invasive cutaneous SCCs identified through the initial
pathology database search of specimens submitted between 1 April 2010 and
31 March 2011. Six were excluded as they were ano-genital or located at non-
cutaneous sites, leaving 512 specimens in 423 patients. The initial pathology
database search for April 2006 to March 2007 identified 431 primary invasive
SCCs that had been submitted over the 12 month period. Ten of these were
excluded upon further review as they were sited in ano-genital, mucosal or
non-cutaneous locations, so in total there were 421 SCCs from 357 patients.
During the 2010-11 period, there were 91 more SCCs in 66 more patients
compared with the 2006-7 data, representing a 22% increase in SCCs
submitted, and an 18.5% increase in the number of patients treated.
Demographics
The demographics of the patients in each of the databases are compared in
Table 25. The male: female ratio was 1:0.54 in 2006-7 and 1:0.61 in 2010-11,
which was not significantly different between the two datasets (p=0.51).
Table 25: Comparison of patient characteristics in 2006-7 and 2010-11 datasets
Characteristic
Number (%) of patients
p-value
ʖ2/independent
sample t-test
2006-7
(N=357)
2010-11
(N=423)
Gender
Male 231 (64.7) 263 (62.2)
0.51Female 126 (35.3) 160 (37.8)
Age
Mean 76.0 years
(range 34–99
years)
Mean 77.7 years
(range 15-101
years)
0.04
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An independent samples t-test revealed that patients treated during 2010-11
were significantly older than those treated during 2006-7 (mean difference =-
1.68, 95% CI -3.28 to -0.078, p=0.04). There was no statistically significant
difference between the mean ages of males and females in the study
population for either of the datasets (independent samples t-test, p=0.416
and p=0.422 for 2006-7 and 2010-11 respectively).
Between 2006-7 and 2010-2011 there were no statistically significant changes
in the distribution of patients according to age group categories (chi-squared
test, p=0.46) (Table 26). However, there may have been a slight increase in
the number of proportion of patients over 80 years between 2006-7 and
2010-11, although it is not possible to confirm the significance of this from
the data available.
Table 26: Number of patients in each age group category for the two datasets
Age category
(years)
Number (%) of patients
2006-7 (n=357) 2010-2011 (n=423)
<40 4 (1.1) 2 (1.1)
40-49 4 (1.1) 4 (1.0)
50-59 24 (6.7) 23 (5.4)
60-69 55 (15.4) 57 (13.5)
70-79 113 (31.6) 125 (29.6)
>80 157 (44.0) 212 (50.1)
The majority of patients had one SCC excised during each of the 12-month
periods (96% for 2006-7 and 94% for 2010-11). During 2006-7, ten (3%)
patients had a second SCC submitted for histopathology, and four patients
(1%) had three. For the 2010-11 12 month period, there were 20 patients
(5%) with a second SCC, three (0.7%) with four SCCs, and one (0.2%) for
whom six separate SCC were submitted (a patient with xeroderma
pigmentosum).
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Specimen types
The types of specimens submitted during each of the two data collection
periods is summarised in Table 27.
Table 27: Comparison of specimen types submitted during 2006-7 and 2010-11
Specimen type Number of specimens (%)
2006-7
(N=421)
2010-11
(N=512)
Excision 298 (70.8) 356 (69.5)
Incisional biopsy 5 (1.2) 3 (0.6)
Punch biopsy 61 (14.5) 83 (16.2)
Shavings 3 (0.7) 9 (1.8)
Curettings 34 (8.1) 25 (4.9)
Widening of
previous excision
5 (1.2) 14 (2.7)
Not specified 15 (3.6) 22 (4.2)
The types of specimens submitted to histopathology did not appear to vary
significantly between 2006-7 and 2010-11 (chi-squared test, p=0.117).
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7.4.2. Specialties treating cutaneous SCCs
The 2010-11 database was analysed according to treating specialities (Figure
46).
Figure 46: Specialties treating cutaneous SCCs (2010-11)
90% (459/512) of SCCs submitted to histopathology were sent by
dermatologists (74%) or plastic surgeons (16%). 5% (26) were sent from GPs,
of which 6 were punch biopsies, 4 were curettings, 1 was an incisional biopsy,
and 1 was not specified. One of the punch biopsies from an SCC located on
the scalp was followed with excision by the GP. The remaining SCCs were sent
from maxilla-facial surgeons (5/512), ENT surgeons (3/512) and
ophthalmological surgeons (1/512).
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7.4.3. Comparison of SCCs treated by dermatologists and
plastic surgeons
Excised SCCs submitted by dermatologists and plastic surgeons were analysed
to see if there were any differences between the types of SCCs that are
treated by these specialties (Table 28).
Table 28: Comparison of SCCs excised by dermatologists and plastic surgeons (2010-2011 dataset)
Dermatology Plastic Surgery p-value
Gender:
Male
Female
65.2% (133/204)
34.8% (71/204)
48.1% (25/52)
51.9% (27/52)
0.023
Mean age (SD) 77.6 (10.4) 76.9 (13.0) 0.692
Mean diameter [mm]
(SD)
12.1 (7.2) 18.8 (13.5) <0.001
Mean depth [mm]
(SD)
3.4 (2.1) 4.2 (4.5) 0.124
Invasion
subcutaneous or
beyond
20.0% (48/240) 29.2% (19/65) 0.111
Poorly differentiated 25.9% (64/247) 33.3% (22/66) 0.230
PNI present 4.1% (10/241) 1.5% (1/65) 0.316
Mean histological
peripheral margin
[mm] (SD)
5.1 (2.0) 5.4 (3.1) 0.436
Mean histological
deep margin [mm]
(SD)
3.5 (2.3) 3.7 (3.2) 0.640
Plastic surgeons excised SCCs from more females than males during the 12
month period analysed; this was a reversal of the male: female ratio of 1: 0.6
across the entire database and was also significantly different from the
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proportion of males to females treated by dermatologists during the same
time period (chi-squared test, p=0.023). Plastic surgeons were also treating
SCCs that were significantly larger in diameter than their dermatology
colleagues (mean diameter 18mm for plastic surgeons compared with 12mm
for dermatologists; (t-test, p<0.001). There were no significant differences
found in the other variables assessed.
7.4.4. Characteristics of tumours
As outcome data was only available for the 2006-7 dataset, these tumours
were analysed for their characteristics and staged according to the AJCC6 ,
AJCC7, BWH criteria and RCPath features.
375 unique SCCs were included in the analysis. There were no significant
differences between the demographics of patients who had excision and
those for whom another type of specimen was submitted but in whom there
was no matching excision specimen (male: female 66.7%:33.3% for excisions
versus 61.7%:38.3% for others [chi-squared test, p=0.407]; mean age 76.0
years (SD11.89) versus 75.6 years (SD 10.19)[independent samples t-test,
p=0.780]).
Tumour characteristics are summarised in Table 29.
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Characteristic Number (%) of tumours (N=375)
Location Head and neck 231 (61.6)
Trunk 23 (6.1)
Upper limb 53 (14.1)
Lower limb 63 (16.8)
Not specified 5 (1.3)
Tumour
diameter
Mean 18.1 mm
Median 12.0 mm
=<2 cm 162 (43.2)
>2 cm 33 (8.8)
Not specified 180 (48.0)
Tumour depth Mean 4.9 mm
Median 3.0 mm
=<2 mm 90 (24.0)
2.1-<=4 mm 124 (33.1)
>4 mm 64 (17.1)
Not specified 97 (25.8)
Level of
invasion
Papillary dermis 5 (1.3)
Upper reticular
dermis
14 (3.7)
Mid reticular dermis 87 (23.2)
Deep reticular dermis 113 (30.1)
Subcutaneous 54 (14.4)
Not specified 102 (27.2)
Differentiation Well/moderately 212 (56.5)
Poor/undifferentiated 88 (23.5)
Not specified 75 (20)
Histological
type
Classic/no special
type
245 (65.3)
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Table 29: Characteristics of SCC treated 2006-7
Anatomical location
There were significant differences in the anatomical location of SCCs between
men and women (chi-squared test, p<0.0001) (Figure 47), where it appeared
that men were more likely to have an SCC located in the head and neck
region, and women to have and SCC on the lower limbs. In the head and nick
region, there was also a statistically significant difference between men and
women in the distribution of their SCCs (chi-squared test, p<0.0001), with
men more likely to have an SCC in the ear area (p<0.0001), whereas women
were more likely to have them on the cheek (p=0.04), lip (p=0.05) or neck
(p=0.03). Although a greater percentage of SCCs in males were located on the
scalp (21.2% versus 9.6% in females), this did not quite achieve statistical
significance (p=0.0687)(Figure 48).
Acantholytic 7 (1.9)
Spindle cell 1 (0.3)
Desmoplastic 3 (0.8)
Not specified 119 (31.7)
Perineural
invasion
Present 16 (4.3)
Not present 268 (71.5)
Not specified 91 (24.3)
Vascular
invasion
Present 6 (1.6)
Not present 278 (74.1)
Not specified 91 (24.3)
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Figure 47: Anatomical distribution of SCCs in males and females (%)
Figure 48: Distribution of head and neck SCC (%) by gender
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7.4.5. Treatment Modality
Treatment modality was not usually recorded on the histopathology database
(362/421 [86%]). Excisional surgery was recorded as the treatment modality
for 57/421(13.5%) of SCCs and Mohs surgery in 2/421 (0.5%).
7.4.6. Clinical excision margin
During 2006-7, clinical excision margins were only recorded for 7 of the 298
excisions (2.3%), ranging from 2mm to 10mm (mean 5mm). Recording of
excision margins was much more complete during 2010-11, with a mean
clinical excision margin of 5.2mm in the 126 of 352 (35.7%) excisions for
which this data was available. These ranged from 1.7mm for a 0.9mm
diameter SCC on the arm to 50mm for a 30mm diameter SCC on the thigh.
The mean clinical excision margin for SCCs that were 2cm or less in diameter
was 4.5mm (n=97), whereas for SCCs greater than 2cm in diameter it was
7.8mm (n=21).
There was a trend towards taking smaller excision margins for SCC located on
the head or neck compared with those elsewhere on the body (mean excision
margins 4.4mm (n=78) and 6.3mm (n=48) respectively), although statistical
significance was not quite reached (independent t-test p=0.072).
7.4.7. Peripheral and deep histological margins
During 2006-7, distance of tumour from the peripheral and deep margins was
recorded in 213 excised SCCs. The mean peripheral histological margin was
5.17mm (range 0 to 28mm) and the mean deep histological margin was
3.52mm (range 0 to 23mm). In 2010-11, distance of tumour to the peripheral
margin was recorded for 301 excisions, and the distance to the deep margin
in 296 excisions. During this time period, the mean peripheral histological
margin was 5.06mm (range 0 to 15mm) and the mean deep margin was
3.5mm (range 0 to 19mm).
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The smallest distances from the edge of tumour to the peripheral and deep
edges of excision specimens were categorised according to the RCPath
minimal dataset proforma for SCCs, and summarised in Table 30.
Table 30: Histological peripheral and deep margins; proportions of excised SCCs according to RCPath
criteria (2006-7 and 2010-11)
Distance from
tumour edge to
specimen edge
(mm)
Number of excisions (%):
Peripheral
Number of excisions (%):
Deep
2006-7
(N=213)
2010-11
(N=301)
2006-7
(N=213)
2010-11
(N=296)
0 (transecting) 4 (1.9) 2 (0.7) 6 (2.8) 8 (2.7)
0.1 to 0.9 (close
but clear)
2 (0.9) 3 (1.0) 21 (9.9) 17 (5.7)
1 to 5mm
(clear)
119 (55.9) 180 (59.8) 142 (66.7) 216 (73)
>5mm (clear) 88 (41.3) 116 (38.5) 44 (20.7) 55 (18.6)
In total there were 7 of 213 SCCs (3.3%) in which the peripheral or deep
margins were transected during 2006-7.
Three SCCs transected both peripheral and deep margins:
1) A 1mm diameter well-differentiated SCC on the neck, 4mm deep and
extending to the mid- reticular dermis
2) An 11mm diameter moderately differentiated SCC on the ear, 3mm
deep and extending to deep reticular dermis
3) A 20mmmoderately differentiated, acantholytic SCC on the cheek,
10mm deep and extending to deep reticular dermis.
Narrow or transecting peripheral histological margins (less than 1mm) were
found in 6/213 (2.8%) of excisions for which this data was available,
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compared with narrow or transecting deep histological margins in 27/213
(12.7%) of excised SCCs. Deep margins were more likely to be involved
(transected or close but clear margin) than peripheral margins, a difference
which was statistically significant (Fisher’s test p<0.001).
Three SCCs, two on the ear and one on the scalp, transected deep margins
but had clear peripheral margins (1mm or greater), 21 had close but clear
deep margin but clear peripheral margins, and one ear SCC had a close
peripheral margin but clear deep margin.
During 2010-11, transecting peripheral or deep margins were recorded in 9 of
301 SCCs (3.0%). One poorly differentiated 25mm diameter SCC located on
the ear transected both peripheral and deep margins. Seven of 296 SCCs
(2.3%) transected the deep margin but had clear peripheral margins of more
than 1mm, whereas one 12mm diameter SCC located on the breast
transected the peripheral margin although the deep margin was clear. Narrow
or transecting peripheral margins were recorded in 5/301(1.7%) of excised
SCCs, and narrow or transecting deep margins in 25/296 (8.4%) SCCs, which
again was a statistically significant difference (Fisher’s test p<0.001).
7.4.8. Tumour classification based upon AJCC staging criteria
Comparison between the sixth and seventh editions of the AJCC T
classifications is summarised in Table 31. The number of SCCs that would be
classified as T2 is upgraded when compared with the earlier sixth edition ,
based upon diameter greater than 2cm, or having a diameter less than 2cm
ǁŝƚŚƚǁŽŽƌŵŽƌĞŽĨƚŚĞĨŽůůŽǁŝŶŐĨĞĂƚƵƌĞƐ PĚĞƉƚŚAN ?ŵŵ ?ůĂƌŬ>ĞǀĞůA?/s ?
perineural invasion; poorly differentiated or undifferentiated; located on ear
or hair-bearing lip.
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Table 31: Comparison of AJCC 6th and 7th editions for SCC T-classification
AJCC sixth edition AJCC seventh edition
Number (%) of excised SCCs
(N=276)
Number (%) of excised SCCs
(N=276)
T1
A? ?ĐŵĚŝĂŵĞƚĞƌ
146 (52.9) T1
A? ?ĐŵǁŝƚŚĨĞǁĞƌƚŚĂŶ ?ŚŝŐŚ ?
risk features*
34 (12.3)
T2
2-5cm diameter
22 (8.0) T2
>2cm with fewer than 2 High-
risk features OR tumour any size
ǁŝƚŚA? ?ŚŝŐŚ ?ƌŝƐŬĨĞĂƚƵƌĞƐ
141 (51.9)
T3
>5cm diameter
7 (2.5) T3
Based on invasion of maxilla,
mandible. Orbit, temporal bone
rather than size
-
Not classifiable from data
available
101 (36.6) Not classifiable from data
available
101 (36.6)
 ?AN ?Đŵ ?AN ?ŵŵĚĞĞƉ ?WE/ ?ůĂƌŬůĞǀĞůA?/s ?ƉŽŽƌůǇĚŝĨĨĞƌĞŶƚŝĂƚĞĚ ?
ear or non-hair-bearing lip
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Of the SCCs with sufficient data to enable T classification, (n=175), 112 (64%)
were less than 2cm in diameter and would only be classified as T2 when
histopathology data was available based upon the presence of 2 or more
additional high-risk features.
7.4.9. Tumour classification based on Brigham andWomens
Hospital Criteria
Excised SCCs with sufficient data were classified according to the BWH
staging, slightly modified according to how data was recorded in the 2006-7
dataset. As nerve calibre was not recorded in the dataset, all PNI was classed
as a high-risk feature. Also, invasion recorded as subcutaneous was
considered a high-risk feature.
The results are summarised in Table 32.
Table 32: Classification of excised SCC based on Brigham and Women's Hospital criteria
Brigham and Womens Hospital classification
Number (%) of excised SCCs
(N=276)
% of classifiable SCCs
(N=137)
T1
No risk factors*
69 (25) 50.4
T2a
1 risk factor
42 (15.2) 30.6
T2b
2-3 risk factors
25 (9.0) 18.3
T3
ш ?ƌŝƐŬĨĂĐƚŽƌƐ
1 (0.4) 0.7
Not classifiable
from data
available
139 (50.4) -
Total 276 (100) 100
*>2cm diameter; PNI; poorly differentiated; subcutaneous or beyond
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7.4.10.Outcome analysis
Outcome data was available for 351/375 (95.2%) of SCCs in total, and for
276/294 (93.8%) of excisions in 265 patients, the results for which are
summarised in Table 33.
Table 33: Overall outcomes within 5 years of treatment for excised SCCs
Outcome Number (%) with outcome
Local recurrence 17/276 (6.2)
Regional recurrence 9/276 (3.3)
Distant metastases 0/265 (0)
All-cause mortality 116/265 (43.8)
SCC-attributable death 4/265 (1.5)
Figure 49 is a flowchart in which the number and types of recurrences are
broken down according to patients’ mortality status at 5 years for both the
entire SCC dataset (all specimen types) and for excision only. Overall mortality
over the 5 years was high given the mean age of the study population, with
149 of the total 337 patients (44.2%) having died during the study period,
with 138 (92.3%) of these dying from an unrelated or unknown cause.
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Figure 49: Flowchart of outcomes for SCCs (all specimen types in black, excisions only in green)
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7.4.11.Outcomes according to AJCC7 and BWH T staging
Subgroup analyses were performed to compare outcomes between the AJCC
classification and the BWH staging (Table 34).
Table 34: Comparison of outcomes based on AJCC (7) T2 staging and modified BWH staging
Number (%) with outcome
Outcome
AJCC7 Brigham and Womens Hospital T staging
T1 T2
p-value
Ȥ2/
Fisher’s
test)
T1 T2a T2b T3 p-
value
Ȥ2 for
trend)
Local
recurrence
(SCC as unit
of analysis)
1/34
(2.9)
13/141
(9.2)
0.31 4/69
(5.8)
4/42
(9.5)
5/25
(20)
0/1
(0)
0.045
Regional
recurrence
(SCC as unit
of analysis)
0/34
(0.0)
7/141
(5.0)
0.34 0/69
(0)
3/42
(7.1)
3/25
(12)
0/1
(0)
0.007
Distant
metastases
(patient as unit
of
analysis)
0/33
(0.0)
0/135
(0.0)
-
0/65
(0)
0/41
(0)
0/24
(0)
0/1
(0)
-
All-cause
death
12/33
(36.4)
67/135
(49.6) 0.18
25/65
(36.9)
24/41
(58.5)
16/24
(66.7)
0/1
(0) 0.004
Death
attributable
to SCC
1/33
(3.0)
2/135
(1.5)
0.48
0/65
(0)
2/41
(4.8)
0/24
(0)
0/1
(0)
0.548
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For SCCs classifiable by AJCC7, there were no statistically significant
differences in outcomes between T1 and T2 tumours (Fisher’s test local
recurrence p=0.31; regional recurrence p=0.34; SCC attributable deaths
p=0.48; all cause deaths p =0.18).
When tumours were classified according to the BWH criteria, there was a
statistically significant increased trend towards local recurrence (chi-squared
test for trend, p=0.045), regional metastases (chi-squared test for trend,
p=0.007), and death from any cause (chi-squared test for trend, p=0.004) with
increasing substage from T1 to T2b. As only one SCC was classified as T3 it
was not included in the analysis. There were only 2 deaths which were
attributable to SCC in the group, both of which occurred in patients who had
tumours classified as T2a according to BWH criteria.
7.4.12.Univariable and multivariable analyses
Local recurrence
Only perineural invasion and perivascular invasion appeared to have an
association with local recurrence (Fisher’s test p=0.05 and p=0.01
respectively); however, the variables were correlated (Fisher’s test p<0.001),
therefore they were assessed separately in the models. None of the
additional variables were found to be significantly associated with local
recurrence during the model fitting process. Therefore the only prognostic
features that are independently associated with local recurrence are PNI and
vascular invasion (Table 35).
Regional recurrence
Only diameter >2cm and vascular invasion appeared to have an association
with regional recurrence (Fisher’s test p=0.06 and p=0.085 respectively).
There didn’t appear to be a correlation between the two prognostic features
(Fisher’s test p=0.41), therefore the variables were included in the same
multivariable model. None of the additional variables were found to be
significantly associated with regional recurrence during the model fitting
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process. However, when diameter and vascular invasion were included in the
model together, the p-value for vascular invasion became non-significant
(p=0.99). Therefore only a diameter >2cm was independently associated with
regional recurrence (odds ratio 5.78, 95% confidence intervals 1.10 to 30.4)
(Table 35).
SCC attributable death
Prognostic features that appeared to be associated with SCC attributable
death were depth>2mm (Fisher’s test, p=0.04), depth >4mm (p=0.06), PNI
(p=0.01), vascular invasion (p=0.01), high-risk pathology type (p=0.05),
ƉĞƌŝƉŚĞƌĂůŚŝƐƚŽůŽŐŝĐĂůŵĂƌŐŝŶA? ?ŵŵ ?ƉA? ? ? ? ? ? ?ĂŶĚĚĞĞƉŚŝƐƚŽůŽŐŝĐĂůŵĂƌŐŝŶ
A? ?ŵŵ ?ƉA? ? ? ? ? ? ?ƵĞƚŽƚŚĞŶƵŵďĞƌŽĨƉƌŽŐŶŽƐƚŝĐĨĞĂƚƵƌĞƐŝĚ ŶƚŝĨŝĞĚĨƌŽŵ
the univariable models, the variables were added in order of significance as
identified in the univariable models. Depth >4mm had a marginally better fit
in the univariable model than depth >2mm; however, only the comparison of
‘missing’ category versus ‘no’ was significantly associated with SCC
attributable death for depth>2mm; and the same was seen for PNI, vascular
invasion and high-risk pathology, therefore none of these features were
included in subsequent models. Thus, the final model only included age,
where increased age was significantly associated with increased odds of SCC
attributable death (odds ratio 1.14, 95% confidence intervals 1.03 to 1.21)
(Table 35).
All-cause mortality
Initially, the only prognostic feature that appeared to be associated with
death from any cause was differentiation (Fisher’s test p=0.01). However,
during the model fitting process, age and gender were also found to be
significantly related to all-cause mortality (Table 35). None of the additional
variables were significantly associated with outcome, although vascular
invasion had borderline significance in the multivariable model (p=0.062).
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Table 35: Summary of prognostic features independently associated with outcome
Odds ratio (95% CI)
Local recurrence:
PNI (yes/no) 4.8 (1.2 to 19.3)
Vascular invasion (yes/no) 10.3 (1.6- 66.1)
Regional recurrence:
Diameter (>2cm versus <2cm) 5.78 (1.10 to 30.4)
SCC attributable death:
Age (in years) 1.14 (1.03 to 1.21)
All-cause death:
Age (in years) 1.10 (1.07 to 1.13)
Gender (male versus female) 1.92 (1.15 to 3.2)
Poor differentiation 2.21 (1.23 to 3.98)
7.4.13. Summary of number of patients potentially eligible for
the proposed trial
Patients will be eligible for recruitment into the proposed trial according to
the T-classification of their SCC, which will be based upon a modification of
the BWH staging criteria (see section 7.2.1 and section 7.4.9). Two scenarios
are presented in Table 36:
(A) numbers are based on a modification of the basic BWH classification
in which T2a tumours have one risk factor (diameter >2cm, level of
invasion subcutaneous or more (although not including bony
invasion), poorly differentiated; PNI), T2b have 2 to 3 of these risk
factors, and T3 have 4 risk factors.
(B) In addition to the above risk factors, depth >4mm is included as one of
the risk factors (section 7.2.1).
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Table 36: Number of patients with excised SCCs potentially eligible for recruiting into trial (first
randomisation)
Scenario for eligibility for entering first stage of trial
Number (%) of
patients (N=131)
A) Brigham and Women’s Hospital T2a/T2b/T3 66 (50.4)
B) Brigham and Women’s Hospital T2a/T2b/T3 including
>4mm depth as inclusion factor
82 (62.6)
In the second stage of the proposed trial eligible patients will be further
randomised to receive either adjuvant radiotherapy or no adjuvant
radiotherapy. Only SCCs that are classified as T2b and therefore have at least
two potentially adverse prognostic features will be eligible for randomisation
into the second stage of the proposed trial. Based on these criteria and from
the total number of patients who have sufficient data with which to classify
their SCC, the number of eligible patients who would potentially be eligible
for the second stage of randomisation is summarised in Table 37.
Table 37: Number of patients with SCC potentially eligible for second-stage randomisation
Scenario for eligibility for entering second stage of trial
Number (%) of
patients (N=131)
A) Brigham and Women’s Hospital T2b/T3 25 (19.1)
B) Brigham and Women’s Hospital T2b/T3 including
>4mm depth as inclusion factor
40 (30.5)
Extrapolation of the above percentage to the total number of patients in the
database gives an approximation of the number of patients that would
potentially be eligible for randomisation into each stage of the proposed trial
for each 12-month treatment period (Table 38).
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Table 38: Approximate number of patients potentially eligible for randomisation into proposed trial
based on SCC T-classification
Approximate number of potential
patients
2006-2010 2010-20112
A) Brigham and Womens Hospital T2a/T2b/T3:
 First surgical randomisation 185 219
 Second ART randomisation 70 83
B) Brigham and Womens Hospital T2b/T3 including >4mm depth as
inclusion factor
 First surgical randomisation 223 264
 Second ART randomisation 109 128
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Discussion7.5
7.5.1. Numbers of SCC treated and demographics of patients
Cutaneous squamous cell carcinoma is a common nonmelanoma skin cancer.
Over the two 12-month data collection periods 421 and 512 non-metastatic
SCCs were submitted to the histopathology laboratory serving a population of
approximately 1,070,000 people under the auspices of the Nottinghamshire
Locality of the East Midlands Cancer Network. This represented an increase of
23% in the number of SCCs submitted and an 18.5% increase in the number of
patients treated between 2006-7 and 2010-11, with an accompanying
significant increase in the mean age of the patients treated from 76 years
during 2006-7 to 78 years during 2010-11. There is likely to have been an
increase in the size of the population at risk in Nottingham during the
intervening years between the two datasets, but as this data was not
examined it is not possible to say whether the incidence of SCC has also
increased. However, the increase in the number of patients treated is an
indication of an increased clinical workload with associated cost and health
services planning implications.
There appeared to be more patients over 80 years of age in the most recent
dataset, although overall there was no significant change between the two
years in terms of age group distribution. Increasing incidence of SCC in older
age groups has been noted in other studies around the world. In Ireland, the
incidence of all NMSCs increased between 1994 and 2011, with significant
increases in SCC annual percentage change for those aged 65 and above, in
contrast to BCCs in which the most significant increases were in the younger
age groups (Deady et al., 2014). A retrospective study of over 50000 NMSCs
in New Zealand found that there had been a 1.1% increase in SCC incidence
between 1999 and 2007, and that during that time it was men aged 80 and
above who had the most significant increase in annual percentage change
(APC) (3.65; p<0.005), contrasting with a concerning increase in APC for BCCs
among younger people, particularly in females in the 40-49 year age group
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(Brougham et al., 2011). The high-profile health awareness ‘Sunsmart’
campaign has been running in Australia since 1981 and it would appear that
the benefits of this in relation to the falling incidence of SCC in younger
people is now being realised, with reported stabilisation of SCC incidence
rates in the under 50s (Staples et al., 2006), and a decrease in the number of
SCCs treated in people aged under 45 years relative to the growth of the
population (Fransen et al., 2012). In the UK, public health campaigns to
promote sun awareness have lagged behind those in Australia; Cancer
Research UK’s ‘SunSmart’ skin cancer prevention campaign was instigated in
2003 (http://www.sunsmart.org.uk/about-sunsmart/). The slight increase in
the number of over 80 year olds treated compared with other age groups in
this study is interesting but needs to be confirmed with trends over a longer
period of time. However, the findings may reflect greater sun awareness over
recent decades, and the improved availability and use of sun-protection
products among younger people. The regular application of sunscreen has
been shown to have long term protective effects against developing SCC,
although the evidence for a clear benefit against BCC and melanoma is less
robust (Green et al., 1999, van der Pols et al., 2006, Green et al., 2010). It will
therefore be interesting to see if UK trends over the next few years mirror
those that are being seen elsewhere in the world.
In this analysis, there was a preponderance for the sun-exposed areas of the
head and neck in both sexes, and an excess of tumours located on the legs in
females and the ears in men, which is consistent with the findings from other
studies (Buettner and Raasch, 1998) (Brewster et al., 2007b) and likely to be a
reflection of the different clothing and hairstyles and exposure of skin from
receding hair. Although men are more commonly affected by SCC than
women, the results from this study have shown that more women than men
are being treated by plastic surgeons, who are also significantly more likely to
be treating larger tumours than their dermatology counterparts. It is
recognised that plastic surgeons tend to be referred larger and more
challenging lesions (Khan et al., 2013), and the reversal of the male to female
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ratio in the patients treated by plastic surgeons may be a reflection of
enhanced cosmetic concerns amongst women and their desire for minimal
scarring on exposed areas such as the face. This would however, need to be
confirmed with larger numbers of patients.
7.5.2. Adequacy of excision
Uncertainty about optimal clinical excision margins for SCCs that are surgically
excised was one of the predominant issues that emerged from the clinician
survey described in chapter 5. The adequacy of excision margins and their
recording in the medical notes is one of the audit points specified in the 2009
updated UK BAD multiprofessional SCC management guidelines (Motley et al.,
2002), and adequacy of resection is also identified as an area for research in
the 2006 NICE guidance (National Institute for Health and Clinical Excellence,
2006). This may explain why the recording of clinical excision size on the
pathology reports was so much more complete in the later dataset (2010-11)
compared with the earlier one in which only 2.3% of excisions had this data
recorded.
It would appear that generally the current margin recommendations are
being adhered to, with a mean margin size of 4.5mm for smaller SCCs, and
7.8mm for larger ones (against recommendations of 4mm for small, well-
defiend low-risk tumours and 6mm for larger and higher risk tumours).
However, in this study the mean clinical margin for SCCs sited on the head or
neck was smaller than that for SCCs located on the limbs or trunk, and
suggests that in cosmetically sensitive areas there may be some compromise
between tissue conservation and strict adherence to recommendations. This
finding has also been noted in audits of plastic surgeons conducted after the
introduction of the guidelines in 2002 (Staiano et al., 2004, Hemington-Gorse
et al., 2006), and more recent audits have indicated that variation still exists
among surgeons regarding adherence to guidelines in relation to the size of
excision margins that are taken (Batchelor and Stables, 2006, Soueid et al.,
2009).
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Adequacy of primary excision is important, and perhaps especially so in areas
where further intervention and reconstruction could compromise cosmesis
and function further. Incomplete excision has been shown to be
independently associated with regional metastasis in one study (odds ratio
2.0) (Mourouzis et al., 2009), and recurrence of 29% of re-excisions that
contained residual tumour was noted in another study (Bovill and Banwell,
2012). Several studies have shown an association between incomplete
excision and location in anatomically complex areas such as the ear, scalp,
nose and cheek (Khan et al., 2013, Brantsch et al., 2008, Bogdanov-
Berezovsky et al., 2005). The findings of this study concur with this. Seven of
213 (3.3%) of SCCs had histological involvement at either the peripheral or
deep edge of the exxicsed specimen, of which three, located on the ear,
cheek and neck, had involvement of both margins. Three of the SCCs that had
involvement of one margin were located on the ear, and the other on the
scalp.
The 3% of SCCs with margin involvement is is somewhat lower than the
pooled incomplete excision rate of 8.8% (95% confidence intervals 5.3 to
13.0) in the 2343 excisions in 11 studies that was found in the systematic
review of case series reported in chapter 4. However, there is lack of
consistency in the literature about what is meant by completeness of exision;
definitions, when provided, include the presence of tumours cells at the
surgical edge, tumour cells at or within 1mm of the resected edge, tumour
cells within one microscopic field (0.5mm), and others simply as ‘close to’ the
margin. The adequacy of excision of SCCs that do not transect the surgical
edge but which are within 1mm is a grey area, and their management is a
cause for debate among clinicians. In this study, 27 (13.6%) of excised SCCs
were either at or within 1mm of the peripheral or deep edge and would
therefore not be eligible to be randomised into the second adjuvant
radiotherapy stage of the proposed trial, which will be discussed in greater
depth in chapter 8. This study indicates that the deep margin is significantly
more likely to be involved than the peripheral margin. Six of the seven
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transecting SCCs (86%) involved the deep margin which is in accordance with
a recent study in which 92% of incomplete SCC excisions by plastic surgeons
were incomplete at the deep margin, even though only 32% had involvement
of the peripheral margin (Khan et al., 2013). There is currently no guidance in
the UK management guidelines (Motley et al., 2002) regarding deep clinical
margins , but as these margins are more frequently implicated than
peripheral margins it is perhaps prudent to have a high suspicion of residual
microscopic disease at the deep margin and excise down to the next fascial
plane beyond apparent macroscopic appeararance (Khan et al., 2013). On the
basis of these findings and for the purposes of the proposed trial (chapter 8),
it will be important not to focus solely on the definition of the peripehral
clinical margin at the the expense of the deep margin; this too will need to be
clearly defined and adhered to in order to minimise the number of potentially
eligible SCCs that are excluded from the second ART randomisation stage of
the trial because the deep histological margin is less than 1mm.
7.5.3. Classification of SCCs
Although only a small percentage of SCCs recur, it is important to identify
those that are at greatest risk of recurring at an early stage. Currently the
definition of ‘high-risk SCC’ is very variable but the development of a
prognostic model is an important step toward targetting the most
appropriate treatments to those who are most likely to benefit from them,
for example adjuvant radiotherapy and nodal staging. In the most recent
American Joint Committee on Cancer (AJCC7) classification, primary SCCs are
classified as being T1 or T2, with higher risk T2 tumours being those greater
than 2cm in horizontal diameter, or smaller than 2cm but with 2 or more
additional characteristics associated with poor prognosis, features which
were not incorporated into previous editions: depth >2mm; Clark level
A?/s ?ƉĞƌŝŶĞƵƌĂůŝŶǀĂƐŝŽŶ ?ƉŽŽƌůǇĚŝĨĨĞƌĞŶƚŝĂƚĞĚŽƌƵŶĚŝĨĨĞƌĞŶƚŝĂƚĞĚ ?ƉƌŝŵĂƌǇƐŝƚĞ
on ear or hair-bearing lip (Edge and Compton, 2010). This has resulted in a
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significant increase in the number of SCCs that have been upgraded to T2
tumours from 8% to more than 50%. Although an improvement on previous
classifications in an attempt to stratify patients more accurately, the new
classification is not without criticism, omitting several variables associated
with high-risk disease, such as host immunosuppresion, previously treated
tumours, and the presence of chronic inflammation or location in burns and
scars, and there is also some confusion regarding the precise lip location (hair-
bearing or non-hair bearing) as defined in the AJCC manual (Buethe et al.,
2011a, Edge and Compton, 2010). An alternative tumour staging system
(BWH) has been proposed in an attempt to offer better prognostic
stratification of AJCC7 T2 tumours, in which T1 tumours have no risk factors
but are upstaged to T2a in the presence of either perineural invasion or
poor/undifferentiated or invasion beyond subcutaneous fat, T2b tumours
have 2-3 risk factors, and T3 tumours have bone invasion or have all 4 risk
factors (>2cm diameter, PNI, poorly differentiated and invasion beyond
subcutaneous fat) (Jambusaria-Pahlajani et al., 2013, Karia et al., 2013).
Using the modified BWH classification, the majority (81%) of the 137 SCCs
that had sufficient data to classify fell into the T1 and T2a categories, with the
remaining 19% being T2b or T3. This corresponds with the breakdown of SCC
according to the original paper in which the BWH scheme was proposed
(Jambusaria-Pahlajani et al., 2013), in which 52% of SCCs were T1, 26% were
T2a, 19% were T2b and 2% were T3, although higher than the proportion of
T2b and T3 SCCs in their subsequent paper, in which only 5% of SCC were
classified as T2b or T3 (Karia et al., 2013). This may be because the definition
of PNI in the second paper was more stringent, and only PNI was only
considered a risk factor if the calibre of the involved nerve was greater than
0.1mm (Karia et al., 2013).
7.5.4. Tumour features associated with prognosis
SCCs spread laterally and vertically and growth may become discontinuous
once deep extension has occurred, which can result in even deeper local
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extension, in-transit metastases, and nodal metastases. The following factors
have been correlated with poor prognosis for recurrence and metastases:
Tumour diameter
Rowe et al (1992) in an analysis of case series found that the local recurrence
rate for tumours >2cm was 15.2% compared to 7.4% for those less than 2cm,
and that metastatic rates were tripled (30.3% vs 9.1%). Other studies have
corroborated these findings. Kraus et al (1998) found that of 16 patients with
regional lymph node metastasis, 13 (81%) had primary tumours larger than
2cm compared to 24% in historical controls, although of the total number of
metastatic tumours they examined in their population, tumour size data was
only available for a limited number as most had been initially treated at other
centres. A threshold size of 2cm for increased propensity to recur and
metastasise has been suggested by several studies (Cherpelis et al 2002;
Griffiths et al 2002; Dinehart et al 1989; Breuninger et al 1990). In a
prospective study by Clayman et al (2005), lesion size greater or equal to 4cm,
along with evidence of perineural invasion and invasion into deep tissues
were the factors most strongly associated with diminished 3-year disease-
specific survival. However, one study of 266 patients with SCC metastatic to
the regional lymph nodes found that most of the primary tumours in the
study population were less than 2cm in diameter (Veness 2006) and
concluded that size alone is probably not an independent predictor of
outcome and other prognostic features also need to be taken into
consideration (Veness 2006).
Tumour depth
Some experts believe that the Breslow tumour thickness of 4-5mm (measured
from the top of the granular layer to the deepest point of invasion) and a
Clark level of IV or V (invasion of reticular dermis and subcutaneous fat) are
the most important prognostic factors for SCC beyond which the rate of
236
metastasis increases significantly (Kraus et al 1998; Dinehart et al 1989;
Breuninger et al 1990). However, the reporting of these measurements has
often been overlooked by pathologists (Khanna 2002). Breuninger et al (1990)
found that in their series of 673 tumours with a median follow-up period of
5.3 years there were no metastases at all in the 325 tumours which were less
than 2mm thick, compared to 13 in the 288 (4.5%) tumours between 2 and 6
mm thick, and 9 of the 60 (15%) of tumours greater than 6mm in depth, and
on the basis of these findings they designated 3 risk groups : 1. ‘No risk’ (less
than 2mm); 2. ‘Low-risk’ (2-6mm deep); and 3. ‘High-risk’ (>6mm deep).
A similar correlation between tumour thickness and metastatic risk has also
been seen in other prospective studies (Breuninger et al 1997; Brantsch et al
2008). For tumours less than 4mm deep or Clark level I-III a metastatic rate of
6.7% was found compared to 45.7% in those tumours greater than 4mm or
Clark level IV or V in the analysis of series by Rowe (1992). The accumulation
of evidence in support of the importance of tumour depth as a prognostic
factor has now been incorporated into the revised American Joint Committee
on Cancer (AJCC) Tumour, Node and Metastasis (TNM) staging system (AJCC
2010), as the previous AJCC staging system assigned horizontal diameter as
being the only important variable in the T stage, a staging system which was
much criticised (Veness 2008).
Histologic differentiation
Several studies have indicated that poorly-differentiated SCCs have a worse
prognosis than those which are well-differentiated on histology (Johnson et al
1992; Mohs 1978; Eroglu 1996). In one series of patients with metastatic SCC,
significantly more patients had poorly-differentiated lesions (44%) compared
to those with well-differentiated SCCs (5%)(Cherpelis et al 2002), which
compares with the 33% metastatic rate for poorly differentiated lesions
compared to 9% for well-differentiated SCCs shown by Rowe et al (1992).
Breuninger et al (1990) found that there was a rapid increase in metastatic
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rate from 4% to 17% between SCCs classed as G3 (poorly differentiated) and
G4 (undifferentiated). However, Rowe et al (1992) suggested that as 64% of
metastatic lesions in their analysis were well-differentiated, the histologic
differentiation may be of limited importance as a prognostic factor on its
own. More recently however, it has been indicated that the presence of
desmoplasia (fine branches of tumour cells at the periphery with surrounding
dermal stromal reaction) may be a particularly strong prognostic feature with
high risk of recurrence and metastasis (Breuninger et al 1997). The authors
found that desmoplastic SCCs were often more advanced at diagnosis and
thicker than ‘common’ SCCs, and that those tumours in their 2-5mm thick
‘low-risk group’ which did metastasise had desmoplastic features.
Anatomic site
SCCs in the region around the ear and lower lip have particularly high local
recurrence rates and metastatic rates compared to those elsewhere (Afzelius
et al 1980; Lee 1996). A local recurrence rate of 18.7% and metastatic rate of
11% were shown by Rowe et al (1992) for SCCs located in the peri-auricular
region, rates which were more than double those seen elsewhere. Tumours in
the region of the lip also had a higher local recurrence rates (11%) and a
markedly higher metastatic rate (14%) than tumours located at other sites.
Even higher rates are seen for SCCs located in non-sun-exposed areas of the
body and those arising in chronic ulcers, sinuses and chronic inflammation,
and in areas of radiation or thermal injury (Rowe et al 1992). Two studies
with 5 year follow-up had an overall metastatic rate of 38% for SCCs arising in
such high-risk sites (Novick et al 1977; Ames et al 1980).
Perineural Invasion
Perineural involvement (PNI) is not a common feature of SCC of the skin,
occurring in approximately 5% of patients with the tumour, and is frequently
an incidental finding on post-operative histology examination (Veness 2006).
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However it is a feature which has been associated with significantly higher
metastatic rates and poor prognosis (Cherpelis et al 2002; Frierson and
Cooper1986). Ballantyne et al (1963) reported that of their 34 cases with PNI,
only 10 were alive and disease free 2 to 5 years later. A 47% local recurrence
rate and 35% metastatic rate with significantly reduced survival after
treatment by surgical excision were reported by Goepfert et al (1984).
Improved prognosis after treatment of PNI by Mohs micrographic surgery has
however been found by Cottel (1982), who reported no local recurrences and
a 6% metastatic rate when the same types of lesions were treated by this
modality, although only seventeen cases were reported.
Variables associated with outcomes in this study
In the univariate analysis in this study, an increase in odds of local recurrence
was seen in patients perineural invasion, which is consistent with other
studies (Jambusaria-Pahlajani et al., 2013, Veness et al., 2006). Vascular
invasion was associated with PNI, but also was independently associated with
an increase in odds of local recurrence. The only variable that was
independently associated with regional metastasis in this study was diameter
greater than 2cm. As discussed above, diameter as an independent factor
associated with the risk of metastasis has also been described in several other
studies (Cherpelis et al 2002; Griffiths et al 2002; Dinehart et al 1989;
Breuninger et al 1990).
Although there were several variables on univariate analysis that appeared to
be associated with SCC related death, on multivariable analysis only age was
found to be significantly related. However, death from any cause appeared to
be significantly associated with age, male gender and a poorly differentiated
tumour.
Unlike some of the studies mentioned above, an association between tumour
depth and outcome was not found in this study. Similarly, location on the lip
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or ear was not found to be significantly associated with outcomes in this
study, in contrast to the studies mentioned above, and the results of the
systematic review and pooled analysis described in chapter 4, in which a
significant association was found between location at the ear and both local
and regional recurrence. It should, however, be noted that the odds ratios for
some of these variables were large, with very wide confidence intervals, and
therefore likely to be a reflection of the small numbers of patients
experiencing outcomes. These results therefore need to be interpreted with
caution.
The high-risk features used in the AJCC7 and BWH classification schemes are
not completely identical to those defined by NICE guidelines as being high-risk
for the purposes of MDT referral and patient management and treatment, in
which tumours greater than 4mm in depth and those extending into
subcutaneous tissue (Clark level V) are considered to be high-risk (Brewster et
al., 2007b).The British Association of Dermatologists (BAD) multiprofessional
guidelines also adopt these criteria in their stratification of low and high risk
SCCs (Motley et al., 2002) and they are adopted as high-risk features in the
Royal College of Pathologists (RCPath) minimum dataset (Chaudhuri et al.,
2006) . Currently the evidence that the presence of lymphovascular invasion
as an independent risk-factor for metastasis and death is limited (Moore et
al., 2005, Mourouzis et al., 2009), but its presence is listed as a high-risk
pathological feature in the RCPath minimum dataset. Similarly, desmoplastic,
acantholytic, spindle, metaplastic, sarcomatoid, adenosquamous growth
patterns and SCCs with an adjacent area of Bowens disease are considered to
be high-risk features by the RCPath and National Clinical Guidelines
(Chaudhuri et al., 2006, Motley et al., 2002)
7.5.5. Outcomes after treatment
Although a common tumour, recurrences from SCC are fortunately rare
although a small subset do go on to have local recurrence after treatment, or
experience spread to the regional lymph nodes or distant organs, and some
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may die as a direct result of their disease. In the present study, 6% of SCCs
recurred locally during the 5-years after treatment, a figure similar to the 5%
local recurrence seen after conventional excision reported in the systematic
review and pooled analysis of case series of treatments for SCC earlier in this
thesis (chapter 4), and the 5% local recurrence reported in a large 10 year
prospective cohort study of 985 patients (Weinstock et al., 1992).
Metastasis to regional lymph nodes occurred in 3% of excised SCCs,
comparable with the 2-3% figure for nodal metastasis recently reported over
a 10 year study period in a retrospective study of 6164 patients (Brougham et
al., 2012), and the 4% after surgical excision in the pooled analysis of case
series reported in chapter 4 of this thesis.
Overall mortality from any cause was high with nearly half of the study
population having died over the 5 years, although this is not entirely
surprising given the advanced age of the group. However, deaths that were
attributable to SCC were rare with less than 2% of the study population dying
as a result of their disease, which is similar to the figures reported in other
studies (Brantsch et al., 2008, Weinstock et al., 1992), and slightly less than
the 4% figure found from the pooled analysis of case series of surgical
excision, which may be partly explained by possible misrecording of deaths as
being due to SCC in what were mostly restrospective studies (chapter 4).
Inaccurate death certification has been recognised as a particular problem for
nonmelanoma skin cancer so this data should be interpreted cautiously
(Weinstock et al., 1992). In the 6 patients with excision in whom death was
attributed to SCC, two had involvement of regional lymph nodes and one had
local recurrence. In this study, no distant metastases were reported within 5
years of treatment. This is not entirely unexpected as distant metastases are
rare in cutaneous SCC; only two studies that were included in the systematic
review of observational studies specifically reported distant metastases after
surgical excision, with one of 211 patients experiencing a distant metastasis in
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one study (Knox et al., 1967) and no distant metastasis in the other
(Donaldson, 2002).
Outcomes after different treatment modalities were not assessed in this
study as most were treated by surgical excision and there were inadequate
numbers which were known to have been treated by other modalities. It is
also possible that SCCs that were treated by destructive modalities such as
cryotherapy or cauterisation and electrodesiccation did not have any
pathology recorded on the database. A recent prospective study of
consecutive nonmelanoma cancers found that recurrence rates were similar
after excision and Mohs surgery, even when the conventional risk factors for
recurrence were adjusted for (Chren et al., 2013), which is supported by the
systematic review and pooled analysis of treatments for SCC in which there
was significant overlap of confidence intervals between different treatment
modalities (chapter 4).
The main reason that a modified BWH classification will be used in the
proposed trial is to help define the highest risk SCCs which will be eligible for
randomisation to receive ART or not. The original papers describing this
alternative scheme found that although the highest T2b and T3 stages made
up only a small percentage of the overall cohort, they accounted for 60% of
the poor outcomes, including 70% of nodal metastases (Karia et al., 2013).
The results from this research found that the proportion of patients who had
local recurrence, regional recurrence or who died from any cause rose with
increasing BWH stage from T1 to T2b. Both SCC-attribuatble deaths occurred
in stage T2a patients, and only one patient had an SCC classifiable as T3 in this
study. As the number of SCCs that had adequate data to be able to classify
them was small compared with the original paper (Karia et al., 2013), the
results of this study need to be be interpreted cautiously. Nevertheless, given
this trend and the data available from the other studies (Jambusaria-Pahlajani
et al., 2013, Karia et al., 2013, Schmitt et al., 2014), using a modification of the
BWH classification would seem a reasonable approach to identifiying those
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SCCs that are at greatest risk of having a poor outcome and therefore being
eligible for the second randomisation stage of the proposed trial.
7.5.6. Implications for future research
The current study forms part of the feasibility work for a future RCT into
management of high-risk SCCs. By comparison of the AJCC7 and modified
BWH staging systems, the results indicate that on the basis of the T
classification, approximately 50% of patients would be eligible to be
randomised into the first surgical stage of the trial (51.9% of classifiable SCCs
were AJCC7 T2 and 50.4% were BWH T2a, T2b or T3). By including depth
greater than 4mm as one of the BWH staging high-risk factors, the percentage
of eligible SCCs would increase to 62.6%.
For the second ART randomisation, use of the modified BWH classification
would allow identification of the highest-risk SCCs with at least two poor
prognostic features and is therefore more useful than AJCC7 staging in the
proposed trial. Based upon modified BWH staging, 37.9% of T2a, T2b or T3
identified for the first randomisation stage would then be eligible to be
randomised into the second stage (19% of the original total); increasing to
48.8% if depth >4mm is included (30.5% of original total). Because
information about several variables is required to be able to completely
classify excised SCCs, incomplete data recording on the pathology database
meant that only 50% of all excised SCCs could be completely classified. In
order to identify eligible SCCs for the proposed trial it will therefore be
necessary to undertake an initial punch biopsy with complete recording of
variable data so that SCCs can then be classified. Extrapolating the results of
the T-classification to the entire population of SCC patients treated during the
12-month period in Nottingham would mean that during 2006-7
approximately 185 of 357 patients would have been potentially eligible to be
randomised into the first stage of the trial, and 70 into the second stage, and
that during 2010-11 there would have been approximately 219 patients of
423, and 83 patients eligible for each stage respectively. By including depth as
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a risk factor, approximate numbers eligible would have increased during
2006-7 to approximately 223 and 109 for first and second randomisation
stages respectively, and during 2010-11 to 264 and 128 respectively. These
figures are based on the assumption that in the proposed trial all tumours
would be classifiable, and that the percentage for each T classification would
be similar to that found in this study.
It is envisaged that these results may be extrapolated to other centres in the
UK based on the size of the population served, in order to calculate the
number of centres that would be required to participate in the trial. The
number of participants needed to be recruited will in turn be based on
powering calculations, which will be informed by the number of those who
experienced adverse outcomes over the course of the five years after
treatment.
A limitation of this study is that the impact of the patients’ immune status on
outcomes was not assessed as this data was generally not recorded on the
pathology database. Nevertheless, this would not affect the assessment of
the number of potentially eligible SCCs for entry into the trial as
immunosuppressed patients would not be excluded from the trial.
7.5.7. Conclusion
Further elucidation of the inter-relationship between the various prognostic
features and outcomes will require large prospective studies to be conducted
and the main objective of this part of the research was to determine the types
and numbers of SCC that are treated in order to guide the design of such a
study. This work has given insight into the demographics of the treated
population in Nottingham, and an overview of the approximate number of
patients from this large regional centre that would potentailly be eligible for
entry into the proposed randomised trial, based on the classification of their
SCCs according to the presence of various prognostic features.
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However, the number of potentially eligible patients does not simply equate
to the number who will ultimately be randomised in the definitive trial.
Potential participants may for various reasons be reluctant to take part in the
proposed trial. In the next chapter, drivers and barriers to recruitment will be
explored in order to assess what factors are likely to affect hypothetical
willingness to take part, and what lessons can be taken forward when
designing the trial in order to optimise recruitment among potential
participants.
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CHAPTER 8:
FEASIBILITY STUDY
WITH PATIENTS
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8 FEASIBILITY STUDYWITH PATIENTS
Abstract8.1
Introduction:
Recruitment into RCTs can be challenging, particularly in cancer studies and in
those in which the target population is predominantly elderly. With the aim of
identifying potential drivers and barriers to recruitment to a proposed two-
stage trial of SCC treatment, a feasibility study comprising a questionnaire and
focus group was conducted with patients who had been treated for SCC
within the previous 12 months, in order to learn lessons from their
experiences and pre-existing knowledge and to inform the design of the
proposed trial by incorporating issues that are important from the patients’
perspective.
Methods:
In the first instance, SCC patients were sent a questionnaire assessing
hypothetical willingness to take part in each stage of the proposed RCT.
Patients’ experiences of treatment and attitudes to research were explored in
depth in a focus group. Thematic framework-analysis of data focussed on four
overarching themes: knowledge of SCC; experiences of treatment; attitudes
towards research; attitudes towards randomisation.
Results:
Generally, patients had poor understanding of SCC but would like to be better
informed. Patients were not overly concerned about randomisation into the
surgical arms of the first stage of the trial, although this would depend on the
location of the tumour, but they expressed more concerns about the second-
stage involving adjuvant radiotherapy. 71% of participants were
hypothetically definitely or probably willing to be randomised into the first
surgical stage, and 58% into the second ART stage. However, there was
confusion about the concept of randomisation and clinical equipoise.
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Conclusions:
The study has given insight into the proposed RCT from patients’ perspective,
and identified issues which will need to be taken into consideration when
presenting the definitive trial if recruitment in a predominantly elderly
population is to be optimised. In particular, the concept of randomisation will
need thorough explanation and careful presentation of the treatment options
in order to establish patient equipoise, especially for the ART stage of the
proposed trial.
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Introduction8.2
This chapter describes feasibility work which was conducted with patients
representative of potential participants in a future RCT of SCC treatments. The
scenarios provided to patients in the questionnaire were based on the results
of the survey work described in chapter 5, in which areas of treatment
uncertainty of clinical importance were delineated by clinicians and from
which possible trial scenarios were identified for further discussion and
development with multidisciplinary collaboration. In this study, the
acceptability of excision of SCC with different sized excision margins followed
by adjuvant radiotherapy or no adjuvant radiotherapy has been explored as
these were among the questions that were considered to be important by
clinicians and which formed the basis of a trial proposal (Chapter 6). However,
the willingness of patients to participate in such a study is unknown. This
study has provided the opportunity to explore issues that are important to
patients with regard to their diagnosis, treatment, and the information they
would like to receive, and to gain insight into their understanding of the
clinical research process and barriers and facilitators to their potential
participation in a RCT in the future which would need to be taken into
account when designing such trials.
8.2.1. Why it was important to conduct this study
It is recognised that recruitment into multi-centre RCTs can be difficult, with
fewer than a third reaching their recruitment target and more than half
requiring extension (Watson and Torgerson, 2006). Recruitment has been
shown to be particularly problematic in cancer trials; only 24.9% of eligible
patients with lung cancer were recruited into a trial involving adjuvant
chemotherapy (Spiro et al., 2000), and only 43% of eligible patients with
metastatic breast cancer in a trial of psychosocial support (Goodwin et al.,
2000). Apart from the funding and ethical implications, this may lead to type II
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error, in which it is concluded incorrectly that there is no significant difference
between the treatment arms due to a lack of power from an inadequate
sample size (Freiman et al., 1978).
The incidence of non-melanoma skin cancers increases with age, with
approximately 80% occurring in people over 60 years, (Diffey and Langtry,
2005) but the recruitment of older patients into clinical trials can be
particularly challenging. It is reported that only a quarter to a third of
potentially eligible older people are enrolled into trials (Townsley et al.,
2005); this may significantly impact upon external validity. From the
retrospective case series of SCCs treated in Nottingham which was described
in chapter 7, the average age at presentation was found to be 75 years. The
RCT proposed and which will be discussed in greater detail in chapter 9 is
therefore going to require successful recruitment from a largely elderly
population.
As there have been no previous RCTs specifically addressing this type of skin
cancer, it is therefore important to examine the beliefs and experiences of a
population representative of potential RCT participants. This will help to
identify possible barriers and drivers to recruitment, thus facilitating the
design of the trial and assessment of the resources required.
8.2.2. Overview of the study design
The importance of participant involvement in the design and conduct of trials
has been increasingly recognised over the last two decades and is now
actively encouraged (Donovan et al., 2002b). For example, participants were
involved in the design and conduct of the prostate testing for cancer and
treatment (ProtecT) feasibility trial, and results from the qualitative work that
were embedded within the study were incorporated into the design of the
main trial and significantly improved recruitment rates (Donovan et al.,
2002a).
Information relating to participants’ attitudes to particular aspects of the trial
and their potential willingness to take part may be gathered in several ways.
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Structured questionnaires, in-depth interviews and focus groups are
frequently used for this purpose (Mao et al., 2014, Kim et al., 2014, Wisinski
et al., 2013, Judge et al., 2013, Leighton et al., 2012, Linden et al., 2007).
Prospective Preference Assessment
In this study, a combination of a mailed questionnaire with open and closed
questions and a focus group was used to collect data from the study
population. The design of the questionnaire was based upon the prospective
preference method (PPA) described by Halpern which was developed as
method by which the motivations and concerns about enrolling into a
planned trial could be evaluated prior to actual recruitment and thus assess
whether there is enthusiasm among potential participants (or clinicians) to
take part (Halpern, 2002). Prospective preference assessment has been used
to forecast recruitment rates in other studies (Halpern et al., 2003, Shah et al.,
2012, Creel et al., 2005).There are several stages involved in PPA: description
of the hypothetical trial; testing participants’ understanding of the vignette;
open-ended questioning to evaluate motivators and barriers to taking part in
the trial; using ordinal response scales to evaluate potential willingness to
participate in the trial if it were to commence in the near future. Eliciting
whether participants have a strong preference for the treatment options or
not is an important element of the assessment and has been shown to
correlate with willingness to participate in RCTs (Mills et al., 2003, Wragg et
al., 2000). This study is a modification of this method in that it the vignette
was not administered by telephone or in a face-to-face interview, but was
sent by mail prior to completion of the questionnaire. Participants’
understanding of the proposed trial was therefore not assessed before the
survey was completed.
Focus Groups
A focus group may be defined as “a group of individuals selected and
assembled by researchers to discuss and comment on, from personal
experience, the topic that is the subject of the research” (Powell and Single,
1996). Originally used in media research to examine the effects of films and
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television programmes in the 1950s, they have become popular in health
research over the past three decades as a tool to investigate the public’s
understanding of illness, health-related behaviours and health education
messages (Kitzinger, 1995). They may be useful at various time points
throughout the life of research programme; in the preliminary stages, during
the main study, or after completion to assess impact and generate ideas for
further research (Woolfall et al., 2014, Kreuger, 1988, Ersser et al., 2013).
Unlike group interviews, focus groups promote self-disclosure among
participants that may not otherwise be revealed from individual interviews or
surveys, and this is particularly the case when the participants perceive
themselves to have similarities with others in the group and in a non-
judgemental environment. By sharing experiences and through discourse with
others who may have a different perspective, participants may start to think
about an issue slightly differently than they would have done prior to
discussion with others, thereby offering the potential for richer data to be
gathered and greater exploration of the research question.
In this study a focus group is used in combination with the questionnaire, a
form of methodological triangulation in which more than one method is used
to collect data. Although the data collected is different, the methods
complement each other thereby increasing the validity of the data and the
utility of the findings (Denzin, 1978).
8.2.3. Thematic Framework Analysis
Thematic framework analysis is a relatively recent approach towards the
analysis of qualitative data that was developed in the 1980s by social policy
researchers at the National Centre for Social Research, but is becoming
increasingly popular in health-related research (Ritchie and Spencer, 1993). It
is a highly-structured matrix-based method that is particularly suited to
research that is time-limited and that has clearly defined goals from the
outset.
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There are five stages to thematic framework analysis, with involvement of at
least two people:
x Familiarisation with the data by reading and re-reading the content
x Construction of thematic framework reflecting the objectives of the
research and based upon a priori issues but developed and refined as
necessary as the process continues
x Indexing the data using codes to identify pieces of data belonging to
the themes
x Charting the coded data into the thematic chart
x Mapping and interpretation of the data by looking for patterns,
associations and explanations in the data.
Critical reflection is a key component throughout this process with
researchers making reflexive notes, impressions of the data and recording
thoughts about the analysis, thus allowing for the development and
refinement of the analytical framework to be made in an iterative manner
until the final framework is agreed and no additional codes emerge.
An advantage of this method is its flexibility as it is not aligned to any one
particular epistemological, philosophical or theoretical approach and can be
adapted for use with many different qualitative approaches in which the
generation of themes is an important component (Gale et al., 2013). It is
particularly useful for analysis of textual data, for example from interviews
and transcriptions of focus groups, allowing comparison and contrasting of
data by theme across multiple cases. Not all research questions are
necessarily best answered through thematic framework analysis; for example,
some research may call for the generation of grounded theory (a
generalizable concept gained inductively rather than deductively from the
data to help understand the social world) which ‘emerges’ from the data
through rigorous and structured analysis and constant comparison between
cases without an a priori framework (Glaser and Strauss, 1967).
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As a method of analysis, a thematic framework approach is therefore ideally
suited to this study in which the goals of the research are defined at the
outset, in this case to support the development of a future trial, allowing the
research objectives to be directly addressed whist also being strongly rooted
in the responses of the study participants.
8.2.4. Objectives of this study
The objectives of this study were:
x To evaluate potential barriers to successful recruitment into a
proposed future two-stage RCT of SCC surgery and adjuvant
radiotherapy.
x To assess likely willingness of patients to be randomised into the
proposed RCT.
x To explore current understanding of their condition, and clinical
research generally in people previously treated for SCC, with a view to
developing appropriate participant information resources for the
proposed RCT.
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Methods8.3
8.3.1. Participant sample
A purposive sample of patients with cutaneous SCC who had been treated by
one of the consultant dermatologists at Nottingham University Hospitals NHS
Trust between 1 January 2012 and 31 December 2012 were sent a letter from
the clinical care team inviting them to take part in the study, along with a
participant information sheet (Appendix 5) explaining the purpose of the
study. Private patients were excluded as Research and Innovation approvals
were for the Nottingham University Hospitals to act as a Participant
Identification Centre for NHS patients only. Consent to take part was implied
by return of a reply slip allowing the research team to contact them. A
minimum sample size of 20 questionnaire respondents was set as this was felt
to be feasible number and would allow for a broad range of opinions to be
canvassed.
8.3.2. Ethical approval
Ethical approval for the study was granted by the Proportionate Review Sub-
Committee of the NRES Committee West Midlands –Coventry and
Warwickshire (REC reference 13/WM/0051) (Appendix 4). Research and
Innovation approval was given by the Nottingham University Hospitals NHS
Trust in its capacity as a Participant Identification Centre, and the study was
included on the NIHR Clinical Research Network Portfolio.
8.3.3. Questionnaire and focus group
A postal questionnaire with open and closed questions relating to the design
of the proposed RCT and hypothetical willingness to be randomised to each
stage was designed. Members of the UK Dermatology Clinical Trials Network
(UKDCTN) Patient Panel piloted the questionnaire and provided feedback
during a workshop session at their annual training day.
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The questionnaire was sent to potential participants identified by the
dermatologist from their patient list and who had been treated for SCC during
2012. Participants were asked to return their completed questionnaire within
14 days of receipt (Appendix 6). Prior to filling in the questionnaire,
participants were first asked to read the accompanying trial scenario which
explained the current uncertainties about what size of excision margin is
optimal and about which patients may or may not benefit from having
additional radiotherapy. This information also explained the process of
randomisation, describing randomisation as being ‘the best method of
producing the fairest results’ in RCTs.
In the questionnaire, participants were asked to rate their willingness to
participate in the proposed trial on a five-point scale (definitely yes, probably
yes, unsure, probably no, definitely no) and asked to explain their reason in
an open-ended format. They were then asked to indicate if they had a strong
preference for one of the treatment arms described over the other, again
with the opportunity for further elaboration.
Demographic data was collected on the participants’ age, employment status
and the highest educational level attained.
At the end of the questionnaire, participants were asked about their
willingness to take part in a focus group, designed to explore patients’
attitudes to research and their condition generally, and to discuss issues
around the trial itself in greater depth. Respondents who expressed an
interest in participating in the focus group were telephoned by the research
team and invited to take part.
Seven participants consented to take part, so one focus group was held,
facilitated by two researchers. Those who took part were asked to respect the
confidentiality of the other participants outside the setting of the focus group,
and were assured that the transcribed recording would be anonymised and
that participants would not be identifiable from any quotes subsequently
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used. All participants signed a consent form before the discussion
commenced (Appendix 7).
Discussion was based around a broad topic guide (Appendix 8), which
included willingness to take part in clinical research generally, willingness to
participate in each stage of the two-stage trial being proposed and possible
barriers to taking part in research. Participants’ use of information resources
and knowledge of their condition was probed to ascertain the needs of
participants in the proposed RCT in terms of information provision. The focus
group lasted approximately 90 minutes and was recorded using digital
recording equipment and transcribed in full by the principle researcher, with
consultation with a second researcher where necessary.
8.3.4. Qualitative data analysis
Qualitative data from the questionnaires and focus group were analysed using
a Thematic Framework Analysis approach (Pope et al., 2000, Ritchie and
Spencer, 1993). An initial a priori thematic framework was constructed from
the literature on clinical treatment and clinical trial recruitment, containing
themes on knowledge of SCC, treatment experiences, attitudes towards
research and understanding of randomisation. The framework was a simple
model constructed selectively to address the research question, and reflecting
the straightforward purpose of this research. Subtopics were amended if
there was an excess of data or if no data were captured for a particular
theme. A thematic map was generated to reflect the content of the focus
group discussion and questionnaire responses and to generate insight into
recruitment to the proposed trial (See Figure 50). Data from the
questionnaires and focus groups were coded, indexed and charted onto the
thematic framework for interpretation according to the research objectives
(as per example in Table 39). This was done by the principle researcher and
checked by a second researcher. Coding was ‘broad-brush’ and largely
descriptive to reflect the straightforward research aims.
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Table 39: An example of the indexing matrix
THEME 1 – TREATMENT
1.1 – Diagnosis 1.2 – Initial
treatment
1.3 –
Problems
1.4 –
Concerns
1.5 -
Support
Q’airre
participant
1
Data reported/
summarised……
[lines x-y]
Data reported/
summarised……
[lines x-y]
Q’airre
participant
2
Data reported/
summarised……
[lines x-y]
Data reported/
summarised……
[lines x-y]
…
Focus
Group 1
Data reported/
summarised……
[transcript lines
x-y]
Data reported/
summarised……
[transcript lines
x-y]
8.3.5. Quantitative data analysis
Demographic data were analysed using SPSS 21 statistical software.
Willingness to participate in both or one of the stages of the proposed trial
was evaluated as a three-category variable: 1) Definitely willing to participate
2) probably willing or unsure 3) Probably or definitely unwilling to participate
(not willing). The treatment preference variables were dichotomised into the
categories ‘strong preference’ and ‘no strong preference’.
The association of age, gender, employment status and educational level with
willingness to be randomised into the stages of the proposed trial and
strength of treatment preference was examined. Age was analysed as a
continuous variable. Employment status was categorised as ‘employed’, ‘not
working due to ill-health’, ‘retired’ or ‘otherwise not working’. Education was
categorised according to the highest educational level attained as either
school (no formal qualifications, school certificate, ‘O’ or ‘A’ levels) or higher
education (university degree or professional).
Statistical significance of variables was assessed by Chi-square probability or
Fisher’s test with 2-tailed p-values. Differences between means were
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statistically significant.
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Figure 50. Thematic framework of factors influencing willingness to participate in a two-stage trial of surgery and adjuvant radiotherapy for SCC
Willingness to be
randomised
Concerns about
randomisation
Understanding
process
Barriers to
taking part
Willingness to
take part
Study design
considerations
Reasons to do
research
Trust in doctorExperiences
and concerns
SCC
Knowledge
Information
provision
Emotional
experiences
Knowledge Attitudes to Research RandomisationTreatment
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Results8.4
Fifty-nine patients were identified as being potentially eligible for the study,
having had surgical excision of an SCC within the specified 12-month period,
and were sent letters inviting them to participate. Thirty reply slips (51%)
were returned, including one informing the team that the patient had
subsequently passed away, so questionnaires were posted to 29 potential
participants. Completed questionnaires were returned for 24 participants
(83%).
Nineteen men (79%) and five women (21%), with a mean age of 73 years (SD
9), took part in the study. Three-quarters (n=18) of participants were retired,
and the remainder were either in full or part-time employment (n=3
participants), self-employed (n=1), or not working due to ill health (n=2).
Educational status varied among respondents, with seven (29%) having
professional and/or postgraduate qualifications, two (8%) holding a university
undergraduate degree, two (8%) having ‘A’ levels, three (13%) having ‘O’
levels or equivalent, one (4%) having a School Certificate, 8 (33%) having no
formal qualifications, and one (4%) not specifying highest educational
attainment.
A total of seven participants also agreed to take part in the focus group (6
men, 1 woman), with a mean age of 70 years (SD 9).
The thematic map was organised according to four overarching themes:
x Knowledge of the condition
x Experiences of treatment
x Attitudes towards research
x Attitudes towards randomisation
8.4.1. Patient knowledge of the condition
Two main areas of knowledge of SCC were identified during the focus group
discussion:
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x Knowledge of SCC itself, including existing knowledge of causes, risk
factors and prognosis
x Information resources used to get information, their adequacy and
requirements for provision of information resources for the proposed
trial.
Knowledge of SCC
Overall participants in the focus group did not feel well informed about their
condition, even though some of them had received treatment for multiple
skin cancers. There was little pre-existing knowledge of SCC prior to diagnosis,
with some participants previously never having heard of it as a discrete type
of skin cancer. Several participants recognised sun exposure as a major risk
factor, and there was some speculation that the reason that males are more
commonly affected than women may be due to females using sun protection
measures more than men.
Participant 1 (Male, 62 years): “.. the reason that theres more men
here, that they get it more than women. Is it because women wear a
lot of make-up on their faces’
Participant 2 (Male, 79 years): “Presumably women are more eager to
use the suncreams. Im thinking of my young daughter and wife, is that
theyre all very keen to protect their skin whereas men dont seem to
bother as much
Most participants had at some time attempted to rationalise why they had
developed the cancer. Exposure of a cut to aluminium and wire, exposure to
grinding dust, radiation treatment, a specific sunburn event, and long-term
medication use were cited as potential causes of individual skin cancers.
Knowledge of prognosis was variable with some participants not being aware
that some SCCs can recur or that there is an increased risk of developing new
skin cancers elsewhere. The more ‘experienced’ skin cancer patients, who had
a history of more than one skin cancer, felt quite confident that they would
know how to recognise a new skin cancer.
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Information provision
Although participants generally had access to information leaflets which were
given to them in clinic explaining the condition and its treatment, some could
not remember much about them, whilst others found the leaflets were quite
useful and interesting. However, there was general agreement that they
could have been much better informed about SCC. Some felt that they had
been given the leaflets and told to go away and read them, but would like to
have had more explanation from the clinicians treating them, although there
was acknowledgement of the workload and time constraints of the medical
staff and potential to compromise time to treatment, which was a concern to
participants.
Participant 1 (Male, 62 years): I got just a leaflet They never
explained. They said Take that, read that. I suppose they were busy
doing other things.
Facilitator: It sounds like the doctors could talk to you a bit more?
Participant 1 (Male, 62 years): Yeah, I think so. Especially those that
are performing surgery on you or putting you under the knife.
Participant 5 (Female, 64 years): Thats going to eat into the time
theyve got and weve said we want quicker treatment.
The internet was another source of information used by those with access to
learn more about their condition, and for some was the main source of
information. This was done independently and they had not been
recommended particular sites by the clinicians.
Another potential source of information was the skin cancer specialist nurse,
and although some participants had been given details of this service during
their treatment, none had actually accessed the facility after treatment. One
participant also admitted that they were attending the focus group as they
felt very poorly informed and were hoping to learn more about SCC from the
session.
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Participants indicated in the discussion that if they were invited to take part in
the proposed RCT, they would like to have a choice of formats through which
participant information is provided. It was felt that a website dedicated to
the trial would be useful, with details of the trial itself and the research team,
with the proviso that any written information, either web-based or in leaflet
form, should be easy to understand and the language not too technical. Some
participants expressed that they would also want to a face-to-face discussion
about the trial, although the concern about taking up too much of the
clinician’s time was again raised. There was general agreement that access to
either a member of the research team or a specialist nurse in order to discuss
the trial itself or their own clinical care would be satisfactory and would
lessen the burden on the clinician.
8.4.2. Experiences of treatment
Three areas were identified regarding treatment experiences:
x Experiences and concerns about diagnosis, referral and treatment
x Emotional experience
x Trust in the clinicians.
Experiences and concerns about diagnosis, referral and treatment
Although all participants had experienced surgical excision of their skin
cancer, there was some variation in their overall experiences and satisfaction
with the service. This was most evident with initial diagnosis and referral,
where delayed diagnosis by their GP was reported by a couple of participants,
which resulted in late referral and the feeling of mistreatment of the
condition:
Participant 2 (Male, 79 years): “The delays for me were treatment by
the doctor [GP], who I felt was mistreating me and I complained and
finally convinced a senior doctor that I had to be referred to
dermatology.
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Questionnaire respondent 7 (Male, 60 years): My main concern was
with the identification of the SCC as this was not identified by my GP
and it was several weeks before I was referred to hospital and the
appropriate action taken. By the time it was dealt with the wound had
grown and resulted in two operations to ensure complete removal.
The concern was raised that GPs should be better educated to recognise skin
cancers at an early stage and to make rapid referrals to the specialist
secondary care team. Timeliness of treatment was important to participants,
and although none expressed dissatisfaction with the two-week wait rule,
some were frustrated that the system could not be bypassed if they
subsequently developed new skin cancers. The idea of a specialist ‘walk-in’
treatment day centre attracted some support during the focus group
discussion.
Overwhelmingly, the most important treatment outcome for focus group
participants was complete removal of their SCC and minimising the chances of
it recurring:
Participant 2 (Male, 79 years): When you find out youre going to
have an op, all you want to do is make sure the cancer is taken away
completely. I dont care how big it is, how deep, but just make sure you
get it all away. That was my attitude to surgery.
The most important outcomes of treatment among the 24 questionnaire
respondents were considered to be removal of the cancer (10/24) and
minimising the risk of recurrence (11/24); for the remaining three
respondents, both outcomes were equally important.
Assurance that the cancer was removed was of greater importance than the
size of the surgical wound itself; nevertheless, concerns were expressed about
donor skin graft sites which may prove to be more problematic than the
recipient site.
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Emotional experience
Anxiety, fear and the need for reassurance that the SCC has been treated
adequately were all experienced by participants, indicating that SCC is a
condition that is viewed as being as serious as other forms of cancer and not
merely a trivial inconvenience to those affected by it:
Participant 1 (Male, 62 years): When you hear that c word, you
naturally assume the worst, whether its a small cancer or a big cancer,
you know, you naturally assume the worst and, I cant think of
anything to say  I want to be on this earth as long as possible.
Anxiety, fear, I experienced all that. When they told me I thought my
world had collapsed.
But the fear and anxiety when youre waiting to have to go and have
it done was horrible, I wouldnt want anybody to go through that. I
thought my world was coming to an end.
Trust in the clinicians
The concept of trust in the treating physician underpinned much of the
discussion in the focus group. Implicit faith in the knowledge and skills of the
specialist was voiced by some of the participants, with unquestioning
acceptance that the treatment they were receiving was in their best interest:
Participant 1 (Male, 62 years): I trust the doctor; I trust doctors
because thats their job you know. I asked the surgeon Did you get it
out? and he says Im doing them every day, I think I got it all, Ive cut
more of it away but I think I got it all out. So I trust him.So I believe, I
believe in my surgeon, and my life was in his hands.
Participant 4 (Male, 81 years): I mean, you just go and he said Well
have to cut it out and you just say Well, all right, just get on with it. I
cant tell them what to do. You just trust them.
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On the other hand, some challenged the belief that the surgeon could
confidently say that all the cancerous tissue had been removed.
Participant 1 (Male, 62 years): The surgeon knows; hes doing them
all them every so when he cuts you open he can see roughly, Im sure
he can see, roughly whats there and what he can get out”
Participant 3 (Male, 67 years): Id be interested to know the answer
to that  can he? Can the surgeon tell when hes chopping away?
Participant 2 (Male, 79 years): No, I dont think he can.
Having confidence in the treating physician as a pre-requisite to participating
in the proposed trial was raised in the questionnaire responses:
Questionnaire respondent 28 (Male, 84 years): I would want to have
faith in the surgeon/consultant giving the advice and/or operating.
Providing information to potential participants about the team involved in the
trial may therefore be an important strategy to increase trust in those who
are going to be administering the treatment arms, thereby encouraging
participation.
8.4.3. Attitudes to Research
Four main areas were identified relating to attitudes towards research:
x Reasons for participating in research
x Study design considerations
x Willingness to participate in the proposed RCT
x Barriers to participating in clinical research.
Reasons for participating in research
During the focus group, both personal and more general reasons for taking
part in clinical research were discussed. There was a general feeling that
clinical research is important in this country. An altruistic sense of giving some
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benefit to others and giving something back for treatment received were
common themes:
Participant 1 (Male, 62years): “I love the thought of helping others if
possible
Participant 3 (Male, 67 years): As for research, Id be delighted to
give something back to the Treatment Centre; theyve treated me so
well.
Participant 6 (Male, 80 years): Im willing to go the extra yard to help
others
Participant 2 (Male, 79 years): Any kind of research is for the benefit
of us all, not just ourselves here but for everybody and it is quite
important.
The idea was also expressed that in addition to helping others, discovering
more about a disease and advancing treatment, the participant themselves
may also benefit from taking part in research:
Questionnaire respondent 9 (Male, 62 years): “As I believe skin cancer
will return to me, I would like to be involved in any research
Study design considerations
The nature of the interventions in the arms of an RCT was considered to be an
important factor which may influence the decision about whether or not to
participate. Further to discussion about trials involving surgery and those
involving new drugs, participants generally felt more comfortable with the
idea of taking part in surgical trials:
Participant 3 (Male, 67 years): I suppose there is a history, not
necessarily in this area, but other researchers, where they have gone
ahead and introduced drugs which have later on proved to be not quite
what they thought. I suppose thalidomide is a name that comes to
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mind, but perhaps more drugs than  I think here were talking more
surgery.
Participant 5 (Female, 64 years): I think it comes from the things
you hear on the news  how somebody died I dont know how many
years ago from taking a tablet from research. So yeah, I would
definitely be more comfortable with surgery
Some participants were less sceptical than others about taking part in drug
trials; although the idea was expressed that wariness about taking part in
such trials may be tempered if they were terminally ill:
Participant 5 (Female, 64 years): “If I was terminally ill I would take
anything; if it didnt help me perhaps it would help someone else in the
future, but yeah, if I was terminally ill that might be different.
The idea that participation in a clinical trial may result in getting a new
treatment or in closer monitoring of their condition had been considered as
an attractive reason to take part, and some agreed that presentation of the
trial in such a way may increase their willingness to participate, although this
was not an issue for everyone.
Willingness to participate in the proposed RCT
There was general agreement in the focus group discussion that, in principle,
participation in the first surgical stage of the proposed trial would not be
overly concerning, although reservations were expressed about having larger
margins for SCCs located on the face, (particularly in younger or female
patients), or periorificially, where function could be compromised.
Participant 5 (Female, 64 years): “I think it could depend on who you
are, how old you are, where it is as to how much . If youre a young
woman you might prefer as little as possible.
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Participant 2 (Male, 79 years): I think the site of this is important too.
Obviously if its on the face you wouldnt be volunteering for 10mm if it
wasnt necessary, and it hasnt been proved necessary yet”
Participant 3 (Male, 67years): I think if its near the eye or any other
opening, if you think its going to affect the working of the eye by
pulling the nerves or damaging the nerves or whatever then I would
think a bit more carefully about this but if its on your shoulder or
whatever, then youd take a bit more.
Participant 1 (Male, 62 years): Id go for that. If its on your face then
go for as little as possible
Problematic skin grafts following surgery had been experienced by some of
the focus group participants, and were discussed as a factor which would
impact negatively on willingness to take part in a trial involving larger excision
margins.
Willingness to participate in the second stage of the proposed RCT, in which
adjuvant radiotherapy after surgical excision will be compared with no
adjuvant radiotherapy, was more reserved. Several participants both in the
focus group and questionnaire respondents, expressed fear over having
additional radiotherapy, with possible side effects and ‘doubts as to whether
radiotherapy really works  too random kill or cure’ being raised as reasons
for reluctance to participate.
One participant who had previously had radiotherapy as part of a trial was
very suspicious that his skin cancer had been caused by the radiotherapy, and
has subsequently been left ‘very frightened of all forms of it’. The
psychological impact of being in the adjuvant radiotherapy arm of the
proposed RCT was also raised as an issue in the focus group discussion, with
the suggestion that the disease would be perceived as being more serious by
the participant:
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Participant 5 (Female, 64 years): I think it would definitely take over
your life and it also becomes in your head more seriousup to 6 weeks,
you know, in your head, its more serious.
Barriers to participation
Other than the specific reasons indicated above regarding willingness to take
part in the individual stages of the RCT, more general barriers to recruitment
were identified in the focus group and questionnaires. Some of these were
age-related: extra visits to hospital; feeling worn-out after hospital visits; lack
of concentration; concern over the future; and pre-existing deafness were
some potential barriers which were of concern to individuals. The
inconvenience of possible extra hospital visits in terms of time commitments,
transport, travel and parking expenses was an important consideration for
some. The retired focus group participants discussed that time may less of an
issue for them but did feel that parking and travel expenses should be
reimbursed for participants.
8.4.4. Attitudes to randomisation
Three areas relating to randomisation in RCTs were identified:
x Understanding of the randomisation process
x Concerns about randomisation
x Hypothetical willingness to be randomised in the proposed RCT.
Understanding randomisation
The concept of randomisation was an area of confusion, with some focus
group participants never having heard of the process and others having vague
ideas about why and how randomisation is done.
Participant 1 (Male, 62 years): “Is that when they pick from all angles,
all walks of life..?
Participant 2 (Male, 79 years): I would imagine its a bit like Ernie
that picks a number out and thats the one you get.
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Participant 7 (Male, 60 years): I think sometimes you use a control,
so sometimes you give a placebo where you get no treatment at all.
Concerns about randomisation
Concerns about randomisation raised by respondents to the questionnaire
(who had been given a brief outline of the randomisation process in the
participant information sheet), related to misunderstanding of the purpose of
randomisation, lack of equipoise and the perceived threat to the optimal care
of the patient.
Questionnaire respondent 9 (Male, 62 years): People might meet
this situation as a life-or-death predicament and would therefore want
the optimal treatment and not be randomised so they take pot-luck 
whether or not radiotherapy is offered when it is something they might
need  not to be withheld therefore.
Questionnaire respondent 10 (Female, 64 years): Fear of not getting
the treatment which is most effective for their SCC
Questionnaire respondent 12 (Male, 76 years): My hesitation arises
out of the obvious concern that the randomised treatment selection
will not be the optimum treatment for me.although I appreciate that
the study is in fact an attempt to establish optimisation.
Interestingly, one participant felt that the uncertainty of the effectiveness of
the different treatment arms in the RCT would actually discourage them from
wanting to take part.
Further to explanation of the randomisation process in the focus group, the
general consensus was that randomisation should not be seen as threat to
the best care of the participant, although there was still some concern about
not getting the usual treatment for a condition and about delays to treatment
which may be incurred during the research process.
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Participant 5 (Female, 64 years): Maybe if I wasnt getting something
that somebody normally got for what I have, so that I was actually not
getting it, then I think..mm, is this the right thing to do?
Participant 6 (Male, 80 years): If you had a very fast growing cancer
like my wife, when you could almost sit at the table and watch it grow,
then youd want it going into fairly quickly.
Hypothetical willingness to be randomised into proposed trial
Questionnaire participants were asked whether they would hypothetically be
prepared to be randomised into one or both stages of the proposed trial.
Eight of the 24 (33%) questionnaire respondents indicated that they would
definitely be willing to be randomised to both stages of the proposed RCT,
and a further 5 (21%) that they would probably be willing to be randomised to
both stages. Two participants (8%) said they definitely would not want to
randomised to either stage, one (4%) probably would not and eight (33%)
were not sure. Two (8%) respondents indicated that they would only want to
be randomised for the first surgical stage of the trial, and an additional two
(8%) would probably be willing to be randomised to the first stage only. One
respondent (4%) indicated willingness to be randomised to the second
adjuvant radiotherapy stage only. Therefore, in total, 17 (71%) participants
indicated definite or probable hypothetical willingness to be randomised into
the first stage of the RCT, and 14 (58%) into the second stage which was not a
statistically significant difference (McNemar’s test, p=0.37).
Those who were hypothetically willing to be randomised into both stages of
the proposed trial were significantly younger than those who were unsure or
unwilling (independent samples t-test, mean difference 8.6 years, 95%
confidence intervals 1.7 to 15.4, p=0.016). With regard to gender, educational
status and employment status, participants did not differ significantly in their
willingness to be randomised into both stages of the proposed trial, although
the study is unlikely to be sufficiently powered to detect differences (Fisher’s
test p=1.00, p=0.42 and p=0.60 respectively (Table 40).
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Table 40: Distribution of participants by willingness to be randomised to both stages of proposed trial
*- independent samples t-test; ** Fisher’s test
Factor Definitely/probably
willing
(N=13)
Not sure/probably or
definitely not willing
(N=11)
Total
(N=24)
P-value
Age (mean ± SD) 68.5 ± 7.8 77.1 ±8.3 72.5 ± 9.0 0.016*
Gender:
Male
Female
10 (53%)
3 (60%)
9 (47%)
2 (40%)
19
5
1.00**
Educational level:
School
Higher/professional
7 (47%)
6 (67%)
8 (53%0
3 (33%)
15
9
0.423**
Employment status:
Employed
Retired/otherwise
not working
3 (75%)
10 (50%)
1 (25%)
10 (50%)
4
20
0.60**
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Treatment preferences
In response to questions about preference for one treatment arm over the
other for each of the stages of the trial, six of those who claimed they would
definitely or probably be willing to be randomised into both stages of the trial
indicated a strong preference for one of the treatment arms. Four of these
respondents favoured a more radical approach, with preference for the larger
surgical excision margin and adjuvant radiotherapy.
Questionnaire respondent 14 (Male, 68 years): Sounds to me like a
better chance of removing everything
Questionnaire respondent 19 (Male, 86 years): “Gives more chance of
removing cancer (10mm margin)
Questionnaire respondent 19 (Male, 86 years): “Again I feel it will
help in complete recovery (ART).”
Cosmetic reasons were given for preference for a smaller margin in the
remaining two participants.
Four participants who were definitely or probably willing and one who was
definitely not willing to be randomised to the first surgical stage expressed a
strong preference for one of the treatment arms (Figure 51). The association
between strength of preference and willingness to be randomised was not
significant (Fisher’s test, p=1.00). Three participants (one of whom was
definitely not willing to be randomised, one who definitely was, and one who
probably would) expressed a preference for a 10mm margin on the grounds
that the wider margin would optimise the chances of removing the cancer.
The remaining two participants both expressed a strong preference for a
6mm margin over 10mm for cosmetic reasons, although both were still
definitely willing to be randomised into the first surgical stage.
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Figure 51: Strength of preference and willingness to be randomised into the first stage
No-one who was definitely willing to be randomised into the second stage of
the proposed trial expressed a strong treatment preference, and one person
who was definitely not willing to be randomised expressed a strong treatment
preference (not to have ART). One other person who was unsure whether
they would be prepared to be randomised into the ART stage also expressed a
strong preference not to receive ART as they attributed their SCC to previous
radiotherapy treatment. Four other participants, three of whom would
probably be willing to be randomised into the ART stage and one who
probably would not, expressed a strong preference to have ART as they felt
they would have a better chance of tumour clearance by receiving ART,
particularly if there was nerve involvement. Overall, the relationship between
strength of preference and hypothetical willingness to be randomised into the
second stage was not statistically significant (Fisher’s test, p=0.66) (Figure 52).
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Age, gender, employment status, and educational level were not significantly
associated with strength of preference for treatment in either of the stages of
the proposed trial (Table 41).
Figure 52: Strength of preference and willingness to be randomised into the second stage
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Table 41: Distribution of participants by strength of preference for one treatment arm over the other for each randomisation stage
* independent samples t-test; ** Fisher’s test
Factor Surgical randomisation
stage
p-value ART randomisation stage p-
value
N=24
Strong
preference
No strong
preference
Strong preference No strong
preference
Age in years (mean ± SD) 69.8 ± 6.9 73.2 ± 9.5 0.47* 73.8 ± 7.2 72.0 ± 9.6 0.68* 72.5 ± 9.0
Gender:
Male
Female
5 (26%)
0 (05)
14 (74%)
5 (100%)
0.19**
6 (32%)
0 (0%)
13 (68%)
5 (1005)
0.20** 19
5
Educational level:
School
Higher/professional
4 (27%)
1 (11%)
11 (73%)
8 (89%)
0.36**
3 (20%)
3 (33%)
12 (80%)
6 (67%0
0.40**
15
9
Employment status:
Employed
Retired/otherwise not working
1 (25%)
4 (20%)
3 (75%)
16 (80%)
1.00**
1 (25%)
5 (25%)
3 (75%)
15 (75%)
1.00**
4
20
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Discussion8.5
This feasibility work has identified some previously recognised factors which
may influence recruitment into clinical trials generally, but is the first that has
specifically addressed recruitment into a trial for cutaneous SCC. By
recognising misunderstandings and concerns about clinical research generally,
and the specific trial proposed, appropriate strategies can be devised to
overcome these and to enhance recruitment.
8.5.1. Patients knowledge of squamous cell carcinoma
Specific knowledge about cutaneous SCC was generally poor, with confusion
about the causes of the condition and its prognosis, even among those who
had a history of previous skin cancers. This confirms the findings of two other
studies that have assessed the knowledge of patients with skin cancer,
although neither of these related specifically to SCC (Bath-Hextall et al., 2013,
Wright and Bramwell, 2001). In terms of recruitment into the proposed trial,
a lack of patient knowledge about SCC in itself should not be a barrier as
potential participants will receive patient information resources providing
background information about SCC, including its natural history, the
treatments options and possible implications of the different treatment arms.
8.5.2. Provision of information
The way that such information is presented will be key to enhancing the
understanding of potential participants. It should be clear, use language that
is appropriate to a lay person and available in a choice of formats. The need
for the provision of high-quality information, appropriate to the needs of the
patient at that point in their diagnosis, and repeated over time, has been
highlighted previously (National Institute for Health and Clinical Excellence,
2006) . Receiving a diagnosis of skin cancer induces anxiety and fear in those
affected, and the lack of recall of information given at initial diagnosis may be
a reflection of the emotional state of the patient at the time (Bath-Hextall et
al., 2013). Skin cancer guidance advises that information provided should
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therefore be repeated over time, and be available in other formats such as
audiotapes of consultations, videos or other specialised materials if
appropriate (National Institute for Health and Clinical Excellence, 2006). This
was raised as an option that potential participants would like to have.
8.5.3. Timeliness of diagnosis and treatment
There was general recognition of the need for rapid diagnosis and treatment
of SCC, and an overwhelming view that the most important outcome of
treatment should be to completely remove the tumour and to minimise the
risk of it recurring. Although generally not a life-threatening condition, those
affected want minimal delays in referral and treatment. Compromised
timeliness of treatment caused by the research process itself would therefore
not be tolerated by potential participants. However, delays previously
experienced by participants in this study were related to diagnosis of SCC
rather than the treatment received after referral to the specialist. Current
recommendations are that patients with suspected cutaneous SCC should be
urgently referred to a specialist and seen within two weeks of referral
(National Institute for Health and Clinical Excellence, 2006, National Institute
for Health and Clinical Excellence, 2005). Perceived delays in referral by the
GP due to misdiagnosis caused frustration and enhanced anxiety for those
who had had such an experience and raised concern that some GPs may not
be adequately educated to diagnose suspected SCC. The ability of GPs to
diagnose skin cancer varies widely (Bedlow et al., 2000, Chen et al., 2001) ,
and although several studies have evaluated the impact of educational
interventions on improving diagnostic accuracy amongst primary healthcare
providers, these tend to be isolated interventions and have generally not
been rigorously evaluated (Goulart et al., 2011). Educational interventions
have been found to be of variable effectiveness (Shariff et al., 2010, Bedlow
et al., 2000), and modifying and maintaining clinical practice in the long-term
can be challenging (Girgis et al., 1995). Studies addressing educational
interventions with outcomes that focus on performance changes are
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therefore required, but outside the remit of the current study and the RCT we
are proposing.
8.5.4. Drivers to participate in clinical research
Understanding of the clinical research process, and how and why
randomisation is done, was lacking among participants in this study.
Nonetheless, there was general consensus that clinical research is important
and that it helps moves treatment forward. A sense of altruism was identified
as a positive driver to participate in research. Additionally, there was some
feeling that having a terminal illness as opposed to less advanced disease in
an individual may enhance this altruistic attitude. Other studies of willingness
to take part in clinical trials in patients with metastatic disease as opposed to
primary disease have confirmed this (Catt et al., 2011, Garcea et al., 2005).
Conversely, reasons to participate may also be in the self-interest of the
individual, based on the belief that the treatment they receive may be an
advantage to them personally, and that by helping to move the evidence base
forward they may themselves benefit from any advances should they require
treatment for the same condition in the future.
8.5.5. Understanding of randomisation
Misunderstanding of the concept of randomisation, or the perceived
advantage of one treatment arm over another, may be seen as threats to
optimal care and may fuel uncertainty and additional anxiety which may
compromise successful trial recruitment. Even though questionnaire
respondents in this study had been given information about the nature of the
randomisation process and its purpose, uncertainties and concerns about
randomisation were evident from their responses, underpinning the need for
clear, accurate provision of such information for potential trial participants.
However, the idea of randomisation is difficult for lay people to accept, and
their interpretation may differ from that of medical professionals, so there
may be a need for further discussions with potential recruits in order that
they are informed sufficiently to be able to give informed consent (Whitley
and Ball, 2002). Furthermore, provision of additional information has been
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shown to sway attitudes positively towards participation in those initially
dissenting from taking part in cancer trials, and careful in-depth discussion
may resolve some of the concerns about randomisation (Jenkins et al., 2010).
8.5.6. Treatment arm preferences
Patient preference for one treatment arm over the other was expressed by
some participants in this study. This included some of those who claimed that
they would be hypothetically willing to be randomised into one or both stages
of the trial, although the perceived benefit of one of the treatment arm is
evidently going to influence their final decision whether to take part and risk
receiving their non-preferred treatment. The relationship between the
strength of preference for one of the treatment arms over the other in each
stage of the proposed trial was not found to be statistically significant.
However, numbers were small so any statistical inferences need to be
interpreted cautiously. Of the two patients who were not willing to be
randomised into the ART stage, one commented that they would not like to
have radiotherapy at all, and the other that they would be concerned about
missing the opportunity to receive a treatment that could be beneficial if they
were randomised to the non-ART arm. Other studies have found a strong
association between willingness to be randomised into trials and strength of
treatment preference, with those expressing a strong preference for a
particular treatment being more reluctant to be randomised (Mills et al.,
2003, Llewellyn-Thomas et al., 1991, Wragg et al., 2000, Creel et al., 2005).
Lack of patient equipoise is a recognised barrier to recruitment (Kaur et al.,
2013), and one that will need to be probed and challenged by researchers and
clinicians who are presenting the trial and taking part in discussions with
potential participants. If potential participants strongly believe that one of the
treatment arms is more likely to benefit them, they may be less willing to
chance receiving a treatment they perceive to be inferior in the process of
randomisation.
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8.5.7. Trust in the clinician
Several studies have found that the clinician introducing the trial to potential
participants has the greatest influence on their decision to take part or not
and that lack of confidence in the doctor will negatively influence this decision
(Ross et al., 1999). The role of trust in the knowledge and advice given by the
clinician has been seen to be of importance to participants in this study. The
level of this trust is therefore likely to have a positive impact on patients’
willingness to take part in the proposed trial. On the other hand, some
patients may feel that the process of randomisation may compromise the
doctor–patient relationship and undermine trust in the doctor, preferring
instead for the clinician to make the any treatment decisions for them. Trust
as a disincentive to participate in trials has also been reported elsewhere
(Dupont and Plummer, 1990). Clinical equipoise in individual clinicians
recruiting participants into trials is of fundamental importance to a trial’s
success and lack of equipoise may be a particular issue in trials involving
surgical interventions (McCulloch et al., 2002, Hamilton et al., 2013).
Additional training of clinicians consenting participants may therefore be
necessary to help overcome this. Another approach would be to run a
parallel, non-randomised preference arm alongside the main RCT (McCulloch
et al., 2002). A parallel study would, however, generate less robust data than
a well-conducted RCT and may impact upon the numbers and types of
patients agreeing to take part in the main RCT. For a condition in which
outcomes after treatment are relatively rare, and which will require
recruitment of a large number of patients in order to enable adequate
powering of the RCT, the loss of potential participants to a non-randomised
study could impact upon the overall success and usefulness of the main RCT.
8.5.8. Possible barriers to recruitment
General willingness to participate in clinical research may be moderated by
factors relating specifically to the trial in question. Regarding the proposed
SCC trial, participation in the surgical stage was seen as less of a threat than,
for example, taking part in a trial involving a new drug or in a trial in which
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there was the possibility of being randomised to a placebo arm, which has
been recognised as a disincentive to participate in trials (Locock and Smith,
2011), (Jenkins et al., 2013). Although almost three quarters of participants
claimed they would definitely or probably be willing to be randomised into
the first surgical stage, the decision about whether to participate or not may
be complicated by potential cosmetic implications, particularly for younger,
female patients and for SCCs located on the face or in a functionally sensitive
area (e.g. around the eye). Overall, hypothetical willingness to be randomised
into the second stage of the proposed trial involving adjuvant radiotherapy
was less enthusiastic, with 54% claiming definite or probable willingness to be
randomised. Concerns about receiving radiation were cited as the major
barrier to participation in those who said they would not be willing to be
randomised. In contrast, of the participants who did claim to be potentially
willing to be randomised, those who expressed a preference for one of the
treatment arms said they had a strong preference to receive the adjuvant
radiotherapy as they felt there was a better chance of it clearing the cancer.
The proportion of potential participants who are hypothetically willing to be
randomised is therefore likely to be an overestimate of the actual numbers,
which will need to be taken into account when designing the trial. Other
patient-related factors were identified as barriers to the proposed trial, and
primarily related to participation in the second radiotherapy stage. Some saw
the extra hospital visits that would be required as part of the radiotherapy
regimen as an inconvenience in terms of time, transport and cost, so the
provision of additional costs for reimbursement of trial-incurred expenses
should be considered as a strategy to encourage participation. Advanced age,
physical frailty, the presence of co-morbidities and uncertainty about the
future were also identified as reasons why some people may be reluctant to
become involved in research. The results of this feasibility study have
indicated that there is a significant difference in the mean ages of those
people would theoretically be prepared to be randomised into either stage of
the trial, with older people being less willing to take part. Age-related factors
are recognised as a significant barrier to recruitment into trials (Townsley et
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al., 2005, McMurdo et al., 2011), yet in the proposed trial the population pool
from which recruits will be drawn will be largely over the age of 70 years.
Exclusion criteria related to comorbid conditions and previous malignancies
may therefore need to be modified in the protocol if older and more frail
patients are to be included in the research and for the trial results to be
externally valid. Extra resources may additionally be required for research
personnel to spend time with older participants to explain the protocol and to
obtain informed consent.
8.5.9. Strengths and limitations of the study
Evaluation of the understanding and concerns about clinical research
generally and the specific trial being developed provides an insight into
potential barriers which may affect the willingness to participate in such a
trial, and the opportunity to incorporate strategies in the protocol to
overcome these barriers.
A limitation of this study is that all participants had previously had surgical
treatment of a cutaneous SCC and therefore had more insight and
expectations of treatment than people presenting for the first time and
invited to participate in the proposed trial. However, as none of them had had
adjuvant radiotherapy after surgery, this insight would be less of an issue for
the second stage of the proposed trial. Most participants in this study would
have regarded their surgical treatment as a ‘cure’, and this may have
influenced their response regarding randomisation into the second stage as
none of them received ART during their own treatment. Nevertheless, it is
possible that actual trial participants who are eligible to be randomised to
receive ART or follow-up alone will have a different perception of ART from
this study group, and that faced with the nature of their condition, concerns
regarding radiotherapy may be less of a concern. An advantage of having
participants with prior treatment experience is that it allows for evaluation of
the needs for the provision of information resources, and, given the lack of a
patient support group for this condition, has supplied a pool of volunteers
who are theoretically willing to review patient materials produced.
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People who returned their questionnaires and who took part in the focus
group may be more motivated to take part in research generally, so the
numbers who declared hypothetical willingness to be randomised may not be
a true reflection of the population pool generally and needs to be interpreted
with caution. Furthermore, an individual’s stated preference in a hypothetical
scenario may not be an accurate reflection of what they would actually decide
in a real-life situation.
Although more males than females participated in this study, this was not
intentional and reflects the demographics of the population that is affected
by this condition.
8.5.10. Summary of the main lessons learnt from this study
x Participants generally had poor understanding of SCC even though all
had experienced treatment of the condition.
x Understanding of the processes of clinical research and randomisation
was poor among participants.
x Overall participants did not regard the proposed RCT as being
unfeasible.
x Randomisation to one of the surgical arms in the first stage of the
proposed trial was not overly concerning for participants, although
willingness to be randomised would depend if their SCC was located in
a cosmetically or functionally-sensitive site.
x Generally participants would be more reluctant to be randomised into
the adjuvant radiotherapy versus no radiotherapy arm of the second
stage of the proposed trial. Concerns about receiving radiation were
cited as the main reason for this.
x Potential participants in a future RCT would want information about
the trial to be provided in a variety of formats.
x The randomisation process will require thorough explanation, and may
require additional time and staff input to ensure that participants are
thoroughly cognisant of the process and to optimise their willingness
to be randomised.
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x The concept of clinical equipoise will need reinforcing in order to
overcome trialists’ and participants’ potential preference for one
treatment arm over the other.
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8.5.11.Conclusions and Implications for research
This study has allowed evaluation of potential barriers to participating in the
proposed skin cancer trial in a population representative of those who would
be eligible to take part in the trial itself. Importantly those who participated in
this study did not reject the proposed trial as being unfeasible.
Actual numbers who are willing to participate in each stage will not be known
until the trial is underway, and the suggestion from this study is that eligible
participants are less likely to want to be randomised into the second stage of
the trial. The incorporation into the protocol of an initial pilot phase to assess
recruitment may therefore be prudent, with an alternative strategy such as a
parallel non-randomised arm if participants express a strong preference for
one treatment over the other or if recruitment does not reach target.
Understanding the needs and concerns of potential participants will allow the
development of appropriate information resources for the trial, which will be
of crucial importance to help potential participants make an informed
decision about whether or not to take part in the trial.
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9 THE TRIAL PROPOSAL
Introduction9.1
The trial proposal described in this chapter is the most recent version
culminating from the research of this thesis and the multidisciplinary
discussions that have been taking place.
As discussed in preceding chapters of this thesis, there has been a lack of
research comparing the effectiveness of SCC treatments, and no RCTs that
have compared different treatments for the primary, non-metastatic SCCs
that are seen most commonly in everyday clinical practice. The work
described in this thesis has been at the heart of the development of a trial
proposal for what will be the first RCT addressing the treatment of SCCs. In
order for this to happen, multidisciplinary collaboration has been essential,
and has therefore involved much discussion and debate. As a result, the
proposal has evolved considerably from the initial ideas for a clinical trial that
emerged from the survey of clinicians in 2010 and which were outlined in
chapter 6.
As the discussions evolved, it was felt that a third MMS arm could usefully be
added to the first randomisation stage so that comparison of outcomes after
surgical excision with the predefined margins and Mohs surgery could be
evaluated prospectively; an area which, as described above, remains
contentious. However, concerns were raised by some of the surgeons that
with technically it is difficult to achieve a clear distinction between 6mm and
10mm margins and that just comparing a surgical margin of 10mm versus
MMS to clearance would actually be preferable and yield the most useful data
about adequacy of surgical excision and a direct comparison between MMS
and standard surgical excision. There has been concurrence regarding the
importance of the second-stage of randomisation to ART versus no ART
throughout the trial development. This design therefore forms the basis for
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the current trial proposal which will be described in section 9.2 of this
chapter.
The history of the trial proposal and its context in relationship to the other
areas of research in this thesis is represented schematically in Figure 53.
The feasibility work with patients (chapter 8 of this thesis) was instigated
during the development stage of the proposed trial to assess the acceptability
of proposed trial with potential participants and to identify potential barriers
to recruitment which may need to be addressed in the protocol. Although the
trial scenario presented to the participants in the feasibility work compared
excision margins of 6mm and 10mm rather than wide local excision with
MMS, the lessons to be taken from it are still valid. Participants had fewer
concerns regarding the surgical stage than the second adjuvant radiotherapy
stage, and it is at this stage where recruitment challenges are most likely to
be encountered. Participants’ information requirements and the need for
careful presentation of the proposed trial so that clinical equipoise is
maintained, particularly in relation to ART, remain the same, regardless of the
exact details of the surgical intervention. One of the most important lessons
from the feasibility work was that understanding of the randomisation
process in the group representative of potential participants was poor, and
this issue will require particular explanation in any SCC trial, and may require
additional resources to be inputted.
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The current trial proposal9.2
The remainder of this chapter will focus on the trial proposal that has evolved
through this research and the multidisciplinary collaboration as described
above.
9.2.1. Aims and Objectives
x To assess whether there is a difference in the rate and timing of
locoregional relapse between patients with high-risk T2 SCCs which
have been excised with a 10mm surgical margin, and those treated
with Mohs micrographic surgery.
x To assess whether there is a difference in the rate and timing of
locoregional relapse in patients who are treated with post-operative
radiotherapy, and those who are treated by excision with a 10mm
margin or Mohs micrographic surgery alone.
x To develop a prognostic model for treatment of patients with high-risk
SCC.
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Figure 53: Development of trial proposal
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9.2.2. Trial Design
The proposed trial is a pragmatic, multicentre, two-stage, non-blinded RCT
comparing excision with a 10mm surgical margin with Mohs micrographic
surgery, and comparing adjuvant radiotherapy after surgery with no adjuvant
radiotherapy (Figure 54). The primary outcome will be time-to-first
locoregional recurrence within 3 years of treatment, although participants
will be followed up for 5 years after the end of treatment for assessment of
late outcomes associated with radiotherapy.
Due to the nature of the interventions, it will not be possible to mask
participants and principal investigators to the treatment allocated, and only
partially possible mask outcome assessors. However, the allocation sequence
will be concealed from participants and investigators so that they are not
aware of the treatment group into which patients will be put prior to
randomisation.
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Figure 54: Outline of proposed SCC trial
BWH T-staging high-risk features:
 'LDPHWHUFP
 Poorly differentiated;
 31,QHUYHFDOLEUHPP
 Invasion beyond fat
*Proposed high-risk features for trial:
 Diameter >2cm;
 Poorly differentiated;
 Extratumoral PNI
 Invasion beyond fat
 Depth >4mm
 Ear or lip location
Outcome assessment and five year follow-up (schedule as per protocol)
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9.2.3. Setting and Target Population
Target population
Participants will be adults (at least 18 years of age) with primary invasive,
non-metastatic high-risk SCC of the skin. The tumour staging criteria
described in Table 22 and which are based on the Brigham and Women’s
Hospital (BWH) proposed criteria(Karia et al., 2013) will be used to identify
patients eligible for entry into the trial. Patients having a T2 SCC with at least
one risk factor (tumour diameter >2cm, poorly differentiated, perineural
invasion, invasion beyond subcutaneous fat >4mm deep, ear or lip location)
will be eligible to be randomised into the first surgical stage of the trial. Only
patients randomised during the first stage of the trial, and who have 2 or 3 of
the above risk factors (i.e. T2b SCCs) will be eligible to be randomised into the
second radiotherapy versus no radiotherapy stage of the trial. Therefore, all
participants will take part in the first stage of the trial, and patients who have
not been randomised in the first stage will not be eligible to participate.
Setting
Recruitment and delivery of the interventions will be provided in secondary
care, with identification of potential participants by the skin cancer MDT. The
trial will be multi-centre. Site selection will be based upon the availability of a
dermatologist or plastic surgeon who is willing to be the Principal Investigator
(PI) for the site; the availability of a Clinical Oncology service that can
administer the adjuvant radiotherapy intervention; and proven track record
of recruiting into other clinical trials.
9.2.4. Eligibility
Inclusion criteria  first stage (10mm excision versus Mohs):
x Patients with a diagnosis of primary, invasive, non-metastatic
cutaneous SCC confirmed on diagnostic biopsy.
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x The SCC is staged as T2 and has at least one high-risk factor, based
upon the staging criteria outlined in section 7.2.1
x A 10mm surgical margin is achievable at the site of the eligible SCC
x The patient is able and willing to give informed consent
Exclusion criteria  first stage:
x Recurrent, previously treated SCC
x Surgery contra-indicated (e.g. Coagulopathy)
x Pregnant or lactating women
Inclusion criteria  second stage (ART versus no ART)
x The patient was randomised to excision with a 10mm margin or Mohs
in the first stage of the trial.
x The SCC is staged as T2b and has 2 or 3 high-risk factors, based on the
staging criteria outlined.
x The patient is able and willing to give informed consent.
Exclusion criteria  second stage:
x The patient was not randomised to one of the surgical arms in the first
stage of the trial.
x History of prior radiotherapy for skin cancer or other conditions
x Radiotherapy contra-indicated – location on back of hand or lower leg
Only one eligible SCC per patient will be randomised. If there is more than
one eligible SCC identified, tumours located on the head and neck area will be
selected in preference to those located on the trunk. When the is more than
one eligible SCC on the head and neck, the SCC that is of greatest concern to
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the patient will be chosen, with selection of the largest eligible SCC if the
patient has no preference.
9.2.5. Randomisation and blinding
The randomisation schedule will be generated by computer using a randomly
varying block size and will be generated and held by the Clinical Trials Unit
administering the trial. The trial administrator will carry out the
randomisation via a web-based system and alert the surgeon as to which
group they are in. The second stage of randomisation will take place after
surgical excision and when histology is known in order to identify those SCCs
meeting the additional layer of eligibility criteria. Only excised SCCs with
ŚŝƐƚŽůŽŐŝĐĂůĐŽŶĨŝƌŵĂƚŝŽŶŽĨĐůĞĂƌĂŶĐĞŽĨA? ?ŵŵĨƌŽŵƚŚĞƉĞƌŝƉŚĞƌĂůŵĂƌŐŝŶ
and fascial plane deeper than the level of invasion for deep margin will be
eligible for randomisation.
There will be no blinding of participants or principal investigators throughout
the trial. Assessors of photographs of cosmetic appearance will be blinded as
to participants’ identity, interventions received and time since treatment.
9.2.6. Interventions
Surgery
In the first stage of the trial, the intervention will be standard surgical excision
with either a 10mmmargin of normal-looking skin around the SCC, or Mohs
surgery to microscopic clearance of tumour. At presentation, all potentially
eligible SCCs will have a diagnostic biopsy. SCCs with at least one high-risk
factor (T2) will be eligible to be entered into the trial. Delivery of the Mohs
micrographic surgery will be by a consultant dermatologist or plastic surgeon
who has undergone a period of additional training in the technique.
Adjuvant Radiotherapy
Adjuvant radiotherapy will be administered by a Clinical Oncologist. The exact
regimen has yet to be finalised, but the total recommended dose is 50-60 Gy
in daily fractions over the course of four to six weeks and should be given
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within 12 weeks of surgical excision. The treated area will include a pre-
defined margin of normal looking skin.
The follow-up of participants who receive only surgery and those who also
have adjuvant radiotherapy will be identical.
9.2.7. OutcomeMeasures
Primary outcomes
Primary outcome will be loco-regional recurrence from initial randomisation
up to 3 years after treatment. A standard definition of local recurrence will be
drawn up to distinguish it from metachronous (new primary) tumours.
Secondary outcomes
The secondary outcomes will be as follows:
x Distant metastases within 3 years of initial randomisation
x Tumour-related death within 3 years of initial randomisation
x Overall disease-free survival (time from randomisation to death from
any cause)
x Completeness of surgical excision by measurement of histologically
clear margin
x Number of Mohs layers required to clearance of tumour
x Quality of Life (QoL) at baseline, and at each follow-up consultation
after completion of treatment. The tool for assessing QoL will be the
Skin Cancer Index (Rhee et al., 2006) which is a validated disease-
specific tool for patients with NMSC
x Cosmetic appearance of treated area assessed photographically at
baseline (post- surgery but before radiotherapy if applicable), and 2
and 5 years post-treatment, by three assessors blinded to participant
identity, treatment allocation and year of follow-up
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x Adverse events data will be collected from all participants
x Within-trial cost analysis from an NHS perspective
9.2.8. Study Schedule and data collection
Screening for the first stage of the trial will take place upon identification of a
high-risk SCC as defined in the trial protocol. This will either be on the initial
visit to the Skin Cancer clinic after referral from primary care, or, for SCCs only
identified as being high-risk after histology results are available and therefore
eligible for randomisation, on the first clinic visit after initial surgery.
Randomisation into the second stage will take place when full histological
classification after surgery is available which will allow for identification of the
highest-risk SCCs as defined in the protocol. Participants potentially eligible
for randomisation will be discussed in the skin cancer MDT. Participants
randomised to receive adjuvant radiotherapy will be treated no more than 12
weeks after their initial surgery.
Participants will be followed up on a 3-monthly basis until first recurrence, or
for 3 years after initial randomisation, with a final assessment at 5 years to
allow for assessment of late outcomes associated with radiotherapy. As this is
a pragmatic trial, there will be a window of flexibility for the 3-monthly visits.
Participants will be given information sheets advising them how to self-
examine the treated area, local skin and lymph nodes, and will have access to
the research team between clinic visits should they have concerns about
recurrences or new tumours.
Histological confirmation of suspected relapses should be sought where
possible. Where histology is not readily obtainable, radiological or
photographic evidence should be recorded of the relapse.
Management of relapses will be at the discretion of the treating clinician in
discussion with the SSMDT. Management of distant metastases may involve
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the enrolment of the patient in other clinical trials appropriate to that
scenario.
The proposed study schedule is outlined in Table 42.
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Table 42: Proposed provisional schedule of study delivery and data collection
Identification
high-risk SCC
D0(a) Within 2
weeks
1
st
post-surgery
visit/Identification
highest risk SCCs
2-12 weeks
post surgery
FOLLOW-UP as per
protocol up to 5
years
5 years
Informed consent and counselling (a) 3
Randomisation to 1
st
stage (surgical) 3
Surgical intervention 3
Outcome measurement  margin clearance/ number of
Mohs layers 3
Baseline QoL 3
Baseline photography, clinician and participant rating for
cosmetic appearance assessment 3
Informed consent and counselling (b) if applicable 3
Randomisation to second stage if applicable (ART) 3
ART intervention 3
Outcome assessment (time to loco-regional recurrence,
distant metastases, SCC related death 3
QoL assessment 3
(6 months, 2 years)
Photographic, clinician and participant rating for
cosmetic outcome assessment
3 (2 years) 3
Overall survival 3
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9.2.9. Health Economics
An economic evaluation will be conducted alongside the trial and will be
incorporated into the protocol. A health economist with experience of cost
analysis will be on the Trial Development Team.
In terms of cost-effectiveness of MMS compared with standard surgical
incision, the current evidence is conflicting. Surgical excision may be
perceived as the cheaper option as it does not involve special training,
multiple procedures over the course of up to a day, and expenditure setting
up and running a MMS service. However, if there actually are significantly
fewer recurrences after MMS, which as discussed above has not conclusively
been shown to be the case for SCC, then the cost-savings may be offset by the
costs of treating recurrences. Cost-effectiveness studies from the United
States suggest that MMS is comparable with, or even less expensive than
standard excision. In 1998 a cost-analysis showed that the cost of MMS was
$1243 versus $1167 for office-based surgical excision with a permanent
section margin control and $1400 for surgical excision with a frozen section
margin control (Cook and Zitelli, 1998). More recent studies have found MMS
to be between 12% and 33% less costly than surgical excision, depending
upon the type of margin control and the setting (office-based or ambulatory
surgical centre, which was associated with increased cost) (Tierney and
Hanke, 2009, Ravitskiy et al., 2012). However, another study from the United
States demonstrated that overall MMS had the highest fees, even when
controlling for factors such as tumour size and H-zone location, and attributed
the difference to the fact that MMS is often done in areas requiring complex
closure for repair (Wilson et al., 2012). The results of costing studies in the
United States may not be readily extrapolated to other countries due to
differences in the general set-up of healthcare systems and the way in which
reimbursement are calculated. A Dutch cost-analysis which was done as part
of the RCT of MMS versus surgical excision for facial BCCs reported that MMS
costs were significantly greater than surgical excision for treating both
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primary and recurrent BCC, and concluded that it was not currently cost-
effective to introduce widescale MMS (Essers et al., 2006). However, final
analysis when 5 year follow-up data were available, found that an
incremental cost-effectiveness ratio (ICER) that was comparable with the cost
of two Mohs procedures (initial treatment and treatment of a recurrence),
made MMS a potentially cost-effective treatment for recurrent BCC, but not
for primary BCC where there was no significant difference in recurrence after
MMS and surgical excision (Mosterd et al., 2008).
Thus, a cost-effectiveness analysis would be an important feature of any trial
comparing MMS with surgical excision for SCC, and would be one factor to
consider when making evidence-based decisions regarding the appropriate
treatment of particular SCC if both techniques are otherwise comparable in
terms of their effectiveness.
No cost-effectiveness studies have specifically evaluated adjuvant
radiotherapy in the treatment of NMSC. One study from the United States,
which included all types of NMSC, reported that at $1303 the total cost of
treatment per patient for radiotherapy (not specifically ART) was more than
five times higher than the cost of surgical excision ($239) and approximately
one and a half times more than MMS ($899) (Joseph et al., 2001). Therefore,
given the absence of any relevant data pertinent to the UK, a cost-
effectiveness evaluation will again be an important component of any trial in
which ART is included as a comparator.
9.2.10. Statistical Analysis and Sample Size
Due to the factorial component of this trial proposal, the sample size
calculation will be done by an experienced statistician who has expertise in
the area and who will be a member of the Trial Development team. An
approximate sample size calculation is given below based upon the data
obtained and discussed earlier in this thesis (chapters 4 and 7). It will be
necessary to recruit a large number of patients if the trial is to be adequately
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powered to detect if there is a clinically significant difference between the
treatment arms as the frequency of recurrence has been shown to be low in
both the systematic review (chapter 4) and in the case series of SCCs treated
in Nottingham (chapter 7).
The purpose of the RCT is to determine the main effects of the interventions
under consideration, therefore, the main hypotheses focuses on the two
primary questions. The researchers do not wish to answer which of the four
possible combinations is the most effective, thus the effect of the interaction
is of marginal interest. The main hypotheses is addressed by assuming that
ART will be equally as effective irrespective of whether the patients received
surgery or MMS in the preceding randomisation phase. This assumption is
likely to be valid since the requirement for a patient to proceed to the second
phase of the randomisation is based on whether there was an absence of
incomplete excision.
The failure rates for local and regional recurrence for surgery (5.4% and 4.4%,
respectively) and MMS (3% and 4.2%, respectively) as determined by the
pooled analyses in Chapter 4 cannot be used directly in the sample size
calculation for the first phase of the trial as they include low and high risk
patients. Additionally, the data provided in the included studies did not allow
for estimations to be determined for just high risk patients. Therefore, using
additional failure rate data on high risk patients from Chapter 7 (BWH
classification T2b), the following range of likely failure rates were used in the
sample size calculations (Table 43):
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Table 43: Estimated outcomes for each intervention (range)
Intervention Local recurrence,
(range)
Regional recurrence,
(range)
Surgery 20% (15%, 25%) 12% (10%, 14%)
MMS 15% (10%, 20%) 8% (6%, 10%)
ART 15% (10%, 20%) 8% (6%, 10%)
The failure rates for local and regional recurrence for adjuvant radiotherapy
(ART) following surgery as determined by the pooled analyses in Chapter 4
were reported separately for lesions with and without PNI, with average
pooled failure rates of 15% for local recurrence and 8% for regional
recurrence. The above table shows the likely failure rates used in the sample
size calculations.
Additionally, from Chapter 4, there was incomplete excision in 8.8% of
surgery patients, although definition of adequacy of excision varied between
the included studies, and from Chapter 7 there was incomplete excision in
14% of surgery patients. Therefore, for the RCT we assumed that incomplete
excision would occur in 14% of surgical patients; thus 86% of patients with
T2b SCCs who were randomised in the first phase to have surgical excision
would be eligible for randomisation in the second phase of the study.
Using the data above, sample sizes for the second phase of the study were
calculated using chi-squared tests for two proportions assuming 5%
significance level (not allowing for multiple testing) and 2.5% significance
(allowing for multiple testing) at 80% and 90% power, assuming that ART was
more effective than no ART:
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ART failure
rate
No ART failure rate Power
of
study
Sample size in
each group
(5%
significance
level)
Sample size in
each group
(2.5%
significance
level)
Local recurrence
15% 20% 80% 945 1137
15% 20% 90% 1252 1471
15% 25% 80% 270 323
15% 25% 90% 354 415
10% 15% 80% 726 870
10% 15% 90% 957 1124
10% 20% 80% 219 261
10% 20% 90% 286 334
20% 25% 80% 1134 1365
20% 25% 90% 1504 1769
Regional recurrence
8% 12% 80% 932 1118
8% 12% 90% 1230 1444
8% 14% 80% 459 549
8% 14% 90% 603 706
6% 10% 80% 771 923
6% 10% 90% 1014 1190
6% 12% 80% 389 464
6% 12% 90% 509 596
10% 14% 80% 1085 1303
10% 14% 90% 1435 1686
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A two sample continuity corrected chi-squared test with a 2.5% significance
level (to account for multiple testing) based on an odds ratio of 1.42 for local
recurrence (15% ART versus 20% no ART) will have 80% power when the
sample size is 2274 (1137 per group) or 90% power when a sample size of
2942 (1471 per group) is used. These sample sizes will also be sufficient to
detect an odds ratios of 1.57 for regional recurrence (8% ART versus 12% no
ART).
As only T2b SCC are eligible for the second phase of the trial, the sample sizes
above are also applicable to T2b SCCs in the first phase of the trial assessing
the effectiveness of surgery with a 10mm surgical margin as compared to
MMS since the likely failure rate for MMS is the same as for ART. Given that
the case series (chapter 7) indicated that there was a significant trend
towards higher risks of local and regional recurrence after surgical excision
from T2a to T2b, T2 SCCs will be stratified into T2a and T2b in the first stage
of the trial to test the null hypothesis that there is no significant difference in
outcomes after wide surgical excision or MMS for T2a and T2b SCCs
separately. For T2a tumours, a two sample continuity corrected chi-squared
test with a 5% significance level based on an odds ratio of 1.42 for local
recurrence (15%MMS versus 20% surgery) will have 80% power when the
sample size is 1890 (945 per group) or 90% power when a sample size of 2504
(1252 per group) is used ().
To determine how many participants are needed for the entire trial, the
sample sizes above for T2b SCCs need to be multiplied by a factor of 1.14% to
allow for 86% complete clearance rates. Thus the total T2b sample sizes
needed are 2595 (1296 per group) for 80% power and 3354 (1677 per group)
for 90% power. Assuming that approximately 48% of all T2 SCCs are T2b
(chapter 7), these figures therefore need to be multiplied by a factor of 2.08
for an estimate of the total number of T2 SCCs that would be required to yield
an adequate number of T2b tumours (which would automatically also give an
adequate number of T2a tumours). Therefore a total of 5400 T2 SCCs would
be required for 80% power for each stage of the trial, and 6988 for 90%
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power. The estimated number of patients at each stage is outlined in Figure
55. The final number of patients needed to be recruited into the RCT needs to
take into account the drop-out rate (for example due to death or withdrawal),
since it would not be valid to assume a worst case scenario where all drop-
outs are assumed to have had a recurrence. If a drop-out rate of 10% is
assumed then the above estimates would need to be further multiplied by a
factor of 1.1%, or 1.25% if a drop-out rate of 20% is assumed.
Feasibility work with patients (chapter 8) indicated that approximately 55%
were hypothetically willing to be randomised into both stages of the trial.
However, if it is assumed that this is likely to be an underestimate and that
more like one third of patients approached will be in practice be willing to be
randomised, then it will be necessary to approach approximately 18000
patients in total to accrue the sample size required for the study to have 80%
power. Thus, it will be necessary to approach approximately 3600 patients
per annum over a recruitment 5-year period. Data from the case series
analysis in Nottingham indicated that there are approximately 270 patients
per annum who would theoretically be eligible for the trial. Therefore, it is
estimated that recruitment would need to take place from 13 centres to
accrue the required number of participants.
Trial participants will be analysed in the groups to which they were
randomised regardless of which treatment they received and all will be
included in the analysis on an intention-to-treat basis.
All analyses will be documented in the Statistical Analysis Plan which will be
finalised prior to database lock. This will also include methods to deal with
missing data and sensitivity and sub-group analyses where appropriate.
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Figure 55: Estimated sample sizes at each stage of the trial
No ART
n=569 (80%)
n=735 (90%)
ART
n=569 (80%)
n=735 (90%)
ART
n=569(80%)
n=735(90%)
10mmmargin First Randomisation Stage
Second Randomisation Stage:
T2b to ART or follow-up only
Assuming 86% are
excised with margin
>1mm
MMS
T2a - Follow-
up as per
protocol
T2b
n=1296(80%)
n=1677(90%)
T2a
n=945(80%)
n=1252(90%)
T2b
n=1296(80%)
n=1677(90%)
T2a
n=945(80%)
n=1252(90%)
No ART
n=569 (80%)
n=735 (90%)
T2a - Follow-
up as per
protocol
T2 SCCs : Total number of T2 SCCs required (assuming 48%
are T2b):
n=5400 (80% power) or n=6988 (90% power)
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9.2.11. Ethical Arrangements
The main ethical issues are:
x That eligible patients should be aware of the uncertainty regarding the
best approach to the management of high-risk primary SCCs
x That trial participation must not delay the pathway to the definitive
treatment of SCC
The key members of the SSMDT managing SCC, typically dermatologists,
clinical oncologists and plastic surgeons, will be local investigators. Approval
by the Research Ethics Committee (REC) and local Research and Development
(R&D) team will be obtained before investigators enrol participants. Clinicians
will retain responsibility to take immediate action to protect the health and
interest of individual participants.
9.2.12.Risk and anticipated benefits for participants
Surgery is the current mainstay of treatment for patients with SCC of the skin
and is generally safe. However, there is a small risk of excessive bleeding and
infection. Some tumours, particularly those that are large or in cosmetically
complex areas may require a flap or graft for repair. Furthermore, patients
who are unable to lie down due to a comorbid condition may not tolerate
Mohs micrographic surgery which is a potentially lengthy procedure.
Radiotherapy is an established treatment modality for cutaneous SCC, either
on its own or as adjuvant therapy, and is generally well tolerated in this
context. As multiple treatment sessions are required patient convenience
may be compromised. Ionising radiation is also associated with a small
increased risk of cutaneous carcinoma within the treatment field. Atrophy,
hypopigmentation, alopecia, and telangiectases are also commonly seen late
cutaneous sequelae of radiotherapy, which may be unacceptable for younger
patients. Due to the risk of radionecrosis, radiotherapy is not advisable for
lesions overlying bone or cartilage.
311
Participants will be made aware of the risks in the participant information
resources and when they are counselled for informed consent and incidence
of adverse events will be monitored throughout the trial.
Potential benefits to participants cannot be guaranteed, although all
participants will have surgical excision to manage their primary disease.
Participants who experience emotional distress as a result of participating in
the trial will be offered details of a counselling service.
9.2.13. Informed Consent
The nature and purpose of both stages of the trial will be explained to
potential participants when they are first approached to take part. However,
they will be required to give their written informed consent separately for
each stage of the trial if applicable. All participants will give their written
informed consent prior to randomisation to one of the two surgical arms.
Participants who are then eligible to take part in the second stage of the trial
on the basis of their high-risk pathology, will give written informed consent
prior to randomisation to receive adjuvant radiotherapy or no adjuvant
radiotherapy. A trained member of the research team will counsel
participants about the reasons that the trial is being conducted, potential
risks associated with the interventions, and the purpose of randomisation.
Participants will have time to consider whether they wish to give their
informed consent, and will have access to a member of the research team to
discuss further if required. Participants’ rights to decline trial participation
without giving a reason will be respected.
9.2.14. Informing Participants of possible benefits and risks
Participant Information Leaflets (PILs) will be prepared in line with current
guidelines and will be informed by the results of the feasibility study which
was undertaken as part of this project. These will contain information about
the trial, how the trial may affect patients, and outline likely benefits and risks
to participants. The trial will also have a dedicated website containing this
information and details of the research team.
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9.2.15.Research Governance
The trial will be run in accordance with the sponsor’s standard operating
procedures (SOPs), and managed through a Clinical Trial Unit with expertise in
cancer trials. An independent Trial Steering Committee (TSC) will be
established prior to initiation of the trial, which will oversee the conduct of
the trial. A Data Monitoring Committee will be set up to ensure participant
safety throughout the trial.
9.2.16.Confidentiality of Data
All participants’ data will be handled and stored in accordance with the
sponsor’s SOPs and the Data Protection Act. Trial documentation will be
retained using secure archiving facilities for 7 years.
9.2.17.Trial Regulation Requirements
As the trial involves radiation, a Medical Physics Expert (a registered clinical
scientist registered with the Health Professions Council) will be involved with
writing the ethics application and a study contact.
The trial will be registered on an approved trial registry prior to the start of
recruitment and the protocol and analysis plan will be published in full.
Ongoing discussions about the proposed trial9.3
The trial proposal outlined above has been extensively discussed with
multidisciplinary colleagues in order to get it to its current stage. However,
there are still some ongoing discussions between dermatology surgeons and
plastic surgeons regarding exact surgical margin size on the head and neck,
and the appropriateness of including Mohs as a comparator for cutaneous
SCCs not located on the head or neck.
The reluctance of some clinicians to excise with a wide margin on cosmetically
sensitive areas such as the face has been alluded to in the results of the
analysis of SCCs in this thesis (chapter 7), where the mean excision margin
around head and neck SCCs appeared smaller than around those located
elsewhere on the body. It has also been noted by others that clinicians will
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take more generous margins around truncal SCCs than recommended in
current guidelines, with many surgeons admitting that they would take
smaller margins than recommended on cosmetically and functionally areas of
the face to avoid creating functional problems which may require extensive
reconstruction (Hemington-Gorse et al., 2006, Staiano et al., 2004).
Reluctance of clinicians to adhere to an excision margin of 10mm could
therefore compromise the conduct of the proposed trial. Therefore, at the
time of writing this thesis, it is envisaged that for SCCs randomised to be
excised by conventional excision, the decision regarding excision margin size
will be made upon tumour diameter for head and neck SCCs, so that SCCs
larger than 2cm in diameter will be excised with a 10mmmargin, whereas
those that are 2cm or smaller will be excised with a 6mmmargin. This will still
provide valuable data regarding the adequacy of each excision margin and will
be more attractive to clinicians who are concerned about cosmetic and
functional implications.
Furthermore, it may not be appropriate to include Mohs micrographic surgery
as one of the surgical treatments for SCCs that are not located on the head
and neck and where potential cosmetic and functional sequelae are not likely
to be as significant. At the time of writing, consideration is therefore being
given to running a second trial of non-head and neck SCCs, in which there will
be a direct comparison of 6mm versus 10mm excision margins, as was
proposed at an earlier stage of the trial development. This would potentially
allow centres to participate which do not have ready access to Mohs facilities,
whilst focussing the Mohs resources that are available on the high-risk head
and neck SCCs. When agreement has been reached on these points, an
application for funding will be submitted during 2014.
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10 IMPACT OF THE RESEARCH AND CONCLUSIONS
Introduction10.1
Historically, there has been little high-quality research that has addressed the
management of SCC as a discrete entity; the assumption that SCC can be
likened to BCC and that they can be studied together is fallacious and both
warrant researching separately. Faced with a lack of good evidence and
management uncertainties, there has much been variation among clinicians
regarding SCC management and a more consistent approach to management
is called for which is based on a stronger evidence-base than has been the
case to date.
Previous chapters in this thesis have outlined the issues that are associated
with research into the treatment of cutaneous SCC (chapter 2), and described
the research that has been done that will inform an RCT directly comparing
surgical treatments and which will also provide evidence on the usefulness or
otherwise of post-operative adjuvant radiotherapy for patients with
particularly high-risk SCCs.
This final chapter is an overview of the impact that this research has had, and
is having, in the field of SCC management, and will also describe how patients
have been involved in the research throughout its different stages.
Suggestions will also be made on possible directions for future SCC research.
Finally I will share a few personal reflections on my involvement with the
research and the lessons that I have learned along the way.
Impact of this research10.2
The work described in this thesis contributes original research to the body of
knowledge relating to the management of cutaneous SCC. Furthermore, it is
contributing to furthering research into what is such a common tumour
throughout the world but which has been so shockingly overlooked in terms
of high-quality research. In Figure 56 the research cycle outlined in chapter 2
is revisited, summarising the individual stages of the projects described within
this thesis.
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Figure 56 : The research cycle revisited
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10.2.1. Guideline development
This body of research commenced with an appraisal of the current evidence-
base for primary non-metastatic cutaneous SCC treatments in the form of two
systematic reviews; a Cochrane systematic review of RCTs and a large
systematic review of case series. These reviews have highlighted the absence
of RCTs to compare SCC treatments and have comprehensively evaluated
current SCC treatments from the best evidence available, with deductions as
far as possible regarding outcomes after different treatments. The Cochrane
systematic review was incorporated into the NICE evidence update of their
‘Improving Outcomes for People with Skin Cancer including Melanoma’ report
(National Institute for Health and Clinical Excellence, 2011), to which I
contributed as a member of the Evidence Update Advisory Group which
appraised and summarised selected new evidence. This emphasised the clear
and urgent need for well-designed clinical trials in the area. An impact is now
also being seen as new and updated SCC clinical management guidelines are
produced. The findings from the evidence appraisal were presented to the
Scottish Intercollegiate Guidelines Network Development Group and are
referred to extensively in the new SCC guidelines that have recently been
published (Scottish Intercollegiate Guidelines Network, June 2014). In
addition, the BAD multiprofessional guidelines that are currently being
updated and are due to be published in 2015 are utilising the evidence from
these systematic reviews. Both sets of management guidelines will have a
direct impact on the management of SCC patients.
10.2.2. Implications for Clinical Practice
The current mainstay of treatment for SCC is surgery, either with
conventional excision of tumour alone with a margin of normal-looking skin,
or Mohs micrographic surgery (MMS). Other treatments in the current
management guidelines (Motley et al., 2002) include radiotherapy, either
alone or as an adjunct to surgery, curettage and cautery, or cryotherapy.
Treatment choice is based upon tumour and patient characteristics. However,
treatment practices such as excision margins and adjuvant radiotherapy are
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not standardised, and vary according to individual clinicians and, in some
cases, the availability of facilities for particular treatments.
The clinician survey and evidence appraisal conducted as part of this research
indicated that there are areas of management uncertainty which are not
addressed in current guidelines. The proposed RCT will provide much needed
evidence to inform future evidence-based guideline development regarding
excision margins, the use of MMS and the role of adjuvant radiotherapy in
treating high-risk SCCs. Stratification of patients according to their risk will
guide clinical practice and will assist with clinical decision-making regarding
the most appropriate treatment for individual patients.
10.2.3. Implications for research
This is the largest programme of dedicated clinical research into SCC
treatment to date, and has stimulated interest in SCC research.
The identification of gaps in the evidence and areas of treatment uncertainty
has resulted in the development of a proposal for the first RCT of its kind for
this very common cancer. Important research questions will be addressed in
this trial:
x Adequacy of excision margins in surgical excision of high-risk SCCs
x Effectiveness of Mohs surgery compared with surgical excision
x The role of adjuvant radiotherapy.
The results of the case series of SCCs submitted to histopathology have given
an indication of the number and types of high-risk SCCs eligible for inclusion
in the RCT, and the frequency of outcomes in patients within 5 years after
treatment, which is informing development of the protocol.
Patients feel that an RCT of SCC treatment is feasible from the perspective of
potential participants. However, they identified that poor understanding of
the nature and purpose of randomisation and perceived lack of equipoise
regarding the treatment arms could be major barriers to successful
recruitment, and will need to be taken into account when presenting the trial
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to participants. Furthermore, their information requirements will be taken
into account when producing participant resources for the trial, to ensure
that these are delivered in the most appropriate formats.
Patient and public involvement10.3
In contrast to some chronic skin diseases, there is no patient support group
for people who are affected by cutaneous SCC. Nevertheless, patients and
stakeholders have been involved throughout the research stages described in
this thesis whenever possible. In terms of future research, early engagement
with all key stakeholders will help to encourage the wide dissemination of the
results of the final study, leading to early adoption of the trial findings, and
impact on guidelines and policies.
Patients themselves have had, and will continue to have, a vital role
throughout the life of the trial. A former skin cancer patient was a co-author
on the Cochrane Systematic Review, providing valuable input from a lay
person’s perspective. Furthermore, the patient representative on the NCRI
subgroup has given insightful comments as the trial proposal has developed
towards a funding application.
However, patients have had the greatest impact on this research in the design
and conduct of the feasibility study. Evaluation of the feasibility of the
proposed trial from the perspective of potential participants was considered
crucial in guiding the design of the proposed RCT. In addition, the early
identification of possible barriers to recruitment was important in order to
develop strategies to optimise recruitment, particularly from a target
population which is predominantly elderly. The feasibility study took the form
of a questionnaire and focus group. We sought the opinion of members of the
Centre for Evidence Based Dermatology patient panel, including some who
had a history of skin cancer themselves, in an interactive workshop session in
which the questionnaire was refined, and delivery of the questionnaire and
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focus group was discussed. Patients who had been treated for SCC over the
course of the previous 12 months and who were representative of the
population from which participants in the proposed RCT will be recruited,
took part in the feasibility study. Key points were identified from this work;
these have already informed the proposed RCT and will continue to do so as
participant resources are developed for the trial:
x Receiving a diagnosis of SCC induces anxiety, and patients may
struggle to recall information given at the initial consultation.
Repeating information and the use of non-written formats such as
videos and audiotapes may help overcome this. The availability of
participant information resources in a variety of formats is desirable.
x Information resources must be in plain language that is easily
understood by patients from a range of educational backgrounds.
x The concept of randomisation is poorly understood and will need
thorough explanation if recruitment to the trial is to be optimised. This
may require additional staff and time resources to ensure participants
understand and are comfortable with its principles.
x Randomisation to one of the surgical arms of the trials would generally
not be problematic for feasibility studies participants, unless the SCC
was located in a cosmetically or functionally sensitive area. Fewer
participants would feel comfortable about being randomised in the
second stage of the trial where they would either receive adjuvant
radiotherapy or follow-up alone without adjuvant radiotherapy,
mainly due to their perceived fear of receiving radiation. This could
impact on the successful recruitment into the latter stage of the
proposed RCT, and is being taken into account when writing
participants’ information sheets: the degree of risk of radiation when
used in this context must be carefully explained and the notion of
clinical equipoise reinforced.
x In view of the advanced age of potential participants in the proposed
RCT, exclusion criteria in terms of existing co-morbidities should not
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be too rigid, and extra staff and time input may be required to allay
the concerns of older patients.
x Financial arrangements should be in place to cover the costs of extra
hospital visits that may be incurred by participants randomised to
receive adjuvant radiotherapy.
x Importantly, potential participants did not reject the proposed RCT as
being unfeasible from a patient’s perspective.
This research has shown that patients with SCC would like to know more
about their condition, but also that there is interest in helping with future
research. It will be important to include a patient representative on the Trial
Steering Committee. Furthermore, from the work there is now a group of
patients from the focus group who are willing to review documents and other
resources produced for participants in the trial.
The future of SCC research10.4
Given the current lack of studies of good methodological quality, there is
certainly scope for the development of further SCC research in the future.
Some possible areas for future research that have emerged as a consequence
of this research are suggested below:
x How is the incidence of cutaneous SCC changing in the UK, and is the
demography of patients who are affected changing? From the analysis
of SCCs treated in Nottingham during two 12-month periods (chapter
7), there is a suggestion that numbers overall are increasing, and that
the mean age of affected patients may be rising.
x The clinician survey (chapter 5) has indicated that, apart from the
areas of uncertainty that will investigated in the proposed trial being
developed as part of this research, there is also interest in the role of
newer agents such as cetuximab to treat SCC.
x The clinician survey (chapter 5) also highlighted a desire for the
optimisation of follow-up schedules for SCCs according to their risk of
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recurrence. As clinicians’ workloads increase, there is a need for more
evidence to support the frequency of follow-up and total duration of
follow-up.
x Furthermore, the qualitative work with patients (chapter 8) suggested
that patients have poor knowledge of their condition even when they
have experienced treatment of several skin cancers. Patients
themselves need to be aware of the potential for recurrence and
second primary tumours between clinician follow-up appointments or
after follow-up. Educational tools aimed at patients or their carers
may be valuable if they improve their ability and confidence to
recognise abnormalities at an early stage, but would warrant
evaluation of their mode of delivery, effectiveness and acceptability
with patients.
Patient-reported outcomes and QoL measures were lacking in the studies that
were appraised in the systematic reviews conducted as part of this thesis
(chapters 3 and 4). They should, however, be integral to future SCC research
as they are recognised as having the potential to improve the quality of the
research by providing evidence from the patient’s perspective. Additionally,
with an ageing population and as the burden of SCC on health service
provision continues to grow, evaluation of cost-effectiveness of different
treatments will be an important consideration.
Personal reflections10.5
Throughout the course of this research I have been very privileged to have
had the opportunity to acquire and develop a new set of skills and
competencies that have enriched me both as a researcher and as an
individual. The nature of the research has called for a broad range of
methodologies; from systematic reviewing through the qualitative and
quantitative methods to the trial development, every stage has had its
challenges to overcome. One of the main lessons I have learned is that it is
sometimes necessary to take a more flexible approach and to keep an open
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mind regarding alternative ways of meeting challenges, but that with
perseverance and patience these challenges will be surmounted.
I have certainly become more adept at dealing with large amounts of
information and data, and my information management skills were definitely
honed whilst dealing with the huge number of potential studies encountered
whilst conducting the systematic review of observational studies. The
development of a more systematic mind-set than I previously possessed was
a great by-product of this work.
The feasibility work with patients afforded me the opportunity to experience
writing a study protocol and regulatory approvals and to manage a study,
teaching me that it is imperative to liaise with others involved in the process
at an early stage in order to facilitate as smooth a passage as possible through
the bureaucratic necessities.
Collaboration and networking with colleagues from many disciplines has been
an important part of this research, and although I have been responsible for
developing and conducting each of the individual stages, the overall
objectives of the work could not have been achieved without the involvement
and co-operation of others. This was particularly true for the clinician survey,
where I needed to liaise with those influential in their respective professional
organisations, and during the development of the trial proposal, in which it
was imperative to bring together those who will ultimately be responsible for
recruiting into and delivering the definitive trial. In an area where there are
so many evidence gaps, this has generated much debate and I have learned
that it takes much patience and negotiation to achieve some sort of
consensus among those who may hold strong professional opinions, and that
the time required to reach this stage should never be underestimated.
Through my work, I have been fortunate to have had the opportunity to meet
and to learn from those who are eminent in the field of NMSC, both within
the university and on a wider scale and to develop my own reputation in the
area. In 2010 I was invited to sit on the NICE skin cancer evidence update
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group which was charged with updating the 2006 NICE guidance ‘Improving
Outcomes for People with Skin Cancer’, through which I learned the steps
that are involved in generating NICE guidance. Additionally I was invited to
present the findings from my systematic review of observational studies to
the SIGN development group in Scotland, which has subsequently
incorporated the results of the work into their management guidelines that
have just been published. I have also been invited to participate in the
development of the BAD management guidelines that are currently in the
process of being updated.
By presenting my research at various meeting and conferences I have had the
opportunity to disseminate the findings to a wider audience and to refine my
presentation skills. I believe that presentation to international audiences
requires a slightly different presentation approach in order to convey the
message of the research to those who do not necessarily speak English as
their native language. It has therefore been a great privilege to present my
research at international conferences, and I have been very fortunate to have
been awarded a Graduate School Travel prize and a Nottingham Centre of
Evidence-Based Health Care Scholarship that have enabled me to do this.
Ultimately the patient is at the heart of the practice of evidence- based
medicine. Listening to patients, communicating with them and getting them
involved in the research really brought this into focus for me when I
conducted the feasibility study and was one of the most rewarding parts of
the work. If my research can in some way contribute to improving the
management and quality of life of these patients, then the (mostly) highs and
(occasional) lows of the past few years will truly have been worthwhile.
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Concluding remark10.6
Patients affected by cutaneous SCC clearly deserve to receive treatments that
are both appropriate for them, and supported by good quality evidence.
However, cutaneous SCC does not behave in the same way as other skin
cancers such as BCC, and the evidence base for treatments is currently very
poor. The work in this research is helping to redress this situation, by
informing guidelines and future clinical decision-making and by generating a
step-change in data needed to effectively plan for a definitive national RCT.
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APPENDICES
APPENDIX 1
INTERVENTIONS FOR NON-METASTATIC SQUAMOUS CELL CARCINOMA OF
THE SKIN (COCHRANE SYSTEMATIC REVIEW) SEARCH STRATEGIES
Specialised Skin Register search strategy
(squamous and cell and carcinoma) or (skin and neoplasm*) or (skin and
cancer*) or (skin and tumour*) or (skin and tumor*) or (non-metastatic and
squamous and cell and carcinoma) or (NMSC) or (non-melanoma and skin and
cancer) AND (cryotherapy or (moh* and surg*) or (excis* and surg*) or
curettage or cauter* or electrosurgery or electrodesiccation or photodynamic
or photochemotherapy or (laser* and surg*) or (laser* and therap*) or
radiotherapy or (intralesional and chemotherap*) or interferon* or retinoi* or
fluorouracil or bleomycin or (solasodine and glycoside*) or (drug* and
therap*))
Cochrane Library search strategy
#1(squamous cell carcinoma) or (skin cancer$) or (skin neoplasm$) or (skin
(tumour$ or tumor$))
#2(non-metastatic squamous cell carcinoma) or (NMSC) or (non-melanoma
skin cancer)
#3MeSH descriptor Carcinoma, Squamous Cell explode all trees
#4MeSH descriptor Skin Neoplasms explode all trees
#5(#1 OR #2 OR #3 OR #4)
#6(cryotherapy) or (cryosurgery) or (moh$ and surgery) or (excision$ and
surgery)
#7(curettage) or (cauter$)
#8(electrosurgery) or (electrodesiccation) or (photodynamic therapy) or
(photochemotherapy)
#9(laser surgery) or (laser therapy) or (radiotherapy) or (interferon$)
#10(intralesional chemotherapy) or bleomycin or fluorouracil or (solasodine
glycoside$) or retinoi$ or cisplatin
#11MeSH descriptor Cryotherapy explode all trees
#12MeSH descriptor Cryosurgery explode all trees
#13MeSH descriptor Mohs Surgery explode all trees
#14MeSH descriptor Curettage explode all trees
#15MeSH descriptor Cautery explode all trees
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#16MeSH descriptor Electrosurgery explode all trees
#17MeSH descriptor Photochemotherapy explode all trees
#18MeSH descriptor Laser Therapy explode all trees
#19MeSH descriptor Radiotherapy explode all trees
#20MeSH descriptor Interferons explode all trees
#21(#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18 OR #19 OR #20 OR #25)
#22(#5 AND #21)
#23SR-SKIN
#24(#22 AND NOT #23)
#25MeSH descriptor Drug Therapy, this term only
MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (human and animals)).sh.
10. 8 not 9
11. squamous cell carcinoma.mp. or exp Carcinoma, Squamous Cell/
12. skin neoplasms.mp. or exp Skin Neoplasms/
13. skin cancer$.mp.
14. (skin tumour$ or skin tumor$).mp. [mp=title, original title, abstract, name
of substance word, subject heading word]
15. non-metastatic squamous cell carcinoma.mp.
16. NMSC.mp.
17. non-melanoma skin cancer.mp.
18. cryotherapy.mp. or exp Cryotherapy/
19. cryosurgery.mp. or exp Cryosurgery/
20. moh's surgery.mp. or exp Mohs Surgery/
21. exp Mohs Surgery/ or mohs.mp.
22. excision$ surgery.mp.
23. curettage.mp. or exp Curettage/
24. cautery.mp. or exp Cautery/
25. cauter$.mp.
26. exp Electrosurgery/ or electrodesiccation.mp.
27. photodynamic therapy.mp. or exp Photochemotherapy/
28. laser surgery.mp. or exp Laser Therapy/
29. radiotherapy.mp. or exp Radiotherapy/
30. intralesional chemotherapy.mp.
31. interferon.mp. or exp Interferons/
32. drug therapy.mp. or exp Drug Therapy/
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33. 11 or 16 or 13 or 17 or 12 or 15 or 14
34. 27 or 25 or 32 or 28 or 21 or 26 or 20 or 22 or 18 or 30 or 24 or 19 or 23 or
31 or 29
35. 33 and 34 and 10
36. limit 35 to yr="2005 -Current"
EMBASE search strategy
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device manufacturer, drug
manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer, drug manufacturer
name]
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. squamous cell carcinoma.mp. or exp Carcinoma, Squamous Cell/
15. skin neoplasms.mp. or exp Skin Neoplasms/
16. skin cancer$.mp.
17. (skin tumour$ or skin tumor$).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
18. non-metastatic squamous cell carcinoma.mp.
19. NMSC.mp.
20. non-melanoma skin cancer.mp.
21. cryotherapy.mp. or exp Cryotherapy/
22. cryosurgery.mp. or exp Cryosurgery/
23. moh's surgery.mp. or exp Mohs Surgery/
24. exp Mohs Surgery/ or mohs.mp.
25. excision$ surgery.mp.
26. curettage.mp. or exp Curettage/
27. cautery.mp. or exp Cautery/
28. cauter$.mp.
29. exp Electrosurgery/ or electrodesiccation.mp.
30. photodynamic therapy.mp. or exp Photochemotherapy/
31. laser surgery.mp. or exp Laser Therapy/
32. radiotherapy.mp. or exp Radiotherapy/
33. intralesional chemotherapy.mp.
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34. interferon.mp. or exp Interferons/
35. drug therapy.mp. or exp Drug Therapy/
36. 14 or 19 or 16 or 20 or 15 or 18 or 17
37. 30 or 28 or 35 or 31 or 24 or 29 or 23 or 25 or 21 or 33 or 27 or 22 or 26 or
34 or 32
38. 36 and 37 and 13
39. limit 38 to yr="2007 -Current"
PsychInfo and AMED search strategy
1. random$.mp. 2. factorial$.mp. 3. placebo$.mp. or PLACEBO/ 4. (doubl$ adj
blind$).mp. 5. (singl$ adj blind$).mp. 6. (assign$ or alloc$).mp. 7.
volunteer$.mp. or VOLUNTEER/ 8. 1 or 2 or 3 or 4 or 5 or 6 or 7 9. squamous
cell carcinoma.mp. or exp Carcinoma, Squamous Cell/ 10. skin neoplasms.mp.
or exp Skin Neoplasms/ 11. skin cancer$.mp. 12. (skin tumour$ or skin
tumor$).mp. 13. 9 or 10 or 11 or 12 14. 8 and 13
LILACS search strategy
Skin Neoplasms/ [Subject descriptor] Carcinoma, Squamous Cell [Subject
Descriptor]
Ongoing Trials Register searches
The metaRegister of Controlled Trials on www.controlled-trials.com (April
2009) using the search terms:SCC, Squamous cell carcinoma, skin cancer, skin
neoplasms, NMSC
The Ongoing Skin Trials register on www.nottingham.ac.uk/ongoingskintrials
in the category 'squamous cell carcinoma'
The Australian and New Zealand Clinical Trials Registry on www.anzctr.org.au
using the search terms: "squamous cell carcinoma of the skin", "cutaneous
SCC", "non-melanoma skin cancer", "NMSC"
The World Health Organisation International Clinical Trials Registry platform
on www.who.int/trialsearch using the search terms: squamous cell
carcinoma,cutaneous squamous cell carcinoma, SCC, non-melanoma skin
cancer, NMSC
The U.S.National Institutes of Health ongoing trials register on
www.clinicaltrials.gov using the search terms: 'squamous cell carcinoma AND
skin', 'cutaneous' AND squamous cell carcinoma', 'non-melanomatous skin
cancer', 'skin neoplasms'
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APPENDIX 2
INTERVENTIONS FOR NON-METASTATIC SQUAMOUS CELL CARCINOMA OF
THE SKIN: A SYSTEMATIC REVIEW AND POOLED ANALYSIS OF
OBSERVATIONAL STUDIES SEARCH STRATEGIES
MEDLINE
1. exp epidemiologic studies/
2. exp case-control studies/
3. exp cohort studies/
4. case control.tw.
5. (cohort adj (study or studies)).tw.
6. Cohort anal$.tw.
7. (Follow up adj (study or studies)).tw.
8. (observational adj (study or studies)).tw.
9. Longitudinal.tw.
10. Retrospective.tw.
11. Cross sectional.tw.
12. Cross-sectional studies/
13. or/1-12
14. (squamous cell carcinoma or skin cancer$ or skin neoplasm$).mp.
[mp=title, original title, abstract, name of substance word, subject heading
word]
15. (skin tumour$ or skin tumor$).mp. [mp=title, original title, abstract, name
of substance word, subject heading word]
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16. (non-metastatic squamous cell carcinoma or NMSC or non-melanoma skin
cancer).mp. [mp=title, original title, abstract, name of substance word,
subject heading word]
17. exp Carcinoma,Squamous Cell/
18. exp Skin neoplasms/
19. 14 or 15 or 16 or 17 or 18
20. (cryotherapy or cryosurgery or (moh$ and surgery) or (excision$ and
surgery)).mp. [mp=title, original title, abstract, name of substance word,
subject heading word]
21. (curettage or cauter$).mp. [mp=title, original title, abstract, name of
substance word, subject heading word]
22. (electrosurgery or electrodesiccation).mp. [mp=title, original title,
abstract, name of substance word, subject heading word]
23. (photodynamic therapy or photochemotherapy).mp. [mp=title, original
title, abstract, name of substance word, subject heading word]
24. (laser surgery or laser therapy or radiotherapy or interferon$).mp.
[mp=title, original title, abstract, name of substance word, subject heading
word]
25. (intralesional chemotherapy or bleomycin or fluorouracil or solasodine
glycoside$).mp. [mp=title, original title, abstract, name of substance word,
subject heading word]
26. (retinoi$ or cisplatin).mp. [mp=title, original title, abstract, name of
substance word, subject heading word]
27. exp Cryotherapy/
28. exp Cryosurgery/
29. exp Mohs Surgery/
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30. excision$ surgery.mp.
31. exp Curettage/
32. exp Cautery/
33. exp Electrosurgery/
34. exp Photochemotherapy/
35. exp Laser Therapy/
36. exp Radiotherapy/
37. Interferons/
38. exp Interferons/
39. Drug Therapy/
40. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or
33 or 34 or 35 or 36 or 37 or 38 or 39
41. 13 and 19 and 40
42. Epidural Neoplasms/ or Salivary Gland Neoplasms/ or Nasopharyngeal
Neoplasms/ or Perivascular Epithelioid Cell Neoplasms/ or Nervous System
Neoplasms/ or Cerebral Ventricle Neoplasms/ or Retinal Neoplasms/ or
Central Nervous System Neoplasms/ or Gingival Neoplasms/ or Jejunal
Neoplasms/ or Neoplasms, Fibrous Tissue/ or Digestive System Neoplasms/ or
Laryngeal Neoplasms/ or Choroid Plexus Neoplasms/ or Palatal Neoplasms/ or
Neoplasms, Mesothelial/ or Urethral Neoplasms/ or Tracheal Neoplasms/ or
Endometrial Neoplasms/ or Brain Stem Neoplasms/ or Neoplasms,
Neuroepithelial/ or Oropharyngeal Neoplasms/ or Uveal Neoplasms/ or
Maxillary Neoplasms/ or Sublingual Gland Neoplasms/ or Pelvic Neoplasms/
or Cecal Neoplasms/ or Urogenital Neoplasms/ or "Neoplasms, Ductal,
Lobular, and Medullary"/ or Stomach Neoplasms/ or Liver Neoplasms,
Experimental/ or Neoplasms, Adipose Tissue/ or Nerve Sheath Neoplasms/ or
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Neoplasms, Bone Tissue/ or Mammary Neoplasms, Animal/ or Mediastinal
Neoplasms/ or Submandibular Gland Neoplasms/ or Sigmoid Neoplasms/ or
Adrenal Gland Neoplasms/ or Cerebellar Neoplasms/ or Pancreatic
Neoplasms/ or Neoplasms, Experimental/ or Tonsillar Neoplasms/ or Spinal
Neoplasms/ or Bronchial Neoplasms/ or Parathyroid Neoplasms/ or Mouth
Neoplasms/ or Thyroid Neoplasms/ or Hypothalamic Neoplasms/ or Common
Bile Duct Neoplasms/ or Supratentorial Neoplasms/ or Respiratory Tract
Neoplasms/ or Optic Nerve Neoplasms/ or Skull Base Neoplasms/ or Pleural
Neoplasms/ or Neoplasms, Connective Tissue/ or Urologic Neoplasms/ or
Abdominal Neoplasms/ or Colorectal Neoplasms, Hereditary Nonpolyposis/ or
Neoplasms, Radiation-Induced/ or Retroperitoneal Neoplasms/ or Vascular
Neoplasms/ or Vulvar Neoplasms/ or Hematologic Neoplasms/ or Bone
Marrow Neoplasms/ or Fallopian Tube Neoplasms/ or Gestational
Trophoblastic Neoplasms/ or Peritoneal Neoplasms/ or Appendiceal
Neoplasms/ or Esophageal Neoplasms/ or Colonic Neoplasms/ or Mammary
Neoplasms, Experimental/ or Biliary Tract Neoplasms/ or Cranial Nerve
Neoplasms/ or "Neoplasms, Cystic, Mucinous, and Serous"/ or Pharyngeal
Neoplasms/ or Neoplasms, Unknown Primary/ or Lung Neoplasms/ or Ovarian
Neoplasms/ or Penile Neoplasms/ or Neoplasms, Nerve Tissue/ or Brain
Neoplasms/ or Parotid Neoplasms/ or Urinary Bladder Neoplasms/ or
Testicular Neoplasms/ or Neoplasms, Muscle Tissue/ or Hypopharyngeal
Neoplasms/ or Otorhinolaryngologic Neoplasms/ or Neoplasms, Gonadal
Tissue/ or "Neoplasms, Complex and Mixed"/ or Soft Tissue Neoplasms/ or
Trophoblastic Neoplasms/ or Rectal Neoplasms/ or Ileal Neoplasms/ or
Gallbladder Neoplasms/ or Mandibular Neoplasms/ or Neoplasms, Second
Primary/ or Breast Neoplasms/ or Genital Neoplasms, Female/ or Intestinal
Neoplasms/ or Kidney Neoplasms/ or "Head and Neck Neoplasms"/ or
Maxillary Sinus Neoplasms/ or Choroid Neoplasms/ or Muscle Neoplasms/ or
Meningeal Neoplasms/ or Adrenal Cortex Neoplasms/ or Splenic Neoplasms/
or Neoplasms, Hormone-Dependent/ or Peripheral Nervous System
Neoplasms/ or Thymus Neoplasms/ or Sweat Gland Neoplasms/ or Endocrine
Gland Neoplasms/ or Neoplasms, Vascular Tissue/ or Conjunctival
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Neoplasms/ or Sebaceous Gland Neoplasms/ or Duodenal Neoplasms/ or
Pituitary Neoplasms/ or Spinal Cord Neoplasms/ or Neoplasms,
Fibroepithelial/ or Uterine Neoplasms/ or Gastrointestinal Neoplasms/ or
Neoplasms, Basal Cell/ or Liver Neoplasms/ or Ureteral Neoplasms/ or Uterine
Cervical Neoplasms/ or Iris Neoplasms/ or Prostatic Neoplasms/ or Thoracic
Neoplasms/ or Colorectal Neoplasms/ or Genital Neoplasms, Male/ or Vaginal
Neoplasms/ or Heart Neoplasms/ or Breast Neoplasms, Male/ or Orbital
Neoplasms/ or Bile Duct Neoplasms/ or "Neoplasms, Germ Cell and
Embryonal"/ or Anal Gland Neoplasms/ or Neoplasms, Plasma Cell/ or
Paranasal Sinus Neoplasms/ or Bone Neoplasms/ or Infratentorial Neoplasms/
or Tongue Neoplasms/ or Femoral Neoplasms/ or Anus Neoplasms/ or Eye
Neoplasms/ or Skull Neoplasms/
43. 41 not 42
44. limit 43 to humans
EMBASE
1. Clinical study/
2. case control study/
3. Family study/
4. Longitudinal study/
5. Retrospective study/
6. Prospective study/
7. Randomized controlled trials/
8. 6 not 7
9. Cohort analysis/
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10. (Cohort adj (study or studies)).mp.
11. (Case control adj (study or studies)).tw.
12. (follow up adj (study or studies)).tw.
13. (observational adj (study or studies)).tw.
14. (epidemiologic$ adj (study or studies)).tw.
15. (cross sectional adj (study or studies)).tw.
16. or/1-5,8-15
17. (squamous cell carcinoma or skin cancer$ or skin neoplasm$).mp.
[mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
18. (skin tumour$ or skin tumor$).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
19. (non-metastatic squamous cell carcinoma or NMSC or non-melanoma skin
cancer).mp. [mp=title, abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade
name, keyword]
20. exp Carcinoma, Squamous Cell/
21. exp Skin Neoplasms/
22. 17 or 18 or 19 or 20 or 21
23. (cryotherapy or cryosurgery or (moh$ and surgery) or (excision$ and
surgery)).mp. [mp=title, abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade
name, keyword]
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24. (curettage or cauter$).mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
25. (electrosurgery or electrodesiccation).mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
26. (photodynamic therapy or photochemotherapy).mp. [mp=title, abstract,
subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword]
27. (laser surgery or laser therapy or radiotherapy or interferon$).mp.
[mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
28. (intralesional chemotherapy or bleomycin or fluorouracil or solasodine
glycoside$).mp. [mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword]
29. (retinoi$ or cisplatin).mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
30. exp Cryotherapy/
31. exp Cryosurgery/
32. exp Mohs Surgery/
33. excision$ surgery.mp.
34. exp Curettage/
35. exp Cautery/
36. exp Electrosurgery/
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37. exp Photochemotherapy/
38. exp Laser Therapy/
39. exp Radiotherapy/
40. Interferons/
41. exp Interferons/
42. Drug Therapy/
43. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or
36 or 37 or 38 or 39 or 40 or 41 or 42
44. 16 and 22 and 43
45. Epidural Neoplasms/ or Salivary Gland Neoplasms/ or Nasopharyngeal
Neoplasms/ or Perivascular Epithelioid Cell Neoplasms/ or Nervous System
Neoplasms/ or Cerebral Ventricle Neoplasms/ or Retinal Neoplasms/ or
Central Nervous System Neoplasms/ or Gingival Neoplasms/ or Jejunal
Neoplasms/ or Neoplasms, Fibrous Tissue/ or Digestive System Neoplasms/ or
Laryngeal Neoplasms/ or Choroid Plexus Neoplasms/ or Palatal Neoplasms/ or
Neoplasms, Mesothelial/ or Urethral Neoplasms/ or Tracheal Neoplasms/ or
Endometrial Neoplasms/ or Brain Stem Neoplasms/ or Neoplasms,
Neuroepithelial/ or Oropharyngeal Neoplasms/ or Uveal Neoplasms/ or
Maxillary Neoplasms/ or Sublingual Gland Neoplasms/ or Pelvic Neoplasms/
or Cecal Neoplasms/ or Urogenital Neoplasms/ or "Neoplasms, Ductal,
Lobular, and Medullary"/ or Stomach Neoplasms/ or Liver Neoplasms,
Experimental/ or Neoplasms, Adipose Tissue/ or Nerve Sheath Neoplasms/ or
Neoplasms, Bone Tissue/ or Mammary Neoplasms, Animal/ or Mediastinal
Neoplasms/ or Submandibular Gland Neoplasms/ or Sigmoid Neoplasms/ or
Adrenal Gland Neoplasms/ or Cerebellar Neoplasms/ or Pancreatic
Neoplasms/ or Neoplasms, Experimental/ or Tonsillar Neoplasms/ or Spinal
Neoplasms/ or Bronchial Neoplasms/ or Parathyroid Neoplasms/ or Mouth
Neoplasms/ or Thyroid Neoplasms/ or Hypothalamic Neoplasms/ or Common
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Bile Duct Neoplasms/ or Supratentorial Neoplasms/ or Respiratory Tract
Neoplasms/ or Optic Nerve Neoplasms/ or Skull Base Neoplasms/ or Pleural
Neoplasms/ or Neoplasms, Connective Tissue/ or Urologic Neoplasms/ or
Abdominal Neoplasms/ or Colorectal Neoplasms, Hereditary Nonpolyposis/ or
Retroperitoneal Neoplasms/ or Vascular Neoplasms/ or Vulvar Neoplasms/ or
Hematologic Neoplasms/ or Bone Marrow Neoplasms/ or Fallopian Tube
Neoplasms/ or Gestational Trophoblastic Neoplasms/ or Peritoneal
Neoplasms/ or Appendiceal Neoplasms/ or Esophageal Neoplasms/ or Colonic
Neoplasms/ or Mammary Neoplasms, Experimental/ or Biliary Tract
Neoplasms/ or Cranial Nerve Neoplasms/ or "Neoplasms, Cystic, Mucinous,
and Serous"/ or Pharyngeal Neoplasms/ or Neoplasms, Unknown Primary/ or
Lung Neoplasms/ or Ovarian Neoplasms/ or Penile Neoplasms/ or Neoplasms,
Nerve Tissue/ or Brain Neoplasms/ or Parotid Neoplasms/ or Urinary Bladder
Neoplasms/ or Testicular Neoplasms/ or Neoplasms, Muscle Tissue/ or
Hypopharyngeal Neoplasms/ or Otorhinolaryngologic Neoplasms/ or
Neoplasms, Gonadal Tissue/ or "Neoplasms, Complex and Mixed"/ or Soft
Tissue Neoplasms/ or Trophoblastic Neoplasms/ or Rectal Neoplasms/ or Ileal
Neoplasms/ or Gallbladder Neoplasms/ or Mandibular Neoplasms/ or
Neoplasms, Second Primary/ or Breast Neoplasms/ or Genital Neoplasms,
Female/ or Intestinal Neoplasms/ or Kidney Neoplasms/ or "Head and Neck
Neoplasms"/ or Maxillary Sinus Neoplasms/ or Choroid Neoplasms/ or Muscle
Neoplasms/ or Meningeal Neoplasms/ or Adrenal Cortex Neoplasms/ or
Splenic Neoplasms/ or Neoplasms, Hormone-Dependent/ or Peripheral
Nervous System Neoplasms/ or Thymus Neoplasms/ or Sweat Gland
Neoplasms/ or Endocrine Gland Neoplasms/ or Neoplasms, Vascular Tissue/
or Conjunctival Neoplasms/ or Sebaceous Gland Neoplasms/ or Duodenal
Neoplasms/ or Pituitary Neoplasms/ or Spinal Cord Neoplasms/ or
Neoplasms, Fibroepithelial/ or Uterine Neoplasms/ or Gastrointestinal
Neoplasms/ or Neoplasms, Basal Cell/ or Liver Neoplasms/ or Ureteral
Neoplasms/ or Uterine Cervical Neoplasms/ or Iris Neoplasms/ or Prostatic
Neoplasms/ or Thoracic Neoplasms/ or Colorectal Neoplasms/ or Genital
Neoplasms, Male/ or Vaginal Neoplasms/ or Heart Neoplasms/ or Breast
373
Neoplasms, Male/ or Orbital Neoplasms/ or Bile Duct Neoplasms/ or
"Neoplasms, Germ Cell and Embryonal"/ or Anal Gland Neoplasms/ or
Neoplasms, Plasma Cell/ or Paranasal Sinus Neoplasms/ or Bone Neoplasms/
or Infratentorial Neoplasms/ or Tongue Neoplasms/ or Femoral Neoplasms/
or Anus Neoplasms/ or Eye Neoplasms/ or Skull Neoplasms/
46. 44 not 45
47. exp Lymphoma/
48. 46 not 47
49. limit 48 to humans
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